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Gene expression analysis in breast cancer 
 
Jai Prakash Mehta 
 
Breast cancer is the most common type of cancer among females, both in incidence and 
death. As meaningful biological understanding of the disease is confounded by the 
existence of various molecular groups and sub-groups, the challenge for targeted drug 
development may lie in understanding the molecular mechanisms of various sub-groups 
in breast cancer.  
 
An in-house breast cancer gene expression dataset comprising 17 normal and 104 tumour 
samples was analysed to identify important genes and pathways relevant to various 
clinical parameters. Our results identified groups of patients with similar expression 
profiles, the possible biology driving them and the clinical implications. Comparing 
Normal and Cancer specimens‟ gene expression profiles, TP53, along with cell cycle 
genes, were up-regulated in cancer samples. Embryonic stem cell pathway genes were 
up-regulated, while fatty acid biosynthesis pathways were down-regulated in tumors vs 
normal.  
 
The cancer specimens largely clustered with respect to ER status. Meta-analysis was 
performed on in-house datasets along with five public datasets to identify ER pathway 
genes. The analysis identified novel genes which had not been previously associated with 
ER-related pathways in cancer. Nuclear receptor pathways were up-regulated in ER-
positive tumors/cell lines. Mining for ESR1-correlated genes across 5897 specimens 
identified FOXA1, SPDEF, C1ORF34 and GATA3 expression to be highly correlated.  
 
Three sub-clusters were identified among the ER-negative cluster. One represented 
ERBB2 over-expressing cluster. Additionally two unique groups of patients, with 
significant differences in survival, previously un-identified by other studies, were 
identified among the ER-negative cluster; a good prognosis cluster with high expression 
of Immune response genes; and a bad prognosis cluster with high expression of 
Ropporin, over-expression of which was also linked to high incidence of relapse in our 
study. siRNA knockdown of Ropporin (ROPN1 and ROPN1B) in the M14 melanoma 
cell line impaired cancer cell motility and invasion. Knockdown of ROPN1B in MDA-
MB-435s reduced motility. In the first study of its kind our results validated the role of 
Ropporin in cancer cell motility and invasion. 
 
A list of 162 relapse-associated prognostically-important genes was used to develop a 
Neural Network back propagation model to predict the clinical outcomes. The model was 
successful in predicting relapse with 97.8% accuracy and outperformed existing models, 
indicating a strong possibility of its use as diagnostic model.  
 8 
 
 
 
 
 
 
 
1.0 Introduction 
 
 
 
 
 
 
 
 
 
 
 9 
1.1 Breast cancer 
In Ireland an average of 2368 new cases of malignant breast cancer are diagnosed in 
females and 21 in males each year. In females, breast cancer is the most frequent cancer 
after skin cancer. Females are estimated to have a 1-in-13 chance of developing cancer of 
the breast by the age of 74 and 969 deaths among females and 6 deaths among males are 
attributed to breast cancer each year, on average. For every five incidences of the disease, 
two deaths occur, and it is the most frequent cause of cancer-related deaths among 
females (The National Cancer Registry Ireland; http://www.ncri.ie).  
1.2 Sub-types in Breast cancer 
Breast cancer is considered a highly heterogeneous group of cancers arising from 
different cell types and each having its own clinical implications. Currently, all breast 
cancers are tested for expression of Estrogen Receptor (ER), Progesterone Receptor (PR) 
and HER2/neu proteins. ER and PR tests are usually done by immunohistochemistry 
whereas HER2/neu is accessed by FISH. This protein profiling of tumors helps to predict 
the eventual prognosis and can assist in the determination of the most appropriate 
treatment for the individual.  
1.2.1 Estrogen receptor (ER) 
 The ER is a member of the nuclear hormone family of intracellular receptors which is 
activated by the hormone 17β-estradiol (Dahlman-Wright et al., 2006). The main 
function of ER is as a DNA-binding transcription factor which regulates gene expression 
(Levin 2005). 
There are two different forms of ER, referred as α and β, each encoded by a separate 
gene. The α isoform is encoded by the ESR1 and the β isoform is encoded by the ESR2 
gene (Cowley et al., 1997). Hormone-activated ERs form dimers (Pace et al., 1997). 
These two forms of ERs are co-expressed in various cell types including thyroid, bone, 
adrenals and female rat brain (Greco et al., 2003; Arts et al., 1997; Couse et al., 1997; 
Kuiper et al., 1997). This may lead to the formation of homodimer ERα (αα) or ERβ (ββ) 
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or heterodimer ERαβ (αβ) (Li et al.,2004; Cowley et al.,1997). There is significant 
overall sequence homology among the two isoforms (Hall, Couse and Korach 2001). 
ESR1 is encoded on chromosome 6 (6q25.1) and ESR2 is encoded on chromosome 14 
(14q) (Menasce et al., 1993; Sluyser et al.,1988). Both ERs are widely expressed in 
different tissue types, however, there are some differences in their expression patterns 
(Couse et al.,1997). ERα is expressed in endometrial, breast cancer cells, ovarian stroma 
cells and in the hypothalamus. ERβ is expressed in kidney, brain, bone, heart, lungs, 
intestinal mucosa, prostate, and endothelial cells. The ERα proteins are regarded as being 
cytoplasmic receptors in their unliganded state, but visualization research has shown that 
a fraction of the ERα resides in the nucleus of ER-negative breast cancer epithelial cells 
(Htun et al., 1999). The ER's helix 12 domain plays an important role in determining 
interactions with co-activators and co-repressors and thereby affecting the respective 
agonist or antagonist effect of the ligand (Ascenzi, Bocedi and Marino 2006, Bourguet, 
Germain and Gronemeyer 2000).  
ERs are over-expressed in around 70% of breast cancer cases, and are referred to as "ER-
positive" tumors. Binding of estrogen to ER stimulates proliferation of mammary cells, 
with the resulting increase in cell division and DNA replication and increases mutation 
rate. This causes disruption of the cell cycle, apoptosis and DNA repair processes 
eventually leading to tumour formation. Additionally, estrogen metabolism leads to the 
production of genotoxic by-products that could directly damage DNA, resulting in point 
mutations (Deroo and Korach 2006). ERα expression is associated with more 
differentiated tumors, while evidence that ERβ is involved is controversial (Herynk and 
Fuqua 2004). However, recent research suggests that ERβ is associated with proliferation 
and a poor prognosis (Rosa et al., 2008). Different versions of the ESR1 gene have been 
identified (with single-nucleotide polymorphisms) and are associated with different risks 
of developing breast cancer (Deroo and Korach 2006). 
Patients with high levels of ER are treated with endocrine therapy (Normanno et al., 
2005). Endocrine therapy for breast cancer involves Selective ER Modulators (SERMS) 
which act as ER antagonists in breast tissue or aromatase inhibitors which work by 
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inhibiting the action of the enzyme aromatase which converts androgens into estrogens 
(Osborne 1999, Tamoxifen for early breast cancer: an overview of the randomised trials. 
Early Breast Cancer Trialists' Collaborative Group 1998). ER status is used to determine 
sensitivity of breast cancer lesions to tamoxifen and aromatase inhibitors (Fabian and 
Kimler 2005). Raloxifene, which has anti-estrogenic behaviour has been used as a 
preventative chemotherapy for women judged to have a high risk of developing breast 
cancer (Oseni et al., 2008). 
1.2.2 Progesterone Receptor (PR) 
The progesterone receptor (PR) also known as NR3C3 (nuclear receptor subfamily 3, 
group C, member 3), is an intracellular steroid receptor that binds progesterone. PR is 
encoded by the PGR gene which lies on chromosome 11 (11q22) (Law et al.,1987). This 
gene has two main forms, A and B that differ in their molecular weight (A: 94kDa and B: 
114kDa) (Horwitz and Alexander 1983). These two isoforms are transcribed from 
distinct, estrogen-inducible promoters within a single-copy PR gene; the only difference 
between them is that the first 164 amino acids of B are absent in A (Giangrande and 
McDonnell 1999).  
PR is expressed in reproductive tissue and has important roles in folliculogenesis, 
ovulation, implantation and pregnancy (Gadkar-Sable et al., 2005). Estrogen is necessary 
to induce the progesterone receptors (PRs) activity (Horwitz, Koseki and McGuire 1978). 
PRs become hyperphosphorylated upon binding of the steroid ligand. PR phosphorylation 
is complex, occurring in different cellular compartments and perhaps requiring multiple 
serine kinases (Takimoto and Horwitz, 1993). After progesterone binds to the receptor, 
restructuring with dimerization follows and the complex enters the nucleus and binds to 
DNA. There, transcription takes place, resulting in formation of messenger RNA that is 
translated by ribosomes to produce specific proteins (Edwards et al., 1995, Li and 
O'Malley 2003). 
About 65% of ER-positive breast cancers are also PR-positive and about 5% of breast 
cancers are ER-negative and PR-positive. If cells have receptors for both hormones or 
receptors for one of the two hormones, the cancer is considered hormone-receptor-
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positive. Co-regulators of PR either enhance or suppress transcription activity and 
thereby modulate the function of the PR. Chromatin high-mobility group protein 1, 
chromatin high-mobility group protein 2, TIP60 (Tat-interacting protein), proline-rich 
nuclear receptor coregulatory protein 1, proline-rich nuclear receptor coregulatory protein 
2, Cdc25B, and GT198 enhance PR transcription activity as demonstrated by transient 
transfection assays (Ko et al.,  2002; Ma et al., 2001; Zhou et al., 2000; Brady et al., 
1999; Verrijdt et al., 2002). Nuclear receptor corepressor, BRCA1 and Ubiquitin-
activating enzyme 3 suppress PR transcription activity (Fan et al., 2002; Gao and Nawaz 
2002). A mutation or change in expression of the co-regulators affects the normal 
function of the PR and may disrupt the normal development of the mammary gland, 
thereby leading to breast cancer (Gao and Nawaz 2002). 
1.2.3 HER2/neu 
HER2/neu (also known as ErbB-2, ERBB2) stands for "Human Epidermal growth factor 
Receptor 2" and is a protein giving higher aggressiveness in breast cancers (Quenel et al., 
1995). It is a member of the ErbB protein family, more commonly known as the 
epidermal growth factor receptor family. HER2/neu belongs to a family of four 
transmembrane receptor tyrosine kinases involved in signal transduction pathways that 
regulate cell growth and proliferation (Zhou and Hung 2003). 
HER2/neu is notable for its role in the pathogenesis of breast cancer and as a target of 
treatment. It is a cell membrane surface-bound receptor tyrosine kinase and is normally 
involved in the signal transduction pathways leading to cell growth and differentiation. 
HER2 is thought to be an orphan receptor, with none of the EGF family of ligands able to 
activate it. However, ErbB receptors dimerise on ligand binding, and HER2 is the 
preferential dimerisation partner of other members of the ErbB family (Olayioye 2001). 
The HER2 gene is a proto-oncogene located at the long arm of chromosome 17 (17q11.2-
q12). 
Approximately 30% of breast and ovarian cancers have an amplification of the HER2/neu 
gene or over-expression of its protein product (Zhou and Hung 2003). Over-expression of 
this receptor in breast cancer is associated with increased disease recurrence and worse 
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prognosis. The poor prognosis may be due to global genomic instability as cells with high 
frequencies of chromosomal alterations have been associated with increased cellular 
proliferation and aggressive behaviour (Ellsworth et al., 2008).  
HER2 is co-localized, and thus most of the time co-amplified, with another proto-
oncogene GRB7 (Vinatzer et al., 2005). Clinically, HER2/neu is important as the target 
of the monoclonal antibody trastuzumab (marketed as Herceptin). Trastuzumab is only 
effective in breast cancer where the HER2/neu receptor is over-expressed. One of the 
mechanisms of how traztuzumab works after it binds to HER2 is by increasing p27, a 
protein that halts cell proliferation (Le, Pruefer and Bast 2005). 
1.2.4 Triple Negative (TN) and basal type of breast cancer 
Breast cancer is termed triple negative (TN) when there is absence of ER, PR and HER2 
receptor proteins. This type of cancer accounts for nearly 20% of all breast cancers (Rhee 
et al., 2008). TN is a heterogeneous group of breast cancer and is commonly associated 
with the worst prognosis (Stockmans et al., 2008). TN breast cancer is associated with 
younger age and more aggressive tumour type. TN breast cancers are generally negative 
for bcl-2 expression but positive for the epidermal growth factor receptor and have a high 
level of p53 and Ki67 expression (Rhee et al., 2008).  
The basal subtype of breast cancer is accompanied by the expression of cytokeratin and 
P-cadherin markers (Paredes et al., 2007). Basal-like carcinomas typically express one or 
more of the basal cytokeratins such as CK5 and CK5/6. CK5 is more sensitive in 
identifying basal-like tumors than CK5/6 (Bhargava et al., 2008, Bryan, Schnitt and 
Collins 2006). The majority of TN breast cancers display a "basal-like" molecular profile 
on gene expression arrays (Anders and Carey 2008). The majority of BRCA1-associated 
breast cancers are TN and basal-like (Anders and Carey 2008). 
1.3 Prognostic markers in breast cancer 
1.3.1 Grade 
The histological grade of a tumour is determined by a pathologist under a microscope. A 
well-differentiated (low grade) tumour resembles normal tissue. A poorly differentiated 
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(high grade) tumour is composed of disorganized cells and, therefore, does not look like 
normal tissue. Moderately differentiated (intermediate grade) tumors are somewhere in 
between. 
The Bloom-Richardson grade (BR grade) (BLOOM and RICHARDSON 1957) is a 
histological grade assigned by pathologists to breast cancers. It is the most common type 
of cancer grade system currently used. It is a semi-quantitative grading method based on 
three morphologic features of invasive breast cancers. The morphologic features that are 
used are: 
 1) Degree of tumour tubule formation i.e. percentage of cancer composed of tubular 
structures 
 2) Tumour mitotic activity or rate of cell division. 
 3) Nuclear polymorphism of tumour cells, nuclear grade, change in cell size and 
uniformity. 
Each of these features is assigned a score ranging from 1 to 3. The scores are then added 
together for a final sum that will be in the range of 3 to 9. This value is then used to grade 
the tumour as follows: 
Value: 3-5 Grade 1 tumors (well-differentiated): Tumors with Grade 1 are associated 
with a good prognosis. 
Value: 6-7 Grade 2 tumors (moderately-differentiated): Tumors with Grade 2 are 
associated with an intermediate prognosis. 
Value: 8-9 Grade 3 tumors (poorly-differentiated): Tumors with Grade 3 are associated 
with a bad prognosis. 
1.3.2 Lymph node metastasis 
Lymph node metastasis is considered an important prognostic parameter in treating breast 
cancer patients. The sentinel node is the first lymph node reached by metastasising cells 
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from a primary tumour. A sentinel node biopsy is a minimally invasive technique to 
identify lymph node metastases (Tanis et al., 2001). Involvement of a lymph node in 
breast cancer significantly correlates with worse prognosis compared with no lymph node 
involvement (Colleoni et al., 2005). Such patients have a higher incidence of death due to 
disease (Jatoi et al., 1999) and should therefore be treated more aggressively. 
1.4 Invasion and Metastasis  
One of the most lethal aspects of breast tumors is their ability to invade the surrounding 
normal mammary tissue and re-locate to other sites in the body distal to the primary 
tumour, whereby tumour growth begins anew (metastasis). While the process by which 
cancer cells lose adherence to the primary tumour and develop migratory and invasive 
capacities has been well-described at the cellular level, the progression of invasion is still 
poorly understood at the molecular level. Cancer cells from a primary tumour enter 
lymphatic and blood vessels, circulate through the bloodstream, and settle down to grow 
within normal tissues elsewhere in the body. Most tumors, if left un-treated can 
metastasize to other parts of body.  
However, there are cancers with very low metastatic potential such as glioma and basal 
cell carcinoma. When tumour cells metastasize, the new tumour is known as a secondary 
or metastatic tumour, and often displays properties of the original (primary) tumour. 
Metastasis can occur long after the apparent elimination of the primary tumour. In breast 
cancer, metastases have been known to occur decades after the primary treatment 
(Karrison, Ferguson and Meier 1999). Cancer cells can exist in three separate states in a 
secondary site, solitary cells in quiescence, active pre-angiogenic micrometastases, in 
which proliferation is balanced with apoptosis and no net increase in tumour size occurs, 
and vascularised metastases, either small and clinically undetectable, or large and 
detectable by current technology (Demicheli 2001).  
Metastatic tumors are very common in the late stages of cancer. The spread of cancer 
cells may occur via the blood or the lymphatic system or through both routes. There is 
also a propensity for certain tumors to metastasize to particular organs (Chambers, 
Groom and MacDonald 2002). Successful formation of metastases requires angiogenesis 
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at the primary tumour, down regulation of cohesive molecules, increased motility of 
tumour cells, invasion into neo-vessels, tumour cell embolism, arrest and attachment in 
capillary beds of distant organs, extravasations and proliferation in the organ parenchyma 
and re-establishment of angiogenesis when the tumour reaches > 1-2 mm in size (Li et 
al., 2000). 
 
 
 
 
 
 
 
Fig 1.4: The metastatic sequence (Geho et al., 2005) 
 1.4.1 Microenvironment of Breast Cancer 
In vivo, every cell functions within its microenvironment. The mammary duct consists of 
epithelial cells surrounded by stroma, including fibroblast cells and other support 
components. A thin layer of extracellular matrix (ECM) lies between epithelial cells and 
stroma (Woodward, Xie and Haslam 1998). The proliferation and phenotype of breast 
epithelial cells are the results of the epithelial-epithelial cell, epithelial-stromal cell and 
epithelial cell-ECM interactions (Haslam and Woodward 2003). Carcinogenesis of the 
breast cells causes both transformation of cells and changes to their microenvironment. 
Four kinds of cell connections are known to be important in maintaining the epithelial 
layer: tight junctions, adherens junctions, desmosomes and gap junctions (Ehmann et al., 
1998). 
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Fig 1.4.1: Model of epithelial-cell–stromal-cell interactions. ECM, extracellular 
matrix; ER, estrogen receptor; PR, progesterone receptor (Haslam and Woodward 
2003). 
The function of these structures is to restrict both free cell movement and infinite 
proliferation. Gap junctions also act as the pathways for cell-cell communication, helping 
the biological signals of a cell, such as cytokines or the products of tumour suppressor 
genes, to pass into the neighbouring cells. Thus, one prerequisite of cell transformation is 
the breakdown of physical connections between cells, which means the loss of cell 
proliferation restriction. Epithelial cells are also found to form physical junctions with the 
ECM and the stroma. In fact, during metastasis, migrating cells alternatively attach to and 
detach from ECM and stroma to move forward (Price, Bonovich and Kohn 1997). 
However, ECM has been shown to serve as a natural physical obstacle of metastasis. 
Some studies have demonstrated that Matrigel, on ECM extract from tumors, promotes 
the formation of tumors and blood vessels in mouse models (Noel and Foidart 1998).  
Fibroblasts are the main cell type in stroma and have a similar influence on epithelial 
cells. When co-injected with Matrigel and mammary tumour cells, fibroblasts accelerated 
tumour formation in a mouse model (Noel and Foidart 1998). Studies have also shown 
that fibroblasts stimulate the movement and proliferation of cancerous epithelial cells 
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when they have direct cell contact in co-culture (Korohoda and Madeja 1997, Olumi, 
Dazin and Tlsty 1998).  
The last phase of primary tumour development is progression, which usually starts with 
growth of the dormant tumour following the promotion phase. The rapid progression 
phase is triggered once the new blood vessels are formed in the primary tumour. As a 
result, the cancer cells acquire the ability to metastasize. 
1.4.2 Angiogenesis 
 With the proliferation of the primary tumour, angiogenesis, or the generation of new 
blood vessels, becomes necessary. Tumors induce blood vessel growth (angiogenesis) by 
secreting various growth factors (e.g. vascular endothelial growth factor (VEGF) and 
basic fibroblast growth factor (bFGF)) (Barinaga 1997). Growth factors such as bFGF 
and VEGF can induce capillary growth into the tumour, which some researchers suspect 
supply required nutrients, allowing for tumour expansion (Hanahan and Folkman 1996; 
Sato et al., 2000; Ferrara 2001). Angiogenesis also increases the possibility of the tumour 
cells to enter into the circulation. Thus, angiogenesis promotes tumour cell invasion. 
1.4.3 Invasion 
 To access the circulation, tumour cells must cross the ECM. This active process is called 
invasion. Invasion is a process that includes proteolysis of the ECM, pseudopodial 
extension and cell migration (Palecek et al., 1997; Wolf et al., 2007b). It usually happens 
when the tumour size is relatively large. On the other hand, ECM and interstitial stroma 
act integrally as the barriers that must be overcome for invasion (Price, Bonovich and 
Kohn 1997, Nicolson 1988; Woodhouse, Chuaqui and Liotta 1997). For example, matrix 
metalloproteinases (MMPs) are over-expressed by most kinds of metastatic cells and are 
essential for degradation of the ECM (Price, Bonovich and Kohn 1997; Sengupta and 
MacDonald 2007). 
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1.4.4 Transport 
Cancer cells can enter into the circulatory system indirectly via the lymphatic system and 
are thus transported to distant tissues (Chambers, Groom and MacDonald 2002). Once 
tumour cells enter the blood circulation, they are exposed to shear stress and  interactions 
with leukocytes which could lead to their destruction. Cancer cells are capable of 
resisting leucocyte mediated distruction by forming a thrombus, adhering to the 
endothelia of ductal structures and thereby protecting themselves from the immune 
system (Bacac and Stamenkovic 2008). Considering the ability of cancer cells to 
proliferate infinitely, formation of secondary tumour growth is not a rare event once 
tumour cells have entered the circulation (Price, Bonovich and Kohn 1997). 
1.4.5 Arrest 
During this step, circulating cancer cells embed into the vascular endothelia forming a 
secondary site for tumour growth. Several factors contribute to this stage; mechanical 
trapping of tumour cells at a secondary site by small capillary beds; clusters of cancer 
cells are blocked at very narrow blood vessels; tumour cell adhesion at a secondary site 
by the expression of appropriate cell surface proteins; cancer cells are recognized and 
bound by receptors on the endothelial duct (Price, Bonovich and Kohn 1997; Nicolson 
1988; Horak and Steeg 2005). 
1.4.6 Extravasation 
Extravasation can be taken as the reverse process of invasion, during which the arrested 
cells enter into the secondary sites and are followed by formation of a new tumour (Price, 
Bonovich and Kohn 1997; Nicolson 1988). Taken together, metastasis is a multi-variable 
process and demonstrates diverse behaviour in different kinds of cancer (Price, Bonovich 
and Kohn 1997; Nicolson 1988). The malignant cell‟s metastatic properties are 
influenced by expression of many genes related to degradative enzymes or their 
inhibitors, cell adhesion components, growth factor receptors, programmed cell death or 
apoptosis, cell-cell communication components, cell motility components and host 
surveillance mechanisms (Price, Bonovich and Kohn 1997; Demicheli et al., 1997; Ben-
Baruch 2008). 
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1.4.7 Breast cancer metastasis-associated genes 
A number of genes have been investigated for changes in expression level during 
progression of breast cancer. An ability to circumvent the defences of the 
microenvironment is critical for progression of mammary tumors to malignancy. This 
process was first investigated by transferring a dominant oncogene into susceptible cells 
and then following progression of malignancy in animal models, such as mouse. Later, it 
was confirmed that the slow, stepwise changes in mammary cancer progression are not 
only qualitative, but can be quantified. Some of these changes can be reversible and do 
not involve dominantly acting oncogenes and tumour suppressor genes (Nicolson 1998). 
Thus, there is still no common cascade of changes to gene expression levels found in 
breast cancer, like that of colon cancer. In addition, oncogenes and tumour suppressor 
genes, genes regulating cell cycle, growth factors and their receptors and intercellular 
communication have become targets of research to better understand the progression of 
breast cancer. A brief description of some of the better known target genes will be 
outlined here.  
ER and PR and their ligands play important roles in the development and function of the 
mammary gland. Normal human mammary epithelial cells express very low or no levels 
of ER and PR. But, in breast cancer patients, about two-thirds of tumour tissues are ER-
positive by immunohistochemical analysis (Allred et al., 1998; Lapidus, Nass and 
Davidson 1998). 
p53 usually functions as a tumour suppressor by regulating transcription, cell cycle, and 
apoptosis. Mutations of p53 detected in breast cancers are primarily point mutations that 
often lead to loss of function of wild type p53 and over-expression of mutant p53 in 
malignant cells (Lacroix, Toillon and Leclercq 2006; Ravaioli et al., 1998). 
The c-erbB-2 or HER2/neu, gene codes for a transmembrane tyrosine kinase and acts as a 
receptor of a group of peptide ligands that can stimulate cell growth, cellular 
differentiation, adhesion and motility. Over-expression of HER2/neu is detected in 20-
30% metastatic breast cancer (Ravaioli et al., 1998; Hyun et al., 2008). 
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The bcl-2 gene is involved in the regulation of cell death, inhibiting apoptosis, and is 
found over expressed in breast cancer. Bcl-2 has been retrospectively considered as a 
potential prognostic factor of breast cancer (Callagy et al., 2006). 
Cyclins are a group of proteins that regulate cell cycle and deregulation of cell cycle 
control is one of the most evident alterations in cancer cell growth. Aberrations in 
sequence and expression of cyclins Bl, Dl, E, etc., are often detected in breast cancer 
(Ravaioli et al., 1998). 
Kai-1 is one of the few metastasis-suppressor genes discovered and was first mapped out 
in prostate cancer (Dong et al., 1995). Later, it was shown that transfection of the Kai-1 
gene into breast cancer cells suppresses their metastatic ability and may be a useful 
marker for staging human breast diseases (Phillips et al., 1998). 
MTAL, a novel gene identified in 1998, is associated with mammary tumour metastasis 
and may also be involved in human breast cell motility and growth regulation. Antisense 
blocking experiments showed that MTAL may stimulate the highly malignant breast 
cancer cells to move into and grow in distant sites such as bone and brain, which are 
common sites for breast cancer metastasis (Nicolson 1998). 
1.5 Gene expression profiling 
Expression microarray profiling is a high throughput technology used in molecular 
biology and biotechnology to simultaneously access the gene expression profile of 
thousands of genes. A typical microarray chip consists of an arrayed series of thousands 
of microscopic spots of DNA oligonucleotides, each containing a small amount of a 
specific DNA sequence. This can be a short section of a gene or other DNA element that 
are used as probes to hybridize a cDNA or cRNA sample under appropriate conditions. 
The hybridization is detected and quantified by fluorescence-based detection of 
fluorophore-labeled targets to determine relative abundance of nucleic acid sequences in 
the sample. 
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In standard microarrays, the probes are attached to a solid surface made of glass or silicon 
by a covalent bond to a chemical matrix via epoxy-silane, amino-silane, lysine and 
polyacrylamide (Derisi 2001). Affymetrix technology uses a photolithographic 
technology to synthesize 25-mer oligonucleotides on a silica wafer 
(http://www.affymetrix.com). Other microarray platforms, such as Illumina, use 
microscopic beads, instead of the large solid support (http://www.illumina.com/).  
1.5.1 Affymetrix microarrays 
The microarray experiments carried out in our study employed the Affymetrix GeneChip 
system. Affymetrix probes are designed using publicly available information. The 
sequences, from which the probe sets were derived, were selected from GenBank, 
dbEST, and RefSeq. The sequence clusters were created from the UniGene database 
(Build 133, April 20, 2001) and then refined by analysis and comparison with a number 
of other publicly available databases, including the Washington University EST trace 
repository and the University of California, Santa Cruz Golden-Path human genome 
database (April 2001 release). Sequences from these databases were collected and 
clustered into groups of similar sequences.  
The probes are manufactured on the chip using photolithography (a process of using light 
to control the manufacture of multiple layers of material), which is adapted from the 
computer chip industry. Each GeneChip contains approximately 1,000,000 features. Each 
probe is spotted as a pair, one being a perfect match (PM), and the other with a mismatch 
(MM) at the centre. These probe pairs allow the quantitation and subtraction of signals 
caused by non-specific cross-hybridisation. The differences in hybridisation signals 
between the partners, as well as their intensity ratios, serve as indicators of specific target 
abundance. Each gene or transcript is represented on the GeneChip by 11 probe pairs. 
The probe sets are given different suffixes to describe their uniqueness and/ or their 
ability to bind different genes or splice variants. 
 “_at” describes probes set that are unique to one gene 
 “_a_at” describes probe sets that recognise multiple transcripts from the same 
gene 
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 “_s_at” describes probe sets with common probes among multiple transcripts 
from separate genes. The _s_at probe sets can represent shorter forms of 
alternatively polyadenylated transcripts, common regions in the 3‟ ends of 
multiple alternative splice forms, or highly similar transcripts. Approximately 
90% of the _s_at probe sets represent splice variants. Some transcripts will also be 
represented by unique _at probe sets. 
 “_x_at” designates probe sets where it was not possible to select either a unique 
probe set or a probe set with identical probes among multiple transcripts. Rules 
for cross-hybridisation are dropped in order to design the _x_at probe sets. These 
probe sets share some probes identically with two or more sequences and 
therefore, these probe sets may cross-hybridise in an unpredictable manner. 
A sample must be registered and an experiment defined in GCOS (GeneChip Operating 
Software) before processing a probe array in the fluidics station or scanning. Once the 
array is scanned, an image file is created called a “.dat” file. The software then computes 
cell intensity data (“.cel” file) from the image file. It contains a single intensity value for 
each probe cell delineated by the grid (calculated by the Cell Analysis algorithm). The 
amount of light emitted at 570nm from stained chip is proportional to the amount of 
labelled RNA bound to each probe. Each spot correspond to individual probe (either 
perfect match or mismatch). The probes for each gene are distributed randomly across the 
chip to nullify any region specific bias. Following this, data analysis algorithms combine 
the probes to the respective intensity of individual transcripts (see section 1.6).   
1.5.2 Microarrays and Breast cancer 
Microarray analyses of clinical breast cancer specimens and cell lines have identified 
gene expression profiles which separated the tumors into various groups and sub-groups. 
These sub-groups have been associated with different clinical outcomes. The various sub-
groups that have been defined using a microarray approach are Luminal A, Luminal B, 
ERBB2 over-expressing, Basal sub-type and Normal-like (Sorlie et al., 2001). The 
Luminal sub-type A identified has a higher ESR1 and ER partner gene over-expression 
than Luminal sub-type B. Luminal sub-type A is considered to have a better prognosis 
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and response to Endocrine therapy than Luminal sub-type B. The ERBB2 and Basal sub-
groups of patients display a more aggressive form of cancer. The ERBB2 group of 
patients respond well to Herceptin. Additionally, an Apocrine (Androgen receptor 
positive) group has been defined based on microarray studies (Farmer et al., 2005). 
Apocrine sub-type is defined as Androgen receptor-positive and negative for Estrogen, 
Progesterone and HER2 protein. Apocrine sub-type of breast cancer is regulated by 
androgen. 
It was previously thought that a few cells from a tumour attain metastatic potential and 
move to different parts of body, where they develop as secondary tumors (Fidler and 
Kripke 1977; Poste and Fidler 1980). With the advent of microarray-based studies, this 
hypothesis has changed and it is now believed that metastasis potential is the property of 
the whole tumour rather than a sub-set of cells as previously thought (Ma et al., 2003; 
Weigelt et al.,  2003). These findings resulted in studies aimed at identifying genes which 
may be involved in metastasis, relapse and shorter survival. These genes have been used 
to develop prognostic models to predict long term relapse (van 't Veer et al.,  2002; 
Huang et al.,  2003; Karlsson et al.,  2008). Following successful attempts to identify the 
prognostic important genes and develop prediction models, microarrays have evolved 
into diagnostic assays. Studies based on gene expression were  later translated to 
diagnostic assays has been approved by the US Food and Drug Administration (FDA; 
http://www.fda.gov/) for routine use on breast cancer patients (see section 1.5.3). Apart 
from predicting clinical outcomes, these kits can also indicate theraputic options for 
patients. 
1.5.3 Gene expression in diagnostics 
1.5.3.1 OncotypeDx 
OncotypeDx, developed by Genomic Health (http://www.genomichealth.com), is a 
diagnostic kit that aims to quantify the likelihood of disease recurrence in women with 
early-stage breast cancer (Paik et al.,  2004) and also assesses the likely benefit from 
certain types of chemotherapy (Paik et al.,  2006). The OncotypeDx diagnostic assay is 
suitable for women with early-stage invasive breast cancer, who are ER-positive and 
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lymph node-negative. Typically in these cases, treatment with hormonal therapy, such as 
tamoxifen, is indicated. OncotypeDx is not suitable for patients with carcinoma in-situ or 
metastatic breast cancer. 
250 candidate genes possibly associated with breast cancer tumour behaviour were 
identified from published literature, genomic databases and microarray experiments. 
These genes were analyzed in 447 patients from three independent clinical studies in 
order to identify a panel of 21 genes strongly correlated with distant recurrence-free 
survival (Paik et al., 2004).  
Group Genes 
Proliferation Ki67, STK15, Survivin, CCNB1, MYBL2 
Invasion MMP11, CTSL2 
HER2 GRB7, HER2 
Estrogen ER, PGR, BCL2, SCUBE2 
Others GSTM1, CD68, BAG1 
Controls ACTB, GAPDH, RPLPO, GUS, TFRC 
Table 1.5.3.1: List of genes on the OncotypeDx assay 
OncotypeDx analyzes expression of these 21 genes from tumour mRNA to determine a 
prognostic recurrence score. The recurrence score is a number between 0 and 100 and 
corresponds to a likelihood of breast cancer recurrence within 10 years of the initial 
diagnosis (Paik et al., 2004). The result was later validated on a very large study of 4,964 
node-negative breast cancer patients (Habel et al., 2006). If sucessful in onward trials, 
this information would help doctors choose the right combination and medicinal dose for 
individual patients. Despite being an expensive test, it could result in considerable cost 
saving considering the fact that chemotherapy can cost thousands of euros per year, per 
patient (Hornberger, Cosler and Lyman 2005). 
OncotypeDx is a non-invasive test that is performed on a small amount of the tissue 
removed during the original lumpectomy, mastectomy, or core biopsy. The tissue sample 
is fixed in formalin and embedded in paraffin so it can be preserved and send to Genomic 
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Health for further diagnostic testing where the RNA is isolated from sectioned tissue 
blocks
 
using the MasterPure Purification kit (Epicenter, Madison, WI) and subsequently 
the assay is performed.  
1.5.3.2 MammaPrint 
MammaPrint is a microarray-based molecular diagnostic test that is used to assess the 
risk that a breast tumour will metastasize to other parts of the body. MammaPrint is 
marketed by Agendia (http://agendia.com) and assesses the risk factor for distant 
metastasis within five to 10 years (Glas et al., 2006). The test is suitable for lymph node-
negative breast cancer patients under 61 years of age with tumors of less than 5cm in 
diameter.  
MammaPrint uses a 70 gene signature, obtained by microarray studies to classify patients 
as low or high risk for recurrence of the disease. The 70 gene signature was previously 
identified by analysing microarray data from 34 patients who developed distant 
metastasis within five years and 44 patients who remained disease free for at least five 
years (van 't Veer et al.,  2002). The results were later validated in independent studies 
(van de Vijver et al.,  2002; Buyse et al.,  2006).  
MammaPrint estimates the expression of 70 identified genes in the tumour sample and 
compares the gene expression profile to reference expression profiles of „Low Risk‟ or 
„High Risk‟ profiles. The risk of tumour recurrence is then determined according to the 
degree of similarity between the tumour gene expression profile and reference profiles 
(van de Vijver et al., 2002). 
A low risk patient has a 95% chance of being metastasis-free within the following five 
years and 90% chance of being metastasis-free within the following 10 years, whereas a 
high risk patient has a 78% chance of being metastasis-free within the following five 
years and 71% chance of being metastasis-free within the following 10 years (van de 
Vijver et al., 2002).  
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1.6 Microarray Data Analysis 
1.6.1 Normalization  
Normalization is the first step in the data analysis process. Normalization is the adjusting 
of microarray data to remove variations that arise from the technology rather than from 
biological differences between the RNA samples. Some of the common normalization 
algorithms for Affymetrix arrays are MAS5 (Pepper et al., 2007), RMA (Irizarry et al., 
2003) and dChip (Li and Hung Wong 2001). 
MAS5 developed by Affymetrix uses a reference (baseline) chip which is used to 
normalise all the experimental chips. The procedure is to adjust the intensity of each  
probes against the corresponding probes on the baseline chip; eliminate the highest 1% of 
probes (and for symmetry the lowest 1%), and fit a regression line to the middle 98% of 
probes.  
dChip uses an array with median overall intensity as the baseline array against which 
other arrays are normalised at probe level intensity. Subsequently a subset of PM 
(“perfect match”) probes, with small within-subset rank difference in the two arrays (also 
known as invariant set), serves as the basis for fitting a normalisation curve.  
RMA employs normalization at probe level using the quantile method. This 
normalization method makes the chips have identical intensity distribution 
1.6.2 Clustering  
Clustering is the grouping of objects based on similarity. In other words it is the 
partitioning of a data set into subsets, so that the data in each subset share some common 
trait. The measure for a common trait is defined before the clustering is performed and is 
often a distance metric defining the relative similarity among the two objects. Data 
clustering is a common technique for statistical data analysis, and has applications to 
many fields, including machine learning, data mining, pattern recognition, image analysis 
and bioinformatics.  
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Clustering gene expression data helps in identifying genes of similar function. These co-
expressed genes with poorly characterized or novel genes may provide a simple means of 
gaining insight to the functions of many genes for which information is not available 
currently (Eisen et al.,  1998). Co-regulated families of genes cluster together, as was 
demonstrated by the clustering of ribosomal genes as a group (Alon et al., 1999). 
Clustering is also used to identify the grouping patterns of specimens and has been 
widely used in studying the heterogeneity of cancer. Clinical breast cancers cluster as 
distinct groups based on their gene expression profiles and can be correlated with clinical 
outcomes (Sorlie et al., 2001).  
Primarily, most clustering techniques use a distance metric to define the similarity or 
difference among the two objects. Some of the most common distance metrics used are 
Euclidean distance, Manhattan distance and Correlation distance. Euclidean distance is 
the distance between two points that would be measured with a simple ruler, and can be 
also calculated by repeated application of the Pythagorean Theorem. Thus the distance 
measure would be: 
Distance = √ (∑ (Xi –Yi)
 2
) 
X and Y are expression vectors of genes or samples.
 
Manhattan distance is the distance between two points expressed as the sum of the 
absolute differences of their coordinates. Therefore the distance between point P1 with 
coordinates (x1, y1) and the point P2 at (x2, y2) would be |x1 - x2| + |y1 - y2|. 
Correlation distance measures the similarity between two points expressed as the 
correlation between the two objects. Often the Pearson correlation measure is taken as 
distance measure for most of the microarray data clustering. Correlation measure value 
range from -1 to +1. Positive values indicate a positive correlation (i.e. increase in value 
of one corresponds to increase in the value of the other). Negative values indicate a 
negative correlation (i.e. increase in value of one corresponds to decrease in value of the 
other and vice versa). A correlation value of 0 indicates no relation between the two 
values.  
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1.6.2.1 Hierarchical clustering 
Hierarchical clustering is a technique to generate a hierarchy among objects based on 
their similarity or differences. The similarity or difference is measured based on the 
distance criteria explained above. Hierarchical clustering may be constructed using an 
agglomerative or divisive approach. The representation of this hierarchy is a tree also 
known as dendrogram, with individual elements at one end and a single cluster 
containing every element at the other (Fig 1.6.2.1.1). Agglomerative algorithms begin at 
the leaves of the tree, whereas divisive algorithms begin at the root. Agglomerative 
clustering can be single linkage clustering, complete linkage clustering or average linkage 
clustering. 
 
Fig 1.6.2.1.1: An example of a tree or dendrogram. The leaves are shown in red and 
the nodes are shown in blue. A leaf reflects the entity and a node reflects the 
relationship between two entities, one entity and one node or among two nodes. 
Single linkage clustering: The distance between groups is defined as the distance between 
the closest pair of objects, and only pairs consisting of one object from each group are 
considered (Fig 1.6.2.1.2). 
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Fig 1.6.2.1.2: Single linkage clustering. The closest element in the cluster is used to 
calculate the reference distance among the two clusters. 
Complete linkage clustering: The complete linkage, also called farthest neighbour 
clustering method is the opposite of single linkage. The distance between groups is 
defined as the distance between the most distant pair of objects, one from each group (Fig 
1.6.2.1.3). 
 
Fig 1.6.2.1.3: Complete linkage clustering. The most distant element in the cluster is 
used to calculate the reference distance among the two clusters. 
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Average linkage clustering: Distance between two clusters is defined as the average of 
distances between all pairs of objects, where each pair is made up of one object from 
each group (Fig 1.6.2.1.4). 
 
Fig 1.6.2.1.4: Average linkage clustering. The average of the element in the cluster is 
used to calculate the reference distance among the two clusters. The green is the 
average or centroid of the cluster. 
Hierarchical clustering has been extensively used in cancer research to identify 
relationship among genes and samples. Hierarchical clustering using multiple markers 
can group breast cancers into various classes with clinical relevance and is superior to 
individual prognostic markers (Makretsov et al., 2004). Hierarchical clustering has been 
widely used in studying the sub-groups in breast cancer (Sorlie et al., 2001; Charafe-
Jauffret et al., 2006; Weigelt et al., 2005; Hu et al., 2006). 
1.6.2.2 K-Means clustering 
The k-means algorithm is an algorithm to cluster objects into k partitions using the 
similarity between the objects. k is the number of partitions/clusters and is provided by 
the user. The algorithm starts by partitioning the input points into k initial sets randomly 
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or by using some heuristic approaches. It then calculates the centroid (mean point), of 
each set. Thereafter, it constructs a new partition by associating each object with the 
closest centroid. The centroids are then recalculated for the new clusters, and the process 
repeated by alternate application of these two steps until convergence, which is obtained 
when the objects no longer switch clusters or the centroids no longer change. K-means is 
one of the most commonly used clustering methods and has a wide application in 
microarray studies (Do and Choi 2008). 
Limitations of k-means clustering (MacKay 2003) 
 
1) Since k-means clustering starts with random seed points, the end result will not be the 
same and will depend on the initial random vector.  
 
2) K-means clustering needs the number of clusters from the uses and forces all the 
genes/samples to fit on those defined number of clusters. 
 
3) Does not work well with non-globular clusters.  Non-globular clusters are those whose 
boundaries are not well defined. 
1.6.3 Principal component analysis 
Principal component analysis (PCA) is a method to reduce multidimensional data sets to 
lower dimensions for easier analysis and visualization. PCA is mathematically defined as 
an orthogonal linear transformation that transforms the data to a new coordinate system 
such that the greatest variance by any projection of the data comes to lie on the first 
coordinate (called the first principal component), the second greatest variance on the 
second coordinate, and so on.  
PCA can be used for dimensionality reduction in a data set by retaining those features of 
the data set that contribute most to its variance, by keeping lower-order principal 
components and ignoring higher-order ones. Lower-order components contain the most 
important essence of the data and higher-order components contain the least important 
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essence of the data. However, this may not be the case with all types of datasets. PCA is 
used in microarray experiments to identify the most significant patterns in the data.  
Raychaudhuri, Stuart and Altman (2000), working with yeast sporulation data, concluded 
that much of the observed variability in the experiment was captured by the first two 
components corresponding to overall induction level and change in induction level over 
time.  
1.7 Classification 
Class predictions are supervised learning algorithms which learn the outcomes from the 
known (“Training”) dataset, in order to accurately predict the outcomes on the new 
(“Test”) datasets. Class prediction has a wide applicability both in research and in 
diagnosis. Some of the most popular algorithms include k-nearest neighbor, Support 
Vector Machines (SVM), Linear Discriminant Analysis (LDA) classification and Neural 
Networks.  
Back-propagation is a class of neural network algorithm which can be used to accurately 
predict the outcomes based on its learning on a known dataset. Neural networks have 
been used extensively in gene-finding (Sherriff and Ott, 2001), protein structure 
prediction (Cai, Liu and Chou 2003), drug screening (Jaiswal and Naik, 2008), cancer 
class prediction and clinical outcome prediction in cancer (De Laurentiis et al.,  1999) 
and other diseases. 
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Fig 1.7.1: Generalized representation of the Multiple Layer Perceptron 
Architecture. Input layer gets the input and the information is processed in the 
network and the output is obtained on the output layer.  
Back-propagation uses the Multiple Layer Perceptron architecture to learn complex 
patterns. The Multiple Layer Perceptron is an architecture whereby the neurons are in 
layers; an input neuron layer where the network gets the input and an output neuron layer 
which gets the output. In between can be n layers of hidden neurons. The neurons in each 
layer are interconnected with all the neurons in the previous and next layer of neurons. 
These interconnections are associated with weights which helps in learning complex 
problems (Haykin 1998). The weights are numbers and contain information on the 
positive or negative regulation of any particular neuron on the closest neuron. The  
weights are adjusted in a way that the more important interconnections attain a higher 
value than the less important interconnections.  
Back propagation, which as the name suggests, is the propagation of error to the previous 
layer of network, is a very efficient method of training the artificial neural networks to 
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perform a particular task. It was first described by Paul Werbos in 1974, but it wasn't 
until 1986, through the work of David E. Rumelhart, Geoffrey E. Hinton and Ronald J. 
Williams, that it gained recognition leading to a renaissance in the field of artificial 
neural network (Rumelhart et al., 1986). 
Back propagation is a supervised learning method and implements the “delta rule”. The 
delta rule is a gradient descent learning rule for updating the weights of the artificial 
neurons in a single-layer perceptron. The algorithm requires a guided training that knows, 
or can calculate, the desired output for any given input. The difference in the expected 
and actual result is termed as error and this error is back-propagated to the network and 
weight correction measures are done in a way to minimize the error. 
1.8 Representative nature of cell line models to clinical conditions  
Cell line models are routinely studied to understand particular biological phenomena, 
with the expectation that discoveries made in these models will provide insight into 
human biology. These models are widely used to explore potential causes and treatments 
for human disease, where experimentation on humans would be unfeasible or unethical. 
Breast cancer cell lines are generated from cells isolated from breast tumour specimens 
and have the capability to divide indefinitely when grown in-vitro under stringent growth 
conditions. This potential makes these cell lines an excellent model of study for 
understanding the basic biology of breast cancer. Many studies which are not possible on 
animal models can be carried out relatively easily on these cell lines.  
There is, however, a great difference in the growth environment of the cancer cells in-
vivo to that of in-vitro. Despite the relatively large number of cancer cell lines currently 
under study in a variety of clinical settings worldwide, so far studies aiming at 
investigating the similarity of cell line models to their respective clinical conditions have 
been very limited. A previous study (Gazdar et al., 1998) found that only a small subset 
of primary breast cancers that display certain features of advanced tumour and poor 
prognosis can be cultured for a lengthy time. This group (Wistuba et al.,  1998) also 
reported that there was an excellent correlation among the cell lines to their clinical 
specimens, in terms of morphological features, presence of aneuploidy, 
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immunohistochemical expression of ER, HER2/neu, p53 proteins, allelic loss at all of the 
chromosomal regions analysed and TP53 gene mutations. A more recent study (Burdall 
et al.,  2003), concluded that most of the currently used cell lines are derived from 
metastatic sites rather than primary tumour and therefore may not be representative of the 
diverse nature of breast cancer. 
The advent of large-scale expression profiling experiments heralded by developments in 
microarray technology has facilitated a whole-genome analysis approach to this question. 
Large-scale expression profiling has made it possible to quantify the gene expression 
profiles of thousands of genes in a single experiment, thereby allowing the comparison of 
different samples on the basis of their full genomic expression profile, rather than on a 
selected number of genes. A previous study (Chang, Hilsenbeck and Fuqua 2005) 
reviewed the role of microarrays in management and treatment of breast cancer, and 
observed that a combined genomic approach should be taken to understand the 
heterogeneity of breast cancer. 
Given the novelty of microarrays, the number of studies utilizing this technology to 
investigate the similarity between the gene expression profiles of cell lines and clinical 
specimens is limited. Previously (Ross and Perou 2001), it has been found that cell lines 
and tumour specimens have distinct gene expression patterns which need to be 
considered for their appropriateness for each subtype of clinical conditions. Another 
study (Dairkee et al., 2004) compared gene expression profiles of early passage tumour 
cultures and immortal cell lines and observed that epithelial cultures isolated from 
primary breast tumors retain the characteristics of the tumour, but these characteristics 
are eliminated following in vitro selection of the rapidly proliferating cell population. In a 
similar comparative study of gene expression profiles of lung cancer cell lines and their 
respective clinical specimens (Wang et al.,  2006), it was observed that 51 of 59 cell lines 
represented their presumed tumors of origin.  
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1.9 Small interfering RNA (siRNA)  
Small interfering RNA (siRNA) is also known as short interfering RNA or silencing 
RNA and covers a class of 20-25 nucleotide-long double-stranded RNA molecules. In the 
late nineties, RNA silencing was
 
discovered in plants during the course
 
of transgenic 
experiments that eventually led to the silencing of
 
the introduced transgene and, in some 
cases, of homologous endogenous
 
genes or resident transgenes (Matzke et al., 1989; Linn 
et al., 1990; Napoli, Lemieux and Jorgensen 1990; Smith et al., 1990; van der Krol et al., 
1990). However, this approach could not be used in mammalian cells as the long double-
stranded RNAs (dsRNAs) triggered a cytotoxic reaction leading to cell death (Hunter et 
al., 1975). This cytotoxic reaction, mediated by the interferon system, protected the 
organism from RNA viruses by sacrificing the infected cell and thus preventing the 
spread of the virus (Stark et al., 1998). It was later reported that the dsRNAs shorter than 
30 nucleotides do not trigger the interferon response; therefore artificially produced 
siRNAs and their delivery into mammalian cells were able to efficiently induce RNA 
silencing (Elbashir et al., 2001).  
1.9.1 Mechanism of action of siRNA 
Long double-stranded RNA (dsRNA) (typically >200 nt) (upon introduction), enters a 
cellular pathway that is commonly referred to as the RNA interference (RNAi) pathway. 
During the initiation stage, long dsRNA is cleaved into siRNA (Hamilton et al., 2002), 
mediated by type III RNase Dicer enzyme. RNase III family members are among the few 
nucleases that show
 
specificity for dsRNAs (Hamilton et al.,  2002) and are 
evolutionarily conserved in
 
worms, flies, fungi, plants, and mammals (Aggarwal et al.,  
2006). Complete digestion, by RNase III enzyme results in dsRNA fragments
 
of 23-
 
to 
28-mer diced siRNA products (Blaszczyk et al., 2001).  
During the effector stage, the siRNAs assemble into endoribonuclease-containing 
complexes known as RNA-induced silencing complexes (RISCs). siRNAs undergo 
unwinding before being incorporated into a high-molecular-weight protein complex 
called RISC (Hammond et al.,  2000). Dicers are part of the RISC complex, which 
includes several different proteins such as the Argonaute gene family members and an 
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ATP-dependant RNA helicase activity that unwinds the two strands of RNA. Functional 
RISCs contain only single stranded siRNA (Martinez et al., 2002). The siRNA strands 
subsequently guide the RISC to complementary RNA molecules, where base pairing 
takes place between the antisense strand of the siRNA and the sense strand of the target 
mRNA. This leads to endonuclease cleavage of the target RNA (Novina and Sharp 2004). 
Gene silencing by RISC is accomplished via homology-dependent mRNA degradation 
(Tuschl et al., 1999; Hamilton et al., 2002), translational repression (Grishok et al., 2001) 
or transcriptional gene silencing (Pal-Bhadra, Bhadra and Birchler 2002) (Fig 1.9.1.1). 
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Fig 1.9.1.1: siRNA mechanism of action. dsRNAs are processed by a host Dicer 
enzyme to form siRNAs. Dicer-processed siRNAs and synthetic siRNAs undergo 
ATP dependent unwinding before being incorporated into a protein complex called 
RISC (RNA-induced silencing complex) that contains single stranded siRNAs. The 
RISC is reconfigured to active RISC which contains the proteins required for 
cleaving the target mRNA at the point where the antisense siRNA binds. After the 
cleavage the active RISC is released to cleave additional mRNA molecules whereas 
the cleaved mRNA is degraded by cellular ribonucleases. 
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1.10 Basal cell carcinoma 
Basal cell carcinoma (BCC) is the most common malignancy in the white-skinned 
population with an estimated 750,000 cases per year in the US, with 175 cases per 
100,000 reported in American men (Chuang et al., 1990). Although not lethal, tumors are 
locally invasive with disfiguring growth in surrounding tissues causing morbidity due to 
prevalent localization of tumors in facial skin. Accordingly, this disease typically has a 
favorable prognosis, as complete surgical excision is almost always curative (Walling et 
al., 2004).  
BCC is a slowly growing tumor occurring in hair-growing squamous epithelium. The 
transformation of basal stem cells located in the hair follicles or basal epidermis gives 
rise to BCC (Backvall et al., 2005). Ultraviolet (UV) radiation is considered the main 
carcinogen (Corona et al., 2001; Kricker et al., 1995) and approximately 80% of the 
tumors occur on the head and neck. If detected early, it can be treated and cured without 
serious side effects (Dua et al., 2004).  
Two main approaches to classify BCC have been suggested based on histopathological 
growth pattern and histological differentiation. To date, no universally agreed 
classification exists and it is regarded that classification based on growth pattern has the 
greatest biological significance (Saldanha, Fletcher and Slater 2003). Several sub-types of 
BCC have been identified- nodular-ulcerated BCC, superficial BCC, sclerosing BCC, 
cystic BCC, linear BCC and micronodular BCC. BCC rarely metastasize with rates 
ranging from 0.003 to 0.55% (Kapucuoglu et al., 2009; Walling et al., 2004). Up to 85% 
of metastasis has the neck or head as the site of the primary tumor (von Domarus and 
Stevens 1984), with at least two-thirds of cases originating from the face (Snow et al., 
1994). The most frequent site of BCC metastasis is regional lymph nodes, followed by 
bone, lung, and liver (Snow et al., 1994; Lo et al., 1991; Martin et al., 2000). 
Furthermore, people with BCC are at higher risks of developing further BCCs and other 
malignancies, including squamous cell carcinomas, malignant melanomas and possibly 
also non-cutaneous malignancies (Wong, Strange and Lear 2003). 
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Previous studies have indicated the role of Sonic Hedgehog (Shh) pathway, via Patched 
(PTCH) gene mutations (Johnson et al., 1996, Gailani et al., 1996), as a key cellular 
signaling event in BCC tumorigenesis. However, relatively little is known about the 
molecular events involved in this disease. A single study of BCC has been reported using 
a cDNA microarray representing 1,718 genes (Howell et al., 2005). 
Immunohistochemical techniques were used to study the expression of several proteins 
including CD10 (Pham et al., 2006; Yada et al., 2004), p63 (Park et al., 2004), low 
expression levels of CD44 (Baum et al., 1996) to associate with the presence of BCC. 
Expression level of the Ki67 antigen differs in BCCs that recur and BCC that do not recur 
(Healy et al., 1995).  
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1.11 Aims 
The overall goal of this project was to study breast cancer with reference to gene 
expression analysis using clinical specimens and in-vitro models. The specific aims of 
this project were: 
 To advance the understanding of the heterogeneity of breast cancer using gene 
expression analysis, and to identify gene expression differences among the 
Normal and Cancer breast tissue and comparing various clinical parameters such 
as ER status, Grade, LN status and Tumour size.  
 To identify gene expression changes that may be linked to clinical outcomes such 
as relapse-free survival and overall survival. 
 To compare our results with various other similar or related studies and identify 
precise genelists which may be linked to disease progression, relapse-free survival 
and overall survival.  
  To compare our results with two of the FDA approved prognostic assays 
MammaPrint and OncotypeDX to identify common genes in both studies which 
may be of common diagnostic importance.  
 To develop a model based on gene expression signatures to predict clinical 
outcomes for breast cancer patients using Back Propagation Neural Network 
algorithm 
 To identify sets of genes whose expression correlate with ER status using gene 
expression data generated in-house & publicly-available clinical and cell line 
datasets  
 To identify prognostically important genes from our microarray study and 
validate their functions in the laboratory using molecular biology techniques such 
as siRNA and cDNA transfection in cancer cell lines, in particular focussing on 
invasion and motility.  
 To identify the representative nature of cell lines to clinical conditions using gene 
expression data. 
 Basal Cell Carcinoma data analysis 
 43 
 
 
 
 
 
 
 
 
 
 
 
2.0 Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 44 
2.1 Microarray data used in this study 
The gene expression profiles of 104 tumors and 17 normal specimens were generated in-
house as a starting point for this study. To complement this analysis, public datasets were 
also downloaded from GEO (Gene Expression Omnibus) for comparison; as outlined. 
2.1.1 Breast cancer clinical microarray dataset generated at NICB 
A total of 104 tumour specimens and 17 normal specimens were obtained from Dr. Susan 
Kennedy (Consultant Histopathologist, St. Vincent‟s University Hospital (SVUH), 
Dublin. The patients underwent potentially curative resection at the hospital and after 
pathological examination; the tumors were snap frozen in liquid nitrogen. The tumors 
were subsequently stored at −70/−80°C and were later processed onto microarray chips 
(see section 2.5.11) by Dr. Lorraine O'Driscoll and Dr. Padraig Doolan.  
Clinical information was obtained from the hospital for all patients. The dataset contains 
information on the following clinical parameters for individual patients: 
 Estrogen Receptor status 
 Censored relapse free survival for 7 years. 
 Type of cancer e.g. lobular, ductal 
 Overall Relapsed status 
 RIP (Event of death due to disease) 
 Relapse within 5 years 
 Survival for 5 years 
 Age at diagnosis 
 Tumour type 
 Tamoxifen treatment status 
 Chemotherapy status 
 Tumour size  
 Tumour grade 
 Lymph Node Status 
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2.1.2 Data obtained from public repositories 
Several published datasets relating to breast cancer were downloaded from the GEO 
(Gene Expression Omnibus) (http://www.ncbi.nlm.nih.gov/geo/), Array Express 
(http://www.ebi.ac.uk/microarray-as/ae/) as well as from independent sources (Table 
2.1.2.1). Datasets from GEO carry a unique GEO ID and more information can be 
obtained by searching for the specified GEO number. For some experiments, gene 
expression values were available as raw data files, while for others they were available as 
processed data. For all the experiments for which raw data is available the data was 
processed using dChip algorithm. The summary of the experiments taken for analysis is 
depicted in Table 2.1.2.1. 
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Experiment Chip type No. of samples Comments 
GEO: GSE3156 
(Bild et al.,  2006) 
U133 Plus2.0 19 Breast Cell 
line 
GEO: GSE3744 
(Richardson et al.,  2006) 
U133 Plus2.0 47 Breast clinical 
specimens 
GEO: GSE2034 
(Wang et al.,  2005; Carroll et al.,  
2006) 
U133A 286 Breast clinical 
specimens 
GEO: GSE2990 
(Sotiriou et al.,  2006) 
U133A 193 Breast clinical 
specimens 
GEO: GSE4922 
(Ivshina et al.,  2006)  
U133A+B 347 Breast clinical 
specimens 
GEO: GSE1456 
(Pawitan et al.,  2005) 
U133A+B 159 Breast clinical 
specimens 
GEO: GSE4570 
(Hoek et al.,  2004) 
U133A 8 Melanoma cell 
lines 
GEO: GSE4587 
(Smith, Hoek and Becker 2005) 
U133 Plus2.0 19 Melanoma 
clinical 
specimens 
GEO: GSE5720 
(Shankavaram et al.,  2007) 
U133A+B 60 Cell lines of 
different origin 
GEO: GSE1133 
(Su et al.,  2004) 
U133A 79 Various tissue 
(van 't Veer et al.,  2002) Hu25K 117 Breast clinical 
specimens 
(Paik et al.,  2004) 
(genes taken from paper) 
PCR-based 
assay 
668 Breast clinical 
specimens 
Array Express E-TABM-185 U133A 5897 Various tissue 
and cell lines 
Table 2.1.2.1: Summary of individual experiments included in study  
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2.1.3 Basal cell carcinoma cancer clinical microarray dataset generated at NICB 
Tissue specimens from twenty cases of BCC were procured at the Blackrock Clinic and 
the Bons Secours Hospitals, Dublin, were examined macroscopically, immediately snap-
frozen in liquid nitrogen, and were subsequently stored at -80°C until required for 
analysis. Five normal skin specimens (from consenting male and female volunteers of a 
similar age range who never had skin cancer) were also included in these studies. 
Following this microarray analysis was performed (see section 2.5.11) by Dr. Lorraine 
O'Driscoll and Dr. Padraig Doolan using Affymetrix U133plus chips 
2.2.1 Normalization and Quantification 
For experiments where raw data files were available, normalisation using the dChip 
algorithm (www.dchip.org) was carried out. DNA-Chip Analyzer (dChip) is a software 
package implementing model-based expression analysis of oligonucleotide arrays and 
several high-level analysis procedures. This model-based approach allowed probe-level 
analysis on multiple arrays. In this normalisation procedure, an array with median overall 
intensity is chosen as the baseline array against which other arrays are normalised at 
probe level intensity. Subsequently a subset of PM (“perfect match”) probes, with small 
within-subset rank difference in the two arrays (also known as invariant set), serves as the 
basis for fitting a normalisation curve. PM (“perfect match”) is the exact match is a 
section of the mRNA sequence whereas MM (“mismatch”) is identical except for one 
base difference from its exact match counterpart. 
2.2.2 Quality inspection  
The following Quality Control measures are reported by dChip 
 Median Intensity: This is the middle intensity (when all chip probe intensities are 
ordered from low to high intensity) of the un-normalized probe values. 
Normalization process brings the median intensity to a comparable level. 
 P (Present) call %: Calls indicate if the transcript is expressed or not. It can be „P‟ 
for “Present”, „M‟ for “Marginal” and „A‟ for “Absent”. Total P calls in an array 
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can vary widely based on the different nature of samples, but usually range from 
40-60% for a cell line experiment and 25-35% for clinical tissue.  
 % Signal outlier: The signal value greater than 80th percentile multiplied by 3 is 
taken as signal outlier and is represented as % signal outlier.  
 % Array outlier: The array-outliers are the arrays whose probe pattern for selected 
probe sets are different from the consensus probe patterns seen in most arrays. If 
the array outlier value increases above 5%, the chip is marked as an outlier chip 
and is marked by „*‟; indicating potential image contamination or sample 
hybridization problem of that array.  
Manual inspection: Apart from the above parameters manual inspection was also 
performed to estimate the quality of individual chips. An example of a good and bad 
quality chip is shown overleaf (Fig 2.2.2.1 and Fig 2.2.2.2). 
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Fig 2.2.2.1: An example of a good quality scan image (image simulated by dChip) 
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Fig 2.2.2.2: A chip with very high background (image simulated by dChip) 
2.2.3 Standard deviation filtration 
This filtration was applied as a prerequisite to Hierarchical clustering. The aim of this 
filtration was to remove genes which had a standard deviation divided by mean i) less 
than 1 across samples or ii) more than 1000 across samples. This process removed genes 
which i) did not fluctuate significantly across samples ii) fluctuated too highly across 
samples to be prognostically valuable 
2.2.4 Hierarchical Clustering 
Hierarchical clustering is a mathematical technique whereby the analysed samples/genes 
are connected iteratively based on their similarity. Samples/genes with similar expression 
patterns are grouped together and are connected by a series of branches, which is called a 
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dendrogram (or clustering tree). Hierarchical clustering was used to see how well 
samples clustered together, identify any sub-groups in the samples and identify correlated 
genes. Cluster analysis was also used to identify significant clinical parameter 
(enrichment analysis) associated with the cluster. The observed and expected clinical 
parameter was calculated for each cluster and the whole data and a hyper geometric 
distribution was used to calculate the p-value for individual clinical parameter in each 
cluster. Similar analysis was performed for clusters of genes enriched for particular Gene 
Ontology and Pathways. Genes in the cluster were compared to genes not in cluster to 
find clusters enriched with gene belonging to a particular gene ontology or pathway. 
2.2.5 Finding significant genes 
The following criterion was used to generate genelists. 
2.2.5.1 Fold change 
Fold change is the ratio of the mean of the experimental group to that of the baseline. It‟s 
a metric to define the gene's mRNA-expression level between two distinct experimental 
conditions.  
2.2.5.2 Difference 
 The difference of Affymetrix expression units (gene expression values obtained after 
dChip processing) was also incorporated for finding differentially regulated genes.  
2.2.5.3 T-test 
The t-test assesses whether the means of two groups are statistically different from each 
other. The t-statistic is calculated as follows: 
t = (XT  ¯  XC) / √ ( varT / nT + varC / nC ) 
XT   mean of Treatment samples 
XC   mean of Control samples 
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varT  variance of Treatment samples 
varC   variance of Control samples 
nT   number of Treatment  samples 
nC   number of Control samples 
Subsequently, the p-value is calculated from the t-test.  
The purpose of the t-test is to evaluate the null hypothesis that there is no difference 
between the means of two samples. The t-test is a parametric test which is used to analyse 
the mean and standard deviation of two or more groups of samples based on a number of 
underlying assumptions, including a normal distribution of the data within the test.  
 
Therefore, hypothesis testing facilitates the calculation of the probability of the observed 
value of the t-statistic occurring based on the assumption that the null hypothesis is true.  
 
For calculation of the probability,  the data is assumed to be normally distributed. By 
convention, a p-value of ≤0.05 is usually considered sufficient to reject the null 
hypothesis, i.e. that there is a real difference between the means (≤0.01 would be 
considered strong evidence) (Stekel, 2003). 
For gene ontology and pathway analysis, the filtration criteria used was as follows: FC>2, 
Difference of means > 100 and p-value ≤ 0.05. For developing the MLPERCEP classifier 
(see section 3.5), a p-value ≤ 0.001 was used. For gene list generation purposes, FC>1.2, 
Difference of means > 100 and p-value ≤ 0.05 was utilised. 
2.2.6 Identifier conversion 
NetAffx from Affymetrix and David and Ease was used for gene identifier conversion. 
This was essential wherever microarray genelists from different platforms were 
compared. 
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2.2.6.1 NetAffx 
NetAffx is provided by Affymetrix (www.affymetrix.com) and provides detailed 
annotation of its probe sets on various chips. Individual and batch query was used at 
various places to convert the Affymetrix identifier to a different identifier or vice versa. 
2.2.6.2 David and Ease 
David and Ease (http://david.abcc.ncifcrf.gov/) is an online tool for gene identifier 
conversion and was used at many places for converting the gene identifier.  
2.2.7 Gene list comparison 
Microsoft Access and Venny were used to compare various genelists. 
2.2.7.1 Microsoft access 
MSAccess is a database-building package that was used to compare different gene lists. 
MSAccess allowed comparison of like genes across multiple lists. It allowed comparison 
of genes and also relevant information such as probe sets, difference of means and p-
values. It was also used as a repository and used for database queries. It was also widely 
used for merging tables and adding annotations to genelists.  
2.2.7.2 Venny 
Venny (http://bioinfogp.cnb.csic.es/tools/venny/index.html) is a Venn diagram-drawing 
software tool that was used to overlap and compare genelists using Venn diagrams. 
2.2.8 GenMAPP 
GenMAPP (http://www.genmapp.org) is a computer application designed to visualize 
gene expression and other genomic data on maps representing biological pathways and 
groupings of genes. It overlays gene-expression data on the pathways incorporating 
colour-coding according to user-defined parameters. Additionally, the MappFinder 
module identifies significant Gene ontologies and pathways affected by the submitted 
genelists. 
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MappFinder 
MAPPFinder is an accessory program that works with GenMAPP and the annotations 
from the Gene Ontology (GO) consortium to identify significant GO and MAPPs. The 
calculations made by MAPPFinder (Fig 2.2.8.1) are intended to give an idea of the 
relative amount of genes meeting the criterion that are present in each GO term or Local 
MAPP.  
 
Fig 2.2.8.1: Calculations made by GenMAPP to calculate the significant of 
individual GO and MAPPs. (Obtained from GenMAPP website) 
Genes meeting the criterion: The number of distinct genes that met the user-defined 
criterion in the Expression Dataset. This may also be referred to as "genes changed." 
Genes measured: The number of distinct genes in the submitted expression dataset that 
were found to link to this GO term or MAPP. 
Genes associated with this GO term or MAPP: The number of genes assigned to this GO 
term or on this MAPP. Also referred to as the number of "Genes in GO" for a specific 
term. 
% genes meeting the criterion: Genes meeting the criterion/genes measured * 100 
% genes measured: Genes measured/genes associated * 100 
Nested numbers: The same 5 calculations are repeated, but as nested numbers.  
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Z score: The standard statistical test under the hypergeometric distribution (Fig 2.2.8.2). 
 
Fig 2.2.8.2: Z-score calculation. (Obtained from GenMAPP website) 
Where N is the total number of genes measured, R is the total number of genes meeting 
the criterion, n is the total number of genes in this specific MAPP, and r is the number of 
genes meeting the criterion in this specific MAPP. A positive Z score indicates that there 
are more genes meeting the criterion in a GO term/MAPP than would be expected by 
random chance. A negative Z score indicates that the there are fewer genes meeting the 
criterion than would be expected by random chance.  
Hypergeometric distribution: The hypergeometric distribution is a discrete probability 
distribution that quantifies the number of successes in a sequence of n draws from a finite 
population without replacement. An example of the hypergeometric distribution is an urn 
with some red marbles and some black marbles and we have knowledge of the ratio of 
them. A handful of marbles is taken and analysed for significant difference between the 
ratio of red to black in the sample and the total population in the urn.  
Permute P and Adjusted P: p-value is calculated based on the Z score and the 
hypergeometric distribution.  A p-value of 0 indicates a value < 0.001. 
2.2.9 Genesis  
Genesis is comprehensive software for microarray data analysis. It is available at 
http://genome.tugraz.at/. This software was used to perform k-means clustering (see 
section 1.6.2.2) and principal component analysis (see section 1.6.3). K-means clustering 
is a mathematical technique where the similar experiments/genes are grouped together. 
Principal component analysis is a mathematical technique to reduce the dimensionality of 
the data, thus giving a deeper insight into hidden patterns that influence the level of 
variation within the dataset. 
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2.2.10 Dev C++ 
Dev C++ is an environment and compiler code used to write and execute C and C++ 
programs. This software is available at http://www.bloodshed.net/devcpp.html 
MLPERCEP was developed using Dev C++.  
2.2.11 C# (C-sharp) 
Borland C# was used to build user interface for the MLPERCEP programs. The software 
is available at http://www.codegear.com/products/bds2006.  
2.2.12 Kaplan-Meier survival function 
 
The Kaplan-Meier estimate (KM) (Kaplan and Meier 1958) estimates the survival 
function from life-time data. In life science research, it is used to compare two groups of 
patients or treatments for differences in survival. Kaplan Meier curves represent the 
proportion of the study population surviving at successive times. Kaplan-Meier curves for 
the parameters of interest and the outcomes are represented on the graph and the p-value 
is used to determine the likelihood that there is no difference between the two survival 
curves. 
 
Kaplan-Meier plots of the estimate of the survival function as a series of steps of 
reducing magnitude. The X-axis normally depicts the time of survival and the y-axis 
represents the percent of patients surviving. The algorithm takes account of censored 
data; loss of part of the sample before the final outcome is observed, e.g. patients leaving 
the study or patients dying due to different causes before the study is completed. The 
survival functions are compared for significant differences using Chi-squared statistics. 
SPSS (http://www.spss.com/) software was used for performing Kaplan-Meier analysis 
which was performed by Dr. Lorraine O'Driscoll, NICB.  
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2.2.13 CLUSTALW 
CLUSTALW (http://www.ebi.ac.uk/Tools/clustalw2/index.html) was used to performing 
multiple sequence alignment. CLUSTALW is an online tool to perform sequence 
alignment. 
2.2.14 BLAST 
BLAST was used to search for homologues sequences. 
 (http://blast.ncbi.nlm.nih.gov/Blast.cgi ) 
2.2.15 Non-parametric analysis 
Non-parametric analysis was performed using MeV (http://www.tm4.org/). The p-value 
was calculated using Wilcoxon test. Wilcoxon rank-sum test is a nonparametric test 
similar to the two sample t-test and is based on the rank order in which the observations 
from the two samples fall. The test is based upon ranking the two sets of sample 
observations as  a combined ranking. Each observation therefore has a rank; the smallest 
has rank 1 and so on.  The Wilcoxon rank-sum test statistic is the sum of the ranks for 
observations from one of the samples. The genes were termed as significant if FC>1.2, 
Difference of means > 100 and p-value ≤ 0.05. 
2.3 Cell Culture Methods 
2.3.1 Water 
Ultra high pure water (UHP) was used in the preparation of all media and solutions. Pre-
treatment of water, involving activated carbon, pre-filtration and anti-scaling was first 
carried out. This water was then purified by a reverse osmosis system (Millipore Milli-
RO 10 Plus, Elgastat UHP), which is low in organic salts, organic matter, colloids and 
bacteria with a standard of 12 - 18 M /cm resistance. 
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2.3.2 Treatment of Glassware 
All solutions for use in cell culture and maintenance were prepared and stored in sterile 
glass bottles. Bottles, lids and all other glassware used for any cell-related work were 
prepared as follows: all glassware and lids were soaked in a 2% (v/v) solution of RBS-25 
(AGB Scientific, 83460) for at least 1hrs. This is a deproteinising agent, which removes 
proteineous material from the bottles. Glassware was scrubbed and rinsed several times 
in tap water; the bottles were then washed by machine using Neodisher detergent, an 
organic, phosphate-based acid detergent. The bottles were then rinsed twice with distilled 
water, once with UHP water and sterilised by autoclaving. 
2.3.3 Sterilisation 
Water, glassware and all thermostable solutions were sterilised by autoclaving at 121°C 
for 20 min under 15 p.s.i. pressures. Thermolabile solutions were filtered through a 0.22 
m sterile filter (Millipore, millex-gv, SLGV-025BS). Low protein-binding filters were 
used for all protein-containing solutions. Acrodisc (Pall Gelman Laboratory, C4187) 
0.8/0.2 m filters were used for non-serum/protein solutions. 
2.3.4 Media Preparation 
Medium was routinely prepared and sterility checked by Mr. Joe Carey (technician) as in 
SOP NCTCC 003-02. 10X media were added to sterile UHP water buffered with HEPES 
(N- [2-Hydroxyethyl]-N‟- [2-ethanesulphonic acid]) (Sigma, H-9136) and NaHCO3 
(BDH, 30151) and adjusted to a pH of 7.45 - 7.55 using sterile 1.5M NaOH and 1.5M 
HCl. The media were then filtered through sterile 0.22 m bell filters (Gelman, 121-58) 
and stored in 500 ml sterile bottles at 4°C.  
The basal media were stored at 4
o
C up to their expiry dates as specified on each 
individual 10X medium container. Working stocks of culture media were prepared as 100 
ml aliquots and supplemented as required. These were stored for up to 3 weeks at 4
o
C; 
after this time, fresh culture medium was prepared. 
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2.4 Maintenance of cell lines 
2.4.1 Safety Precautions  
All cell culture work was carried out in a class II down-flow re-circulating laminar flow 
cabinet (Nuaire Biological Cabinet) and any work which involved toxic compounds was 
carried out in a cytoguard (Gelman). Strict aseptic techniques were adhered to at all 
times. The laminar flow cabinet was swabbed with 70% industrial methylated spirits 
(IMS) before and after use, as were all items used in the cabinet. Each cell line (including 
low and high passage cells) was assigned specific media and waste bottles and only one 
cell line was used at a time in the cabinet, which, was allowed to clear for 15 min 
between different cell lines. The cabinet and incubators were cleaned each week with 
industrial detergents (Virkon, Antec. International; TEGO, TH. Goldschmidt Ltd.). A 
separate Laboratory coat was kept for aseptic work and gloves were worn at all times 
during cell work.  
2.4.2 Culture of Adherent Cell Lines 
The cell lines used during the course of this study, their sources and their basal media 
requirements are listed in Table 2.4.2.1. Cell lines were generally maintained in 25 cm
2
 
(Costar, 3056) and 75 cm
2
 flasks (Costar, 3376) and fed every two to three days. 
Cell Line Media Cell Type 
MDA-MB-435S RPMI with 10% FCS Breast/Melanoma 
M14 RPMI with 10% FCS Melanoma 
MDA-MB-231 RPMI with 10% FCS Breast 
Table 2.4.2.1: Cell Lines used in this study  
MDA-MB-435s was earlier thought to be a breast cell line, but recent analysis using gene 
expression and clustering of this cell line with melanoma cell lines indicates the origin of 
this cell line to be melanoma (Rae et al., 2007; Ellison et al., 2002). 
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2.4.2.1 Subculture of Adherent Cell Lines 
Prior to subculture cells were always monitored for any contamination and were only 
sub-cultured when the cells were 70-80% confluent. During routine sub-culturing or 
harvesting of adherent cell lines, cells were removed from their flasks by enzymatic 
detachment. 
Medium were emptied from cell culture flasks and rinsed with a pre-warmed (37°C) 
trypsin/EDTA (Trypsin Versene - TV) solution (0.25% trypsin (Gibco, 25090-028), 
0.01% EDTA (Sigma, E-5134) solution in PBS (Oxoid, BR14a)). The purpose of this 
was to inhibit any naturally occurring trypsin inhibitor which would be present in residual 
serum. Fresh TV was then placed on the cells (2ml/25cm
2
 flask or 3ml/75cm
2
 flask) and 
the flasks incubated at 37°C until the cells were detached (5-10 min). The flasks were 
struck once, roughly, to ensure total cell detachment. The trypsin was deactivated by 
addition of an equal volume of growth medium (i.e. containing 10% serum). The entire 
solution was transferred to a 20ml sterile universal tube (Greiner, 201151) and 
centrifuged at 1,000 rpm for 5 min. The resulting cell pellet was resuspended in pre-
warmed (37°C) fresh growth medium, counted (see section 2.4.3) and used to re-seed a 
flask at the required cell density or to set up an assay. 
2.4.3 Cell Counting 
Sample of this mixture was applied to the chamber of a haemocytometer over which a 
glass cover slip had been placed. Cells in the 16 squares of the four outer corner grids of 
the chamber were counted microscopically. An average per corner grid was calculated 
with the dilution factor being taken into account. Final cell numbers were multiplied by 
10
4
 to determine the number of cells per ml (volume occupied by sample in chamber is 
0.1cm x 0.1cm x 0.01cm i.e. 0.0001cm
3
; therefore cell number x 10
4
 is equivalent to cells 
per ml).  
2.4.4 Cell freezing  
Cryoprotective medium or freezing medium was prepared in complete culture medium 
containing 10% dimethylsulfoxide (DMSO) (Sigma, D-5879) and filter sterilised using 
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0.22 µm filter and syringe. The appropriate number of cryogenic vials (Greiner, 122 278) 
were labelled with the cell line, passage no and date. Cells were trypsinised as outlined 
previously (see section 2.4.2.1). The supernatant from the centrifuged cells were removed 
and resuspend the cell pellet in 1 ml of fresh media. Freezing medium (10% DMSO) was 
slowly added drop wise to the cell suspension to give a final concentration to 5% of 
DMSO, and a final cell concentration of 5 x 10
6
 – 1 x 107 cells/ml. This step was very 
important, as DMSO is toxic to cells. When added slowly, the cells had a period of time 
to adapt to the presence of the DMSO, otherwise cells may have lysed. 1.5-1.8 mls of the 
DMSO-containing cell suspension was then added to each of the vials. The cryovials 
were which were quickly placed at –80oC. To allow long term storage of cell stocks, cells 
were frozen and cryo-preserved in liquid nitrogen at temperatures below –180oC. 
2.4.5 Cell Thawing 
Prior to the removal of a cryovial from the liquid nitrogen stores for thawing, a sterile 
universal tube containing growth medium was prepared for the rapid transfer and dilution 
of thawed cells to reduce their exposure time to the DMSO freezing solution which is 
toxic at room temperature. The cryovial was removed and thawed quickly by rubbing by 
hand. When almost fully thawed, the DMSO-cell suspension was quickly transferred to 
the media-containing universal and centrifuged at 1,000 rpm for 5 min. the DMSO-
containing supernatant removed and the pellet re-suspended in fresh growth medium. 
Thawed cells were then placed into 25cm
2
 tissue culture flasks with 5mls of the 
appropriate type of medium and allowed to attach overnight. After 24hrs, the cells were 
re-fed with fresh medium to remove any residual traces of DMSO. 
2.4.6 Sterility Checks 
Sterility checks were routinely carried out on all media, supplements and TV used for cell 
culture. Samples of basal media were inoculated into Columbia blood agar plates (Oxoid, 
CM331), Sabauraud dextrose (Oxoid, CM217) and Thioglycollate broth (Oxoid, CM173) 
which when combined detect most contaminants including bacteria, fungus and yeast. 
Growth media (i.e. supplemented with serum) were sterility checked at least 3 days prior 
to use by incubating samples at 37°C. These were subsequently examined for turbidity 
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and other indications of contamination. Freshly thawed cells were also subjected to 
sterility checks. 
2.4.7 Mycoplasma Analysis 
Mycoplasma examinations were carried out routinely (at least every 3 months) on all cell 
lines used in this study. This analysis was preformed by Michael Henry and Shane Kelly 
at the National Institute for Cellular Biotechnology (NICB). 
2.4.7.1 Indirect Staining Procedure 
In this procedure, Mycoplasma-negative NRK cells (a normal rat kidney fibroblast line) 
were used as indicator cells and incubated with supernatant from test cell lines to test for 
Mycoplasma contamination. NRK cells were used for this procedure because cell 
integrity is well maintained during fixation. A fluorescent Hoechst stain was utilised 
which binds specifically to DNA and so will stain the nucleus of the cells in addition to 
any Mycoplasma DNA present. A Mycoplasma infection would thus be seen as small 
fluorescent bodies in the cytoplasm of the NRK cells and occasionally outside the cells.  
NRK cells were seeded onto sterile cover slips in sterile Petri dishes (Greiner, 633 185) at 
a cell density of 2x10
3
 cells per ml and were allowed to attach overnight at 37°C in a 5% 
CO2 humidified incubator. 1 ml of cell-free supernatant (cleared by centrifugation at 
1,000 rpm for 5 min) from each test cell line was then inoculated onto a NRK cover slip 
and incubated as before until the cells reached 20-50% confluency (4-5 days). After this 
time, the waste medium was removed from the Petri dish; the cover slips (Chance 
Propper, 22 x 22 mm) were washed twice with sterile PBS, once with a cold 
PBS/Carnoys (50/50) solution and fixed with 2 ml of Carnoys solution (acetic acid: 
methanol - 1:3) for 10 min. The fixative was then removed and after air-drying, the cover 
slips were washed twice in deionised water and stained with 2 ml of Hoechst 33258 dye 
(BDH) (50 ng/ml) for 10 min. 
From this point on, work proceeded in the dark to limit quenching of the fluorescent 
stain. The cover slips were rinsed three times in PBS. They were then mounted in 50% 
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(v/v) glycerol in 0.05 M citric acid and 0.1 M disodium phosphate and examined using a 
fluorescence microscope with a UV (ultraviolet) filter.  
Prior to removing a sample for Mycoplasma analysis, cells were be passaged a minimum 
of 3 times after thawing to facilitate the detection of low-level infection. Optimum 
conditions for harvesting supernatant for analysis occur when the culture is in log-phase 
near confluency and the medium has not been renewed in 2-3 days. 
2.5 Analytical Techniques  
2.5.1 Preparation of total RNA from cells using RNeasy Mini Prep Kit 
High quality RNA was isolated from cells using the RNeasy mini-kit (Qiagen, 74104). 
Cell pellets for RNA extraction (stored at –80oC) were re-suspended in 1.2 ml of buffer 
RLT (supplemented with 10µl/ml of β-mercaptoethanol) and vortexed to loosen the 
pellets. The samples were completely homogenised by passing the lysate at least 5 times 
through a blunt 20-gauge needle (0.9 mm diameter) fitted to an RNase-free syringe. One 
volume (1.2 ml) of 70% ethanol was added to the homogenised samples and mixed well 
by pipetting. This mixture was then loaded in 700 µl aliquots on to an RNeasy mini 
column, which was placed in a collection tube and centrifuged at 8,000 x g for 15 sec 
(this was continued until the entire mixture had been passed through the column). Once 
all the homogenised cells had been passed through the column, the washes were carried 
out. Initially 700 µl RW1 was loaded on to the column and centrifuged at 8,000 x g for 
15 sec. This was closely followed by 2 washes in buffer RPE (also followed by 
centrifuging at 8,000 rpm for 15 sec). To completely dry the spin column, it was placed 
in a fresh collection tube and centrifuged at full speed for 1 min. The RNA was eluted by 
passing two lots of 25 µl RNase free water (supplied) through the column by centrifuging 
it at 8,000 rpm for 1 min. The eluted RNA was then quantified (see section 2.5.2). 
2.5.2 RNA Quantification using NanoDrop 
The NanoDrop ND-1000 is a full-spectrum (220-750nm) spectrophotometer that 
measures 1 µl samples with high accuracy and reproducibility. It uses a sample retention 
technology that relies on surface tension alone to hold the sample in place eliminating the 
 64 
A B
A 
C
A 
need for cuvettes and other sample containment devices. In addition, the NanoDrop has 
the capability to measure highly concentrated samples without dilution (50X higher 
concentration than the samples measured by a standard cuvette spectrophotometer).  
To quantify an RNA sample, 1µl of the sample is pipetted onto the end of a fibre optic 
cable (the receiving fibre, Fig 2.5.2.1 (A)). A second fibre optic cable (the source fibre, 
Fig 2.5.2.1 (B)) is then brought into contact with the liquid sample causing the liquid to 
bridge the gap between the fibre optic ends. The gap is controlled to a 1mm path (Fig 
2.5.2.1 (C)). A pulsed xenon flash lamp provides the light source and a spectrometer 
utilising a linear CCD array is used to analyse the light after passing through the sample. 
The instrument is controlled by special software run from a computer, and the data is 
logged in an archive file on the computer.  
When measurement of the sample is complete, the sample can be simply wiped away 
using a soft laboratory wipe. This is sufficient to prevent sample carryover because each 
measurement pedestal is a highly polished end of a fibre optic cable, with no cracks or 
crevices for leftover sample to reside. 
Fig 2.5.2.1: Samples are quantified by loading 1µl onto the receiving fibre (A), the 
source fibre, connected to the sampling arm (B) is brought down into contact with 
the sample allowing a 1mm gap between the upper and lower pedestal (C), through 
which the light is passed. (Pictures adapted from ND-1000 Spectrophotometer users 
manual V 3.1.0).  
RNA (like DNA) was quantified using an ND-1000 spectrophotometer. The ND-1000 
software automatically calculated the quantity of RNA in the samples using the OD260. 
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 i.e. OD260 x 40 x Dilution Factor/1000 = RNA content ( g/ l) 
 The software simultaneously measured the OD280 of the samples allowing the purity of 
the sample to be estimated. 
Purity = OD260/OD280 
This was typically in the range of 1.8-2.0. A ratio of <1.6 indicated that the RNA may not 
be fully in solution. The RNA was diluted to 1 g/ l stocks for the subsequent reverse 
transcription (RT) protocol (see section 2.5.4).  
2.5.3 RNA amplification, labelling and fragmentation of cRNA in preparation for 
hybridisation to Affymetrix array chips 
Components required for this protocol were included in the Two-Cycle Target Labelling 
and Control Reagents (Affymetrix, P/N 900494) and MEGAscript High Yield 
Transcription Kit, Ambion Inc, P/N 1334 with the exception of Ethanol (Sigma, E7023). 
The positive control Poly-A RNA is firstly diluted before spiking in with the sample 
RNA. Affymetrix supply a Eukaryotic Poly-A RNA Control Kit along with the Two-
Cycle Target Labelling and Control Reagents. The kit is designed specifically to provide 
exogenous positive controls to monitor the entire GeneChip eukaryotic target labelling 
process.  It is important to note that the Poly-A spikes were made up in non-stick RNase/ 
DNase free tubes (Ambion cat no. 12450(1.5ml)/ 12350(0.5ml)), which prevents the 
Poly-A spikes from sticking to the sides of the tubes and interfering with the final 
concentration of the positive controls.  
The tube with first strand cDNA synthesis master mix (Table 2.5.3.1) was then flicked 
and centrifuged briefly. 2µl of this mix was added to 2µl of the 50ng/µl RNA sample. 
The tubes were flicked and centrifuged briefly before being incubated for 6 min at 70°C. 
They were then incubated for 2 min on ice and centrifuged briefly. 
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Reagents Amount 
Poly-A RNA Control 2μl 
T7-Oligo (dT) Primer (50 μM) 2μl 
RNA + RNase-free water 16μl 
Table 2.5.3.1: First-Strand cDNA Synthesis 
The first cycle, first strand master mix was prepared as in Table 2.5.3.2. It is worth noting 
that Affymetrix suggest that if there are more than 2 samples that it is prudent to include 
extra to compensate for potential pipetting inaccuracy or solution lost during the process. 
The 5µl of first strand master mix was added to each sample, the tube gently flicked, 
briefly centrifuged and placed immediately at 42°C for 1hr and 72°C for 10 min before 
being placed on ice for 2 min. 
Reagents Amount 
5X 1st strand buffer 2μl 
DTT (0.1M) 1μl 
dNTP (10mM) 0.5μl 
RNase Inhibitor  0.5μl 
Superscript II 1µl 
Total 7μl 
Table 2.5.3.2: 1st strand master mix 
The first cycle second strand master mix was prepared by adding following reagents 
(Table 2.5.3.3). This 10µl mix was then added to each tube which were then flicked and 
centrifuged briefly before being placed at 16°C for 2hrs and 75°C for 10 min and then ice 
for 2 min. 
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 Reagents Amount 
RNase-free Water 4.8μl 
dNTP (10mM) 0.4μl 
MgCl2 (17.5mM)  4μl 
E. coli DNA Polymerase 0.6μl 
RNase H 0.2μl 
Total Volume 10μl 
Table 2.5.3.3: Second-strand master mix  
The components for the first cycle IVT amplification (Ambion Megascript T7 kit) were 
assembled at room temperature. 5µl of each of the components ATP, CTP, UTP, GTP, 
enzyme mix and 10 x reaction buffers were added together for each sample included 
before being added to each sample. The tubes were gently flicked, centrifuged and placed 
at 37°C for 16hrs. 
 
 Reagents Amount 
10X Reaction Buffer  5μl 
CTP Solution  5μl 
GTP Solution  5μl 
10X Reaction Buffer  5μl 
CTP Solution  5μl 
GTP Solution  5μl 
Total Volume  30μl 
Table 2.5.3.4: First-Cycle, IVT Master Mix 
The cRNA was then purified using the GeneChip Sample Cleanup module (Affymetrix, 
900371) as recommended by the manufacturers instructions. 
The quantity of the cRNA was subsequently checked by diluting 2µl of cRNA in 18µl of 
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H2O and reading the quantity by using the NanoDrop (see section 2.5.2). 600ng is 
required for the second cycle of the protocol. 2µl of freshly diluted random primers 
(3µg/µl) was added to each sample and the tubes were flicked, centrifuged briefly and 
placed at 70°C for 10 min before being placed on ice for 2 min.  
The second cycle first strand mix was prepared by adding each reagent together as in 
Table 2.5.3.5 for each sample included. This 9µl was added to each sample before they 
were flicked, centrifuged and placed at 42°C for 1hr and ice for 2 min. After this, 1µl of 
RNase H was added to each sample before they were flicked, spun, and placed at 37°C 
for 20 min, 95°C for 5 min and ice for 2 min.  
 Reagents Amount 
5X 1st Strand Reaction Mix  4μl 
DTT, 0.1M  2μl 
RNase Inhibitor  1μl 
dNTP (10mM) 1μl 
SuperScript II  1μl 
Total Volume  9μl 
Table 2.5.3.5: Second-Cycle, First-Strand Master Mix 
4µl of a freshly prepared aliquot of T7 Oligo dT primer was added to each sample before 
they were flicked, centrifuged briefly and incubated at 70°C for 6 min and ice for 2 min. 
The second cycle second strand master mix was prepared by adding the following in a 
tube for each sample required (Table 2.5.3.6). This 125µl master mix was added to each 
sample before being flicked, centrifuged briefly and incubated for 2 hrs at 16°C. T4 DNA 
polymerase (2µl) was then added to each sample before incubating at 16°C for a further 
10 min. After incubating the samples at 4°C for 2 min, they were immediately purified 
using the GeneChip Sample Cleanup module (Affymetrix, 900371) following the 
manufacturers instructions. 
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 Reagents Amount 
RNase-free Water  88μl 
5X 2nd Strand Reaction Mix  30μl 
dNTP, 10mM  3μl 
E. coli DNA Polymerase I  4μl 
Total Volume  125μl 
Table 2.5.3.6: Second-Cycle, Second-Strand Master Mix 
All 12µl of cDNA were used for the second IVT step. The reagents required for this step 
were assembled at room temperature. The master-mix included 8µl RNase- free water, 
4µl of IVT labelling buffer, 12µl IVT labelling NTP mix and 4µl labelling enzyme mix 
for each sample included. The 28µl volume was added to each sample before flicking, 
centrifuging briefly and incubating at 37°C for 16 hrs. 
The biotin-labelled cRNA was purified using the GeneChip Sample Cleanup module 
(Affymetrix, 900371), as recommended by the manufacturers, and quantified using a 
NanoDrop. For quantification of cRNA when using total RNA as starting material, an 
adjusted cRNA yield needed to be calculated to reflect carryover of unlabeled total RNA. 
Using an estimate of 100% carryover, the formula below was used to determine adjusted 
cRNA yield: 
Adjusted cRNA yield = RNAm - (total RNAi) (y) 
Where, RNAm = amount of cRNA measured after IVT (µg), total RNAi = starting 
amount of total RNA (µg), y = fraction of cDNA reaction used in IVT  
The final step of the entire process was to fragment 20µg of the biotin-labelled cRNA by 
adding 8µl of fragmentation buffer to 20µg of cRNA and bringing the total volume of the 
reaction to 40µl, so that the concentration of the cRNA is 0.5µg/µl. This mix was 
incubated for 35 min at 94°C. From the fragmented cRNA 30µl (=15µg) was hybridised 
to the Affymetrix U133-plus-2 chip.  
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2.5.3.1 Probe Array Scan 
After staining and washing, the chips were scanned using an Affymetrix GeneChip 
Scanner 3000 (Affymetrix, 00-0186). The sample door on the scanner was opened and 
the probe array was inserted into the holder. Affymetrix GeneChip Operating Software 
(GCOS) runs all aspects of the array process, saving images of the scanned probe array in 
a data file (*.dat). GCOS automatically calculates the *.cel (Cell Intensity File) file from 
each *.dat file, which contains a single intensity value for each probe cell delineated by 
the grid (calculated by the Microarray Suite 5.0 (MAS5.0) algorithm) (ref- Affymetrix, I. 
Statistical Algorithms Description Document. 2002.  
http://www.affymetrix.com/support/technical/whitepapers.affx ). The chip File (*.chp) 
generated from the analysis of a probe array contains qualitative and quantitative analysis 
for every probe set. The report file (*.rpt) generated by GCOS summarizes the data 
quality information for a single experiment. The report is generated from the analysis 
output file (*.chp). 
2.5.3.2 Quality assessment of Affymetrix microarray chips 
The quality of the data generated with Affymetrix microarray chips was assessed based 
on different criteria including the scaling factor, background and noise levels, GAPDH 
3‟/ 5‟ ratios and the % Present call. 
Scaling factor: The scaling factor was the multiplication factor applied to each signal 
value on an array. A scaling factor of 1.0 indicates that the average array intensity was 
equal to the target intensity. Scaling factors vary across different samples and so there 
were no set guidelines for any particular sample type. However, Affymetrix advise that 
for replicates and comparisons involving a relatively small number of changes, the 
scaling/normalization factors (calculated by the global method) should be comparable 
among arrays. Larger discrepancies among scaling/normalization factors (e.g., three-fold 
or greater) may indicate significant assay variability or sample degradation leading to 
noisier data.  
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Background and noise levels: Although there are no official guidelines regarding 
background, Affymetrix has found that typical Average Background values range from 
20 to 100 for arrays scanned with the GeneChip® Scanner 3000. Arrays being compared 
should ideally have comparable background values. A high background (over 60%) 
implies that impurities, such as cell debris and salts, are binding to the probe array in a 
non-specific manner, and that these substances are fluorescing at 570nm (the detection 
wavelength). This non-specific binding (noise) causes a low signal-to-noise ratio (SNR), 
meaning that transcripts present at very low levels in the sample may be incorrectly 
called as “Absent”. High background creates an overall loss of sensitivity in the 
experiment 
GAPDH 3‟/ 5‟ ratios: β-actin and GAPDH are used to assess RNA sample and assay 
quality for the majority of GeneChip expression arrays. Specifically, the Signal values of 
the 3‟ probe sets for β-actin and GAPDH are compared to the Signal values of the 
corresponding 5‟ probe sets. The ratio of the 3‟ probe set to the 5‟ probe set is generally 
no more than 3 for the 1-cycle assay. A high 3‟ to 5‟ ratio may indicate degraded RNA or 
inefficient transcription of ds cDNA or biotinylated cRNA. 3‟ to 5‟ ratios for internal 
controls are displayed in the Expression Report (.rpt) file. 
%Present call: The number of probe sets called “Present” relative to the total number of 
probe sets on the array is displayed as a percentage in the Expression Report (.rpt) file. 
Percent present (%P) values depend on multiple factors including cell/tissue type, 
biological or environmental stimuli, probe array type, and overall quality of RNA. 
Replicate samples should have similar %P values. Extremely low %P values are a 
possible indication of poor sample quality. In practice, % present calls averaged between 
40-60% for cell line RNA and 15-25% for clinical specimens. 
2.5.4 Reverse Transcription of RNA from cells (cDNA Synthesis) 
For cDNA synthesis High-Capacity cDNA Reverse Transcription Kit was used (Applied 
BioSystems, 43755750). The components of the kit were allowed to thaw on ice. RT 
master mix was also prepared on ice as described in Table 2.5.4.1.  
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Component Volume (µl) 
10X RT Buffer 2 
25X dNTP Mix (100 mM) 0.8 
10X Random Primers 2 
MultiScribe Reverse Transcriptase 1 
Nuclease-free H2O 4.2 
Total 10 
Table 2.5.4.1: 2X RT Master Mix 
10μl of 2X RT master mix were pipetted into each 0.5 ml eppendorf tube (Eppendorf, 
0030 121 023). To this eppendorf tube 10μl of RNA sample (400ng) was mixed by 
pipetting up and down few times. The tubes were then briefly centrifuged to spin down 
the contents and to eliminate any air bubbles and placed on ice until ready to be loaded in 
the thermal cycler. The thermal cycler was programmed as per Table 2.5.4.2. 
Step 1 Step 2 Step 3 Step 4 
Temperature (
o
C) 25 37 85 4 
Time 10 min 120 min 5 sec ∞ 
Table 2.5.4.2: Programme for thermal cycler  
2.5.5 Quantitative real time RT-PCR (qRT-PCR) 
TaqMan probes are oligonucleotides that have fluorescent reporter dyes attached to the 5' 
end and a quencher moiety coupled to the 3' end. These probes are designed to hybridize 
to an internal region of a PCR product. In the unhybridized state, the proximity of the 
fluor and the quench molecules prevents the detection of fluorescent signal from the 
probe. During PCR, when the polymerase replicates a template on which a TaqMan 
probe is bound, the 5'- nuclease activity of the polymerase cleaves the probe. This 
decouples the fluorescent dye thus, increasing the fluorescence in each cycle, 
proportional to the amount of probe cleavage. 
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2.5.5.1 Primer Design 
Primer design was done using Primer Express from Applied BioSystems 
(http://www.appliedbiosystems.com) and the primers were ordered from MWG 
(http://www.mwg-biotech.com/). The primers were designed across the introns, making 
them specific for detection of RNA. Since the two genes under study (ROPN1 and 
ROPN1B was 95% homologous, the region with maximum variability among the two 
genes was taken for the design of forward primers, reverse primers and probe.  
2.5.5.2 qRT-PCR 
The TaqMan quantitative Real time PCR (qRT-PCR) analysis was preformed using the 
Applied BioSystems. In order to exclude any amplification product derived from 
genomic DNA or any other contaminant that could contaminate the RNA preparation, 
total RNA without reverse transcription was used as a negative control. Water on its own 
was used as a negative control to detect the presence of any contaminating RNA or DNA. 
Reagents  Volume 
Nuclease-Free water (Ambion, 9930) 5µl 
TaqMan® Fast Universal PCR master mix (2 X) (Applied 
BioSystems, 4352042) 10µl 
Forward primer 1µl 
Reverse primer 1µl 
Probe 1µl 
Total 18µl 
Table 2.5.5.2.1: qRT-PCR Reaction Mixture 
18µl of reaction master mix (Table: 2.5.5.2.1) was added to the MicoAmp fast optical 96-
well reaction plate (Applied BioSystems, 4346906) followed by 2µl of the cDNA. 
 
 74 
Step 
Denature PCR 
HOLD 
CYCLE (40 cycles) 
Denature Anneal/Ext 
Time 20 sec 3 sec 30 sec 
Temp 95
o
C 95
o
C 60
o
C 
Table 2.5.5.2.2: Thermal cycling conditions used in this study 
Cycle threshold: The Threshold is the level of detection or the point at which a reaction 
reaches a fluorescent intensity above background. The threshold line is set in the 
exponential phase of the amplification for the most accurate reading. The cycle at which 
the sample reaches this level is called the Cycle Threshold, Ct. 
Relative Quantification: Relative quantification determines the change in expression of a 
nucleic acid sequence (target) in a test sample relative to the same sequence in a 
calibrator sample (control). 
2.5.6 Large scale plasmid preparation 
Luria-Bertani (LB Broth) was prepared as per Table 2.5.6 and was autoclaved. An aliquot 
of 10 mls LB Broth was taken in a 20 ml universal. Ampicillin was added to this broth at 
a concentration of 100μg/ml and inoculated with 10-20µl of glycerol stock for one unique 
clone. This was grown for 6-7hrs in an upright shaker at 37
o
C and ~300rpm. This was 
further inoculated into a 1000 ml flask with 400 mls of LB Broth containing amplicillin 
antibiotic (100μg/ml). The culture was incubated at 37oC with vigorous shaking 
(~300rpm) for ~8hrs. The bacterial cells were then harvested by centrifugation at 6000xg 
for 15 min at 4
o
C. Plasmid DNA was then extracted using the Qiagen Endofree Plasmid 
Purification Kit (Qiagen, 12362) (see section 2.5.6.1). DNA concentration was 
determined by measuring using NanoDrop at OD260nm (see section 2.5.2). 
 
 75 
Reagents Volume 
Peptone 20g/L 
Yeast Extract 10g/L  
NaCl 5g/L 
Table 2.5.6: 2X-LB broth (low-salt) media preparation  
2.5.6.1 Isolation of plasmid DNA using Qiagen Endofree Plasmid Purification Kit 
Pelleted bacterial cells were resuspended in 250μl Buffer P1 with RNase A until no 
clumps were visible. This was then transfered to a microcentrifuge tube. 250μl of Buffer 
P2 was added to this mixture and mixed thoroughly by inverting the tube gently 4–6 
times until the solution became viscous and slightly clear. To this mixture 350μl of 
Buffer N3 was added and mixed immediately and thoroughly by inverting the tube 4–6 
times till the solution became cloudy. This solution was then centrifuged for 10 min at 
13,000 rpm (~17,900 x g). During centrifugation the vacuum manifold and QIAprep spin 
columns (Qiagen, 27104) were prepared. The supernatant from this was pipetted to the 
QIAprep spin column. The vacuum source was then switched on to draw the solution 
through the QIAprep spin columns. The QIAprep spin column was washed by adding 0.5 
ml Buffer PB and the vacuum source was switched on. After the solution had moved 
through the column, the vacuum source was switched off. This wash step removed trace 
nuclease activity. The QIAprep spin column was again washed by adding 0.75 ml Buffer 
PE. The vacuum source was again switched on to draw the wash solution through the 
column and then switched off. The QIAprep spin columns were then transferred to a 
microcentrifuge tube and centrifuged for 1 min. This step removed residual Buffer PE 
and ethanol from Buffer PE that may inhibit subsequent enzymatic reactions. The 
QIAprep column was then placed in a clean 1.5 ml microcentrifuge tube and DNA was 
eluted by adding 50μl Buffer EB (10mM Tris·Cl, pH 8.5) the center of the QIAprep spin 
column. The QIAprep spin column was allowed to stand for 1 min and then centrifuged 
for 1 min. 
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2.5.7 Plasmid transfection protocol 
To determine the optimal conditions for plasmid transfection in 6-well plates, an 
optimisation with GFP plasmid was carried. Cell suspensions were prepared at 2x10
5
 
cells per ml of plating media and plated one day in advance in 6-well plate (2 ml per 
well). Solutions of GFP plasmid at a concentration of 2µg/µl were prepared in optiMEM 
(Gibco, 31985). Lipofectamine 2000 (2, 4, 6µl) solutions were prepared in 500µl 
optiMEM and incubated at room temperature for 5 min. After incubation, the 
lipofectamine- optiMEM solution was added to each GFP plasmid. These solutions were 
mixed well and incubated for a further 20 min at room temperature. 500 l of the 
plasmid/lipofectamine solutions were added to a 6-well plate. The plates were mixed 
gently and incubated at 37 C for 5hrs. After 5hrs, the transfection mixture was removed 
from the cells and the plates were fed with fresh medium. After 72hrs, cells were 
observed under the fluorescent microscope. The conditions chosen for large-scale use 
were those that showed the most fluorescent cells and fewest dead floating cells.  
The plasmid in bacteria was obtained from Open Biosystems 
(http://www.openbiosystems.com). Details are in Table 2.5.7. 
Gene Accession Vector  Catalogue 
ROPN1 BC132744.1, 
BC132744 
PCR4-TOPO MHS4426-
99240150 
ROPN1B BC015413, 
BC015413.1, 
BG034740.1, 
BG034740 
PCMV-SPORT6 MHS1010-58339 
Table 2.5.7: Details of the cDNA used in the study 
2.5.8 RNA interference (RNAi) 
RNAi was carried out using small interfering RNAs (siRNAs) to silence specific genes. 
The siRNAs used were purchased from Ambion Inc (USA). Details of the individual 
siRNA are listed in Table 2.5.7.1. These siRNAs were 21-23 bp in length and were 
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introduced to the cells via reverse transfection with the transfection agent NeoFx 
(Ambion Inc., 4511). The details of siRNA used are listed in Table 2.5.8. The siRNA 
obtained was 5nmol and was diluted with 100µl nuclease free water to obtain a stock of 
50µM. The transfection solution was prepared using 30nm siRNA and 4µl of NeoFx.  
The amount of siRNA used was calculated as follows: 
Amount required = (required concentration / existing concentration) x total transfection 
volume 
In this case; Amount required = (30 x 10
-9 
g / 50 x 10
-6 
g) x 1100µl = 0.66µl/well 
This amount was diluted with 50µl of optiMEM. Similarly NeoFx was diluted with 50µl 
optiMEM. Both were incubated for 10 min, mixed, again incubated for 10 min and then 
placed in the wells of 6 well plates. Cell suspension @2 x 10
5 
per
 
well was placed on top 
of the siRNA solution and mixed. This was placed in incubator at 37 C. The media was 
changed after 24hrs and the assay was performed after 72hrs following transfection.  
Gene Ambion Catalogue Ambion siRNA Id 
ROPN1B 16708A 279600 
ROPN1B 16708A 279601 
ROPN1B 16708A 279602 
ROPN1 4392420 S29402 
ROPN1 4392420 S29404 
Negative Control 4611 Negative control 1 
Table 2.5.8: Ambion siRNA details used in the study 
2.5.9 Western Blot analysis 
2.5.9.1 Lysis of cell pellet 
A stock of lysis buffer was prepared using the reagents as shown in table 2.5.9.1.1. 
Working lysis buffer was prepared fresh every time before use as shown in the table 
2.5.9.1.2. 
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Reagents Volume 
1M Tris pH 7.4 2 ml 
3M NaCl 1.66 ml 
1M NaF 5 ml 
10% NP40 1 ml 
H2O 90.34 ml 
Total 100 ml 
Table 2.5.9.1.1: NP40 Lysis Buffer Stock 
 
Reagents Volume 
100mM Sodium Orthovanidate 10 l 
100mM PMSF 10 l 
Protease Inhib Cocktail 40 l 
NP40 Lysis Buffer 940 l 
Total 1000 l 
Table 2.5.9.1.2: Working Lysis Buffer 
After 72hrs of transfection, the cells were lysed in the 6-well plate. Prior to lysis, the 
plate was washed twice with cold PBS and drained of all supernatant. Cold lysis buffer 
(40 l) was added to the cells, dropping it evenly over the whole well/plate. The cells 
were scraped from the well and all the lysed/scraped cells were gathered in one corner of 
the well. The solution was pipetted up and down without frothing and placed in a pre-
chilled eppendorf tube (Eppendorf, 0030 121 023). The tube was vortexed for 30-60 sec 
until the solution was homogenised. The tube was placed on ice for 20 min and 
centrifuged at maximum speed in a microfuge for 15 min. The supernatant was 
transferred to a fresh chilled eppendorf tube and immediately quantified for protein (see 
section 2.5.9.2). The samples were prepared with 2-5X loading buffer (Sigma, S-3401) 
and water was added to make the all the samples at the same concentration. Parafilm was 
wrapped around the lids of the eppendorfs (to avoid evaporation) and the samples were 
boiled for 3-5 min. If not used immediately, the samples were stored at –20oC until 
needed. 
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2.5.9.2 Protein Quantification 
Lysed samples were removed from the freezer and placed on ice. A BSA standard of 1 
mg/ml was prepared in UHP. Diluted BSA Standards was prepared and 5μl of standard 
and 5μl of sample were placed in triplicate wells on a 96-well plate (Costar, 3596). The 
Biorad Dc Protein Assay (Biorad, 500-0116) was used for protein quantification. 25μl of 
Reagent A (containing 20μl Reagent S (Biorad, 500-0115) per ml of Reagent A (500-
0113)) followed by 200μl of Reagent B (Biorad, 500-0114) were added to each test well. 
The plate was kept at room temperature for 15 min prior to reading on the Spectra Max 
Plus using a softmax Lowry protein assay (750nm) program. 
2.5.9.3 Gel electrophoresis 
Proteins for Western blot analysis were separated by SDS-polyacrylamide gel 
electrophoresis (SDS-PAGE). Resolving and stacking gels were prepared as outlined in 
table 2.5.8.4.1 and poured into clean 10 cm x 8 cm gel cassettes, separated by 0.75 cm 
plastic spacers. The plates were cleaned by tap water, followed by UHP. After drying, the 
plates were wiped down in one direction using tissue paper soaked in 70% Industrial 
Methylated Spirits (IMS). The spacers and comb used were also cleaned in this way. 
After these had dried, the resolving gel was poured first and allowed to set for 20 min at 
room temperature. The stacking gel was then poured and a comb was placed into the 
stacking gel in order to create wells for sample loading. Once set, the gels could be used 
immediately or wrapped in wet tissue paper and stored at 4
o
C for 24hrs. 
1X running buffer (Table 2.5.9.3) was added to the running apparatus before samples 
were loaded. The samples were loaded onto the stacking gels, in equal amounts relative 
to the protein concentration of the sample. The empty wells were loaded with loading 
buffer. 
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Reagents Volume 
Glycine 14.4 g 
Tris 3.03 g 
SDS 1g 
H2O 1L 
Table 2.5.9.3: Running Buffer Components 
The samples were loaded including 7µl of molecular weight colour protein markers (New 
England Biolabs, P7708S). The gels were run at 200 V, 45mA for approximately 1.5hrs. 
When the bromophenol blue dye front was seen to have reached the end of the gels, 
electrophoresis was stopped. 
2.5.9.4 Western blotting  
Following electrophoresis, the acrylamide gels were equilibrated in transfer buffer (2mM 
Tris, 192mM glycine (Sigma, G-7126) pH 8.3-8.5 without adjusting) for 10 min. The 
protein in the gels was transferred onto nitrocellulose membranes (Boehringer 
Mannheim, 1722026) by semi-dry electroblotting. Eight sheets of Whatman 3 mm filter 
paper (Whatman, 1001824) were soaked in transfer buffer and placed on the cathode 
plate of a semi-dry blotting apparatus (Biorad, 170-3940). Excess air was removed from 
between the filters by rolling a universal tube (Sterilin, 128a) over the filter paper. A 
piece of nitrocellulose membrane, cut to the same size of the gel, was prepared for 
transfer (soaked in transfer buffer) and placed over the filter paper, making sure there 
were no air bubbles.  
The acrylamide gel was placed over the nitrocellulose membrane and eight more sheets 
of pre-soaked filter paper were placed on top of the gel. Excess air was again removed by 
rolling the universal over the filter paper. The proteins were transferred from the gel to 
the nitrocellulose at a current of 34mA at 15V for 24-25 min.  
All incubation steps from then on, including the blocking step, were carried out on a 
revolving apparatus (Stovall, Bellydancer) to ensure even exposure of the blot to all 
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reagents. The nitrocellulose membranes were blocked for 2hrs at room temperature with 
fresh 5% non-fat dried milk (Cadburys, Marvel skimmed milk) in Tris-buffered saline 
(TBS) with 0.5% Tween (Sigma, P-1379). After blocking, the membranes was washed 3 
x 5 min using 1X TBS/PBS. The membrane was then incubated with 5 to 10 mls primary 
antibody (concentration of primary antibody was used as in Table 2.5.9.4.2) for 1hr. 
Details of the antibody used is listed in Table 2.5.9.4.2. The membrane was again was 
washed 3 x 5 min using 1X TBS/PBS and then incubated in secondary antibody (Mouse 
antibody diluted at 1/1000) (DakoCytomation, P 0260). Finally the membrane was 
washed 3 x 5 min using 1X TBS/PBS. Bound antibody was detected using enhanced 
chemiluminescence (ECL) (Amersham, RPN2109) (see section 2.5.9.5). 
Components Resolving 
gel (7.5%) 
Resolving 
gel (12%) 
Stacking  
Acrylamide stock(Sigma, A3574) 3.8 mls 5.25 mls 0.8 mls 
Ultra pure water 8.0 mls 6.45 mls 3.6 mls 
1.5M-Tris/HCl, pH 8.8(BioRad, 161-0798) 3.0 mls 3.0 mls - 
1.25M-Tris/HCl, pH 6.8(BioRad, 161-0799) - - 0.5 mls 
10% SDS(Sigma, L-4509) 150 mls 150 mls 50 mls 
10% Ammonium persulphate(Sigma, A-1433) 60 mls 60 mls 17 mls 
TEMED(Sigma, T-8133) 10 mls 10 mls 6 mls 
Table 2.5.9.4.1: Preparation of electrophoresis gels 
Note: *Acrylamide stock solution consists of 29.1g acrylamide (Sigma, A8887) and 0.9g 
NN‟-methylene bis-acrylamide (Sigma, 7256) dissolved in 60ml UHP water and made up 
to 100ml final volume. The solution was stored in the dark at 4
o
C for up to 1 month. All 
components were purchased from Sigma, SDS (L-4509), NH4-persulphate (A-1433) and 
TEMED, N,N,N,N‟-tetramethylethylenediamine (T-8133). 
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Antibody Dilution/Concentration Supplier Cat. No.  
Ropporin 1/1000 Abnova H00054763-M03  
α tubulin  1/5000  Abcam ab7291 
Table 2.5.9.4.2: List of primary antibodies used for western blot analysis 
2.5.9.5 Enhanced chemiluminescence detection 
Protein bands were developed using the Enhanced Chemiluminescence Kit (ECL) 
(Amersham, RPN2109) according to the manufacturer‟s instructions. The blot was 
removed to a darkroom for all subsequent manipulations. A sheet of parafilm was 
flattened over a smooth surface, e.g. a glass plate, making sure all air bubbles were 
removed. The membrane was placed on the parafilm, and excess fluid removed. 1.5 mls 
of ECL detection reagent 1 and 1.5 mls of reagent 2 were mixed and covered over the 
membrane. Charges on the parafilm ensured the fluid stayed on the membrane. The 
reagent was removed after one minute and the membrane covered in cling film. The 
membrane was exposed to autoradiographic film (Boehringer Mannheim, 1666916) in an 
autoradiographic cassette for various times, depending on the signal (30s – 15 min). The 
autoradiographic film was then developed.  
The exposed film was developed for 5 min in developer (Kodak, LX24, and diluted 1:6.5 
in water). The film was briefly immersed in water and fixed (Kodak, FX-40, diluted 1:5 
in water), for 5 min. The film was transferred to water for 5 min and then air-dried. 
2.5.10 Invasion assay 
2.5.10.1 Reconstitution of ECM proteins.  
Matrigel (Sigma, E-1270) was diluted to a working stock of 1 mg/ml in serum free 
DMEM. Aliquoted stocks were stored at –20oC. 
2.5.10.2 In vitro invasion assays 
100µl of matrigel were placed into each insert (Falcon, 3097) (8.0µm pore size, 24-well 
format) and kept at 4
o
C for 24hrs. The insert and the plate were then incubated for one 
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hour at 37
o
C to allow the proteins to polymerize. Cells were harvested and resuspended 
in culture media at 1 × 10
6
 cells/ml. Excess media/PBS was removed from the inserts, 
and they were rinsed with culture media. 100µl of the cell suspension was added to each 
insert and 500µl of culture medium was added to the well underneath the insert. Cells 
were incubated for 24hrs. After this time period, the inside of the insert was wiped with a 
cotton swab dampened with PBS, while the outer side of the insert was stained with 
0.25% crystal violet for 10 min and then rinsed in distilled water and allowed to dry. The 
inserts were then viewed and photographed under the microscope. The invasion assays 
were quantified by counting cells in 10 random fields within a grid at 20x objectives and 
graphed as the total number of cells invading at 200 x magnifications.  
2.5.11 Motility assay 
Motility assays were carried out as described in section 2.5.10.2, without the addition of 
ECM. 
2.5.12 Microsoft PowerPoint 
Microsoft PowerPoint is a presentation program developed by Microsoft. All the non-
referenced diagrams (Fig 1.6.2.1.1, Fig 1.6.2.1.2, Fig 1.6.2.1.3, Fig 1.6.2.1.4, Fig 1.7.1, 
Fig 1.10.1.1 and Fig 3.5.2.1) were drawn using Microsoft PowerPoint.  
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3.1 Breast Cancer clinical specimens 
Microarray gene expression profiling of 17 normal breast tissue specimens and 104 breast 
cancer specimens was performed using Affymetrix U133 Plus2.0 arrays as outlined in 
section 2.5.3. The aim was to study the clinical heterogeneity among breast tumors using 
gene expression data. Additionally the following comparisons based on clinical data were 
performed to study important genes, ontologies and pathways affected by the changing 
gene lists: 
 1) Normal vs. tumour 
 2) Estrogen receptor-negative vs. Estrogen receptor-positive 
 3) Lymph node-negative vs. Lymph node-positive 
 4) Grade 1 vs. Grade 2 
 5) Grade 2 vs. Grade 3 
 6) Tumour Size < 2.8cm vs. > 2.8 cm 
 7) Patients who did not relapse vs. patients who did relapse (Overall relapse) 
 8) Patients who survived vs. patients who did not survive (Overall survival) 
9) Patients who did not relapse within 5 years vs. patients who did relapse within 
5 years (Relapse 5yrs) 
10) Patients who survived for 5 years vs. patients who did not survive beyond 5 
years (Survival 5 yrs) 
3.1.1 Data Normalization and Quantification 
 The microarray raw data files were normalized and quantified using the dChip algorithm 
as outlined in section 2.2.1).  
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3.1.2 Data Filtration 
Data filtration was applied on 54,675 genes present on U133 Plus2.0 chip (see section 
2.2.3), to remove genes which i) did not fluctuate very highly across samples and ii) 
fluctuated too highly across samples to be trustworthy. Genes with a Standard deviation / 
Mean i) below 1 or ii) above 1000 were removed from further analysis. This set of genes 
was used for Hierarchical clustering. 10,243 genes passed this criterion and were used to 
carry out clustering analysis of clinical specimens.  
3.1.3 Hierarchical Clustering 
Hierarchical clustering (see section 2.2.4) was performed on the 10,243-member filtered 
gene list. The correlation values between the samples were calculated and two-way 
clustering was performed using the correlation values. The distance metric used was 1-
correlation and the clustering algorithm used was Average linkage clustering. Prior to 
clustering, the individual samples were standardised as follows: the expression of the 
individual genes was subtracted from their means for that sample and divided by their 
respective standard deviation. The results are shown in Figs 3.1.3.1-3.1.3.4. Fig 3.1.3.1 
shows all the specimens and Fig 3.1.3.2 – Fig 3.1.3.4 displays the individual sub-clusters. 
The dendrogram has specimens on both axes and the intersection point between any two 
samples represents the correlation value among the two specimens. The colours on the 
heat map represent the correlation values among the specimens. Red colours indicate 
positive correlation, blue colours indicate negative correlation and white colours indicate 
zero correlation. Different shades of red and blue reflect the relative correlation values. 
The diagonal red line is because of the correlation values of 1 among the identical 
samples. Blocks of red therefore represents similar specimens and also indicate how 
homogenous or heterogeneous the various groups of specimens are.  
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The hierarchical clustering results identify several groups of samples which correlate 
with different clinical parameters. The Normal samples largely clustered together. 
Among the tumors, the samples largely clustered based on the ER status. The clustering 
results have been divided into groups represented as A, B, C, D and E and are denoted 
just below the tree in Fig 3.1.3.1 and are all shown separately in greater detail in Figs 
3.1.3.2 - Fig 3.1.3.4.  
The first observation to be made is that the tumour specimens largely clustered as a 
separate group. However, there was one cancer specimen (S30) which clustered with the 
normal specimens. Additionally, there were 3 normal specimens (N4, N5 and N6) which 
clustered within group E of the cancer specimens. A very high correlation was observed 
between the normal specimens in Cluster A compared to the various cancer groups and 
sub-groups. The other important criterion on which the specimens clustered was Estrogen 
receptor status. Cluster C is enriched with ER-negative specimens whereas clusters D and 
E are highly enriched with ER-positive specimens. The details of the individual clusters 
and their correlation with clinical parameters are detailed below. 
Individual clusters were compared to identify genes important to that cluster. A nearest 
cluster comparison approach was used so as to mask the confounding factors. 
Additionally this approach helped in keeping the sample size of each group to a 
comparable level. Bigger groups were also compared to each other with an aim to obtain 
the hierarchy of the heterogeneity of breast cancer. 
Cluster A: This group comprised 14 normal specimens and one cancer specimen (S30). 
This group represents a very tight cluster as the level of correlation among samples as 
indicated by the strength of red colour is very high (Fig 3.1.3.1, Fig 3.1.3.2). However, 
three of the normal specimens (N4, N5 and N6) did not cluster with this group.  
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Fig 3.1.3.2: Enlarged view of the cluster A and B from the Fig 3.1.3.1. The colours 
on the heat map represent the correlation values among the specimens. Red colours 
indicate positive correlation, blue colours indicate negative correlation and white 
colours indicate zero correlation. Different shades of red and blue reflects the 
relative correlation values. Group A is composed of 14 normal samples and 1 
tumour sample (S30). Group B is the cluster closest to the normal sample group.  
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Cluster B: This group was enriched for patients who are ER-negative, relative to the other 
categories. The other linked clinical parameters are depicted in Table 3.1.3.1. The group 
that clusters closest to cluster B is the Normal specimen cluster (A)  
Significance analysis (as described in section 2.2.4) was carried out on this cluster and 
the significant clinical parameters specific to this cluster was identified (Table 3.1.3.1). 
Clinical  Status Represented Total p-value 
ER Negative 6/9 34/122 0.0139 
Age50 <50 5/9 27/122 0.0248 
Type  Lobular 4/9 17/122 0.0215 
Tamoxifen Not taken 6/9 26/122 0.0030 
Grade 1 3/9 11/122 0.0343 
Table 3.1.3.1: Clinical parameters over-represented in Cluster B. „Clinical‟ refers to 
the parameter of interest. „Status‟ indicates the particular frame of reference for 
that clinical parameter. The „Represented‟ column indicates the number of 
specimens of the total number of specimens within Cluster B that display those 
values for that parameter. „Total‟ indicates the total number of specimens for that 
clinical status over the whole sample dataset. Based on the ratio of „Represented‟ 
and „Total‟, the p-value is calculated.  
While comparing cluster A and B, cluster B did not display a higher expression of ESR1 
as this cluster is enriched for ER-negative specimens; however ERBB2 expression was 
found to be high (FC: 2.46) in Cluster B specimens. ESR1 gene and ERBB2 gene are 
important in breast cancer classification. 
Cluster C: This group was enriched for patients who are ER-negative and have undergone 
chemotherapy (see Table 3.1.3.2). By looking at the hierarchical clustering (Fig 3.1.3.3), 
it seems that many of the tumors isolated from patients in this group are of histologic 
Grade 3 (31 specimens are of Grade 3 out of total of 43 specimens in cluster C), despite 
the fact that grade was not identified by the significance analysis. None of the samples in 
this group was of Grade 1. This group was also enriched by patients who relapsed within 
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7 years (41/43) and who did not survive beyond 7 years (39/43). Close examination of 
this group (based on the dendrogram and heat map) reveals that there are 3 sub-groups in 
this main group. However, no clinical parameters associated with any of the sub-groups 
were identified as statistically-relevant by significance analysis.  
 
Fig 3.1.3.3: Enlarged view of the cluster C from Fig 3.1.3.1. This group of specimens 
is enriched for ER-negative patients (52.4%). However there are many ER-positive 
specimens in this group (40.5%). This group signifies a very high level of diversity 
as can be seen from the clustering patterns. There are three sub-clusters in this 
cluster (marked by red lines). 
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Clinical  Status  Represented Total p-value 
ER negative 23/43 34/122 0 
Chemo yes 23/43 50/122 0.0304 
Table 3.1.3.2: Clinical parameters over-represented in cluster C  
Cluster C is highly heterogeneous groups with three distinct sub-clusters. The left cluster 
was compared to (middle + right) cluster. Similarly the middle cluster was compared to 
(left + right) cluster and the right cluster was compared to (left + middle) cluster. The 
nearest cluster comparison approach was used so as to mask out the confounding factors. 
Table 3.1.3.3, 3.1.3.4 and 3.1.3.5 lists the top 10 genes (based on Fold change) among 
each comparison. 
Probe set Gene Baseline Experiment FC Difference p-value 
205475_at SCRG1 11.91 297.67 24.98 285.76 0.02769 
229341_at TFCP2L1 18.83 382.88 20.33 364.04 0.028253 
242488_at --- 13.63 244.75 17.96 231.13 0.00699 
213456_at SOSTDC1 13 224.4 17.27 211.4 0.021923 
220425_x_at ROPN1B 18.82 316.25 16.81 297.43 0.028281 
224191_x_at ROPN1 24.19 401.57 16.6 377.38 0.03536 
231535_x_at ROPN1 30.22 441.08 14.6 410.86 0.032765 
220559_at EN1 24.27 311.89 12.85 287.62 0.023241 
204733_at KLK6 21.32 222.4 10.43 201.08 0.036002 
204855_at SERPINB5 89.09 786.11 8.82 697.02 0.001439 
Table 3.1.3.3: Genes up-regulated in left cluster in comparison to (middle + right) 
cluster 
The left sub-cluster is enriched with patients who relapsed (9/13). One of the important 
and novel genes identified in the table above is Ropporin (ROPN1, ROPN1B). Further 
work on this gene is presented in section 3.6 
 93 
Probe set gene Baseline Experiment FC Difference p-value 
205213_at CENTB1 5.22 147.31 28.21 142.08 0.002377 
208450_at LGALS2 10.24 193.39 18.89 183.15 0.00811 
216510_x_at IFI6  18.12 309.82 17.1 291.7 0.005858 
211650_x_at IL8 24.77 373.07 15.06 348.3 0.003931 
211637_x_at LOC652128 17.04 249.1 14.62 232.06 0.006901 
214777_at --- 31.89 464.36 14.56 432.47 0.004748 
216365_x_at IGL@  27.27 368.26 13.5 340.99 0.02424 
211908_x_at IL8 24.93 334.96 13.44 310.03 0.005076 
216430_x_at SCGB2A2 10.06 124.5 12.37 114.44 0.013686 
211634_x_at IGHM 11.83 145.43 12.3 133.6 0.04216 
Table 3.1.3.4: Genes up-regulated in middle cluster in comparison to (left + right) 
cluster 
The middle cluster is enriched with patients who did not relapse (12/19). The genes in the 
middle cluster are enriched for immune response function (IF16, IF8, LOC652128, IGL, 
and IGHM). 
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Probe set gene Baseline Experiment FC Difference p-value 
207802_at CRISP3 31.13 1080.8 34.72 1049.67 0.037581 
232547_at SNIP 33.68 645.21 19.16 611.53 0.002929 
213557_at CRKRS 84.5 807.21 9.55 722.71 0.002197 
234354_x_at ERBB2 27.95 221.59 7.93 193.64 0.003465 
238360_s_at --- 16.19 127.13 7.85 110.94 0.00764 
213551_x_at PCGF2 145.63 1078.29 7.4 932.66 0.004555 
226727_at LOC284106 183.4 1352.26 7.37 1168.85 0.010993 
214239_x_at PCGF2 273.49 1956.67 7.15 1683.19 0.003642 
239224_at FBXL20 23.02 148.81 6.47 125.79 0.003134 
203496_s_at PPARBP 248.16 1585.54 6.39 1337.37 0.005646 
Table 3.1.3.4: Genes up-regulated in right cluster in comparison to (left + middle) 
cluster 
The right cluster is enriched with patients who relapsed (7/11). Among other important 
genes, this cluster over-expresses ERBB2 which is known to confer bad prognosis on 
breast cancer patients. 
Cluster D: This group was enriched for tumors which are mainly ER-positive (all samples 
apart from one), Grade 1 and lobular.  
Clinical  Status Represented Total p-value 
Type Lobular 8/31 17/122 0.0324 
Grade 1 6/31 11/122 0.0302 
Table 3.1.3.5: Clinical parameters over-represented in cluster D 
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Fig 3.1.3.4 Enlarged view of cluster D and E from the Fig 3.1.3.1. These clusters are 
highly enriched for ER-positive specimens. Cluster D has only 1 ER-negative 
specimen and the Cluster E has 3 ER-negative specimens.  
Cluster E: This group was also enriched for patients with ER-positive tumors. However 
there were 3 ER-negative and 3 Normal specimens in this group. No particular clinical 
parameter was identified by significance analysis for this group, however when combined 
with Cluster D, the significance analysis identified the combination group to be 
associated with overall survival and censored relapse free survival (Table 3.1.3.6). 
Despite both clusters D and E being enriched for ER-positive specimens, ER was not 
identified by the significance analysis, possibly due to its prevalence in Cluster C and B. 
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Clinical  Status Represented Total p-value 
CenRFC7 0 21/55 25/122 0 
OSSur7 0 24/55 32/122 0.001 
Table 3.1.3.6: Clinical parameters over-represented in clusters D and E. Both the 
clusters were combined to perform this analysis. 
Cluster D and Cluster E both are enriched with ER-positive patients, however cluster D 
have an overall higher expression of ESR1 (FC: 2.65) and other ER related genes, 
including GATA3 (FC: 1.64), FOXA1 (FC: 1.65), SPDEF (FC: 1.67) and TFF3 (FC: 
1.59). 
Cluster C was compared to Cluster D+E. As expected, ESR1 (FC: 3.04) and other ER 
related genes e.g. GATA3 (FC: 2.1), FOXA1 (FC: 1.73), SPDEF (FC: 1.6) and TFF3 
(FC: 1.9) were up-regulated in Cluster D+E. 
The above results correlating different clusters with clinical parameters was also 
corroborated by the results of Kaplan Myer analysis performed by Dr Lorraine O'Driscoll 
(Fig 3.1.3.5) and described in section 2.2.12. 
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Fig 3.1.3.5: KM analysis on various groups identified by Hierarchical clustering. 
The different colour line represents the survival of patients of each group. BLUE: 
Cluster E; GREEN: Cluster D; VIOLET: Cluster C (Middle sub-cluster); 
YELLOW: Cluster C (Right sub-cluster); GREY: Cluster C (Left sub-cluster) 
The results indicate that the Ropporin-enriched cluster (Grey) has the worst survival 
compared to patients belonging to other groups. This was followed by ERBB2 over-
expressing cluster (Yellow). These two groups of patients were enriched for ER-negative 
specimens. Another ER-negative enriched group (Violet) with a high expression of 
immune response genes displayed a much better survival. Among the groups of ER-
positive patients, one with high expression of ER partner genes (Blue) had a marginally 
better prognosis than the other ER-positive patients with relatively low level of ER genes 
(Green).  
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3.1.3.1 Two-way Hierarchical clustering  
 
Two-way clustering is a highly computationally-intensive process if the number of genes 
and/or number of samples included is very large. For this reason, a more stringent 
differentially expressed genelist (p ≤ 0.05, Fold Change (FC) ≥ 2 and Difference > 100) 
was generated comparing the normal vs. tumour gene expression profiles, yielding a total 
of 3924 differentially expressed (2166 up-regulated and 1758 down-regulated) genes and 
separate 2-way clustering analyses were performed. The gene clusters with enriched 
genes for similar functions and pathways was identified (see section 2.2.4).  
 
3.1.3.1.1 Up-regulated Genes 
Two-way hierarchical clustering was performed on all specimens using the differentially 
expressed genelist (p ≤ 0.05, Fold Change (FC) > 2 and Difference > 100) comparing 
cancer specimens and normal specimens. The distance metric used was 1-correlation and 
the clustering algorithm used was Average linkage clustering. Prior to clustering, the 
individual samples were standardised as follows: the expression of the individual genes 
was subtracted from their respective means and divided by their respective standard 
deviation. 2166 genes passed the filtration criteria and the two-way hierarchical 
clustering was performed using this list (Fig 3.1.3.1.1) 
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Fig 3.1.3.1.1: Two-way clustering of samples and genes using up-regulated genes only. 
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As can be seen from Fig. 3.1.3.1.1, normal samples and tumour samples largely clustered 
separately. Four (n5, 14, p18, n6) of the normal specimens did not cluster with the rest of 
the normals. The second most important clinical parameter on which the clustering was 
visually observed was Estrogen Receptor. Clusters of co-expressed genes with similar 
functions/pathways were identified  in the dendrogram. There were a total of 487 clusters 
of genes with significant Gene ontology terms (p < 0.001). The functions along with the 
number of genes are listed in Appendix 1. 10 pathways were also identified which were 
significant (p < 0.001) in various clusters Table 3.1.3.1.1. The individual clusters are 
shown in Appendix 2 (Fig A1 - Fig A9). "*" indicates this cluster includes all genes. 
Therefore they have not been shown in Appendix 2 
Pathway Changed Measured p-value 
Cell cycle * 22 220 0.000014 
DNA replication 7 103 0.000862 
Glycosphingolipid metabolism 6 102 0.000905 
Inflammatory Response Pathway 7 15 0 
Circadian Exercise 4 15 0.000289 
Androgen and estrogen metabolism 4 30 0.000271 
Proteasome Degradation 5 17 0.000045 
Nitrogen metabolism 5 69 0.000892 
O-Glycan biosynthesis 4 58 0.000695 
Nuclear Receptors 4 14 0.000335 
Table 3.1.3.1.1: Significant pathways in clusters of genes among the up-regulated 
genes.  
3.1.3.1.2 Down-regulated Genes 
Similarly, two-way clustering was performed separately on down regulated genes (p ≤ 
0.05, Fold Change (FC) > -2 and Difference > -100) comparing cancer specimens and 
normal specimens. The distance metric used was 1-correlation and the clustering 
algorithm used was Average linkage clustering. Prior to clustering, the individual 
 101 
samples were standardised as follows: the expression of the individual genes was 
subtracted from their means for that sample and divided by their respective standard 
deviation. 1758 genes passed the filtration criteria and the two-way hierarchical 
clustering was performed on them (Fig 3.1.3.1.2) 
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Fig 3.1.3.1.2: Two-way clustering of sample and genes on down-regulated genes. 
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As before, the normals and tumors largely clustered as distinct groups, with 4 of the 
normals (n5, n4, p18, n6) not clustering with the rest of the normals. No clinical 
parameter was found to be significant among the clusters (see section 2.2.4). Clusters of 
co-expressed genes with similar functions/pathways were identified in the dendrogram. 
There were a total of 382 clusters of genes with significant Gene ontology terms (p < 
0.001). The functions along with the number of genes are listed in Appendix 1. 25 
pathways were also identified which were significant (p < 0.001) in various clusters 
Table 3.1.3.1.2. The individual clusters are shown in Appendix 3 (Fig A1 - Fig A6). "*" 
indicates this cluster includes all genes. Therefore they have not been shown in Appendix 
3. These seem to be normal metabolic processes which are down-regulated in tumour 
samples. 
Pathway Changed Measured p-value 
Glycolysis / Gluconeogenesis * 18 272 0.000064 
Fatty acid metabolism * 24 272 0 
Glycogen Metabolism * 15 272 0.000511 
Pyruvate metabolism * 13 272 0.000004 
Propanoate metabolism * 10 272 0.000001 
Tyrosine metabolism * 14 272 0.000035 
Fatty Acid Degradation * 11 272 0.000058 
Glutathione metabolism * 11 272 0.000348 
Krebs-TCA Cycle * 12 272 0.000163 
Citrate cycle / TCA cycle * 11 272 0.000003 
Glycerolipid metabolism * 22 272 0.000041 
Lysine degradation * 10 272 0.000626 
Fatty Acid Synthesis * 12 272 0.000001 
Bile acid biosynthesis * 15 272 0 
Valine, leucine and isoleucine degradation * 17 272 0 
Ascorbate and aldarate metabolism * 5 272 0.000183 
Small ligand GPCRs * 10 272 0.000101 
Methane metabolism  6 210 0.000985 
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Histidine metabolism  5 104 0.00087 
Tryptophan metabolism  7 71 0.000827 
Glycine, serine and threonine metabolism  5 60 0.000881 
Phenylalanine metabolism  4 49 0.000889 
Arginine and proline metabolism  4 29 0.00065 
Integrin-mediated cell adhesion  5 18 0.000975 
GPCRs Class A Rhodopsin-like  4 4 0.000019 
Table 3.1.3.1.2: Significant pathways in clusters of genes among the up-regulated 
genes. 
3.1.4 Comparison criteria: Normal vs. cancer specimens 
Identifying genes up-regulated or down-regulated in cancer vs. normal helps us in better 
understanding the cancer dynamics and help identify markers and treatment targets for 
breast cancer.  
A total of 17 normal breast specimens and 104 breast cancer specimens were compared 
for gene expression changes using data generated from an in-house microarray 
experiment as previously detailed.  
Up-regulated gene transcripts:  
4,213 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 
1.2 and Difference > 100) in cancer specimens compared to normal specimens. Genes 
were ranked by fold change and, based on this criterion, the top 20 genes are listed in 
Table 3.1.4.1.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions represented are listed in Table 3.1.4.2.  
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
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0.05) and the 10 most significant pathways are listed in Table 3.1.4.3. Embryonic stem 
cells (Fig 3.1.4.1) and Cell cycle (Fig 3.1.4.2) pathways were observed to be enriched by 
the up-regulated genes. 
Down-regulated gene transcripts: 
3235 genes were identified as significantly down-regulated (p ≤ 0.05, FC< -1.2 and 
Difference< -100) in cancer specimens compared to normal specimens. Genes were 
ranked by fold change and, based on this criterion, the top 20 genes are listed in Table 
3.1.4.4.  
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and 10 most significant functions represented are listed in Table 3.1.4.5. 
Pathway analysis was performed using GenMAPP on the down-regulated genes (p ≤ 
0.05, FC<-2, and Difference < -100). Significant pathways were identified based on p-
value (p ≤ 0.05) and the 10 most significant pathways are listed in Table 3.1.4.6. Fatty 
acid Biosynthesis (Fig 3.1.4.3) pathways were observed to be enriched by the down-
regulated genes.           
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Probe set gene Baseline Experiment FC p-value 
205916_at S100A7 1 406.87 406.87 0.000514 
205941_s_at COL10A1 2.65 478.64 180.62 0 
226548_at SBK1 1.17 160.03 136.8 0 
213201_s_at TNNT1 2.31 314.01 135.96 0 
208502_s_at PITX1 1 106.63 106.21 0 
207802_at CRISP3 2.01 182.44 90.77 0.004065 
239983_at SLC30A8 5.27 350.19 66.44 0.000373 
204915_s_at SOX11 3.4 186.95 54.92 0 
236885_at LOC92312 3.16 160.97 50.96 0 
220318_at EPN3 2.9 138.45 47.74 0 
204351_at S100P 16.14 757.64 46.94 0 
229341_at TFCP2L1 2.31 103.09 44.61 0.000727 
231352_at SLC22A8 3.62 141.75 39.12 0 
217428_s_at COL10A1 12.95 498.17 38.47 0 
206502_s_at INSM1 4.43 151.87 34.32 0.026509 
228969_at AGR2 20.64 705.66 34.19 0 
220414_at CALML5 8.25 279.3 33.86 0.000001 
1558281_a_
at MGC9712 3.94 132.13 33.58 0 
229158_at WNK4 4.39 143.38 32.65 0 
204913_s_at SOX11 4.77 153.22 32.14 0.00001 
Table 3.1.4.1: Genes up-regulated in cancer specimens in comparison to normal 
specimens 
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GOID GO Name Changed Measured p-value 
5581 Collagen 12 30 0 
785 Chromatin 30 124 0 
278 Mitotic cell cycle 38 177 0 
7067 Mitosis 31 135 0 
87 M phase of mitotic cell cycle 31 137 0 
5584 Collagen type I 3 3 0 
5694 Chromosome 43 230 0 
279 M phase 35 176 0 
6333 Chromatin assembly or disassembly 25 114 0 
8094 DNA-dependent ATPase activity 11 35 0 
Table 3.1.4.2 Functions enriched among genes up-regulated in cancer in comparison 
to normal specimens 
MAPP Name Changed Measured p-value 
1-Tissue-Embryonic Stem Cell 15 47 0 
Cell cycle KEGG 22 89 0 
M phase of mitotic cell cycle 25 124 0 
Chromatin 29 152 0 
mRNA processing Reactome 25 125 0 
2-Tissues-Blood and Lymph 16 78 0 
Rhodopsin-like receptor activity 5 240 0 
GPCRDB Class A Rhodopsin-like 3 253 0 
Chromatin assembly or disassembly 24 139 0.001 
Establishment and or maintenance of chromatin 
architecture 
34 217 0.001 
Table 3.1.4.3: Pathways enriched among genes up-regulated in cancer in 
comparison to normal specimens 
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Fig 3.1.4.1: Embryonic stem cells pathway. Red indicates up-regulated genes in 
cancer specimens in comparison to normal specimens. Green indicates down-
regulated genes in cancer specimens in comparison to normal specimens.  
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Fig 3.1.4.2: Cell cycle pathways. Red indicates up-regulated genes in cancer 
specimens in comparison to normal specimens. Green indicates down-regulated 
genes in cancer specimens in comparison to normal specimens. 
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Probe set Gene Baseline  Experiment  FC p-value 
228880_at LOC339984 248.01 1.42 -174.51 0.000056 
222083_at GLYAT 445.31 2.58 -172.89 0.000075 
204997_at GPD1 721.75 5.14 -140.45 0.000013 
1558421_a_at LOC400258 1347.45 13.29 -101.39 0.000089 
220736_at SLC19A3 366.24 3.63 -100.91 0.000028 
213515_x_at 
HBG1, 
HBG2 1036.62 11.04 -93.92 0.022274 
201539_s_at FHL1 1048.5 12.75 -82.21 0.000024 
243311_at 
RP5-
1103G7.6 1258.94 18.22 -69.09 0.000183 
222226_at SAA3P 145.13 2.13 -68.07 0.00477 
243813_at --- 129.99 1.95 -66.7 0.004182 
210298_x_at FHL1 1198.5 18.47 -64.88 0.000029 
210106_at RDH5 831.47 12.95 -64.21 0.000011 
235708_at KLB 736.68 12.68 -58.09 0.00003 
234943_at --- 108.54 1.87 -57.96 0.005823 
237154_at HSD11B1 1378.6 24.14 -57.11 0.000022 
219140_s_at RBP4 3687.79 65 -56.74 0.000016 
228168_at ATP5G3 102.45 1.83 -55.88 0.002188 
208383_s_at PCK1 1328 25.05 -53.01 0.000014 
207092_at LEP 4466.38 88.5 -50.47 0.000006 
209980_s_at SHMT1 111.96 2.42 -46.31 0.000878 
Table 3.1.4.4: Genes down-regulated in cancer specimens in comparison to normal 
specimens 
 
 
 
 111 
GOID GO Name Changed Measured p-value 
9109 Coenzyme catabolism 12 22 0 
46356 Acetyl-CoA catabolism 11 21 0 
6099 Tricarboxylic acid cycle 11 21 0 
16628 
Oxidoreductase activity, acting 
on the CH-CH Group of donors, 
NAD or NADP as acceptor 9 15 0 
51187 Cofactor catabolism 12 26 0 
6629 Lipid metabolism 82 535 0 
9060 Aerobic respiration 12 28 0 
16491 Oxidoreductase activity 85 579 0 
4300 Enoyl-CoA hydratase activity 5 6 0 
Table 3.1.4.5: Functions enriched among genes down-regulated in cancer in 
comparison to normal specimens 
MAPP Name Changed Measured p-value 
Fatty Acid Synthesis BiGCaT 15 22 0 
Propanoate metabolism 14 27 0 
Citrate cycle TCA cycle  13 24 0 
Mitochondrial fatty acid betaoxidation 10 16 0 
Valine leucine and isoleucine degradation 17 39 0 
Fatty Acid Beta Oxidation Meta BiGCaT 14 32 0 
Adipogenesis 34 130 0 
Pyruvate metabolism 14 34 0 
1-Tissue-Muscle fat and connective 20 65 0 
Fatty acid metabolism 20 66 0 
Table 3.1.4.6: Pathways enriched among genes down-regulated in cancer in 
comparison to normal specimens 
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Fig 3.1.4.3: Fatty acid biosynthesis pathways. Red indicates up-regulated genes in 
cancer specimens in comparison to normal specimens. Green indicates down-
regulated genes in cancer specimens in comparison to normal specimens. 
3.1.5 Comparison criteria: Estrogen receptor-negative vs. Estrogen receptor-
positive 
Estrogen receptor (ER) status is important in identifying patients who are likely to 
respond from endocrine therapy. Identifying genes up and down regulated in ER-positive 
vs. ER-negative patients is important to get a better understanding of the significance of 
ER pathway. 
A total of 34 ER-negative breast specimens and 67 ER-positive breast cancer specimens 
were compared for gene expression changes. 
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Up-Regulated gene transcripts: 
855 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in ER-positive breast cancer specimens compared to ER-negative 
specimens. Genes were ranked by fold change and, based on these criteria, the top 20 
genes are listed in Table 3.1.5.1.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions are listed in Table 3.1.5.2.  
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
0.05) and significant pathways are listed in Table 3.1.5.3. The Nuclear receptors pathway 
was observed to be enriched by the up-regulated genes. 
Down-regulated gene transcripts: 
1145 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) 
< -1.2 and Difference < -100) in ER-positive breast cancer specimens compared to ER-
negative specimens. Genes were ranked by fold change and, based on these criteria, the 
top 20 genes are listed in Table 3.1.5.4.  
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.5.5.  
Pathway analysis was performed using GenMAPP database on the down-regulated genes 
(p ≤ 0.05, FC<-2, and Difference < -100). Significant pathways were identified based on 
p-value (p ≤ 0.05) and the significant pathways are listed in Table 3.1.5.6. Genes specific 
to blood and lymph tissue pathway were observed to be enriched by the down-regulated 
genes. 
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Probe set Gene Baseline Experimental FC p-value 
236445_at LOC731986 6.71 264.52 39.43 0.000901 
1494_f_at CYP2A6 49.93 606.61 12.15 0.024179 
242301_at CBLN2 10.41 116.75 11.21 0.012938 
210272_at CYP2B7P1 39.93 438.38 10.98 0.000165 
1552507_at KCNE4 65.09 511.13 7.85 0.000406 
1562821_a_at DSCAM 69.35 536.03 7.73 0.017704 
206754_s_at CYP2B7P1 189.29 1445.09 7.63 0.000069 
205696_s_at GFRA1 42.88 291.22 6.79 0 
230163_at LOC143381 82.42 558.14 6.77 0 
239983_at SLC30A8 76.2 505.49 6.63 0.004899 
218332_at BEX1 79.39 510.9 6.44 0.00405 
240192_at FLJ45983 24.51 135.67 5.54 0.000012 
222379_at --- 60.8 331.69 5.46 0.000691 
220540_at KCNK15 42.8 215.18 5.03 0.000035 
211712_s_at ANXA9 52.94 251.19 4.74 0.000007 
1555997_s_at IGFBP5 51.64 230.38 4.46 0.001196 
227550_at LOC143381 211.8 933.96 4.41 0.000002 
203999_at --- 35.44 147.18 4.15 0.012644 
241368_at LSDP5 55.83 222.53 3.99 0.000033 
226271_at GDAP1 79.83 307.42 3.85 0.017169 
Table 3.1.5.1: Genes up-regulated in ER-positive specimens in comparison to ER-
negative specimens 
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GOID GO Name Changed Measured p-value 
30027 Lamellipodium 2 15 0 
902 Cellular morphogenesis 7 236 0 
5006 
Epidermal growth factor 
receptor activity 2 7 0.002 
31252 Leading edge 2 18 0.002 
9653 Morphogenesis 9 522 0.002 
7584 Response to nutrient 2 15 0.003 
17162 
Aryl hydrocarbon receptor 
binding 1 1 0.004 
42995 Cell projection 3 65 0.004 
1786 Phosphatidylserine binding 1 1 0.005 
31667 Response to nutrient levels 2 19 0.005 
Table 3.1.5.2: Functions enriched among genes up-regulated in ER-positive 
specimens in comparison to ER-negative specimens. 
MAPP Name Changed Measured p-value 
Nuclear Receptors 2 38 0.039 
IL-3 NetPath 15 3 101 0.039 
Synthesis and Degradation of Ketone 
Bodies KEGG 1 5 0.04 
Butanoate metabolism 2 38 0.042 
2-Tissues-Endocrine and CNS 3 103 0.042 
Table 3.1.5.3 Pathways enriched among genes up-regulated in ER-positive 
specimens in comparison to ER-negative specimens. 
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Probe set Gene Baseline Experimental FC p-value 
216365_x_at 
IGL@, 
CPVL 228.98 31.35 -7.3 0.042385 
220425_x_at ROPN1B 164.84 24.84 -6.64 0.012712 
205363_at BBOX1 205.39 33.76 -6.08 0.004225 
224191_x_at ROPN1 187.87 31.7 -5.93 0.027217 
213711_at KRT81 587.61 103.04 -5.7 0.022424 
231535_x_at ROPN1 210.24 37.59 -5.59 0.023043 
219225_at PGBD5 169.43 31.97 -5.3 0.033009 
206165_s_at CLCA2 175.85 34.81 -5.05 0.044217 
212531_at LCN2 219.97 43.92 -5.01 0.030348 
210147_at ART3 126.27 25.23 -5 0.040628 
237625_s_at --- 427.38 86.05 -4.97 0.038949 
220559_at EN1 141 29.54 -4.77 0.03141 
214777_at --- 273.81 59.04 -4.64 0.033383 
217528_at CLCA2 232.94 50.85 -4.58 0.039492 
211881_x_at IGLJ3 532.05 118.48 -4.49 0.047763 
223468_s_at RGMA 482.4 108.43 -4.45 0.00109 
202037_s_at SFRP1 1122.95 256.41 -4.38 0.005489 
209396_s_at CHI3L1 802.87 188.9 -4.25 0.022891 
235209_at RPESP 316.05 76.29 -4.14 0.029573 
211798_x_at IGLJ3 611.25 150.68 -4.06 0.044385 
Table 3.1.5.4: Genes down-regulated in ER-positive specimens in comparison to ER-
negative specimens 
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GOID GO Name Changed Measured p-value 
45012 MHC class II receptor activity 3 13 0 
19884 
Antigen presentation, 
exogenous antigen 3 13 0 
19886 
Antigen processing, exogenous 
antigen via MHC class II 3 14 0 
19221 
Cytokine and chemokine 
mediated signaling pathway 3 15 0 
9607 Response to biotic stimulus 24 845 0 
6952 Defense response 22 806 0 
6955 Immune response 19 716 0 
50896 Response to stimulus 34 1754 0 
6032 Chitin catabolism 2 7 0.001 
4568 Chitinase activity 2 7 0.001 
Table 3.1.5.5: Functions enriched among genes down-regulated in ER-positive 
specimens in comparison to ER-negative specimens. 
MAPP Name Changed Measured p-value 
2-Tissues-Blood and Lymph 14 78 0 
1-Tissue-Blood and Lymph 13 168 0 
Phosphatidylinositol signaling system 7 122 0.004 
Kit-Receptor NetPath 6 4 67 0.017 
B Cell Receptor NetPath 12 6 158 0.039 
Table 3.1.5.6: Pathways enriched among genes down-regulated in ER-positive 
specimens in comparison to ER-negative specimens. 
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3.1.6 Comparison criteria: Lymph node-negative vs. Lymph node-positive 
Positive lymph node status indicates the spread of disease and is an indicator of 
aggressive disease. Identifying genes up and down regulated in Lymph node-positive vs. 
lymph node-negative patients may help identify biomarkers and targets for aggressive 
disease. 
A total of 45 lymph node-negative specimens and 59 lymph node-positive specimens 
were compared for gene expression changes. 
Up-regulated gene transcripts: 
102 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in lymph node-positive specimens compared to lymph node-
negative specimens. Genes were ranked by fold change and, based on this criterion, the 
top 20 genes are listed in Table 3.1.6.1.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions are listed in Table 3.1.6.2.  
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
0.05) and listed in Table 3.1.6.3  
Down-regulated gene transcripts: 
126 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in lymph node-positive specimens compared to lymph node-
negative specimens. Genes were ranked by fold change and, based on these criteria, the 
top 20 genes are listed in Table 3.1.6.4.  
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Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.6.5.  
Pathway analysis was performed using GenMAPP on the down-regulated genes (p ≤ 
0.05, FC<-2, and Difference < -100). No pathway was found to be significantly affected 
(p ≤ 0.05). 
Probe set Gene Baseline Experiment FC P value 
208161_s_at ABCC3 114.65 288.11 2.51 0.030769 
232547_at SNIP 78.47 197.18 2.51 0.031976 
201467_s_at NQO1 104.07 252.98 2.43 0.014538 
213557_at CRKRS 105.28 252.03 2.39 0.013519 
213551_x_at PCGF2 172.75 355.64 2.06 0.009378 
204942_s_at ALDH3B2 367.35 737.26 2.01 0.012173 
201525_at APOD 607.61 1214.76 2 0.03805 
236885_at LOC92312 104.67 204.99 1.96 0.003213 
201080_at PIP5K2B 460.62 888.4 1.93 0.013447 
202991_at STARD3 126.81 241.75 1.91 0.005253 
226727_at LOC284106 230.36 437.84 1.9 0.03065 
214239_x_at PCGF2 354.75 670.7 1.89 0.012442 
228854_at --- 129.08 243.04 1.88 0.037461 
210519_s_at NQO1 424.43 779.09 1.84 0.011794 
224784_at MLLT6 199.44 367.65 1.84 0.01422 
204351_at S100P 528.01 935.78 1.77 0.045632 
227512_at LOC92312 160.25 281.39 1.76 0.003296 
226346_at LOC92312 266.36 463.27 1.74 0.006202 
222706_at CCDC49 175.35 302.95 1.73 0.013138 
201400_at PSMB3 1252.09 2107.56 1.68 0.003089 
Table 3.1.6.1: Genes up-regulated in lymph node-positive specimens in comparison 
to lymph node-negative specimens 
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GOID GO Name Changed Measured p-value 
3955 
NAD(P)H dehydrogenase 
(quinone) activity 1 2 0.001 
4128 Cytochrome-b5 reductase activity 1 5 0.002 
4030 
Aldehyde dehydrogenase 
[NAD(P)+] activity 1 5 0.003 
46209 Nitric oxide metabolism 1 13 0.003 
6809 Nitric oxide biosynthesis 1 13 0.003 
7271 Synaptic transmission, cholinergic 1 8 0.004 
16652 
Oxidoreductase activity, acting on 
NADH or NADPH, NAD or 
NADP as acceptor 1 8 0.004 
7270 Nerve-nerve synaptic transmission 1 10 0.004 
8514 Organic anion transporter activity 1 10 0.006 
4028 Aldehyde dehydrogenase activity 1 13 0.006 
Table: 3.1.6.2: Functions enriched among genes up-regulated in lymph node-
positive specimens in comparison to lymph node-negative specimens 
MAPP Name Changed Measured p-value 
Sterol biosynthesis 1 19 0.015 
Phenylalanine metabolism 1 21 0.023 
Nuclear receptors in lipid metabolism and 
toxicity 1 33 0.029 
Oxidative Stress 1 28 0.031 
Tyrosine metabolism 1 50 0.046 
Histidine metabolism 1 43 0.048 
Table: 3.1.6.3: Pathways enriched among genes up-regulated in lymph node-positive 
specimens in comparison to lymph node-negative specimens 
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Probe set Gene Baseline Experiment FC P value 
1562309_s_at PHF21B 203.88 33.16 -6.15 0.029485 
205710_at LRP2 186.27 51.63 -3.61 0.027245 
226269_at GDAP1 439.22 124.8 -3.52 0.048222 
229947_at PI15 1154.42 334.98 -3.45 0.006649 
221796_at NTRK2 342.72 102.47 -3.34 0.047688 
205794_s_at NOVA1 496.28 183.17 -2.71 0.023049 
230863_at --- 484.5 185.15 -2.62 0.024507 
232687_at --- 241.09 91.97 -2.62 0.021802 
205567_at CHST1 253.67 112.66 -2.25 0.043266 
211421_s_at RET 321.52 144.02 -2.23 0.017844 
205472_s_at DACH1 518.9 258.04 -2.01 0.032869 
213832_at --- 364.12 185 -1.97 0.01482 
225123_at --- 432.05 227.79 -1.9 0.014714 
1570344_at --- 314.92 168.16 -1.87 0.01455 
205471_s_at DACH1 381.97 205.01 -1.86 0.035402 
228915_at DACH1 474.53 254.77 -1.86 0.024403 
225613_at MAST4 691.74 373.56 -1.85 0.031486 
227192_at PRRT2 291.04 161.4 -1.8 0.04585 
1554007_at ZNF483 250.9 140.49 -1.79 0.009076 
244696_at AFF3 379.29 219.24 -1.73 0.016035 
Table 3.1.6.4: Genes down-regulated in lymph node-positive specimens in 
comparison to lymph node-negative specimens 
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GOID GO Name Changed Measured p-value 
45130 
Keratan sulfotransferase 
activity 1 1 0 
7456 
Eye development (sensu 
Endopterygota) 1 1 0 
43121 Neurotrophin binding 1 3 0 
7497 Posterior midgut development 1 1 0.001 
7494 Midgut development 1 1 0.001 
42339 Keratan sulfate metabolism 1 2 0.001 
48565 Gut development 1 2 0.002 
30304 Trypsin inhibitor activity 1 3 0.002 
6012 Galactose metabolism 1 7 0.003 
1654 Eye development 1 9 0.004 
Table: 3.1.6.5: Functions enriched among genes down-regulated in lymph node-
positive specimens in comparison to lymph node-negative specimens 
3.1.7 Comparison criteria: Grade 1 vs. Grade 2 
Higher Grade cancers are more aggressive. Identifying genes up and down regulated in 
patients with high grade tumors vs. low grade tumors may help identify biomarkers and 
targets for aggressive disease. 
A total of 11 specimens with Grade 1 cancer and 40 specimens with Grade 2 cancers 
were compared for gene expression changes.  
Up-regulated gene transcripts: 
275 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in Grade 2 specimens compared to Grade 1 specimens. Genes 
were ranked by fold change and, based on this criterion, the top 20 genes are listed in 
Table 3.1.7.1.  
 123 
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the10 most significant functions are listed in Table 3.1.7.2.  
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
0.05) listed in Table 3.1.7.3.  
Down-regulated gene transcripts: 
75 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < -
1.2 and Difference < -100) in Grade 2 specimens compared to Grade 1 specimens. Genes 
were ranked by fold change and, based on these criteria, the top 20 genes are listed in 
Table 3.1.7.4. 
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.7.5. 
Pathway analysis was performed using GenMAPP on the down-regulated genes (p ≤ 
0.05, FC<-2, and Difference < -100). No pathway was found to be significantly affected 
(p ≤ 0.05).  
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Probe set Gene Baseline Experiment FC p-value 
221107_at CHRNA9 11.95 163.02 13.64 0.02427 
210576_at CYP4F8 15.69 162.6 10.36 0.038742 
202917_s_at S100A8 117.23 819.95 6.99 0.027742 
203915_at CXCL9 95.42 616.34 6.46 0.01134 
230966_at IL4I1 30.59 168.93 5.52 0.015138 
1562821_a_at DSCAM 82.14 447.18 5.44 0.017192 
202672_s_at ATF3 102.7 416.69 4.06 0.000924 
204533_at CXCL10 64.57 261.66 4.05 0.042573 
221667_s_at HSPB8 154.17 605.27 3.93 0.004196 
203645_s_at CD163 64.84 249.67 3.85 0.044332 
202768_at FOSB 75.36 286.7 3.8 0.001608 
203936_s_at MMP9 229.25 870.22 3.8 0.016992 
210163_at CXCL11 42.15 156.18 3.71 0.017085 
217388_s_at KYNU 119.89 416.78 3.48 0.007713 
221491_x_at HLA-DRB1 85.24 296.62 3.48 0.000384 
215049_x_at CD163 86.73 292.72 3.37 0.042521 
203290_at HLA-DQA1 58.37 187.41 3.21 0.021995 
202988_s_at RGS1 56.62 177.43 3.13 0.001173 
211143_x_at NR4A1 62.24 193.85 3.11 0.000432 
229476_s_at THRSP 89.79 274 3.05 0.012882 
Table 3.1.7.1: Genes up-regulated in Grade 2 specimens in comparison to Grade 1 
specimens 
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GOID GO Name Changed Measured p-value 
42379 Chemokine receptor binding 5 44 0 
8009 Chemokine activity 5 44 0 
1664 G-protein-coupled receptor binding 5 52 0 
19363 Pyridine nucleotide biosynthesis 2 10 0 
6955 Immune response 17 716 0 
9607 Response to biotic stimulus 18 845 0 
42364 Water-soluble vitamin biosynthesis 2 13 0 
6952 Defense response 17 806 0 
42330 Taxis 6 116 0 
6935 Chemotaxis 6 116 0 
Table 3.1.7.2: Functions enriched among genes up-regulated in Grade 2 specimens 
in comparison to Grade 1 specimens 
MAPP Name Changed Measured p-value 
1-Tissue-Blood and Lymph 5 168 0.001 
BCell Receptor NetPath_12 3 158 0.034 
Table 3.1.7.3: Pathways enriched among genes up-regulated in Grade 2 specimens 
in comparison to Grade 1 specimens 
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Probe set Gene Baseline Experiment FC p-value 
221207_s_at NBEA 202.86 79.62 -2.55 0.038106 
206509_at PIP 4995.37 1998.45 -2.5 0.031477 
204014_at DUSP4 1377.66 585.14 -2.35 0.034649 
229331_at SPATA18 196.9 84.09 -2.34 0.015777 
205009_at TFF1 3627.58 1582.24 -2.29 0.024715 
226034_at --- 1763.7 800.52 -2.2 0.023362 
201445_at CNN3 353.94 178.34 -1.98 0.039975 
204633_s_at RPS6KA5 289.74 147.1 -1.97 0.012653 
204635_at RPS6KA5 243.95 126.37 -1.93 0.006307 
204686_at IRS1 603.2 330.01 -1.83 0.023378 
243495_s_at --- 274.03 154.92 -1.77 0.01535 
208978_at CRIP2 243.56 139.62 -1.74 0.031256 
204623_at TFF3 3889.12 2265.98 -1.72 0.046233 
238044_at --- 260.61 154.2 -1.69 0.047571 
227769_at --- 254.05 151.79 -1.67 0.024086 
202936_s_at SOX9 838.74 508.58 -1.65 0.012404 
227856_at C4orf32 882.22 533.75 -1.65 0.047376 
226989_at RGMB 408.82 249.54 -1.64 0.02876 
228496_s_at CRIM1 1155.66 722.16 -1.6 0.021534 
229478_x_at BIVM 296.93 190.88 -1.56 0.025046 
Table 3.1.7.4: Genes down-regulated in Grade 2 specimens in comparison to Grade 
1 specimens 
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GOID GO Name Changed Measured p-value 
8330 
Protein tyrosine/threonine 
phosphatase activity 1 3 0.001 
51018 Protein kinase A binding 1 9 0.002 
17017 MAP kinase phosphatase activity 1 10 0.002 
5802 Golgi trans face 1 14 0.002 
6892 Post-Golgi transport 1 15 0.006 
8138 
Protein tyrosine/serine/threonine 
phosphatase activity 1 39 0.012 
19901 Protein kinase binding 1 43 0.014 
7586 Digestion 1 52 0.014 
19900 Kinase binding 1 49 0.017 
4725 Protein tyrosine phosphatase activity 1 76 0.019 
Table 3.1.7.2: Functions enriched among genes down-regulated in Grade 2 
specimens in comparison to Grade 1 specimens 
3.1.8 Comparison criteria: Grade 2 vs. Grade 3 
Higher Grade cancers are more aggressive. Identifying genes up- and down-regulated in 
patients with high grade tumors vs. low grade tumors may help identify biomarkers and 
targets for aggressive disease. 
A total of 40 specimens with Grade 2 cancer and 53 specimens with Grade 3 cancer were 
compared for gene expression changes.  
Up-regulated gene transcripts: 
930 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in Grade 3 specimens compared to Grade 2 specimens. Genes 
were ranked by fold change and, based on these criteria, the top 20 genes are listed in 
Table 3.1.8.1.  
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Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions are listed in Table 3.1.8.2. 
Pathway analysis was performed using GenMAPP database on the up-regulated genes (p 
≤ 0.05, FC>2, and Difference > 100). Significant pathways were identified based on p-
value (p ≤ 0.05) and are listed in Table 3.1.8.3. 
Down-regulated gene transcripts: 
596 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in Grade 3 specimens compared to Grade 2 specimens. Genes 
were ranked by fold change and, based on these criteria, the top 20 genes are listed in 
Table 3.1.8.4. 
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.8.5. 
Pathway analysis was performed using GenMAPP database on the down-regulated genes 
(p ≤ 0.05, FC<-2, and Difference < -100). Significant pathways were identified based on 
p-value (p ≤ 0.05) and are listed in Table 3.1.8.6. 
 
 129 
Probe set Gene Baseline Experiment FC p-value 
215729_s_at VGLL1 8.32 121.89 14.65 0.004585 
204602_at DKK1 28.8 212.85 7.39 0.002297 
213711_at KRT81 73.65 492.39 6.69 0.007681 
234764_x_at LOC96610 47.16 206.44 4.38 0.016944 
231535_x_at ROPN1 32.27 138.4 4.29 0.037289 
212531_at LCN2 40.45 171.13 4.23 0.01685 
237625_s_at --- 77.24 319.08 4.13 0.027354 
223062_s_at PSAT1 67.35 257.38 3.82 0.000293 
204751_x_at DSC2 41.88 152.19 3.63 0.002025 
215189_at KRT86 45 159.32 3.54 0.009247 
213060_s_at CHI3L2 121.29 427.27 3.52 0.00917 
220625_s_at ELF5 149.21 512.18 3.43 0.005103 
226960_at UNQ473 47.89 150.55 3.14 0.027938 
206714_at ALOX15B 86.79 267.16 3.08 0.03856 
216401_x_at --- 122.68 374.9 3.06 0.036479 
201195_s_at SLC7A5 157 461.06 2.94 0.006608 
1560818_at LOC387895 120.25 348.45 2.9 0.023133 
213680_at KRT6B 197.82 570.54 2.88 0.01229 
204855_at SERPINB5 89.41 254.12 2.84 0.015386 
222549_at CLDN1 154.73 438.34 2.83 0.016607 
Table 3.1.8.1: Genes up-regulated in Grade 3 specimens in comparison to Grade 2 
specimens 
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GOID GO Name Changed Measured p-value 
5882 Intermediate filament 5 92 0 
45111 
Intermediate filament 
cytoskeleton 5 92 0 
278 Mitotic cell cycle 4 177 0 
5856 Cytoskeleton 9 710 0 
15288 Porin activity 2 20 0.001 
19212 Phosphatase inhibitor activity 2 25 0.002 
51301 Cell division 4 153 0.002 
5198 Structural molecule activity 8 673 0.002 
16781 
Phosphotransferase activity, 
paired acceptors 1 1 0.003 
4756 Selenide, water dikinase activity 1 1 0.003 
Table 3.1.8.2: Functions enriched among genes up-regulated in Grade 3 specimens 
in comparison to Grade 2 specimens 
MAPP Name Changed Measured p-value 
1-Tissue-Embryonic Stem Cell 4 47 0 
2-Tissues-Muscle Fat and Connective 4 82 0 
2-Tissues-Blood and Lymph 4 78 0.001 
Cell cycle KEGG 3 89 0.02 
Streptomycin biosynthesis 1 4 0.022 
Vitamin B6 metabolism 1 6 0.034 
Cell Cycle-G1 to S control Reactome 2 67 0.05 
Table 3.1.8.3: Pathways enriched among genes up-regulated in Grade 3 specimens 
in comparison to Grade 2 specimens 
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Probe set Gene Baseline Experiment FC p-value 
221107_at CHRNA9 163.02 13.2 -12.35 0.025506 
241811_x_at --- 122.75 10.29 -11.93 0.013787 
210576_at CYP4F8 162.6 20.88 -7.79 0.045351 
1560850_at --- 193.12 47.72 -4.05 0.042593 
206799_at SCGB1D2 1482.2 461.3 -3.21 0.006931 
219602_s_at FAM38B 149.67 48.6 -3.08 0.004821 
205440_s_at NPY1R 1193.02 388.98 -3.07 0.01136 
233059_at --- 472.38 157.13 -3.01 0.04971 
241368_at LSDP5 277.55 93.45 -2.97 0.002462 
235976_at SLITRK6 636.62 217.17 -2.93 0.039497 
213651_at PIB5PA 308.74 105.94 -2.91 0.000372 
227550_at LOC143381 928.69 327.47 -2.84 0.000501 
229975_at --- 1105.68 390.97 -2.83 0.006145 
203980_at FABP4 1345.62 486.59 -2.77 0.009236 
228766_at --- 671.85 245.4 -2.74 0.024059 
204018_x_at HBA1 193.91 72.2 -2.69 0.046376 
209458_x_at HBA1 187.28 69.6 -2.69 0.04667 
243241_at --- 447.87 170.16 -2.63 0.024914 
229580_at --- 418.9 160.07 -2.62 0.002053 
205696_s_at GFRA1 278.61 108.16 -2.58 0.003903 
Table 3.1.8.4: Genes down-regulated in Grade 3 specimens in comparison to Grade 
2 specimens 
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GOID GO Name Changed Measured p-value 
3867 
4-aminobutyrate transaminase 
activity 1 1 0.002 
47298 
(S)-3-amino-2-methylpropionate 
transaminase activity 1 1 0.002 
16167 
Glial cell line-derived neurotrophic 
factor receptor activity 1 2 0.002 
15674 
Di-, tri-valent inorganic cation 
transport 3 112 0.002 
4060 
Arylamine N-acetyltransferase 
activity 1 2 0.003 
5010 
Insulin-like growth factor receptor 
activity 1 3 0.003 
30284 Estrogen receptor activity 1 2 0.004 
9448 
Gamma-aminobutyric acid 
metabolism 1 2 0.004 
6631 Fatty acid metabolism 3 135 0.004 
45839 Negative regulation of mitosis 1 2 0.005 
Table 3.1.8.5: Functions enriched among genes down-regulated in Grade 3 
specimens in comparison to Grade 2 specimens 
MAPP Name Changed Measured p-value 
1-Tissue-Muscle_fat_and_connective 5 65 0 
2-Tissues-Endocrine_and_CNS 3 103 0.007 
Circadian_Exercise 2 48 0.017 
Bile_acid_biosynthesis 2 37 0.02 
Fatty_acid_metabolism 2 66 0.04 
Table 3.1.8.6: Pathways enriched among genes down-regulated in Grade 3 
specimens in comparison to Grade 2 specimens 
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The transcripts in the Grade 1 vs. 2 comparisons and Grade 2 vs. 3 comparisons were 
cross compared to identify transcripts which progressively increase with grade. Table 
3.1.8.7 list the transcripts which progressively increased or decreased with grade. 
Transcripts with different trends of expression were removed from the list.
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Probe Name Grade 1 vs. 2 Grade 2 vs. 3 
230966_at IL4I1 5.52 2.26 
204655_at CCL5 2.05 1.81 
209644_x_at CDKN2A 1.9 2.43 
219806_s_at C11orf75 1.89 1.51 
204994_at MX2 1.77 1.52 
216397_s_at BOP1 1.77 1.38 
219402_s_at DERL1 1.71 1.51 
219202_at RHBDF2 1.6 1.65 
201201_at CSTB 1.52 1.48 
200632_s_at NDRG1 1.4 1.72 
201433_s_at PTDSS1 1.4 1.36 
218499_at RP6-213H19.1 1.4 1.3 
222977_at SURF4 1.39 1.32 
218151_x_at GPR172A 1.36 1.45 
201587_s_at IRAK1 1.35 1.49 
225751_at RBM17 1.34 1.3 
208691_at TFRC 1.34 1.24 
201772_at AZIN1 1.32 1.26 
208693_s_at GARS 1.3 1.4 
200844_s_at PRDX6 1.3 1.24 
201527_at ATP6V1F 1.3 1.24 
222992_s_at NDUFB9 1.26 1.22 
217835_x_at C20orf24 1.26 1.21 
225334_at C10orf32 -1.41 -1.3 
227856_at C4orf32 -1.65 -1.37 
Table 3.1.8.7: Transcripts progressively increasing or decreasing with increase in 
grade 
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3.1.9 Comparison criteria: Tumour Size < 2.8cm vs. > 2.8 cm 
Large size tumors are more aggressive. Identifying genes up- and down-regulated in 
patients with large tumors vs. small tumors may help identify biomarkers and targets for 
aggressive disease. 
A total of 56 specimens with tumour size less than 2.8cm and a total of 48 specimens 
with tumour size greater than 2.8cm were compared for gene expression changes.  
Up-regulated gene transcripts: 
36 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in tumour size greater than 2.8cm compared to tumour size less 
than 2.8cm. Genes were ranked by fold change and, based on these criteria, the top 20 
genes are listed in Table 3.1.9.1.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the significant functions are listed in Table 3.1.9.2. 
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). No pathway was found to be significantly affected (p ≤ 
0.05). 
Down-regulated gene transcripts: 
139 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in tumour size greater than 2.8 compared to tumour size less 
than 2.8. Genes were ranked by fold change and, based on this criteria, the top 20 genes 
are listed in Table 3.1.9.3. 
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.9.4.  
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Pathway analysis was performed using GenMAPP database on the down-regulated genes 
(p ≤ 0.05, FC<-2, and Difference < -100). No pathway was found to be significantly 
affected (p ≤ 0.05). 
Probe set Gene Baseline Experimental FC p-value 
235210_s_at RPESP 119.16 294.12 2.47 0.04609 
223895_s_at EPN3 269.69 631.28 2.34 0.003628 
219300_s_at CNTNAP2 87.71 195.71 2.23 0.037062 
220318_at EPN3 92.13 192.54 2.09 0.007949 
235203_at --- 146.71 249.42 1.7 0.015045 
243552_at --- 296.91 474.03 1.6 0.036136 
1556316_s_at LOC284889 263.36 410.07 1.56 0.000235 
201562_s_at SORD 353.7 540.08 1.53 0.04714 
213971_s_at SUZ12 196.02 299 1.53 0.041818 
214295_at KIAA0485 304.21 452.79 1.49 0.014113 
210002_at GATA6 210.51 311.08 1.48 0.031133 
225203_at PPP1R16A 255.24 367.22 1.44 0.009487 
235079_at --- 266.76 384.43 1.44 0.023296 
1553303_at C16orf46 629.84 905.39 1.44 0.028459 
213577_at SQLE 588.55 841.36 1.43 0.037003 
242824_at NFIA 430.72 610.49 1.42 0.045806 
200641_s_at YWHAZ 289.37 393.34 1.36 0.043948 
208972_s_at ATP5G1 854.63 1162.89 1.36 0.010666 
226616_s_at NDUFV3 350.37 475.02 1.36 0.017362 
208104_s_at TSC22D4 339.09 459.32 1.35 0.02723 
Table 3.1.9.1: Genes up-regulated in tumour size greater than 2.8 in comparison to 
tumour size less than 2.8  
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GOID GO Name Changed Measured p-value 
8038 Neuron recognition 1 5 0.002 
8037 Cell recognition 1 16 0.005 
19226 Transmission of nerve impulse 1 226 0.022 
8289 Lipid binding 1 195 0.027 
Table 3.1.9.2: Functions enriched among genes up-regulated in tumour size greater 
than 2.8 in comparison to tumour size less than 2.8  
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Probe set Gene Baseline Experimental FC p-value 
205358_at GRIA2 421.5 60.72 -6.94 0.048872 
243722_at PYDC1 164.35 36.57 -4.49 0.02198 
203029_s_at PTPRN2 220.94 88.15 -2.51 0.048149 
220414_at CALML5 383.44 161.31 -2.38 0.028932 
202768_at FOSB 244.75 113.18 -2.16 0.0116 
202506_at SSFA2 317.81 152.65 -2.08 0.020651 
221667_s_at HSPB8 531.42 255.95 -2.08 0.028217 
204351_at S100P 975.59 515.89 -1.89 0.021114 
204363_at F3 328.01 177.65 -1.85 0.019519 
219440_at RAI2 414.68 236.28 -1.76 0.017806 
203423_at RBP1 435.93 249.66 -1.75 0.019874 
212771_at C10orf38 251.59 147.36 -1.71 0.035128 
218976_at DNAJC12 943.16 562.33 -1.68 0.028794 
208078_s_at SNF1LK 361.28 220.95 -1.64 0.014417 
211026_s_at MGLL 282.48 175.3 -1.61 0.010454 
207992_s_at AMPD3 292.54 182.61 -1.6 0.009085 
204489_s_at CD44 439.87 278.4 -1.58 0.002035 
219681_s_at RAB11FIP1 390.62 252.8 -1.55 0.03929 
204550_x_at GSTM1 327.44 213.13 -1.54 0.030244 
223251_s_at ANKRD10 784.11 516.69 -1.52 0.005009 
Table 3.1.9.3: Genes down-regulated in tumour size greater than 2.8 in comparison 
to tumour size less than 2.8  
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GOID GO Name Changed Measured p-value 
4971 
Alpha-amino-3-hydroxy-5-methyl-4-
isoxazole propionate selective glutamate 
receptor activity 1 3 0.003 
15277 Kainate selective glutamate receptor activity 1 8 0.005 
19198 
Transmembrane receptor protein 
phosphatase activity 1 18 0.006 
5001 
Transmembrane receptor protein tyrosine 
phosphatase activity 1 18 0.006 
4970 Ionotropic glutamate receptor activity 1 18 0.009 
5234 Glutamate-gated ion channel activity 1 19 0.009 
8066 Glutamate receptor activity 1 38 0.02 
5231 
Excitatory extracellular ligand-gated ion 
channel activity 1 45 0.02 
122 
Negative regulation of transcription from 
RNA polymerase II promoter 1 65 0.022 
6986 Response to unfolded protein 1 41 0.023 
Table 3.1.9.4: Functions enriched among genes down-regulated in tumour size 
greater than 2.8 in comparison to tumour size less than 2.8  
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3.1.10 Comparison criteria: Patients who did not relapse vs. patients who did 
relapse (Overall relapse) 
Identifying genes up- and down-regulated in patients who relapse vs. those who did not 
may help identify biomarkers and targets for aggressive disease and can lead to 
development of diagnostic assays. 
A total of 56 patients who did not relapse and 48 patients who relapsed were compared 
for gene expression changes 
Up-regulated gene transcripts: 
323 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in tumour specimens of the patients who relapsed compared to 
tumour specimens of the patients who did not relapse. Genes were ranked by fold change 
and, based on this criterion, the top 20 genes are listed in Table 3.1.10.1. As can be seen 
from this comparison, the Ropporin transcripts were significantly differentially-expressed 
in relapsed vs. non- relapsed tumour specimens.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 20 most significant functions are listed in Table 3.1.10.2. 
Pathway analysis was performed using GenMAPP database on the up-regulated genes (p 
≤ 0.05, FC>2, and Difference > 100). Significant pathways were identified based on p-
value (p ≤ 0.05) and are listed in Table 3.1.10.3.  
Down-regulated gene transcripts: 
476 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in tumour specimens of the patients who relapsed compared 
to tumour specimens of the patients who did not relapse. Genes were ranked by fold 
change and, based on this criterion, the top 20 genes are listed in Table 3.1.10.4. 
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Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.10.5.  
Pathway analysis was performed using GenMAPP on the down-regulated genes (p ≤ 
0.05, FC<-2, and Difference < -100). Significant pathways were identified based on p-
value (p ≤ 0.05) and listed in Table 3.1.10.6. Muscle, fat and connective tissue specific 
genes pathway (Fig 3.1.10.1) were observed to be enriched by the down-regulated genes. 
 142 
Probe set Gene Baseline Experimental FC p-value 
224191_x_at ROPN1 25.01 148.64 5.94 0.01968 
220425_x_at ROPN1B 24.85 125.74 5.06 0.015855 
231535_x_at ROPN1 32.75 162.84 4.97 0.021558 
214595_at KCNG1 58.43 228.4 3.91 0.004431 
212531_at LCN2 50.9 169.1 3.32 0.044731 
206023_at NMU 48.79 156.42 3.21 0.019771 
220625_s_at ELF5 176.3 536.45 3.04 0.010197 
232547_at SNIP 77.12 227.4 2.95 0.020363 
235209_at RPESP 86.61 254 2.93 0.040668 
242350_s_at ST8SIA6 81.48 227.73 2.79 0.017142 
204855_at SERPINB5 101.99 278.81 2.73 0.020136 
235210_s_at RPESP 115.69 303.22 2.62 0.039636 
223062_s_at PSAT1 95.93 243.48 2.54 0.00843 
205044_at GABRP 376.38 932.57 2.48 0.0153 
208103_s_at ANP32E 116.16 266.76 2.3 0.001988 
213557_at CRKRS 117.88 271.12 2.3 0.027907 
204304_s_at PROM1 215.84 492.38 2.28 0.022001 
223748_at SLC4A11 125.62 286.45 2.28 0.023205 
202504_at TRIM29 104.11 234 2.25 0.02805 
213551_x_at PCGF2 180.1 387.69 2.15 0.012842 
Table 3.1.10.1: Genes up-regulated in tumour specimens of patients who relapsed in 
comparison to the tumour specimens of patients who did not relapse 
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GOID GO Name Changed Measured p-value 
8603 
cAMP-dependent protein kinase regulator 
activity 2 11 0 
15288 Porin activity 2 20 0 
15267 Channel or pore class transporter activity 4 376 0 
4648 Posphoserine transaminase activity 1 1 0.002 
42816 Vitamin B6 metabolism 1 2 0.002 
8614 Pyridoxine metabolism 1 2 0.002 
42819 Vitamin B6 biosynthesis 1 2 0.002 
8615 Pyridoxine biosynthesis 1 2 0.002 
19887 Potein kinase regulator activity 2 49 0.002 
19867 Outer membrane 2 60 0.003 
5215 Transporter activity 6 1412 0.004 
19207 Kinase regulator activity 2 55 0.005 
7340 Acrosome reaction 1 5 0.006 
6564 L-serine biosynthesis 1 8 0.006 
19861 Fagellum 1 9 0.008 
15106 Bicarbonate transporter activity 1 10 0.008 
15380 Anion exchanger activity 1 10 0.008 
5452 Inorganic anion exchanger activity 1 10 0.008 
6940 Regulation of smooth muscle contraction 1 9 0.009 
15301 Anion:anion antiporter activity 1 11 0.009 
Table 3.1.10.2: Functions enriched among genes up-regulated in tumour specimens 
of patients who relapsed in comparison to tumour specimens of patients who did not 
relapse 
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MAPP Name Changed Measured p-value 
1-Tissue-Endocrine and CNS 3 210 0.001 
Vitamin B6 metabolism 1 6 0.008 
Glycine serine and threonine metabolism 1 35 0.041 
Table 3.1.10.3: Pathways enriched among genes up-regulated in tumour specimens 
of patients who relapsed in comparison to tumour specimens of patients who did not 
relapse 
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Probe set Gene Baseline Experimental FC p-value 
242301_at CBLN2 134.72 15.37 -8.76 0.01888 
210576_at CYP4F8 124.3 16.15 -7.69 0.033726 
229764_at FAM79B 457.64 75.47 -6.06 0.001887 
243929_at ZNF533 200.31 52.69 -3.8 0.024215 
235978_at FABP4 142.81 40.78 -3.5 0.031338 
205710_at LRP2 160.38 50.4 -3.18 0.026702 
205380_at PDZK1 403.12 129.03 -3.12 0.008031 
210222_s_at RTN1 199.84 64.09 -3.12 0.017134 
202833_s_at SERPINA1 492.17 177.02 -2.78 0.012344 
205794_s_at NOVA1 455.57 165.34 -2.76 0.012041 
203029_s_at PTPRN2 222.84 85.37 -2.61 0.03321 
203485_at RTN1 688.43 264.94 -2.6 0.008909 
214440_at NAT1 1861.54 757.62 -2.46 0.000972 
235976_at SLITRK6 604.94 256.63 -2.36 0.034647 
218398_at MRPS30 621.53 265.65 -2.34 0.002144 
231207_at --- 328.23 143.94 -2.28 0.004513 
227600_at --- 305.13 134.82 -2.26 0.001608 
205696_s_at GFRA1 273.91 122.45 -2.24 0.00585 
219197_s_at SCUBE2 747.54 334.52 -2.23 0.016711 
211429_s_at SERPINA1 1076.28 485 -2.22 0.003786 
Table 3.1.10.4: Genes down-regulated in tumour specimens of patients who relapsed 
in comparison to the tumour specimens of patients who did not relapse 
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GOID GO Name Changed Measured p-value 
4421 
Hdroxymethylglutaryl-CoA synthase 
activity 1 2 0.001 
46912 
Transferase activity, transferring acyl 
groups, acyl groups converted into alkyl on 
transfer 1 4 0.001 
8393 Fatty acid (omega-1)-hydroxylase activity 1 2 0.002 
6629 Lipid metabolism 5 535 0.002 
4060 Arylamine N-acetyltransferase activity 1 2 0.003 
16167 
Glial cell line-derived neurotrophic factor 
receptor activity 1 2 0.006 
51244 Regulation of cellular physiological process 0 2727 0.01 
50791 Regulation of physiological process 0 2822 0.01 
46847 Filopodium formation 1 6 0.011 
43088 Regulation of Cdc42 GTPase activity 1 6 0.011 
Table 3.1.10.5: Functions enriched among genes down-regulated in tumour 
specimens of patients who relapsed in comparison to tumour specimens of patients 
who did not relapse 
MAPP Name Changed Measured p-value 
1-Tissue-Muscle fat and connective 3 65 0.001 
Synthesis and Degradation of ketone 
Bodies KEGG 1 5 0.009 
Synthesis and degradation of ketone 
bodies 1 6 0.013 
Table 3.1.10.6: Pathways enriched among genes down-regulated in tumour 
specimens of patients who relapsed in comparison to tumour specimens of patients 
who did not relapse 
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3.1.11 Comparison criteria: Patients who survived vs. patients who did not survive 
Identifying genes up- and down-regulated in patients who survived vs. those who did not 
survive may help identify biomarkers and targets for aggressive disease and can lead to 
development of diagnostic assays. 
Tumour specimens of 69 patients who survived and a total of 35 patients who did not 
survive were compared for gene expression changes.  
Up-regulated gene transcripts: 
385 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in tumour specimens of the patients who did not survive compared 
to tumour specimens of patients who survived. Genes were ranked by fold change and, 
based on these criteria, the top 20 genes are listed in Table 3.1.11.1.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions are listed in Table 3.1.11.2.  
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
0.05) and listed in Table 3.1.11.3.  
Down-regulated gene transcripts: 
993 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in tumour specimens of the patients who did not survive 
compared to tumour specimens of patients who survived. Genes were ranked by fold 
change and, based on these criteria, the top 20 genes are listed in Table 3.1.11.4 
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.11.5.  
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Pathway analysis was performed using GenMAPP database on the down-regulated genes 
(p ≤ 0.05, FC<-2, and Difference < -100). Significant pathways were identified based on 
p-value (p ≤ 0.05) and listed in Table 3.1.11.6.  
Probe set Gene Baseline Experiment FC p-value 
210147_at ART3 23.95 129.59 5.41 0.030235 
212531_at LCN2 45.81 224.84 4.91 0.021047 
232547_at SNIP 79.47 282.82 3.56 0.021477 
214595_at KCNG1 79.42 249.59 3.14 0.020733 
206023_at NMU 57.62 178.51 3.1 0.047878 
223748_at SLC4A11 118.87 361.86 3.04 0.007922 
242350_s_at ST8SIA6 91.89 264.11 2.87 0.033159 
204855_at SERPINB5 117.94 302.9 2.57 0.038883 
223062_s_at PSAT1 108.16 272.54 2.52 0.014909 
223075_s_at C9orf58 362.21 878.02 2.42 0.013435 
227512_at LOC92312 156.91 375.07 2.39 0.000142 
204914_s_at SOX11 111.97 264.92 2.37 0.02351 
226346_at LOC92312 266.6 598.08 2.24 0.000878 
210513_s_at VEGFA 97.12 215.63 2.22 0.032837 
236885_at LOC92312 115.01 253.34 2.2 0.0041 
204915_s_at SOX11 135.5 290.79 2.15 0.042257 
213523_at CCNE1 141.89 303.3 2.14 0.041275 
202991_at STARD3 140.04 294.74 2.1 0.010777 
203496_s_at PPARBP 321.49 670.52 2.09 0.042681 
213551_x_at PCGF2 204.66 411.53 2.01 0.041232 
Table 3.1.11.1: Genes up-regulated in tumour specimens of patients who did not 
survive in comparison to tumour specimens of patients who survived 
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GOID GO Name Changed Measured p-value 
4648 Phosphoserine transaminase activity 1 1 0 
30521 Androgen receptor signaling pathway 2 32 0 
30518 
Steroid hormone receptor signaling 
pathway 2 43 0 
30522 
Intracellular receptor-mediated signaling 
pathway 2 45 0 
35257 Nuclear hormone receptor binding 2 43 0.001 
51427 Hormone receptor binding 2 43 0.001 
30947 
Regulation of vascular endothelial growth 
factor receptor signaling pathway 1 1 0.002 
48010 
Vascular endothelial growth factor 
receptor signaling pathway 1 1 0.002 
30949 
Positive regulation of vascular endothelial 
growth Factor receptor signaling pathway 1 1 0.002 
42816 Vitamin B6 metabolism 1 2 0.002 
Table 3.1.11.2: Functions enriched among genes up-regulated in tumour specimens 
of patients who did not survive in comparison to tumour specimens of patients who 
survived. 
MAPP Name Changed Measured p-value 
Id NetPath 5 2 51 0.001 
Vitamin B6 metabolism 1 6 0.017 
Hypertrophy model 1 20 0.025 
Glycine serine and threonine 
metabolism 1 35 0.034 
Table 3.1.11.3: Pathways enriched among genes up-regulated in tumour specimens 
of patients who did not survive in comparison to tumour specimens of patients who 
survived 
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Probe set Gene Baseline Experiment FC p-value 
206502_s_at INSM1 230.98 7.19 -32.13 0.025417 
206325_at SERPINA6 120.98 18.06 -6.7 0.039756 
229764_at FAM79B 391.54 60.87 -6.43 0.001304 
210222_s_at RTN1 185.27 40.52 -4.57 0.002024 
243929_at ZNF533 178.14 41.83 -4.26 0.013087 
205380_at PDZK1 369.77 93.07 -3.97 0.002203 
209706_at NKX3-1 310.19 81.64 -3.8 0.001471 
203485_at RTN1 648.43 187.63 -3.46 0.00067 
219197_s_at SCUBE2 739.18 213.92 -3.46 0.000281 
205794_s_at NOVA1 420.34 125.93 -3.34 0.002229 
229004_at --- 364.9 118.18 -3.09 0.000052 
205913_at PLIN 152.71 51.4 -2.97 0.02848 
227742_at CLIC6 461.51 156.68 -2.95 0.028478 
227182_at SUSD3 407.14 138.95 -2.93 0.000177 
228554_at --- 519.6 177.93 -2.92 0.007057 
227929_at --- 163.39 59.85 -2.73 0.03079 
232176_at SLITRK6 341.94 125.18 -2.73 0.02738 
203413_at NELL2 283.89 104.48 -2.72 0.003488 
228390_at --- 515.22 189.51 -2.72 0.000006 
210272_at CYP2B7P1 375.11 141.21 -2.66 0.043449 
Table 3.1.11.4: Genes down-regulated in tumour specimens of patients who did not 
survive in comparison to tumour specimens of patients who survived 
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GOID GO Name Changed Measured p-value 
45010 Actin nucleation 1 1 0.001 
5925 Focal adhesion 1 1 0.001 
30027 Lamellipodium 2 15 0.001 
31252 Leading edge 2 18 0.001 
7494 Midgut development 1 1 0.002 
7497 Posterior midgut development 1 1 0.002 
9441 Glycolate metabolism 1 1 0.003 
18445 Prothoracicotrophic hormone activity 1 2 0.003 
7388 Posterior compartment specification 1 2 0.004 
7387 Anterior compartment specification 1 2 0.004 
Table 3.1.11.5: Functions enriched among genes down-regulated in tumour 
specimens of patients who did not survive in comparison to tumour specimens of 
patients who survived 
MAPP Name Changed Measured p-value 
1-Tissue-Muscle fat and connective 4 65 0.001 
Adipogenesis 3 130 0.018 
Circadian Exercise 2 48 0.019 
Synthesis and Degradation of Ketone Bodies 
KEGG 1 5 0.025 
Id NetPath 5 2 51 0.025 
Synthesis and degradation of ketone bodies 1 6 0.029 
2-Tissues-Internal Organs 3 137 0.034 
Apoptosis 2 82 0.044 
Table 3.1.11.6: Pathways enriched among genes down-regulated in tumour 
specimens of patients who did not survive in comparison to tumour specimens of 
patients who survived 
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3.1.12 Comparison criteria: Patients who did not relapse within 5 years vs. patients 
who did relapse within 5 years. 
Identifying genes up- and down-regulated in patients who relapse vs. those who did not 
may help identify biomarkers and targets for aggressive disease and can lead to 
development of diagnostic assays.  
Tumour specimens of 54 patients who did not relapse within 5 years and a total of 41 
patients who relapsed within 5 years were compared for gene expression changes. 
Up-regulated gene transcripts: 
318 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in tumour specimens of the patients who relapsed compared to 
tumour specimens of patients who did not relapse. Genes were ranked by fold change 
and, based on these criteria, the top 20 genes are listed in Table 3.1.12.1. As can be seen 
from this comparison, the Ropporin transcripts were significantly differentially-expressed 
in the 5 year relapse vs. non- relapsed tumour specimens.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions are listed in Table 3.1.12.2. 
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
0.05) and listed in Table 3.1.12.3.  
Down-regulated gene transcripts: 
680 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in tumour specimens of the patients who relapsed compared 
to tumour specimens of patients who did not relapse. Genes were ranked by fold change 
and, based on these criteria, the top 20 genes are listed in Table 3.1.12.4. 
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Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.12.5. 
Pathway analysis was performed using GenMAPP on the down-regulated genes (p ≤ 
0.05, FC<-2, and Difference < -100). Significant pathways were identified based on p-
value (p ≤ 0.05) and listed in Table 3.1.12.6. 
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Probe set Gene Baseline Experiment FC p-value 
224191_x_at ROPN1 20.3 162.32 8 0.019245 
220425_x_at ROPN1B 17.82 139.52 7.83 0.010956 
204437_s_at FOLR1 21.98 151.16 6.88 0.014061 
231535_x_at ROPN1 26.52 180.61 6.81 0.017972 
204855_at SERPINB5 73.65 316.13 4.29 0.004791 
229341_at TFCP2L1 38.76 157.15 4.05 0.030912 
209842_at SOX10 56.05 226.31 4.04 0.015137 
220625_s_at ELF5 146.44 582.94 3.98 0.006595 
202037_s_at SFRP1 221.42 865.31 3.91 0.014187 
206023_at NMU 45.81 177.39 3.87 0.014196 
212531_at LCN2 50.64 195.86 3.87 0.031797 
202036_s_at SFRP1 169.73 623.66 3.67 0.00988 
223748_at SLC4A11 91.73 328.87 3.59 0.003251 
219795_at SLC6A14 44.12 155.01 3.51 0.005238 
214595_at KCNG1 68.69 232.46 3.38 0.012411 
235209_at RPESP 87.61 291.55 3.33 0.030122 
232547_at SNIP 79.78 259.39 3.25 0.022409 
209466_x_at PTN 269.74 870.2 3.23 0.040297 
223468_s_at RGMA 110.09 348.4 3.16 0.012154 
235210_s_at RPESP 115.26 349.68 3.03 0.02415 
Table 3.1.12.1: Genes up-regulated in tumour specimens of patients who relapsed 
within 5 years in comparison to tumour specimens of patients who did not relapse 
within 5 years 
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GOID GO Name Changed Measured p-value 
8603 
cAMP-dependent protein kinase 
regulator activity 2 11 0 
15288 Porin activity 2 20 0 
30528 Transcription regulator activity 11 1171 0 
19212 Phosphatase inhibitor activity 2 25 0.002 
3712 Transcription cofactor activity 4 253 0.002 
4648 
Phosphoserine transaminase 
activity 1 1 0.003 
3824 Catalytic activity 5 4622 0.003 
19215 Intermediate filament binding 1 1 0.004 
8614 Pyridoxine metabolism 1 2 0.004 
8615 Pyridoxine biosynthesis 1 2 0.004 
Table 3.1.12.2: Functions enriched among genes up-regulated in tumour specimens 
of patients who relapsed within 5 years in comparison to tumour specimens of 
patients who did not relapse within 5 years. 
MAPP Name Changed Measured p-value 
2-Tissues-Muscle Fat and 
Connective 2 82 0.017 
1-Tissue-Endocrine and CNS 3 210 0.018 
Vitamin B6 metabolism 1 6 0.019 
Wnt NetPath 8 2 109 0.033 
2-Tissues-Internal Organs 2 137 0.04 
Inositol phosphate metabolism 2 134 0.041 
Table 3.1.12.3: Pathways enriched among genes up-regulated in tumour specimens 
of patients who relapsed within 5 years in comparison to tumour specimens of 
patients who did not relapse within 5 years. 
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Probe set Gene Baseline Experiment FC p-value 
206502_s_at INSM1 287.37 9.91 -28.99 0.025471 
214320_x_at CYP2A6 816.58 36.86 -22.15 0.009574 
1494_f_at CYP2A6 695.91 33.63 -20.7 0.024309 
221107_at CHRNA9 127.61 9.11 -14 0.019025 
1562309_s_at PHF21B 190.53 15.67 -12.16 0.007264 
206325_at SERPINA6 136.76 13.02 -10.5 0.038544 
242301_at CBLN2 138.45 15.99 -8.66 0.021921 
205357_s_at AGTR1 590.42 69.39 -8.51 0.012981 
210576_at CYP4F8 126.86 17.06 -7.44 0.039621 
210272_at CYP2B7P1 487.73 67.47 -7.23 0.000966 
229764_at FAM79B 455.26 72.92 -6.24 0.002773 
236445_at LOC731986 266.11 44.94 -5.92 0.01803 
226269_at GDAP1 427.06 79.73 -5.36 0.010084 
218332_at BEX1 594.77 112.33 -5.29 0.008856 
206754_s_at CYP2B7P1 1573.54 302.78 -5.2 0.000651 
240192_at FLJ45983 154.22 30.82 -5 0.00002 
226271_at GDAP1 371.16 75.86 -4.89 0.012719 
205509_at CPB1 2047.11 450.59 -4.54 0.011659 
205794_s_at NOVA1 497.24 122.38 -4.06 0.001487 
203029_s_at PTPRN2 247.3 61.96 -3.99 0.004993 
Table 3.1.12.4: Genes down-regulated in tumour specimens of patients who relapsed 
within 5 years in comparison to tumour specimens of patients who did not relapse 
within 5 years 
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GOID GO Name Changed Measured p-value 
4867 Serine-type endopeptidase inhibitor activity 5 78 0 
4866 Endopeptidase inhibitor activity 5 124 0 
30414 Protease inhibitor activity 5 125 0 
30027 Lamellipodium 2 15 0.001 
31252 Leading edge 2 18 0.001 
42995 Cell projection 3 65 0.001 
4857 Enzyme inhibitor activity 5 220 0.001 
45010 Actin nucleation 1 1 0.002 
5925 Focal adhesion 1 1 0.002 
7494 Midgut development 1 1 0.003 
Table 3.1.12.5: Functions enriched among genes down-regulated in tumour 
specimens of patients who relapsed within 5 years in comparison to tumour 
specimens of patients who did not relapse within 5 years. 
MAPP Name Changed Measured p-value 
Valine leucine and isoleucine degradation 2 39 0.021 
1-Tissue-Internal Organs 5 244 0.021 
Synthesis and Degradation of Ketone Bodies 
KEGG 1 5 0.024 
Gamma Hexachlorocyclohexane degradation 2 45 0.025 
1-Tissue-Endocrine and CNS 4 210 0.039 
Synthesis and degradation of ketone bodies 1 6 0.041 
Ethylbenzene degradation 1 8 0.042 
Table 3.1.12.6: Pathways enriched among genes down-regulated in tumour 
specimens of patients who relapsed within 5 years in comparison to tumour 
specimens of patients who did not relapse within 5 years 
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3.1.13 Comparison criteria: Patients who survived for 5 years vs. patients who did 
not survive for 5 years. 
Identifying genes up- and down-regulated in patients who survive vs. those who did not 
may help identify biomarkers and targets for aggressive disease and can lead to 
development of diagnostic assays  
Tumour specimens of 64 patients who survived for 5 years and a total of 29 patients who 
did not survive for 5 years were compared for gene expression changes.  
Up-regulated gene transcripts: 
400 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) > 1.2 
and Difference > 100) in tumour specimens of the patients who did not survived for 5 
years compared to tumour specimens of patients who did survive for 5 years. Genes were 
ranked by fold change and, based on these criteria, the top 20 genes are listed in Table 
3.1.13.1.  
Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, and 
Difference > 100). Significant functions were identified based on p-value (p ≤ 0.05) and 
the 10 most significant functions are listed in Table 3.1.13.2.  
Pathway analysis was performed using GenMAPP on the up-regulated genes (p ≤ 0.05, 
FC>2, and Difference > 100). Significant pathways were identified based on p-value (p ≤ 
0.05) and listed in Table 3.1.13.3. 
Down-regulated gene transcripts: 
969 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change (FC) < 
-1.2 and Difference < -100) in tumour specimens of the patients who did not survived for 
5 years compared to tumour specimens of patients who did survive for 5 years. Genes 
were ranked by fold change and, based on these criteria, the top 20 genes are listed in 
Table 3.1.13.4. 
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Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-2, 
and Difference < -100). Significant functions were identified based on p-value (p ≤ 0.05) 
and the 10 most significant functions are listed in Table 3.1.13.5. 
Pathway analysis was performed using GenMAPP database on the down-regulated genes 
(p ≤ 0.05, FC<-2, and Difference < -100). Significant pathways were identified based on 
p-value (p ≤ 0.05) listed in Table 3.1.13.6. 
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Probe set Gene Baseline Experiment FC P value 
213456_at SOSTDC1 10.09 117.71 11.67 0.022369 
210147_at ART3 15.75 142.8 9.06 0.02646 
204437_s_at FOLR1 24.9 178.39 7.16 0.031434 
220425_x_at ROPN1B 22.83 153.17 6.71 0.043523 
220559_at EN1 19.75 129.15 6.54 0.043512 
212531_at LCN2 52.76 256.71 4.87 0.030136 
220625_s_at ELF5 147.31 652.97 4.43 0.011091 
206373_at ZIC1 31.32 137.98 4.41 0.005065 
204855_at SERPINB5 82.13 357.9 4.36 0.008081 
204086_at PRAME 39.82 172.45 4.33 0.048485 
206023_at NMU 49.78 208 4.18 0.030535 
209842_at SOX10 61.23 252.8 4.13 0.036135 
232547_at SNIP 87.64 323.76 3.69 0.026748 
223748_at SLC4A11 103.94 380.55 3.66 0.006712 
242350_s_at ST8SIA6 83.55 296.44 3.55 0.029189 
1553613_s_at FOXC1 188.81 651.73 3.45 0.008375 
214595_at KCNG1 78.07 262.27 3.36 0.03416 
219795_at SLC6A14 48.81 161.81 3.32 0.021036 
202036_s_at SFRP1 206.71 678.3 3.28 0.041266 
226907_at PPP1R14C 44.8 144.93 3.24 0.044567 
Table 3.1.13.1: Genes up-regulated in tumour specimens of patients who did not 
survive for 5 years in comparison to tumour specimens of patients who did survive 
for 5 years 
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GOID GO Name Changed Measured p-value 
19212 Phosphatase inhibitor activity 3 25 0 
6563 L-serine metabolism 2 13 0 
9070 Serine family amino acid biosynthesis 2 12 0.001 
19888 Protein phosphatase regulator activity 3 45 0.001 
19208 Phosphatase regulator activity 3 46 0.001 
4864 Protein phosphatase inhibitor activity 2 24 0.002 
8076 
Voltage-gated potassium channel 
complex 3 80 0.002 
9069 Serine family amino acid metabolism 2 27 0.003 
5249 Voltage-gated potassium channel activity 3 96 0.003 
4648 Posphoserine transaminase activity 1 1 0.004 
Table 3.1.13.2: Functions enriched among genes up-regulated in tumour specimens 
of patients who did not survive for 5 years in comparison to tumour specimens of 
patients who did survive for 5 years 
MAPP Name Changed Measured p-value 
Glycine serine and threonine 
metabolism 2 35 0.002 
1-Tissue-Endocrine and CNS 3 210 0.008 
Vitamin B6 metabolism 1 6 0.018 
Methionine metabolism 1 14 0.026 
Blood Clotting Cascade 1 20 0.049 
Table 3.1.13.3: Pathways enriched among genes up-regulated in tumour specimens 
of patients who did not survive for 5 years in comparison to tumour specimens of 
patients who did survive for 5 years 
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Probe set Gene Baseline Experiment FC P value 
206502_s_at INSM1 243.97 8.12 -30.05 0.028369 
214320_x_at CYP2A6 693.76 34.24 -20.26 0.009304 
1494_f_at CYP2A6 588.77 31.16 -18.89 0.024325 
236538_at GRIA2 178.03 10.14 -17.56 0.040355 
205358_at GRIA2 389.59 27.73 -14.05 0.020555 
221107_at CHRNA9 109.73 8.28 -13.25 0.017158 
1562309_s_at PHF21B 164.82 12.69 -12.99 0.006251 
210576_at CYP4F8 113.27 9.13 -12.4 0.022252 
205357_s_at AGTR1 516.17 50.59 -10.2 0.009019 
236445_at LOC731986 241.86 25 -9.67 0.006299 
242301_at CBLN2 119.14 16.62 -7.17 0.024079 
240192_at FLJ45983 140.56 21.15 -6.65 0.000002 
219557_s_at NRIP3 245.85 37.19 -6.61 0.006063 
229764_at FAM79B 399.62 65.3 -6.12 0.002428 
210272_at CYP2B7P1 419.42 78.88 -5.32 0.003092 
233059_at --- 458.13 86.09 -5.32 0.002482 
219197_s_at SCUBE2 824.53 159.59 -5.17 0.00001 
226269_at GDAP1 374.8 73.26 -5.12 0.00918 
210222_s_at RTN1 186.12 41 -4.54 0.003962 
203029_s_at PTPRN2 224.07 51.34 -4.36 0.002727 
Table 3.1.13.4: Genes down-regulated in tumour specimens of patients who did not 
survive for 5 years in comparison to tumour specimens of patients who did survive 
for 5 years 
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GOID GO Name Changed Measured p-value 
50381 Unspecific monooxygenase activity 4 24 0 
5006 Epidermal growth factor receptor activity 2 7 0 
16712 
Oxidoreductase activity, acting on paired 
donors, with incorporation or reduction of 
molecular oxygen, reduced flavin or 
flavoprotein as one donor, and 
incorporation of one atom of oxygen 4 29 0 
46906 Tetrapyrrole binding 4 77 0.001 
20037 Heme binding 4 77 0.001 
4497 Monooxygenase activity 4 86 0.001 
50878 Regulation of body fluids 4 98 0.001 
16705 
Oxidoreductase activity, acting on paired 
donors, With incorporation or reduction of 
molecular oxygen 4 99 0.001 
19752 Carboxylic acid metabolism 9 409 0.001 
6082 Organic acid metabolism 9 411 0.001 
Table 3.1.13.5: Functions enriched among genes down-regulated in tumour 
specimens of patients who did not survive for 5 years in comparison to tumour 
specimens of patients who did survive for 5 years. 
MAPP Name Changed Measured p-value 
Synthesis and Degradation of Ketone Bodies 
KEGG 1 5 0.041 
Valine leucine and isoleucine degradation 2 39 0.045 
1-Tissue-Endocrine and CNS 5 210 0.045 
 Table 3.1.13.6: Pathways enriched among genes down-regulated in tumour 
specimens of patients who did not survive for 5 years in comparison to tumour 
specimens of patients who did survive for 5 years 
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3.1.14 Comparing gene lists to identify bad prognosis genes  
The gene lists generated above (Relapse 5 years 0 vs. 1 (Rel5) (see section 3.1.12), 
Survival 5 years 0 vs. 1 (Sur5) (see section 3.1.13), Overall Relapsed 0 vs. 1 (Relapsed) 
(see section 3.1.10) and RIP 0 vs. 1 (see section 3.1.11)) were compared to identify genes 
common to all the gene lists. The DE genes in all these comparisons are linked to bad 
outcome and an overlap of these lists was carried out to identify any high-value common 
targets among them. The number of genes common to these gene lists is depicted in the 
Venn diagram in Fig 3.1.14.1. The total number of common genes in all the gene lists 
was 384. These gene lists were further compared with lymph node 0 vs. 1 (Fig: 3.1.14.2), 
as lymph node-positive is linked to bad prognosis, and a final list of 74 genes were 
identified common to all comparisons was identified. The genes common to all the five 
lists are shown in Table 3.1.14.1 (up-regulated genes) and Table 3.1.14.2 (down-
regulated genes). 
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Fig 3.1.14.1: Venn diagram representing the number of genes common to two or 
more comparisons. There were a total of 384 genes common to all the 4 gene lists.  
 
Fig 3.1.14.2: Venn diagram representing the number of genes common to the 384 genes 
identified earlier (Fig 3.1.14.1) with the Lymph node 0 vs. 1. There were a total of 74 
genes common to all.  
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Probe Set 
Gene 
Symbol Rel5 Relapsed RIP Sur5 LN status 
232547_at SNIP 3.25 2.95 3.56 3.69 2.51 
213551_x_at PCGF2 2.36 2.15 2.01 2.25 2.06 
236885_at LOC92312 2.47 1.99 2.2 2.92 1.96 
202991_at STARD3 1.9 1.83 2.1 2.2 1.91 
214239_x_at PCGF2 2.13 1.93 1.94 2.14 1.89 
227512_at LOC92312 2.57 2.07 2.39 2.8 1.76 
226346_at LOC92312 2.42 2.06 2.24 2.79 1.74 
222706_at CCDC49 1.94 1.8 1.9 2.12 1.73 
201400_at PSMB3 1.71 1.73 1.78 1.84 1.68 
216836_s_at ERBB2 1.81 1.61 1.85 1.99 1.67 
203287_at LAD1 1.9 1.85 1.94 1.98 1.63 
224447_s_at C17orf37 1.63 1.59 1.78 1.9 1.58 
213230_at CDR2L 1.69 1.48 1.77 1.9 1.52 
210827_s_at ELF3 1.51 1.65 1.5 1.51 1.49 
230660_at SERTAD4 2.04 1.62 1.64 1.8 1.47 
234464_s_at EME1 1.68 1.54 1.76 1.84 1.44 
212680_x_at PPP1R14B 1.59 1.57 1.59 1.66 1.41 
205107_s_at EFNA4 1.63 1.41 1.51 1.64 1.41 
203430_at HEBP2 1.38 1.34 1.37 1.42 1.36 
201584_s_at DDX39 1.47 1.47 1.33 1.45 1.33 
223993_s_at CNIH4 1.31 1.28 1.32 1.34 1.32 
200660_at S100A11 1.3 1.36 1.42 1.38 1.31 
209609_s_at MRPL9 1.39 1.36 1.4 1.54 1.31 
213668_s_at SOX4 1.39 1.35 1.47 1.43 1.29 
208540_x_at LOC729659 1.3 1.33 1.44 1.38 1.28 
222400_s_at ADI1 1.35 1.24 1.28 1.27 1.28 
203315_at NCK2 1.34 1.32 1.33 1.43 1.27 
200888_s_at RPL23 1.37 1.33 1.3 1.42 1.26 
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222036_s_at SLC12A4 1.29 1.39 1.41 1.37 1.26 
222396_at HN1 1.32 1.3 1.4 1.41 1.24 
203956_at MORC2 1.24 1.4 1.39 1.32 1.24 
200882_s_at PSMD4 1.23 1.23 1.21 1.21 1.21 
Table 3.1.14.1: 32 gene transcripts, comprising 29 unique genes up-regulated and 
common to the 5 comparisons, making them indicative of a clinically poor prognosis 
Probe Set  
Gene 
Symbol Rel5 Relapsed RIP Sur5 
LN 
status 
205794_s_at NOVA1 -4.06 -2.76 -3.34 -3.77 -2.71 
211421_s_at RET -3.27 -1.9 -2.31 -2.8 -2.23 
205225_at ESR1 -2.51 -1.64 -1.77 -2.51 -1.46 
244696_at AFF3 -2.45 -1.93 -2.24 -2.59 -1.73 
227198_at AFF3 -2.38 -1.71 -1.79 -2.34 -1.59 
213832_at --- -2.34 -2.2 -2.29 -2.96 -1.97 
236194_at --- -1.96 -1.98 -2.13 -2.24 -1.68 
201311_s_at SH3BGRL -1.94 -1.48 -1.92 -1.91 -1.42 
225123_at --- -1.87 -1.8 -1.8 -1.81 -1.9 
225613_at MAST4 -1.84 -1.76 -1.81 -1.98 -1.85 
204072_s_at FRY -1.79 -1.54 -1.74 -2.12 -1.51 
227192_at PRRT2 -1.79 -1.71 -1.83 -1.88 -1.8 
222653_at PNPO -1.78 -1.54 -1.57 -1.71 -1.43 
221874_at KIAA1324 -1.77 -1.61 -2.04 -2.59 -1.47 
226939_at CPEB2 -1.73 -1.37 -1.45 -1.83 -1.48 
238883_at THRAP2 -1.67 -1.38 -1.46 -1.71 -1.53 
223204_at C4orf18 -1.65 -1.38 -1.49 -1.86 -1.41 
201312_s_at SH3BGRL -1.58 -1.44 -1.75 -1.74 -1.29 
227856_at C4orf32 -1.58 -1.51 -1.68 -1.61 -1.36 
225561_at SELT -1.54 -1.3 -1.51 -1.7 -1.25 
212209_at THRAP2 -1.54 -1.31 -1.33 -1.53 -1.42 
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201413_at HSD17B4 -1.5 -1.35 -1.46 -1.5 -1.25 
214924_s_at TRAK1 -1.47 -1.41 -1.52 -1.59 -1.32 
212208_at THRAP2 -1.47 -1.36 -1.35 -1.47 -1.43 
221918_at PCTK2 -1.44 -1.34 -1.41 -1.54 -1.29 
212207_at THRAP2 -1.41 -1.35 -1.34 -1.49 -1.4 
200940_s_at RERE -1.4 -1.32 -1.45 -1.51 -1.25 
243993_at PCTK2 -1.38 -1.41 -1.37 -1.36 -1.51 
201334_s_at ARHGEF12 -1.37 -1.36 -1.38 -1.36 -1.22 
223342_at RRM2B -1.36 -1.25 -1.37 -1.35 -1.26 
217122_s_at SLC35E2 -1.35 -1.22 -1.38 -1.46 -1.23 
225176_at LNPEP -1.34 -1.29 -1.34 -1.38 -1.22 
225363_at PTEN -1.33 -1.38 -1.52 -1.41 -1.31 
200850_s_at AHCYL1 -1.32 -1.28 -1.38 -1.38 -1.21 
218518_at C5orf5 -1.3 -1.3 -1.43 -1.4 -1.26 
227227_at LOC728871 -1.29 -1.24 -1.41 -1.35 -1.34 
224876_at C5orf24 -1.28 -1.26 -1.39 -1.37 -1.22 
218248_at FAM111A -1.27 -1.4 -1.44 -1.31 -1.23 
200848_at AHCYL1 -1.26 -1.29 -1.28 -1.3 -1.25 
224928_at SETD7 -1.25 -1.21 -1.42 -1.45 -1.2 
200761_s_at ARL6IP5 -1.24 -1.29 -1.4 -1.31 -1.22 
243249_at ACIN1 -1.23 -1.3 -1.26 -1.22 -1.29 
Table 3.1.14.2: 42 gene transcripts, comprising 32 unique known genes and three 
unannotated transcripts, down-regulated and common to the 5 comparisons, making 
them indicative of a clinically good prognosis. 
 
3.1.15 Non-parametric analysis 
 
Non-parametric analysis was performed on the following clinical parameters as described 
in section 2.2.15.  The null hypothesis tested was the mean of the two groups under 
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consideration are equal under an assumption that the data may not be normally 
distributed. 
 Normals/Tumour specimens  
Number of Up-Regulated genes: 4057 (4213 using parametric test) 
Number of Down-Regulated genes: 3379 (3235 using parametric test) 
 Estrogen Receptor status 
Number of Up-Regulated genes: 869 (855 using parametric test) 
Number of Down-Regulated genes: 1288 (1145 using parametric test) 
 Overall Relapsed status 
Number of Up-Regulated genes: 279 (323 using parametric test) 
Number of Down-Regulated genes: 504 (476 using parametric test) 
 RIP (Event of death due to disease) 
Number of Up-Regulated genes: 429 (385 using parametric test) 
Number of Down-Regulated genes: 1005 (993 using parametric test) 
 Relapse within 5 years 
Number of Up-Regulated genes: 288 (318 using parametric test) 
Number of Down-Regulated genes: 724 (680 using parametric test) 
 Survival for 5 years 
Number of Up-Regulated genes: 471 (400 using parametric test) 
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Number of Down-Regulated genes: 946 (969 using parametric test) 
 
 Tumour size  
Number of Up-Regulated genes: 67 (36 using parametric test) 
Number of Down-Regulated genes: 39 (139 using parametric test) 
 Tumour grade 1 vs 2 
Number of Up-Regulated genes: 108 (275 using parametric test) 
Number of Down-Regulated genes: 197 (75 using parametric test) 
 Tumour grade 2 vs 3 
Number of Up-Regulated genes: 846 (930 using parametric test) 
Number of Down-Regulated genes: 743 (596 using parametric test) 
 Lymph Node Status 
Number of Up-Regulated genes: 122 (102 using parametric test) 
Number of Down-Regulated genes: 110 (126 using parametric test) 
 
The genelists generated from this study are included on the CD with this thesis. 
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3.1.16 Summary  
This section identified various sub-groups of breast cancer and its association with clinical 
and gene expression data. Our results confirmed many of the existing groups and also 
identified new groups with clinical relevance. The Ropporin-expressing clusters of 
patients had a bad prognosis, whereas immune response expressing cluster of patients had 
a good prognosis. Clinical parameters were compared to identify gene expression 
changes. Gene ontology and pathways analysis was performed on these gene lists. 
Ropporin gene was identified as expressed in patients who relapsed and was studied in 
detail. 
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3.2 Comparing in-house gene lists with publicly available datasets  
 This section deals with comparing our in-house results with publicly available datasets. 
3.2.1 Comparison with public datasets on the Affymetrix GeneChip platform  
The in-house data was compared to 4 publicly available datasets for genes commonly 
associated with bad prognosis. Overall Relapse was taken as a common measure for 
comparison across different experiments. A gene list was created for each individual 
experiment comparing the patients who relapsed vs. patients who did not relapse. The 
filtration criteria for identifying differentially-expressed genes as outlines in section 2.2.5 
(FC>1.2, Difference>100 and p-value≤0.05) was taken for all the experiments. The 
number of patients who relapsed / did not relapse and the numbers of differentially-
expressed (DE) genes in each experiment are listed in Table 3.2.1.1. 
Experiment No. of Non-
relapsed patients 
No. of Relapsed 
patients 
No. of DE genes in 
each respective list 
In-house dataset 57 48 799 
GSE4922 160 89 67 
GSE1456 119 40 500 
GSE2990 139 40 153 
GSE2034 107 179 377 
Table 3.2.1.1: The above table represents the number of relapsed / non-relapsed 
patients in each experimental group and the number of differentially-expressed 
genes in each experimental group. 
The gene lists generated were compared for genes common to all five experimental 
groups. However, no transcripts were found to be common across all the experiments. 
Therefore, a separate approach was taken to identify transcripts which changed in any 3 
out of the 5 comparisons. To perform this task, a C program was written as this task was 
not possible to achieve using available software. Following this comparison, 22 
transcripts were identified which were either up- or down-regulated in a minimum of 3 
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out of the 5 experimental groups (Table 3.2.1.2). There were 4 genes which were 
differentially-regulated in four out of five experiments; these are highlighted in bold. 
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Probe Set 
Gene 
Symbol 
In-
house GSE4922 GSE1456 GSE2990 GSE2034 
201041_s_at DUSP1 NS -1.22 -1.48 -1.28 NS 
201841_s_at HSPB1 NS 1.26 1.56 1.29 1.21 
202489_s_at FXYD3 1.32 NS 1.42 1.23 NS 
202503_s_at KIAA0101 NS 1.27 1.49 1.29 1.23 
202768_at FOSB -1.86 -1.46 -2.17 NS NS 
202954_at PAK3 1.41 1.24 1.35 1.33 NS 
204026_s_at ZWINT NS 1.26 NS 1.29 1.21 
204607_at HMGCS2 -2.02 -1.57 NS -1.97 NS 
208451_s_at C4A NS -1.28 -1.47 -1.27 NS 
209189_at FOS -1.42 -1.3 -1.67 -1.4 NS 
209772_s_at CD24 1.94 1.44 1.8 NS NS 
211429_s_at SERPINA1 -2.22 NS NS -1.49 -1.82 
212592_at IGJ NS NS -1.35 -1.52 -1.52 
212593_s_at PDCD4 -1.39 NS -1.24 NS -1.22 
214428_x_at C4A -1.48 -1.25 -1.46 NS NS 
218039_at NUSAP1 NS NS 1.47 1.33 1.24 
218336_at PFDN2 1.26 NS 1.28 NS 1.21 
218807_at VAV3 -1.37 NS -1.26 -1.24 NS 
219956_at GALNT6 -1.58 NS 1.55 1.36 NS 
222077_s_at RACGAP1 NS NS 1.33 1.36 1.32 
222453_at CYBRD1 -1.61 -1.22 -1.55 NS NS 
227182_at SUSD3 -1.9 -1.38 -1.51 NS NS 
Table 3.2.1.2: 22 transcripts DE in 3 out of the 5 experimental groups, incorporating 
the fold change in each experimental group when comparing the patients who 
relapsed vs. the patients who did not relapse. A positive fold change indicates that 
gene to be over-expressed in patients who relapsed in comparison to the patients 
who did not relapse. NS (non significant) = gene not differentially-expressed in that 
experimental group.  
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3.2.2 Comparison in-house relapse and lymph node gene list with OncotypeDx genes 
OncotypeDx from Genomic Health (www.genomichealth.com) is a PCR based laboratory 
test that predicts the likelihood of breast cancer recurrence in women with newly 
diagnosed and early stage invasive breast cancer. It also estimates the benefits from 
hormone therapy and chemotherapy. The development of this test followed on from the 
research carried out by Paik et al., (2004) where they identified 16 genes which have a 
prognostic importance in predicting relapse and survival. The aim of this study was to 
compare these 16 genes with our in-house study of microarray experiments on breast 
cancer.  
The 16 genes of OncotypeDx were mapped to 41 Affymetrix transcripts (Table 3.2.2.1) 
using the NetAffx Analysis Center (http://www.affymetrix.com/analysis/index.affx) and 
these Affymetrix IDs were used to compare with our results of overall relapse (see 
section 3.1.10) and lymph node metastasis (see section 3.1.6).  
Gene Symbol Corresponding Affy Ids 
MKI67 
212020_s_at 
212021_s_at 
212022_s_at 
212023_s_at 
AURKA 
204092_s_at 
208079_s_at 
 208080_at 
BIRC5 
202094_at 
202095_s_at 
210334_x_at 
CCNB1 
228729_at 
214710_s_at 
MYB12 201710_at 
GRB7 210761_s_at 
HER2 210930_s_at 
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216836_s_at 
234354_x_at 
MMP11 
235908_at 
203878_s_at 
203876_s_at 
CTS12 210074_at 
GSTM1 
204550_x_at 
215333_x_at 
CD68  203507_at 
BAG1 
202387_at 
229720_at 
211475_s_at 
ESR1 
205225_at 
217163_at 
211233_x_at 
211234_x_at 
211235_s_at 
211627_x_at 
215552_s_at 
217190_x_at 
PGR 208305_at 
BCL2 
203685_at 
207004_at 
203684_s_at 
207005_s_at 
SCUBE2 219197_s_at 
Table 3.2.2.1: Affymetrix Probe set IDs for the 16 genes of OncotypeDx  
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The OncotypeDx genes were compared with in-house gene expression data of patients 
who relapsed vs. patients who did not relapse (Fold change > 1.2, Difference > 100 and 
p-value≤0.05).  
There were a total of five genes common to the two lists, all with the same trend of 
expression. Over-expression of AURKA, BIRC5 and ERBB2 were associated with 
higher overall relapse in our study and were related to high risk of recurrence on 
OncotypeDx, whereas over-expression of ESR1 and SCUBE2 were associated with lower 
overall relapse in our study and were related to low risk of recurrence on OncotypeDx 
(Table 3.2.2.2). 
Probe Set Name Gene Symbol In-House OncotypeDX 
208079_s_at AURKA 1.32 +1 
202095_s_at BIRC5 1.55 +1 
216836_s_at ERBB2 1.61 +1 
205225_at ESR1 -1.64 -1 
219197_s_at SCUBE2 -2.23 -1 
Table 3.2.2.2: Comparing gene expression values of in-house study on patients who 
relapsed vs. patients who did not relapse with the OncotypeDx gene lists. Positive 
value represents over-expression of gene to be association with higher recurrence of 
disease and negative value represents over-expression of gene to be association with 
lower recurrence of disease.  
The OncotypeDx genes were also compared with gene expression data of patients with 
no lymph node metastasis and patients who had lymph node metastasis (Fold change > 
1.2, Difference > 100 and p-value≤0.05) from our in-house dataset. There were only two 
genes common to these lists (Table 3.2.2.3). ERBB2 expression was up-regulated in 
lymph node-positive patients in our study and was related to high risk of recurrence on 
the OncotypeDx. ESR1 expression was down-regulated in lymph node-positive patients 
in our study and was related to low risk of recurrence on the OncotypeDx. 
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Probe Set Name Gene Symbol In-House OncotypeDx 
216836_s_at ERBB2 1.67 +1 
205225_at ESR1 -1.46 -1 
Table 3.2.2.3: Genes common to in-house study comparing gene expression values of 
lymph node-positive patients vs. lymph node-negative patients with the OncotypeDx 
gene lists. A positive value represent over-expression of that gene to be association 
with higher recurrence of disease and a negative value represents over-expression of 
that gene to be association with lower recurrence of disease.  
3.2.3 Comparison in-house relapse and lymph node gene list with MammaPrint 
genes 
MammaPrint (Agendia http://www.agendia.com/), like OncotypeDx, is a molecular 
diagnostic kit which is used to assess the risk of breast tumor spread to other parts of the 
body. The development of this test is a follow on from the research carried out by van`t 
Veer et al., (2002) where they identified 70 transcripts which had a prognostic 
importance in predicting metastasis. These genes were mapped to Affymetrix Ids using 
gene symbols in a batch query to the NetAffx Analysis Center 
(www.affymetric.com/netaffx). For the Contig Ids, their corresponding Accession nos. 
were obtained from the table provided by the van`t Veer group. These Accession nos. 
were then searched in the unigene database using David and Ease (see section 2.2.6) to 
obtain the corresponding gene symbol which was then searched in the NetAffx Analysis 
center. In all, 45 unique genes from the van‟t Veer study was mapped to 81 Affymetrix 
transcripts (Table 3.2.3.1). The remaining 25 genes (AL080059, LOC51203, 
AA555029RC, DC13, AL137718, PK428, HEC, UCH37, KIAA1067, SERF1A, OXCT, 
L2DTL, AF052162, KIAA0175, SM20, DKFZP564D0462, MP1, FLJ11190, LOC57110, 
DHX58, AP2B1, CFFM4, HSA250839, CEGP1, ALDH4, and KIAA1442) were not 
identified by batch analysis in NetAffx as being present on the Affymetrix arrays. 
Following this, these 25 genes were searched manually and respective affymetrix 
identifier was allocated to them (Table 3.2.3.1). These were not identified in the batch 
analysis, because many were old gene names or less known alias of the genes. Still we 
 179 
were not able to associate AL080059, AA555029RC, and AF052162 with any affymetrix 
identifier. 
Gene Symbol Probe Set ID 
AKAP2 
202759_s_at 
202760_s_at 
226694_at 
AP2B1 
200612_s_at 
200615_s_at 
BBC3 211692_s_at 
C9orf30 1552277_a_at 
CCNE2 
205034_at 
211814_s_at 
CDCA7 
224428_s_at 
230060_at 
CENPA 
204962_s_at 
210821_x_at 
COL4A2 
211964_at 
211966_at 
DCK 203302_at 
DIAPH3 
220997_s_at 
229097_at 
232596_at 
ECT2 
219787_s_at 
234992_x_at 
237241_at 
ESM1 208394_x_at 
EXT1 201995_at 
FBXO31 
219784_at 
219785_s_at 
223745_at 
224162_s_at 
FGF18 
206987_x_at 
211029_x_at 
211485_s_at 
214284_s_at 
231382_at 
FLT1 
204406_at 
210287_s_at 
222033_s_at 
232809_s_at 
GMPS 214431_at 
GNAZ 204993_at 
GPR180 231871_at 
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232912_at 
GSTM3 
202554_s_at 
235867_at 
IGFBP5 
1555997_s_at 
203424_s_at 
203425_s_at 
203426_s_at 
211958_at 
211959_at 
LOC643008 229740_at 
LOC728492 
219982_s_at 
223538_at 
223539_s_at 
MCM6 
201930_at 
238977_at 
MMP9 203936_s_at 
NMU 206023_at 
ORC6L 219105_x_at 
PECI 
218025_s_at 
218009_s_at 
QSOX2 
227146_at 
235239_at 
RAB6B 
210127_at 
221792_at 
225259_at 
RFC4 204023_at 
RTN4RL1 230700_at 
RUNDC1 
226298_at 
235040_at 
SLC2A3 
202497_x_at 
202498_s_at 
202499_s_at 
216236_s_at 
222088_s_at 
TGFB3 
1555540_at 
209747_at 
WISP1 
206796_at 
211312_s_at 
ZNF533 
1555800_at 
1555801_s_at 
229019_at 
LOC51203 218039_at 
DC13 218447_at 
AL137718 220997_s_at 
PK428 214464_at 
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 240735_at 
HEC 204162_at 
UCH37 219960_s_at 
220083_x_at 
1570145_at 
KIAA1067 215413_at 
212026_s_at 
212034_s_at 
212035_s_at 
SERF1A 223539_s_at 
219982_s_at 
223538_at 
OXCT 202780_at 
244134_at 
L2DTL 222680_s_at 
218585_s_at 
KIAA0175 204825_at 
SM20 220956_s_at 
223083_s_at 
224314_s_at 
221497_x_at 
223045_at 
227147_s_at 
DKFZP564D0462 213094_at 
MP1 205273_s_at 
217971_at 
FLJ11190 1552520_at 
1552521_a_at 
LOC57110 219983_at 
219984_s_at 
DHX58 219364_at 
AP2B1 200615_s_at 
200612_s_at 
CFFM4 223344_s_at 
HSA250839 219686_at 
CEGP1 219197_s_at 
ALDH4 203722_at 
KIAA1442 233850_s_at 
Table 3.2.3.1: Affymetrix Id corresponding to genes on MammaPrint  
The 123 mapped transcripts from the van‟t Veer study were compared with our in-house 
gene expression data of patients who relapsed (overall relapse) vs. patients who did not 
relapse (Fold change > 1.2, Difference > 100 and p-value ≤ 0.05) (see section 3.1.10). 
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There were a total of five genes common to the two lists. These 3 genes displayed the 
same trend of expression between the two studies. Over-expression of NMU, GMPS and 
MELK were associated with a poor prognosis (higher incidence of relapse in our study 
and greater chance of distant metastasis in the van‟t Veer study), whereas over-
expression of PECI and SCUBE2 was associated with good prognosis (lower incidence 
of relapse in our study and less chance of distant metastasis in the van‟t Veer study) 
(Table 3.2.3.2). 
Probe Set ID Gene Symbol In-house MammaPrint 
206023_at NMU 3.21 +1 
214431_at GMPS 1.28 +1 
204825_at MELK, KIAA0175 1.57 +1 
218025_s_at PECI -1.29 -1 
219197_s_at  SCUBE2, CEGP1 -2.23 -1 
Table 3.2.3.2: Genes common to in-house study comparing gene expression values of 
patients who relapsed vs. patients who did not relapse with the MammaPrint gene 
lists. A positive value represents over-expression of each gene and its association 
with poor prognosis while a negative value represents over-expression of gene and 
its association with good prognosis.  
A similar overlap comparison was also performed using the MammaPrint 70 gene 
signature and our in-house generated gene list comparing lymph node-negative vs. lymph 
node-positive (Fold change > 1.2, Difference > 100 and p-value≤0.05) (see section 3.1.6). 
However, no transcripts were identified common to both studies. 
3.2.4 Summary 
The analysis compared our findings to similar other studies. The analysis found HSPB1, 
KIAA0101, PAK3 genes to be up-regulated in patients who relapsed. AP1 transcriptional 
factor genes FOSA, FOSB were down-regulated in patients who relapsed. We also 
identified common genes to two of the breast cancer diagnostic assay (OncotypeDx and 
MammaPrint) and our in-house study. NMU, GMPS, MELK, PECI and SCUBE2 were 
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common genes on MammaPrint and our in-house study. AURKA, BIRC5, ERBB2, 
ESR1 and SCUBE2 were common to OncotypeDx and our in-house study. 
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3.3 Meta analysis of Estrogen receptor pathway genes using gene expression 
data. 
The in-house generated dataset, together with 5 published datasets from GEO (Table 
3.3.0.1) were subjected to meta-analysis to identify genes significantly up or down-
regulated in estrogen receptor-positive and negative specimens.  
Five of these experiments were from clinical studies while one study was on breast 
cancer cell lines (GSE3156). All these experiments were carried out on Affymetrix 
GeneChip U133A or U133Plus2.0 arrays. Details of these experiments are listed in 
Materials and Methods (see section 2.1.2). The minimum number of common 
transcripts in all experiments was 22,283. That is the number of transcripts in U133A 
chip. 
The normalization method used and number of ER-positive and ER-negative 
specimens in each experiment is listed in the Table 3.3.0.1. 
GEO Id No of ER(-) specimens No of ER(+) specimens 
In-house 34 68 
GSE3156 11 8 
GSE3744 18 15 
GSE2034 77 209 
GSE2990 34 149 
GSE4922 34 211 
Table 3.3.0.1: The above table lists the normalization type and the number of 
ER-positive (+) and ER-negative (-) samples in each experimental group. 
GSE3156 is the cell-line dataset while all others are clinical specimens.  
Individual experiments were compared for differentially-expressed genes when 
comparing the ER-positive specimens to ER-negative specimens. Only those genes 
were taken for further analysis which had the p-value ≤ 0.05, Fold change > 1.2 and 
Difference > 100 when comparing the ER-positive specimens to ER-negative 
specimens. The gene list generated by each experiment was compared to each other to 
find common transcripts that changed in two or more experiments. The numbers of 
common transcripts in any two comparisons are listed in Table 3.3.0.2. 
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GEO Id In-house GSE3156 GSE3744 GSE2034 GSE2990 GSE4922 
In-house 2000 410 702 819 443 751 
GSE3156  3715 481 576 315 414 
GSE3744    2394 1031 639 968 
GSE2034      3447 1027 1167 
GSE2990        1607 780 
GSE4922          2054 
Table 3.3.0.2: The above table represents the number of transcripts which are 
common to any two comparisons.  
Gene lists were also compared to identify common genes across all experiments. This 
analysis identified a set of 82 transcripts which were differentially up or down-
regulated across all the six experiments. Out of these 82 transcripts, 62 were up-
regulated and 20 transcripts were down-regulated in ER-positive specimens in 
comparison to ER-negative specimens.  
3.3.1 Up-regulated gene transcripts 
These transcripts, together with Affy IDs and associated fold changes are listed in 
Table 3.3.1.1.  
 
Probe Set 
ID 
Gene 
Symbol 
In-
House GSE4922 GSE3744 GSE2990 GSE2034 GSE3156 
211712_s_at ANXA9 4.74 3.55 11.15 3.52 3.38 6.5 
213234_at KIAA1467 3.6 2.63 3.45 2.12 2.49 2.13 
206401_s_at MAPT 3.54 3.03 4.54 2.13 3.63 12.43 
205225_at ESR1 3.53 6.04 40.74 4.71 8.88 15.27 
214440_at NAT1 3.53 4.19 13.32 3.19 6.07 4.58 
203928_x_at MAPT 3.44 3.04 4.15 2.19 3.44 5.83 
204540_at EEF1A2 3.41 2.04 4.93 2.89 3.41 2.08 
215304_at THSD4 3.2 2.95 5.85 2.18 2.92 2.51 
203929_s_at MAPT 3.17 3.69 5.79 2.32 4.09 8.68 
 186 
205009_at TFF1 2.53 4.34 59.3 2.66 8.89 60.56 
214053_at ERBB4 2.49 2.61 6.06 2.37 3.01 5.28 
203963_at CA12 2.48 3.72 9.43 2.54 3.37 3.8 
204508_s_at CA12 2.48 5.03 11.83 3.16 4.03 5.1 
209460_at ABAT 2.43 3.54 5.9 3.41 4.07 10.54 
209459_s_at ABAT 2.23 3.31 6.29 3.28 4.33 11.58 
209603_at GATA3 2.14 3.39 5.78 2.25 4.75 5.08 
219741_x_at ZNF552 2.12 1.7 3.27 2.2 1.83 3.5 
214164_x_at CA12 2.06 3.68 11.48 2.58 3.57 3.23 
215867_x_at CA12 2.05 3.73 11.23 2.55 3.29 3.14 
218195_at C6orf211 2.03 2.65 3.47 1.73 3.27 5.13 
201841_s_at HSPB1  2.02 1.63 2.88 1.82 1.81 1.95 
203571_s_at C10orf116 2.01 2.06 7 1.77 3.2 13.28 
202089_s_at SLC39A6 2 3.51 6.11 2.22 3.85 4 
205862_at GREB1 1.99 5 16.28 1.88 4.07 60.55 
209602_s_at GATA3 1.99 3.21 7.02 2.13 4.44 4.4 
218211_s_at MLPH 1.98 2.01 6.23 1.78 2.69 1.95 
209604_s_at GATA3 1.97 2.72 6.62 1.99 3.61 3.9 
41660_at CELSR1 1.97 2.41 3.03 2 3.17 2.81 
35666_at SEMA3F 1.88 1.48 2.17 1.31 1.64 2.15 
213441_x_at SPDEF 1.87 1.27 2.69 1.48 1.64 3.2 
204862_s_at NME3 1.8 1.67 2.23 1.58 1.88 2.61 
209681_at SLC19A2 1.8 1.65 3.88 1.92 2.26 2.38 
218931_at RAB17 1.8 1.6 1.98 1.83 1.39 2.48 
201349_at SLC9A3R1 1.77 1.51 2.3 1.91 1.65 4.32 
209623_at MCCC2 1.74 1.8 2.12 1.67 1.95 1.62 
216092_s_at SLC7A8 1.74 1.8 2.88 1.46 1.9 4.35 
205081_at CRIP1  1.72 1.6 3.03 2 2.77 23.88 
221139_s_at CSAD 1.72 1.72 2.33 1.39 1.8 1.7 
204798_at MYB 1.68 2.51 2.57 1.65 2.9 5.18 
212099_at RHOB 1.66 2.03 3.96 1.53 1.95 2.43 
202454_s_at ERBB3 1.62 1.53 2.23 1.44 1.65 2.91 
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205074_at SLC22A5 1.62 1.48 2.22 1.7 1.51 1.68 
202088_at SLC39A6 1.61 2.89 6.24 2.12 3.12 3.15 
204667_at FOXA1 1.61 1.91 4.97 1.67 2.58 3 
201596_x_at KRT18 1.6 1.6 2.71 1.73 2.02 1.67 
201754_at COX6C 1.6 1.53 1.97 1.56 1.75 1.4 
204623_at TFF3 1.6 2.91 20.95 2.05 4.55 59.8 
205376_at INPP4B 1.58 1.99 4 1.98 2.53 2.7 
210652_s_at C1ORF34 1.56 2.57 2.82 1.95 2.55 3.5 
212446_s_at LASS6 1.51 1.34 1.89 2.13 1.58 2.36 
212208_at THRAP2 1.49 1.43 1.5 1.51 1.48 2.2 
212209_at THRAP2 1.48 1.56 1.93 1.73 1.62 2.62 
218259_at MKL2 1.44 1.65 2.01 1.67 1.61 1.91 
209008_x_at KRT8 1.41 1.37 2.21 1.23 1.32 2.39 
218807_at VAV3 1.4 1.87 2.38 1.48 2.55 2.6 
200670_at XBP1 1.37 1.75 3.41 1.43 2.33 3.37 
201650_at KRT19 1.37 1.45 1.96 1.48 1.7 2.54 
209110_s_at RGL2 1.34 1.35 1.96 1.29 1.37 1.6 
203476_at TPBG 1.31 1.88 3.02 1.4 1.69 1.55 
201236_s_at BTG2 1.28 1.62 2.69 1.46 1.94 2.45 
218966_at MYO5C 1.28 1.31 1.76 1.46 1.62 1.86 
217979_at TSPAN13 1.21 1.37 3.23 1.59 1.82 3.57 
Table 3.3.1.1: The above table lists the 62 transcripts which were up-regulated in 
ER-positive patients/cell-lines. 
Gene ontology analysis was performed on genes up-regulated in a minimum of 3 out 
of 6 (50%) experimental groups. This approach was taken so as to increase the size of 
the DE genes for GO and Pathway analysis keeping the background gene list free 
from DE genes. The assumption taken was that if a gene is found DE in 50% of the 
experimental cohorts analysed, it is very likely to be involved in the ER metabolism. 
Similarly for the background gene list, only those genes were included which were 
not found to be DE in any of the experimental groups. 
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The background gene list included those genes which were not differentially-
expressed in any of the experimental groups. There were a total of 935 genes which 
were up-regulated in a minimum of 3 out of 6 experimental groups. Similarly 15859 
genes taken as background were found to be non-significant in all of the experimental 
groups. 
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GOID GO Name Changed Measured Z Score 
6829 Zinc ion transport 3 6 4.272 
15175 Neutral amino acid transporter activity 4 10 4.244 
16461 Unconventional myosin 2 3 4.18 
5010 
Insulin-like growth factor receptor 
activity 2 3 4.18 
51183 Vitamin transporter activity 2 3 4.18 
4165 
dDdecenoyl-CoA delta-isomerase 
activity 2 3 4.18 
16675 
Oxidoreductase activity, acting on heme 
group of donors 5 15 4.161 
16676 
Oxidoreductase activity, acting on heme 
group of donors, oxygen as acceptor 5 15 4.161 
4129 Cytochrome-c oxidase activity 5 15 4.161 
15002 Heme-copper terminal oxidase activity 5 15 4.161 
15804 Neutral amino acid transport 3 7 3.854 
5006 Epidermal growth factor receptor activity 3 7 3.854 
4303 Estradiol 17-beta-dehydrogenase activity 3 7 3.854 
4866 Endopeptidase inhibitor activity 14 82 3.819 
30414 Protease inhibitor activity 14 83 3.767 
41 Transition metal ion transport 6 23 3.756 
50982 Detection of mechanical stimulus 1 1 3.753 
50974 
Detection of mechanical stimulus during 
sensory perception 1 1 3.753 
9592 
Detection of mechanical stimulus during 
sensory perception of sound 1 1 3.753 
8389 Coumarin 7-hydroxylase activity 1 1 3.753 
Fig 3.3.1.2: GO analysis on up-regulated genes 
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MAPP Name Changed Measured Z Score 
1-Tissue-Muscle fat and connective 9 44 3.55 
Nuclear Receptors 7 34 3.148 
Electron Transport Chain 10 58 3.113 
Androgen-Receptor NetPath 2 13 88 2.927 
Valine leucine and isoleucine biosynthesis 2 5 2.912 
Pantothenate and CoA biosynthesis 3 11 2.659 
Smooth muscle contraction 15 122 2.368 
Ethylbenzene degradation 2 7 2.256 
Glutamate metabolism 4 22 2.083 
Wnt NetPath 8 11 89 2.038 
Fig: 3.3.1.3: Pathways analysis on up-regulated genes 
3.3.2 Down-regulated transcripts 
Twenty transcripts were down-regulated in all experimental groups. They are listed in 
Table 3.3.2.1.
 191 
 
Probe Set 
ID 
Gene 
Symbol 
In-
House GSE4922 GSE3744 GSE2990 GSE2034 GSE3156 
202037_s_at SFRP1 -4.38 -2 -6.32 -2.04 -3.31 -6.13 
202036_s_at SFRP1 -4 -2.08 -8.44 -1.83 -4.05 -10.37 
201012_at ANXA1 -2.63 -1.21 -1.75 -1.3 -1.35 -3.74 
212771_at C10orf38 -2.17 -1.62 -4.14 -1.74 -2.14 -3.46 
213113_s_at SLC43A3 -2.08 -1.77 -2.03 -1.34 -1.69 -4.84 
201300_s_at PRNP -1.9 -1.28 -1.84 -1.36 -1.55 -2.53 
208627_s_at YBX1 -1.83 -1.71 -2.81 -1.56 -1.61 -1.39 
212276_at LPIN1 -1.83 -1.44 -2.39 -1.62 -2.23 -2.13 
202342_s_at TRIM2 -1.79 -1.71 -3.48 -1.57 -2.22 -7.87 
200600_at MSN -1.77 -1.39 -1.7 -1.26 -1.94 -9.79 
221059_s_at COTL1 -1.64 -1.68 -1.81 -1.47 -2.13 -4.08 
200790_at ODC1 -1.51 -1.68 -2.04 -1.44 -1.75 -1.98 
218856_at TNFRSF21 -1.5 -1.69 -1.82 -1.56 -2.13 -2.66 
208628_s_at YBX1 -1.47 -1.53 -2.06 -1.35 -1.54 -1.38 
212274_at LPIN1 -1.37 -1.77 -2.72 -1.64 -2.12 -2.32 
212501_at CEBPB -1.37 -1.4 -1.58 -1.37 -1.58 -1.82 
212263_at QKI -1.31 -1.22 -1.89 -1.36 -1.54 -2.27 
201231_s_at ENO1 -1.3 -1.33 -1.76 -1.24 -1.72 -1.62 
218618_s_at FNDC3B -1.25 -1.23 -1.58 -1.29 -1.58 -2.98 
212345_s_at CREB3L2 -1.2 -1.27 -1.75 -1.27 -1.43 -1.86 
Table 3.3.2.1: The above table lists the transcripts which were up-regulated in 
ER-negative patients/cell-lines 
Gene ontology analysis was performed on genes down-regulated in a minimum of 3 
out of 6 experimental groups. The background gene list included those genes which 
were not DE in any of the experimental groups. There were a total of 697 genes which 
were down-regulated in a minimum of 3 out of 6 experimental groups. Similarly 
15859 genes taken as background were found non-significant in all of the 
experimental groups.  
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GOID GO Name Changed Measured Z Score 
7051 Spindle organization and biogenesis 6 12 6.794 
6270 DNA replication initiation 6 15 5.892 
226 Microtubule cytoskeleton organization 
and biogenesis 9 33 5.524 
16875 Ligase activity, forming carbon-oxygen 
bonds 8 28 5.39 
16876 Ligase activity, forming aminoacyl-
tRNA and related compounds 8 28 5.39 
8452 RNA ligase activity 8 28 5.39 
4812 tRNA ligase activity 8 28 5.39 
6261 DNA-dependent DNA replication 12 55 5.355 
9607 Response to biotic stimulus 64 633 5.337 
278 Mitotic cell cycle 21 133 5.28 
6418 tRNA aminoacylation for protein 
translation 8 29 5.252 
43038 Amino acid activation 8 29 5.252 
43039 tRNA aminoacylation 8 29 5.252 
3690 Double-stranded DNA binding 6 18 5.209 
49 tRNA binding 4 9 5.149 
51301 Cell division 18 110 5.063 
7049 Cell cycle 50 476 4.974 
7017 Microtubule-based process 15 85 4.967 
8283 Cell proliferation 43 389 4.962 
6260 DNA replication 17 104 4.913 
Table 3.3.2.2: Significant functions over-represented among ER-negative 
specimens.  
Pathway analysis was performed using GenMAPP. Significantly affected pathways 
were identified using the enrichment analysis in a way similar to that for Gene 
ontology. The statistically-significant pathways (top 10 based on Z-score) are listed in 
Table 3.3.2.3. Ropporin gene, expression specific to testis was also found to be up-
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regulated in ER-negative specimens in 3 out of 6 studies (Fig 3.3.2.1). However this 
pathway was not found to be significant. 
MAPP Name Changed Measured Z Score 
Cell cycle KEGG 19 69 6.548 
Aminoacyl tRNA biosynthesis 7 18 5.183 
Streptomycin biosynthesis 2 2 5.055 
Cell Cycle G1 to S control reactome 13 54 4.794 
DNA replication reactome 9 32 4.567 
Vitamin B6 metabolism 3 6 4.037 
2-Tissues-Blood and lymph 12 59 3.9 
One carbon pool by folate 4 13 3.272 
Galactose metabolism 5 21 2.93 
T-Cell-Receptor NetPath 11 15 107 2.731 
Table 3.3.2.3: Significant pathways over-represented among ER-negative 
specimens. 
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Fig 3.3.2.1: Testis specific genes up-regulated in ER-negative specimens. 
ROPN1B and ROPN1 has special significance and was studied in further detail 
(see section 3.6)  
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3.3.3 Genes correlated with ESR1 
ESR1 is the key gene involved in estrogen receptor pathway. The estrogen receptor 
pathway is very complex involving interaction of large number of genes, including 
many transcriptional factors. Detailed study of these genes could help in better 
understanding of the disease and development of better treatment options. This 
analysis was aimed at identifying genes whose expression patterns are correlated with 
ESR1. Gene expression profiles of 5897 samples representing diseased, normal 
human specimens and cell lines were obtained from Array Express E-TABM-185 (see 
section 2.1.2). The challenge was to mine large datasets for gene interaction network 
analysis. Because of the extremely large dataset, C programs were written to process 
the data. 
The first step in the data reduction effort was to filter out the genes which did not 
change much over the dataset, i.e. genes with low variation across samples. Only 
those genes which had a standard deviation greater than and equal to 1 across all 
samples were selected for further analysis. A total of 11,099 genes passed this 
criterion. The C program using Dev C++ (see section 2.2.10) was written for this 
analysis. 
The ESR1 gene has been shown to play an essential role in estrogen receptor 
metabolism. Using the set of identified 11,099 genes, the dataset was mined to 
identify highly correlated genes (Correlation > 0.75). A C program using Dev C++ 
(see section 2.2.10) was written to generate the correlation values among genes. 
FOXA1, GATA3, SPDEF and C1ORF34 were the only genes which had a correlation 
greater than 0.75 with ESR1. To get a deeper insight into how other genes correlate 
with estrogen metabolism, genes correlated with FOXA1, GATA3, SPDEF and 
C1ORF34 were identified (Correlation > 0.75) Many genes were identified which 
correlated with FOXA1, SPDEF and C1ORF34 and this information was used to 
create the network shown in Fig 3.3.3.1. However, no genes other than ESR1 were 
found to be correlated with GATA3. All these genes were also found to be up-
regulated in ER-positive tumour specimens in the previous analysis (see section 
3.3.1).  
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Fig 3.3.3.1: The above figure represents a correlation network among genes 
identified using 5897 samples. The correlation cut-off of 0.75 was used to filter 
genes. There were only 4 genes (FOXA1, GATA3, C1ORF34 and SPDEF) which 
correlated with ESR1 expression. However, there were many more genes which 
co-regulated with FOXA1, C1ORF34 and SPDEF. 
3.3.4 Correlation patterns among genes 
The correlation pattern among the ESR1-correlated genes (FOXA1, GATA3, 
C1ORF34, SPDEF) were plotted in excel to get a deeper understanding of the 
expression relationships between these genes (Fig 3.3.4.1 – Fig 3.3.4.9). The results 
indicate that, apart from one exception (that between genes SPDEF and FOXA1), 
there is independency of expression between each of the genes i.e. although the 
expression is correlated; the expression of one can be independent of the other. 
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However, there was an interesting relationship observed between the correlation 
patterns of SPDEF and FOXA1. The expression of FOXA1 was independent of the 
expression of SPDEF. However, the expression of SPDEF seems likely to be 
dependent on the expression of FOXA1 (Fig 3.3.4.1).  
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Fig 3.3.4.1: Correlation pattern between FOXA1 and SPDEF. Each axis 
represents the expression values of that individual gene. 
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Fig 3.3.4.2: Correlation pattern of ESR1 and FOXA1. Each axis represents the 
expression values of that individual gene. 
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Fig 3.3.4.3: Correlation pattern between ESR1 and GATA3. Each axis 
represents the expression values of that individual gene. 
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Fig 3.3.4.4: Correlation pattern between ESR1 and C1ORF34. Each axis 
represents the expression values of that individual gene. 
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Fig 3.3.4.5: Correlation pattern between ESR1 and SPDEF. Each axis represents 
the expression values of that individual gene. 
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FOXA1 and GATA3 correlation
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Fig 3.3.4.6: Correlation pattern in FOXA1 and GATA3. Each axis represents the 
expression values of that individual gene. 
 
Fig 3.3.4.7: Correlation pattern between FOXA1 and C1ORF34. Each axis 
represents the expression values of that individual gene. 
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Fig 3.3.4.8: Correlation pattern between GATA3 and C1ORF34. Each axis 
represents the expression values of that individual gene. 
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Fig 3.3.4.9: Correlation pattern between GATA3 and SPDEF. Each axis 
represents the expression values of that individual gene. 
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3.4.5 Hierarchical clustering, Principal component analysis and k-means analysis 
on ESR1 correlated genes. 
Hierarchical clustering (Fig 3.4.5.1) and Principal component analysis (Fig 3.4.5.2) on 
the expression values of these 5 ESR1-correlated genes was utilized across all 
samples to identify similarities among the expression patterns of these genes. Both 
methods indicated that the FOXA1 and SPDEF expression were very similar to each 
other. 
 
Fig 3.4.5.1: Hierarchical clustering showing relationship among genes.  
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Fig 3.4.5.2: PCA showing relationship among genes. SPDEF and FOXA1 are 
close to each other on a 3-D representation of the data. 
To get a deeper insight on how the expression patterns of these 5 genes are distributed 
across all samples, k-means clustering was performed on all samples (5897) using the 
expression values of these 5 genes only (Fig 3.4.5.3). The individual genes were mean 
centered and divided by standard deviation. The total number of clusters generated 
was 12, the number of iterations was 200 and the distance criteria were Euclidean 
distance.  
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The biggest cluster (3209 samples; Cluster 8) represented specimens which express 
low levels of these 5 genes. The next biggest cluster (899 samples; Cluster 9) 
represented specimens where all these 5 genes are highly expressed. This result also 
indicated that in some of the specimens, ESR1 can be highly expressed even when 
other four genes are not expressed very highly (Cluster 5). Another interesting result 
is that the GATA3 expression can be independent of that of the other genes (Clusters 
2 and 6).  
All the five genes expressing together is the most obvious result from this study 
(Cluster 9) indicating that mostly these genes are co-expressed. Individual genes can 
be expressed without depending on the expression of other genes. However, no cluster 
with high expression of SPDEF and low expression of FOXA1 was observed, 
indicating that the expression of SPDEF may be dependent on the expression of 
FOXA1. 
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Fig 3.4.5.3: k-means clustering using all samples and 5 genes. The individual 
genes were mean centered and divided by standard deviation. The total number 
of clusters generated was 12. Number of iteration was 200 and the distance 
criteria were Euclidean distance. Total numbers of samples were 5897 
3.4.6 Summary 
The analysis identified important genes to ER pathway. ESR1, GATA3, FOXA1, 
SPDEF and C1ORF34 were found to be highly correlated and up-regulated in ER-
positive specimens. Nuclear receptor pathway was found to be up-regulated in ER-
positive tumors. Using gene expression data a gene interaction network was 
constructed around ESR1 gene, an important gene in the ER metabolism. The results 
also indicated that SPDEF expression may be dependent on the expression of 
FOXA1. SPDEF gene was identified to be up-regulated in ER-negative specimens.  
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3.4 Gene expression signature for HER2  
This section analyses three publicly available datasets to identify 
diagnostic/prognostic markers associated with HER2-positive tumors. 
3.4.1 HER2-positive vs. HER2-negative 
Clinical (GSE-1456 and GSE-3744) and Cell Line (GSE-3156) datasets (see section 
2.12) were cross compared to identify genes up- and down-regulated in HER2-
negative vs. positive patients. The number of specimens in each group and the number 
of DE genes (p ≤ 0.05, Fold Change (FC) > 1.2 and Difference > 100) are listed in 
Table 3.4.1.1. There were 13 transcripts common across all the experiments (Fig 
3.4.1.1) 
GEO Accession HER2 - HER2 + Up-regulated Down-regulated 
GSE-1456 144 15 421 314 
GSE-3744 24 8 101 290 
GSE-3156 14 4 898 2616 
Table 3.4.1.1: Number of HER2 samples in each experimental group and the 
number of DE genes in individual comparison 
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Fig 3.4.1.1: Common DE transcripts across experiments. Venny (see section 
2.2.7.2) was used to draw this Venn diagram.  
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The 6 up-regulated transcripts in all experimental groups are listed in Table 3.4.1.2. 
The 7 down-regulated transcripts in all experimental groups are listed in Table 
3.4.1.3. 
probe set gene GSE-1456 GSE-3744 GSE-3156 
216836_s_at ERBB2 4.8 17.17 7.51 
224447_s_at C17orf37 4.42 9.54 6.24 
202991_at STARD3 3.36 6.3 5.49 
224576_at ERGIC1 1.58 1.98 2.23 
215380_s_at C7orf24 1.52 1.79 1.96 
223847_s_at ERGIC1 1.49 1.83 1.75 
Table 3.4.1.2: Up-regulated transcripts in all experimental groups 
probe set gene GSE-1456 GSE-3744 GSE-3156 
223475_at CRISPLD1 -2.69 -8.46 -7.53 
202037_s_at SFRP1 -2.5 -4.89 -7.37 
202036_s_at SFRP1 -2.37 -5.57 -22.38 
218094_s_at DBNDD2  -1.91 -2.88 -3.41 
205383_s_at ZBTB20 -1.53 -1.76 -2.92 
235308_at ZBTB20 -1.4 -2.01 -3.97 
212190_at SERPINE2 -1.36 -2.09 -9.01 
Table 3.4.1.3: Down-regulated transcripts in all experimental groups 
3.4.2 Summary  
This section identified ERBB2, C17orf37, STARD3, ERGIC1 and C7orf24 as up-
regulated among HER2-positive patients.  
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3.5 Development of MLPERCEP, a software tool for predicting relapse in breast 
cancer 
Neural Network Multiple Layer Perception (MLPERCEP), using Back Propagation 
Algorithm, was used to accurately predict relapse in breast cancer patients. A stand-
alone piece of software, MLPERCEP was developed to implement Back Propagation 
Algorithm. The software is available at http://www.bioinformatics.org/mlpercep/ 
3.5.1 Design 
The MLPERCEP software is a collection of individual programs written in C 
language. Each of the C programs is complemented with the graphics user interface 
written in C# and the individual sets can be accessed from the main user interface also 
in C#. The C programs extensively use dynamic memory allocation and utilization of 
hard disk space to make the program practically handle extremely large networks and 
datasets. To run the software, the .NET runtime environment from Microsoft 
(http://www.microsoft.com/downloads/details.aspx?FamilyID=0856EACB-4362-
4B0D-8EDD-AAB15C5E04F5&displaylang=en) must be installed. 
3.5.2 Architecture 
 The architecture of the MLPERCEP back propagation algorithm is shown below. The 
software has an input neuron layer, a hidden neuron layer and an output neuron layer 
(Fig 3.5.2.1.) 
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Fig 3.5.2.1: Architecture of back propagation algorithm. 
The number of input neuron depends on the number of inputs. The inputs can be 
binary or floating numbers. However, the results are more accurate if values within -1 
and 1 are used. Currently the software supports only binary outputs i.e. 0 or 1 or any 
value between them. The hidden layer is the generalization layer and can be varied by 
the user. The very high number of hidden neurons may lead to quicker learning, but 
may fail to generalize. However, a very small number of neurons may not allow the 
network to train at all. Some of the other fine tuning parameters are learning rate, 
momentum, error cut-off, maximum number of iterations and leave-one-out cross-
validation. 
3.5.2.1 Algorithm  
The algorithm was adapted from the book by Simon Haykin “Neural Network. A 
comprehensive foundation” (Haykin 1998) 
Forward propagation: 
Hidden layer output Hi = F (
ni
i 0
wi × Ii ) 
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w is weight of input to hidden interconnection and I is the input signal, n is the 
number of input neuron.  
Output O = F (
nh
h 0
Wh × Hh ) 
W is weight of hidden to output interconnection and H is the output of hidden neuron, 
n is the number of hidden neuron. 
H is the output of hidden neuron and O is the output of output neuron 
w and W are the weights of input-hidden and hidden-output connection. 
F is sigmoid activation function F(x) = 1/(1+e
-x
) 
Backward error propagation and weigh correction 
Output layer error vector D = O (1-O)(T-O)  
T is the desired output 
Adjusting the hidden layer weights 
∆Wi = αHD + θ∆Wi-1 
α is the learning rate, θ is the momentum 
Hidden layer error vector Ei = Hi(1-Hi)WiD 
∆wi = αIiE + θ∆wi-1 
The above process is iterated till the error sum of squares drops to user defined value 
or the maximum iteration is reached. 
Added features include equal loading of positive and negative examples. This avoids 
the algorithm‟s propensity to predict more efficiently on class with more examples at 
the cost of the class with fewer examples. Another important feature is the run time 
randomization of input examples. This avoids the problem of the network falling in 
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local minima. Additional features include leave-one-out cross-validation. This has an 
advantage on judging the systems efficacy on small datasets where dividing the 
datasets as training and testing datasets becomes impractical.  
3.5.3 Software Modules  
Following installation, the application can be launched from Start  All programs  
MLPERCEP or from a shortcut on the desktop if it has been made during the 
installation process. A window appears as shown in Fig 3.5.3.1. 
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 Fig 3.5.3.1: Start up screen of MLPERCEP. 
Clicking on the individual button will activate the respective program. 
3.5.3.1 Training program  
This program trains the network. Clicking on the Training button will produce a 
window as shown in Fig 3.5.3.1.1.  
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Fig 3.5.3.1.1: Back propagation training program.  
Training file: “Upload” button to select the file to be trained. A sample format is 
shown below. It should be a text file. 
Samples 4   
Parameters 2   
Sample1 0 0 0 
Sample2 1 0 1 
Sample3 1 1 0 
Sample4 0 1 1  
The first line should contain the word “samples” or any other word followed by the 
total number of samples. In this example, it is 4. 
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The second line should contain the word “parameters” or any other word followed by 
the total number of input parameters (this will be also taken as the number of input 
neurons). In this example it is 2. 
From the third line onwards, the first word should contain the sample name and the 
second column should be the expected output. The others in the row are the inputs to 
the system. It can be binary, e.g. 0 and 1, or it can be decimal (e.g. 0.02). The program 
will give optimum results only when the data range is between -1 and 1. 
If the data has samples as columns and parameters as rows (e.g. microarray data), 
utility programs “Format Data” can be used. If the data is of DNA sequences, the 
utility tool “Format sequence data” can be used. This tool will easily convert data to 
the above-mentioned format. 
Weight Output file: All the information of the training in the form of weights will be 
saved in this file. 
No of hidden neurons: This denotes the total number of hidden neurons the network 
should have. Ideally it should be less than the number of input neurons. If the 
numbers of hidden neurons are very less, it is possible the system will never learn. 
However on the other hand if the number of hidden neurons is very high, it may lead 
to better learning but behave poorly in generalization.  
Learning rate: Learning rate decides the speed by which the network will learn. A 
very small learning rate may take an infinite time for the network to learn. On the 
other hand a very high learning rate may lead to error bumping and the network not 
being trained at all. The optimum learning rate for most of the problems lies in the 
range of 0.4 to 0.6. 
 Momentum: During the training process, the error convergence reaches a local 
minima and no further convergence takes place. Placing a momentum (normally 
between 0.2 - 0.8) helps it come out of the local minima and proceed to the global 
minima. 
Error cut-off: Error reduces with iteration and the program will stop execution once it 
reaches the error cut-off or the maximum number of iterations. 
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Maximum iteration: The total number of training cycles performed by the program. 
However if the error reaches below error-cut-off, the program will stop. The lower the 
error cut-off, the better the results are. 
Copy: The program makes a copy of the dynamic changing weights after “copy” 
number of iterations. So if the program is stopped between iterations, the user can 
obtain the previous copy of the weights. 
Cross validation output file: By default, the system does not perform any cross-
validation. If a file name is provided, the system will perform cross-validation. The 
system performs a leave-one-out cross-validation which is a very computationally-
intensive process.  
Train: Clicking on “Train” will open an MSDOS window as shown below (Fig 
3.5.3.1.2). 
 
Fig 3.5.3.1.2: MSDOS screenshot showing error sum of squares 
These values are the error sum of squares. Ideally these values should decrease with 
time, indicating that the network is learning. The error sum of squares will reach zero 
when the software reaches the minimum error cut off or the maximum iteration is 
reached. If the error is not further reducing, the MSDOS window can be closed and 
the last set of weights will be taken for further calculations.  
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3.5.3.2 Testing  
After training the data the network can be used for testing on the unknown samples. 
Clicking on “Testing” button will activate the window shown in Fig 3.5.3.2.1. 
  
Fig 3.5.3.2.1: Back propagation testing program. 
Weight File: The training program exports the knowledge in the form of a weight file. 
The weights are the optimised weights for correct prediction.  
Testing File: The data format is the same as that for the training program. However, it 
does not need to have the target as the second row.  
Output file: File where the results are to be saved.  
Data contains expected output: If the test set data contains information on the output 
for each sample, check this option to test the algorithm efficiency 
Click on “Test” and the testing program will start.  
3.5.3.3 Map data between 0 and 1  
Since the expression values may be quite high, this tool maps the data between 0 and 
1. It uses the following calculation. 
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New value = (Old value - Minimum value for that gene)/ (Maximum value for that 
gene - Minimum value of that gene) 
This tool should be used only after the feature selection; otherwise it will map the less 
changing data also between 0 and 1 thereby magnifying the error.  
The data should be in the following format. It should be in a text file. 
Identifier s1 s2 s3 s4 s5 s6 
Target 1 0 0 1 1 0 
G1 3 8 2 9 1 2 
G2 9 4 2 9 6 5 
G3 3 2 7 9 3 2 
First row and column should contain the word “Identifier”, or any other word, 
followed by the names of the identifiers.  
Second row first column should contain the word “Target”, or any other word. 
Following this should contain the expected output of that sample, 0 for one class and 
1 for the other class. If this row is present, the option “Second column contains target” 
should be checked. 
The following rows should contain gene identifier followed by expression values.  
Clicking on “Map values between 0 and 1” will activate the window shown in Fig 
3.5.3.3.1. 
 219 
 
Fig 3.5.3.3.1: Map data between 0 and 1. 
3.5.3.4 Formatting data  
This program will convert gene expression data to the format in which the training 
program can accept. Clicking on “Format microarray data” will activate the window 
shown in Fig 3.5.3.4.1. 
  
Fig 3.5.3.4.1: Format microarray data. 
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The data should be in the following format. It should be a text file. 
Identifier s1 s2 s3 s4 s5 s6 
Target 1 0 0 1 1 0 
G1 3 8 2 9 1 2 
G2 9 4 2 9 6 5 
G3 3 2 7 9 3 2 
The first row and column should contain the word Identifier, or any other word 
followed by the names of the Identifier.  
The second row, first column should contain the word “Target” or any other word. 
Following this should contain the expected output of that sample 0 for one class and 1 
for the other class. This row is essential for the training data. However it is optional 
for the testing data. If this row is present the option “Second column contains target” 
should be checked or else unchecked. Target can be in the second row even in the 
testing file. In such case it will give a comparative result with the expected output. 
The following rows should contain gene identifier followed by expression values 
Input file: Select the file to be formatted.  
Output file: Specify the output file name.  
Divide values by: The program trains best when the data range is in between 0 and 
1. So if the data lies outside this range, divide the values by a particular number so as 
the values fall between 0 and 1.  
Randomize samples: Randomizing samples is always helpful for the training. It 
randomizes the order of training examples fed to the program. If all positive examples 
are shown at one time and all the negative examples after that, then the system keeps 
on forgetting the previous class. Therefore it is essential to train the network with 
alternating positive and negative examples, so that the network remains balanced and 
does not deviate towards predicting one class at the cost of other. 
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Second row contains target: The second row should contain the known outcomes of 
individual samples as shown in the previous example and this is a must for the 
training file. However, it‟s optional for the testing set.  
Click on “Format”. The output file will be placed in the working folder. 
 3.5.3.5 Format Sequence data  
If the data is in the form of a DNA sequence, this utility tool will format the data to 
numeric values. The submitted sequence should be in FASTA format. 
Click on “Format Sequence Data” will activate the window shown in Fig 3.5.3.5.1. 
  
 Fig 3.5.3.5.1: Format DNA sequence. 
An example of input data is shown below: 
>Seq1 Hypothetical gene 
ATGCGTA 
>Seq2 Kinase 
TTCTAAC 
This step will be repeated. The first word will be taken as the sequence name. For the 
above example it will be Seq1 and Seq2 
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Negative training file: Upload the file with sequences which belong to one group. 
Here it will be assigned 0. 
Positive training file: Upload the file with sequences which belong to the other group. 
Here it will be assigned 1. 
The sequence are numerically transferred as  
A  0 0 
T  0 1 
G  1 0 
C  1 1 
Unidentified bases will be assigned 0 0. The length of sequences should be equal. 
Output file: Specify the output file name. 
Click on “format”. The output file will be placed in the working folder  
 For testing purposes, only one file is needed. Leave the field “Positive Training File” 
empty. The system will consider that the formatting is done for the testing purpose 
3.5.3.5 Analyse Results  
This tool can be used to analyse the results obtained from the cross validation study or 
after testing on a new result where the expected output is known. Clicking on 
“Analyse Results” will activate the window shown in Fig 3.5.3.5.1. 
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Fig 3.5.3.5.1: Analyse results. 
Input file name: Input file name contains the actual output of each sample along with 
the expected value/class. It is the output of testing or cross-validation. 
Positive and negative cut-off: Values between the positive and negative cut-off won‟t 
be considered for classification and their class would be considered as undermined. 
Having a stringent cut-off will increase the accuracy; however it will increase the 
number of samples as undetermined. 
The output includes Overall accuracy, Positive and Negative accuracy, True and False 
positive rates. “Positive accuracy” (also known as true positive rate) is the accuracy of 
positive class. Similarly, negative accuracy (also known as true negative rate) is the 
accuracy of the other class. False positive rate and false negative rate are the error 
rates associated with the positive and negative class respectively. 
An example of the result file is shown below 
Positive cut-off:  0.750000 
Negative cut-off:  0.250000 
Total number of samples: 34 
Total number of samples which could not be classified: 1 
Total number of samples which were accounted:  33 
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a=19 b=0 c=1 d=13 
Positive accuracy: 0.928571 
Negative accuracy: 1.000000 
Accuracy:  0.969697 
True positive rate: 0.928571 
False positive rate: 0.000000 
True negative rate: 1.000000 
False negative rate: 0.071429 
The calculations are shown below.  
 Predicted Actual 
a 0 0 
b 1 0 
c 0 1 
d 1 1 
 
Positive accuracy = d/(d+c) 
Negative accuracy = a/(a+b) 
Overall Accuracy = (a+d)/(a+b+c+d)) 
True positive rate = d/(c+d) 
False positive rate = b/(a+b) 
True negative rate = a/(a+b) 
False negative rate = c/(c+d) 
3.5.4 Results  
The aim was to develop a classifier to predict relapse in breast cancer patients. 
Differentially-expressed genes were generated by comparing the patients who 
relapsed (overall relapse) compared to patients who did not relapse. The total number 
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of samples was 105. The filtration criteria used was p ≤ 0.001. There were a total of 
162 genes meeting the criteria and a classifier was developed on those genes. The 
162-member gene signature expression values was normalised to between 0 and 1, as 
discussed in section 3.5.3.3. The data was used to optimize the neural network back 
propagation program. The optimization was done by varying the number of hidden 
neurons, learning rate and the momentum. The results are indicated in Fig 3.5.4.1, Fig 
3.5.4.2 and Fig 3.5.4.3 
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Fig 3.5.4.1: Leave-one-out cross validation accuracy on varying the hidden 
neurons  
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Fig 3.5.4.2: Leave-one-out cross validation accuracy on varying the learning rate 
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Fig 3.5.4.2: Leave-one-out cross validation accuracy on varying the momentum. 
The results indicate that 4, 8 and 10 hidden neurons gave better accuracy. 4 hidden 
neurons were taken for further analysis as lower number of hidden neuron makes the 
training process fast and should perform better on independent validation. A learning 
rate of 0.2 and 0.4 was found to give a better accuracy. Therefore a learning rate of 
0.4 was taken to obtain faster learning. Lower momentum performed better. Therefore 
a momentum of 0.1 was taken for subsequent analysis. 
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Optimised parameters were used: (Hidden neurons: 4; Learning rate: 0.4; Momentum: 
0.1; Error cut-off: 0.04; Maximum number of iterations: 10000). The leave-one-out 
cross-validation method was used to estimate the accuracy of the model. Additionally, 
another classifier was developed using Support Vector Machines using GEMS 
software. Default parameters were used (SVM cost: 100; SVM kernel: Polynomial 
and SVM kernel parameter (degree): 1) using the same dataset.  
When the cut-off 0.75 and 0.25 was used, the accuracy of the back propagation model 
was 97.8%. However there were a total of 11 specimens which could not be 
classified. When the cut-off was taken as 0.5, and all the specimens were grouped, the 
overall accuracy was 93.3%. The detail results are shown in Table 3.5.4.1. A support 
vector machine algorithm using the above data was able to classify with an accuracy 
of 93.3%. 
 Parameters Positive cut-off: 0.75 
Negative cut-off: 0.25 
Positive cut-off: 0.5 
Negative cut-off: 0.5 
A 51 53 
B 2 4 
C 0 3 
D 41 45 
Unclassified 11 0 
Accuracy 0.978723 0.933333 
True positive rate 1 0.937500 
False positive rate 0.037736 0.070175 
True negative rate 0.962264 0.929825 
False negative rate 0 0.062500 
Table 3.5.4.1: Results from Back propagation cross validation program. 
A cDNA microarray dataset generated by van‟t Veer et al., (2002), was used to 
develop a classifier to predict distant metastasis. This was done to judge how the 
algorithm performs on cDNA microarray data. The total number of specimens used 
was 78. DE genes (p < 0.001) were used to develop the classifier. The number of 
genes that passed this criterion was 117, and a classifier was developed on them. The 
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data was used without any transformation as the cDNA microarray values were close 
to 0 as the data was log ratio. Default parameters for both were used and leave-one-
out cross-validation was performed. When the cut-off 0.75 and 0.25 was used, the 
accuracy of the back propagation model was 89.7%. However, there were a total of 10 
specimens which could not be classified. When the cut-off was taken as 0.5, and all 
the specimens were grouped, the overall accuracy was 87.1%. The detail results are 
shown in Table 3.5.4.2. A support vector machine using the above data and default 
parameters was able to classify the data with an accuracy of 82.05%. 
 Parameters Positive cut-off: 0.75 
Negative cut-off: 0.25 
Positive cut-off: 0.5 
Negative cut-off: 0.5 
A 37 40 
B 2 4 
C 5 6 
D 24 28 
Unclassified 10 0 
Accuracy 0.897059 0.871795 
True positive rate 0.827586 0.823529 
False positive rate 0.051282 0.090909 
True negative rate 0.948718 0.909091 
False negative rate 0.172414 0.176471 
Table 3.5.4.2: Results from Back propagation cross validation program. 
3.5.5 Summary 
A back propagation algorithm was successfully developed as a user-friendly software 
package which can be used to develop a prognostic model for breast cancer. The 
results generated were at par or better than Support Vector Machines in predicting 
relapse and distant metastasis in two of the datasets tested. 
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3.6 Functional analysis on ROPN1B 
Ropporin is a sperm-specific protein and is associated with sperm motility (Fujita et 
al., 2000). Its expression was also found in motile cilia helping them to move in one 
direction in a synchronised pattern (Newell et al., 2008). Ropporin (ROPN1 and 
ROPN1B) was identified as differentially-expressed in several gene lists commonly 
associated with bad prognosis in our breast cancer investigation (see section 3.1) This 
gene was significantly up-regulated in patients who relapsed, patients who did not 
survive beyond 5 years, patients who relapsed within 5 years and patients with ER-
negative tumors. Additionally this gene was up-regulated in one of the sub-groups of 
ER-negative breast cancer with a high incidence of relapse (see section 3.1.3). The 
gene was also up-regulated in the ER-negative subgroup in 3 out of 6 datasets 
comparing ER-negative and ER-positive specimens (see section 3.3.2). There was a 
total of 4 probe sets representing the Ropporin gene on the Affymetrix U133 Plus2.0 
microarray chip, which when annotated in NetAffx, corresponded to two highly 
homologous gene targets, ROPN1 and ROPN1B, located at two different loci on the 
same chromosome.  
3.6.1 Similarity and difference among ROPN1B and ROPN1 
3.6.1.1 Sequence similarity 
Using ClustalW, ROPN1B and ROPN1 were found to be 97% identical based on 
DNA (Coding sequence) sequence similarity (Fig 3.6.1.1.1) and 95.7% identical 
based on the predicted protein sequence similarity (Fig 3.6.1.1.2).  
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Fig 3.6.1.1.1: DNA sequence alignment for ROPN1 and ROPN1B 
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Fig 3.6.1.1.2: Protein sequence alignment for ROPN1 and ROPN1B 
3.6.1.2 Design of gene specific primers for ROPN1 and ROPN1B 
TaqMan primers were designed for ROPN1 and ROPN1B using primer express from 
ABI (see section 2.5.5.1). The primers were designed using the most variable region 
of the gene (close to 3‟ region). The forward and reverse primers were on different 
exons making it specific to detect mRNA only.  
ROPN1 primers:  
Sense: TGT CAG CAG GAT GCT AAA CTA CAT G Tm: 61.3, GC content 44% 
Location: 878 – 902 on NM_017578.2 
Antisense: ATT TTG GGT GGT ATA TGG GTT TCA Tm: 57.6, GC content: 37.5% 
Location: 1062-1039  
Probe: CAG CTG GAG TAA AAG CAC AAT TTT GGC AA Tm: 63.9, GC content 
41.4%, 5‟ JOE 3‟ TAMARA Location: 969 – 997 
ROPN1B primers: 
Sense: TGT CAG CAG GAT GCT AAA CTA CAT T Tm: 59.7 GC content: 40% 
Location: 765-789 in NM_ 001012337.1 
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Antisense: AGG TGG TAT ATG GGT TTA TCA TTC TGA Tm: 59, GC content 
37% Location: 942-916 
Probe: TGG CTG GAG TAA CAG CAC AAT TTT GGC Tm: 65. GC content: 48.1 
5‟ FAM 3‟ TAMRA Location 856 - 882 
Specificity of primers: ROPN1 and ROPN1B plasmids in bacteria were obtained from 
Open Biosystems (see section 2.5.7). The plasmids were isolated using mini-prep kit 
from Qiagen (see section 2.5.6.1). qRT-PCR was performed on these plasmids for 
both genes. 
To determine the efficacy of the ROPN1 and ROPN1B primers in differentiating their 
respective cDNAs, qRT-PCR experiments were set up utilizing both sets of primers 
on both plasmid preps from both genes. As can be seen in Fig 3.6.1.2.1, the designed 
ROPN1 primers were specific to ROPN1 and did not amplify ROPN1B. 
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Fig 3.6.1.2.1: ROPN1 qRT-PCR on ROPN1 expression plasmid preps. ROPN1 
primers amplified ROPN1 gene transcript from ROPN1 expression plasmid 
preps and did not amplify ROPN1B. On the X-axis, the first letter indicates the 
target (i.e. cDNA; A-ROPN1, B-ROPN1B) source, the second letter indicates the 
primer type and the number indicates the 1/x dilution. On the Y-axis, “Ct” refers 
to “Cycle Threshold” and is a measure of the cycle number at which the 
fluorescence generated within a reaction crosses the threshold. It is inversely 
correlated to the logarithm of the initial copy number.  
The ROPNIB primers were efficient in detecting ROPN1B cDNA. However, 
ROPN1B primers did amplify ROPN1 but at a later cycle (~6 Ct), making the 
detection of ROPN1 by ROPN1B primer 100-fold less specific compared to its ability 
to detect ROPN1B (Fig 3.6.1.2.2). Every 3.2 Ct difference is equivalent to a 10 fold 
difference in gene expression. Due to the sequence conservation between ROPN1 and 
ROPN1B, it was impossible to design alternate primers. As a result, it was concluded 
that to accurately assess ROPN1B expression using these primers, all ROPN1B qRT-
PCR experiments would be complemented with ROPN1 expression, to identify 
whether a given expression value was due to ROPN1B or ROPN1.  
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Fig 3.6.1.2.2: ROPN1B qRT-PCR on ROPN1/ROPN1B expression plasmid 
preps. The X/Y axes are as detailed for Fig 3.6.1.2.1. The detection of ROPN1 by 
ROPN1B primer was 100-fold less specific compared to its ability to detect 
ROPN1B.  
3.6.1.3 Affymetrix probe presentation of Ropporin (ROPN1 and ROPN1B) 
There are four probe sets representing Ropporin gene on Affymetrix U133 plus 
arrays, whereas there is only one on the U133A chip. To get a deeper understanding 
regarding which probes represent ROPN1 and which represented ROPN1B sequences 
for all these probes were BLASTED. 
Probe: 233203_at: On Affymetrix arrays probe ID with “_at” are considered as unique 
to the specified gene and are not supposed to hybridize with other genes. BLASTING 
the sequence resulted in no match with any of the reference sequence of ROPN1 or 
ROPN1B. However, there was a match with ROPN1 gene (not the reference 
sequence) (Fig 3.6.1.3.1). 
Two years previously when there was no reference sequence available for ROPN1, it 
was assumed that this probe represented ROPN1. And since this probe was not 
expressing in our study, it was assumed that the expression detected was due to 
ROPN1B and not ROPN1. With the updated annotation and qRT-PCR results, it was 
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concluded (at a much later date) that the unique probe for ROPN1 (233203_at) on 
Affymetrix chip is a faulty probe and does not represent ROPN1.  
 
Fig 3.6.1.3.1: BLAST result for 233203_at probe sequence. No BLAST hit was 
obtained for reference sequence for ROPN1 and ROPN1B 
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Probe 231535_x_at: BLAST results indicate this probe to represent ROPN1 gene (Fig 
3.6.1.3.2). No hit was obtained for ROPN1B reference sequence. 
 
Fig 3.6.1.3.2: BLAST result for 231535_x_at probe sequence. BLAST hit was 
obtained for reference sequence for ROPN1 and no hit was obtained for 
reference sequence for ROPN1B. 
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Probe 224191_x_at: BLAST results indicate this probe to represent both ROPN1B 
and ROPN1 gene. A 100% match was obtained for ROPN1B reference sequence (Fig 
3.6.1.3.3) and 99% match was obtained for ROPN1 reference sequence (Fig 
3.6.1.3.4). 
 
Fig 3.6.1.3.3: BLAST result for 224191_x_at probe sequence 
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Fig 3.6.1.3.4: BLAST result for 224191_x_at probe sequence  
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Probe 220425_x_at: BLAST results indicate this probe to represent ROPN1B. A 
100% match was obtained for ROPN1B reference sequence (Fig 3.6.1.3.5) and 97% 
match was obtained for ROPN1 reference sequence (Fig 3.6.1.3.6). 
 
Fig 3.6.1.3.5: BLAST result for 220425_x_at probe sequence 
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Fig 3.6.1.3.6: BLAST result for 220425_x_at probe sequence  
Therefore probe set 231535_x_at was taken to represent ROPN1 and probe set 
220425_x_at was taken to represent ROPN1B. 233203_at was no longer considered 
to represent Ropporin. 
3.6.2 Expression of ROPN1 and ROPN1B in normal and cancerous breast tissue 
3.6.2.1 Expression of ROPN1 and ROPN1B in our in-house study 
Ropporin (ROPN1 and ROPN1B) expression was examined in our in-house study 
using both microarray and qRT-PCR. 
3.6.2.1.1 Results from microarray 
On average, ROPN1 was 4.97-fold up-regulated in patients who relapsed and 
ROPN1B was 5.06-fold up-regulated in patients who relapsed compared to patients 
who did not relapse (overall). ROPN1 was 6.81-fold up-regulated in patients who 
relapsed within 5 years and ROPN1B was 7.83-fold up-regulated in patients who 
relapsed within 5 years compared to those who remained disease-free for 5 years. 
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High expression of ROPN1 and ROPN1B was observed in one of the sub-cluster 
enriched with ER-negative specimens. This cluster had the worst survival in 
comparison to other clusters (see section 3.1.3).  
ROPN1B (220425_x_at) was not expressed among 54/57 (94.7%) of the patients who 
did not relapse, however it was expressed in 13/48 (27.1%) of the patients who did 
relapse based on the cut-off of 100 Affymetrix unit. Similarly ROPN1 (231535_x_at) 
was not expressed among 53/57 (92.9%) of the patients who did not relapse, however 
it was expressed in 14/48 (29.1%) of the patients who did relapse.  
3.6.2.1.2 Survival analysis 
Survival analysis (see section 2.2.12) was performed on ROPN1B and ROPN1 using 
Present/Absent Affymetrix calls. ROPN1B expression has significantly correlated 
with relapse-free survival (p-value =0.0340) but not with overall survival (p-value 
=0.3894) (Fig 3.6.2.1.2.1). Absence of ROPN1B gene expression is positively linked 
to relapse-free survival; however no relation was observed for overall survival. 
However, ROPN1 expression did not significantly correlate with relapse free survival 
(p-value =0.122) or with overall survival (p-value =0.37) (Fig 3.6.2.1.2.2). This 
analysis was performed by Dr. Lorraine O'Driscoll. 
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Fig 3.6.2.1.2.1: The figure on the left denotes survival curve for Relapse-free 
Survival for ROPN1B; the figure on the right denotes the survival curve for 
Overall Survival for ROPN1B. X-axis denotes the survival in days; Y-axis 
denotes the percent of patients still surviving. 
 
Fig 3.6.2.1.2.2: The figure on the left denotes survival curve for Relapse-free 
Survival for ROPN1; the figure on the right denotes the survival curve for 
Overall Survival for ROPN1. X-axis denotes the survival in days; Y-axis denotes 
the percent of patients still surviving. 
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3.6.2.1.3 Results from qRT-PCR 
In order to confirm the microarray findings, qRT-PCR was performed on only 94 of 
the 104 clinical specimens from our in-house study, due to the lack of available RNA 
for the remaining clinical specimens. ROPN1 was found to be 2.33-fold down-
regulated (baseline mean 2.39, SD 6.4; experimental mean 1.81, SD 6.4) in patients 
who relapsed, whereas ROPN1B was found to be 6.28-fold up-regulated (baseline 
mean 1.02, SD 2.4; experimental mean 11.37, SD 57.1) in patients who relapse. 
3.6.2.2 Expression in normal tissue  
The GSE1133 dataset (see section 2.1) was used to find the expression levels of 
ROPN1B in various tissues. Since the dataset is obtained from the U133A chip, 
information about ROPN1 was unavailable. This dataset includes gene expression 
data on 79 different human tissues (data shown for the top 20 organs in descending 
order of expression of ROPN1B represented by 220425_x_at) thereby providing 
ample opportunity to study distribution of ROPN1B gene expression in different 
human organs (see section 2.1.2). The results indicate that ROPN1B is very highly 
expressed in testis followed by ganglion and marginally in skin, medulla, trachea, 
heart and liver (Table 3.6.2.2.1). 
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Tissue 
Expression of 220425_x_at (ROPN1B) 
Affymetrix units 
Testis interstitial 5656.1 
Testis 4401 
Testis leydig cell 3411.75 
Testis germ cell 3011.7 
Testis seminiferous tubule 2962.4 
Superior cervical ganglion 1547.65 
Trigeminal ganglion 966.3 
Ciliary ganglion 484.7 
Skin 358.9 
Medulla oblongata 310.6 
Atrioventricular node 306.5 
Dorsal root ganglion 283.9 
Heart 263 
Liver 257.9 
Adrenal cortex 251.4 
Prostate 245.9 
Trachea 243.2 
Appendix 237.6 
Cingulate cortex 226.3 
Cerebellum peduncles 201.4 
Table 3.6.2.2.1: Expression levels of ROPN1B (220425_x_at) in various tissues.  
3.6.2.3 Expression in cancer cell lines  
The GSE5720 dataset (see section 2.1) was used to find the expression levels in 
various cancer cell lines. This dataset constitutes gene expression values of 60 cell 
lines of different origins, thereby giving ample opportunity to find cell lines which 
express gene of our interest, so that functional validation can be performed. 
Expression of ROPN1 and ROPN1B was observed in melanoma cell lines UACC-
257, SK-MEL-28, MALME-3M, MDA-MB-435S (breast/melanoma), MDA-N, 
UACC-62, SK-MEL2, SK-MEL-5 and M14 (Table 3.6.2.3.1). 
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Cell Line 
231535_x_at 
ROPN1 
220425_x_at 
ROPN1B 
224191_x_at 
ROPN1+ROPN1B 233203_at 
UACC-257  376.5 910.4 392.1 21.4 
SK-MEL-28  356.8 450 307.7 37.6 
MALME-3M  176.9 241.8 213 22.4 
UACC-62  170.8 171.4 132.3 17.7 
MDA-N  112.9 216.5 150.5 9.6 
SK-MEL-2  174.4 154 207.7 26.8 
MDA-MB-
435S  99.7 225.7 84.4 10.8 
SK-MEL-5  164.5 149.2 130.3 32 
M14  90.8 85.5 86.4 11.5 
Hs578T  122.8 31.1 103.6 118.6 
Table 3.6.2.3.1: Expression levels of ROPN1 and ROPN1B in various cancer cell 
lines. 
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3.6.2.4 Expression in melanoma and melanocyte cell lines  
The GSE4570 dataset (see section 2.1) was used to estimate the expression level of 
Ropporin in normal melanocyte and metastatic melanoma cell lines. The dataset 
constitutes of 6 metastatic melanoma cell lines and 2 normal melanocyte cell line. The 
aim was to study the expression levels of Ropporin in normal melanocyte and 
metastatic melanoma. A low expression of ROPN1B was observed in normal 
melanocyte (NM1 and NM2) and high expression was observed in metastatic 
melanoma cell lines (WW165, YUCAL, YUHEIK, YUMAC, MNT1, YUSIT1) (Fig 
3.6.2.4). Since the dataset was on U133A chip no information regarding the 
expression level of ROPN1 was available. 
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Fig 3.6.2.4: Expression level of ROPN1B (220425_x_at) in melanocyte and 
metastatic melanoma cell lines (Affymetrix unit). WW165, YUCAL, YUHEIK, 
YUMAC, MNT1 and YUSIT1 are metastatic melanoma cell lines, whereas NM1 
and NM2 are melanocyte cell lines.  
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3.6.2.5 Melanoma clinical specimens  
The GSE4587 dataset (see section 2.1) was used to estimate the expression changes of 
Ropporin during the different stages of melanoma progression. The results show that 
ROPN1 and ROPN1B expression progressively increase with disease progression and 
is highest in metastatic growth phase melanoma and lymph node metastasis (Fig 
3.6.2.5). The results positively associates Ropporin gene to disease progression and 
metastasis in clinical specimens. 
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Fig 3.6.2.5: ROPN1 and ROPN1B expression in melanoma progression. The 
number of samples in each group are (Normal: 2; Benign nevus: 2 ; Atypical 
nevus: 2 ; Melanoma in situ: 2 ; Vertical growth phase melanoma: 2; Metastatic 
growth phase melanoma: 2; Lymph node metastasis: 3.  
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3.6.2.6 Multiple Myeloma  
The GSE4581 dataset (see section 2.1) was used to estimate the expression of ROPN1 
and ROPN1B in multiple myeloma. The aim was to study the expression pattern of 
Ropporin in multiple myeloma. This result shows that both ROPN1 and ROPN1B are 
expressed in most of the multiple myeloma patients (Fig 3.6.2.6). Additionally, probe 
set 233203_at also expresses in many of the specimens, indicating the possibility of 
more isoforms of this gene.  
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Fig 3.6.2.6: ROPN1 and ROPN1B expression in myeloma clinical specimens  
3.6.2.7 qRT-PCR assessment of ROPN1B and ROPN1 expression in various 
melanoma cell lines 
The expression of ROPN1B and ROPN1 was not found in any of the breast cancer 
cell lines (based on microarray and qRT-PCR), except for MDA-MB-435s. At the 
time, MDA-MB-435S was considered a breast cancer cell line. But recently the cell 
line has become controversial as far as its origin is concerned. Recent studies have 
reported that this cell line might be a melanoma cell line, rather than a breast cancer 
cell line (see section 2.4.2). In order to identify a suitable cell line model for 
functional validation, ROPN1 and ROPN1B expression was examined by qRT-PCR 
in various cell lines (Breast: HCC1954, HCC1419, HCC1937, BT-20, MCF-7, MDA-
MB-231, MDA-MB-468 & SKBR3; Melanoma: MDA-MB-435S; HT144, SK-MEL-
28, MEL-5, M14). ROPN1 and ROPN1B expression was detected in the 
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breast/melanoma cell line MDA-MB-435S and all the melanoma cell lines tested. A 
high amount of expression of ROPN1B relative to ROPN1 was observed in MDA-
MB-435s and SK-MEL-28. ROPN1 was detected in all of the cell lines with 
expression of ROPN1B (Fig 3.6.2.7).  
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Fig 3.6.2.7: ROPN1B and ROPN1 expression in various melanoma cells. Ct is the 
Cycle Threshold. A lower Ct indicates higher expression. A high expression of 
ROPN1B was observed in MDA-MB-435s and SK-MEL-28. Nearly equal 
amounts of ROPN1 and ROPN1B expression were observed in M14, HT-144 and 
SK-Mel-5. The error represents the Standard Deviation observed among three 
technical replicates. 
3.6.3 siRNA knockdown of ROPN1 and ROPN1B in melanoma cell lines 
Since Ropporin plays an important role in sperm motility, our study aimed to 
investigate the possible role of Ropporin in cancer cell motility and invasion, which is 
a prime requirement for disease progression in melanoma, multiple myeloma and 
breast cancer. siRNAs targeting ROPN1 and ROPN1B were obtained from Ambion 
(see section 2.5.7).  
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3.6.3.1 ROPN1B siRNA on MDA-MB-435S 
3.6.3.1.1 Gene Expression Knockdown Analysis 
MDA-MB-435s cells were transfected with three different ROPN1B siRNA and qRT-
PCR (see section 2.5.4) was performed after 72hrs. qRT-PCR analysis confirmed the 
knockdown of ROPN1B using ROPN1B-1 siRNA (75.3%), ROPN1B-2 siRNA 
(69.6%) and ROPN1B-3 siRNA (56.6%) compared to scrambled transfected cells (Fig 
3.6.3.1.1).  
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Fig 3.6.3.1.1.1: ROPN1B qRT-PCR on ROPN1B-siRNA transfected MDA-MB-
435s cells. Knockdown was observed in siRNA knockdown cells. ROPN1B-1 
siRNA (75.3%), ROPN1B-2 siRNA (69.6%) and ROPN1B-3 siRNA (56.6%) 
compared to scrambled transfected cells. RQ is relative quantification with 
reference to scrambled. 
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Expression of ROPN1 mRNA was also checked in ROPN1B-siRNA-transfected 
MDA-MB-435s cells using qRT-PCR. ROPN1B-2 siRNA showed 19.8% and 
ROPN1B-3 siRNA showed 53.7% knockdown of ROPN1 in siRNA transfected cells 
compared to scrambled transfected cells (Fig 3.6.3.1.2). A surge in the expression of 
ROPN1 mRNA (141.4%) was observed in ROPN1B-1-siRNA-transfected cells 
compared to scrambled transfected cells (Fig 3.6.3.1.2).  
 
Fig 3.6.3.1.1.2: ROPN1 qRT-PCR on ROPN1B-siRNA transfected MDA-MB-
435s cells. ROPN1B-1 siRNA showed 141.4% increased expression of ROPN1 
whereas ROPN1B-2 siRNA showed 19.8% and ROPN1B-3 siRNA showed 53.7% 
knockdown of ROPN1 compared to scrambled transfected cells. 
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3.6.3.1.2 Western Blot Analysis 
A western blot was performed to check protein expression of Ropporin in three 
different ROPN1B siRNA transfected MDA-MB-435s cells (Fig 3.6.3.1.3). As can be 
seen, ROPN1B-3 transfection resulted in the highest amount of Ropporin knockdown. 
 
 
 
 
 
 
 
Fig 3.6.3.1.2: Ropporin western blot on ROPN1B siRNA transfected MDA-MB-
435S cells. Knockdown was observed following use of ROPN1B-siRNA3 and 
marginal knockdown was observed in ROPN1B-siRNA1- and ROPN1B-siRNA2-
transfected cells. 
3.6.3.1.3 Motility Assay  
MDA-MB-435s cells were transfected with three different siRNAs specific to 
ROPN1B and its effect on motility was observed (see section 2.5.10). The assay was 
performed in triplicates. There was significant loss of motility (ROPN1B-1 p-value 
=0.02; ROPN1B-2 p-value =0.02; ROPN1B-3 p-value =0.006) in the ROPN1B-
siRNA transfected cells compared to scrambled transfected cells (Fig 3.6.3.1.3). 
ROPN1B-1 siRNA showed 50.8%, ROPN1B-2 siRNA showed 55.4% and ROPN1B-
3 siRNA showed 60.1% reduced motility compared to scrambled transfected cells. 
This study indicates that the ROPN1B gene plays a role in the motility of this cancer 
cell line. 
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Fig 3.6.3.1.3: Motility assay on siRNA transfected MDA-MB-435S cells. All 
assays were performed in triplicate. There was significant reduction of motility 
in siRNA knockdown cells (ROPN1B-1 p-value =0.02; ROPN1B-2 p-value = 0.02; 
ROPN1B-3 p-value = 0.006). Y-axis denotes relative motility compared to 
scrambled. The error bar represents the standard deviation among three 
experimental repeats. 
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ROPN1 siRNA was not examined in MDA-MB-435s because of the low expression 
of ROPN1 in MDA-MB-435s. Invasion assay generated highly variable (un-
reproducible) results and was therefore removed from analysis. Often the cell line 
turns out to be non-invasive. 
3.6.3.2 ROPN1B and ROPN1 siRNA in M14 
The M14 melanoma cell line expressed both ROPN1 and ROPN1B in nearly equal 
amounts (Fig 3.6.2.7.1). siRNA knockdown was performed for ROPN1 using two 
ROPN1-specific siRNAs (ROPN1-1 and ROPN1-2) and ROPN1B using two 
ROPN1B-specific siRNAs (ROPNB-1 and ROPNB-2). 
3.6.3.2.1 Gene Expression Knockdown Analysis 
qRT-PCR analysis on the siRNA-transfected M14 cells confirmed the knockdown of 
ROPN1B (Fig 3.6.3.2.1.1) mRNA compared to scrambled transfected cells. 
ROPN1B-1 siRNA showed 62.4% and ROPN1B-2 siRNA showed 78.4% knockdown 
compared to scrambled transfected cells. ROPN1-1 siRNA showed 4% increased 
expression and ROPN1-2 siRNA showed 19.9% knockdown of ROPN1B in M14 
transfected cells compared to scrambled transfected cells (Fig 3.6.3.2.1.2).  
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Fig 3.6.3.2.1.1: ROPN1B qRT-PCR on ROPN1B-siRNA- and ROPN1-siRNA-
transfected M14 cells. The percent knockdown of each siRNA is indicated in the 
bar chart. 62.4% knockdown was observed for ROPN1B-1 siRNA and 78.4% 
knockdown was observed for the ROPN1B-2 siRNA. ROPN1-1 siRNA showed 
4% increase in expression (probably a noise), whereas ROPN1-2 showed 19% 
decrease in expression 
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Expression of ROPN1 mRNA was also checked using qRT-PCR in the ROPN1B-
siRNA- and ROPN1-siRNA-transfected M14 cells, 72hrs after transfection. qRT-PCR 
analysis confirmed the knockdown of ROPN1 mRNA (Fig 3.6.3.2.2) in siRNA 
transfected M14 cells compared to scrambled transfected cells. ROPN1B-1 siRNA 
showed 40.2%, ROPN1B-2 siRNA showed 58.5%, ROPN1-1 siRNA showed 42.7% 
and ROPN1-2 siRNA showed 45.5% knockdown compared to scrambled transfected 
cells (Fig 3.6.3.2.1.2).  
 
 
 
 
 
 
 
 
Fig 3.6.3.2.1.2: ROPN1 qRT-PCR on ROPN1B-siRNA- and ROPN1-siRNA-
transfected M14 cells. Knockdown of ROPN1 by both ROPN1-siRNA and 
ROPN1B-siRNA was observed.  
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3.6.3.2.2 Western Blot Analysis 
Western blot analysis was performed to analyse the expression of Ropporin protein in 
M14 cells 72hrs after transfection with ROPN1-siRNA and ROPN1B-siRNA. 
Western blot also showed knockdown of Ropporin in siRNA transfected cells (Fig 
3.6.3.2.2) compared to scrambled transfected cells. Alpha tubulin was used as a 
loading control for the samples. As can be seen, ROPN1-siRNA transfection resulted 
in the highest amount of Ropporin knockdown.  
 
 
 
 
 
 
 
 
Fig 3.6.3.2.2: Ropporin western blot on siRNA transfected M14 cells. Good 
knockdown of Ropporin was observed after ROPN1 siRNA and marginal 
knockdown after ROPN1B siRNA transfection. 
3.6.3.2.3 Motility Assay 
ROPN1- and ROPN1B-siRNA knockdown was carried out to determine the effect of 
knockdown on motility in M14. As can be seen in Fig 3.6.3.2.4, there was significant 
loss of motility (ROPN1B-1 p-value =0.0002; ROPN1B-2 p-value =0.002; ROPN1-1 
p-value =0.003; ROPN1-2 p-value =0.001) observed in ROPN1-siRNA-transfected 
and ROPN1B-siRNA transfected cells compared to scrambled-transfected cells. 
Transfection with ROPN1B-1 and ROPN1B-2 siRNA demonstrated a 31.2% and 
33.2% reduction in motility, respectively, while transfection with ROPN1-1 and 
ROPN1-2 siRNA showed a 17.1% and 37.0% reduction in motility, respectively, 
compared to scrambled transfected cells (Fig 3.6.3.2.3). 
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Fig 3.6.3.2.3: Motility assay on siRNA transfected M14 cells. The assay was 
performed in triplicate. Y-axis defines the relative motility compared to 
scrambled. Significant reductions in motility were observed in siRNA transfected 
cells. The error bar represents the standard deviation among the three 
experimental repeats. 
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3.6.3.2.4 Invasion Assay 
Invasion assays were performed on M14 cells 72 hrs following transfection with 
ROPN1- and ROPN1B-siRNAs. There was significant loss of invasion (Fig 3.6.3.2.2) 
(ROPN1B-1 p-value =0.003; ROPN1B-2 p-value ~ 0; ROPN1-1 p-value ~ 0; 
ROPN1-2 p-value ~ 0) in ROPN1-siRNA- and ROPN1B-siRNA-transfected M14 
cells compared to cells transfected with scrambled control. Transfection with 
ROPN1B-1 and ROPN1B-2 siRNA demonstrated a 47.7% and 56.4% reduction in 
invasion respectively, while transfection with ROPN1-1 and ROPN1-2 siRNA 
showed a 31.4% and 57.2% reduction in invasion respectively, compared to 
scrambled transfected cells (Fig 3.6.3.2.4).  
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Fig 3.6.3.2.4: Invasion assays on siRNA transfected M14 cells. Assays performed 
in triplicate. Y-axis defines the relative invasion compared to scrambled. 
Significant reductions in invasion observed in ROPN1/ROPN1B-siRNA 
transfected cells. The error bar represents the standard deviation among the 
three experimental repeats. 
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3.6.4 ROPN1 and ROPN1B cDNA over-expression studies 
ROPN1 cDNA in PCR4-TOPO plasmid (PCR4-TOPO-ROPN1) and ROPN1B cDNA 
in PCMV-SPORT6 plasmid (PCMV-SPORT6-ROPN1B) were obtained from Open 
Biosystems (see section 2.5.6). These plasmids were used to over-express these genes 
in the MDA-MB-231, MDA-MB-435s and M14 cell lines. 
3.6.4.1 Over-expression of ROPN1B in MDA-MB-231  
MDA-MB-231 cells were transfected with ROPN1B plasmid (PCMV-SPORT6-
ROPN1B) and empty plasmid (PCMV-SPORT6) (see section 2.5.6).  
3.6.4.1.1 qRT-PCR analysis 
qRT-PCR was performed to determine expression of the gene in the transfected cells. 
There was 8226.1-fold up-regulation of ROPN1B RNA in the PCMV-SPORT6-
ROPN1B transfected cells compared to the PCMV-SPORT6 transfected cells (Fig 
3.6.4.1.1). The high fold was due to zero expression in un-transfected cells.  
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Fig 3.6.4.1.1: ROPN1B qRT-PCR. ROPN1B over-expression was observed in 
ROPN1B transfected MDA-MB-231 cells. 
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3.6.4.1.2 Invasion Assay 
MDA-MB-231 was transfected with PCMV-SPORT6-ROPN1B and PCMV-SPORT6 
and invasion assays were carried out on the transfected cells. Results indicate a 
significant (p-value =0.003) loss in invasion following PCMV-SPORT6-ROPN1B 
transfection (Fig 3.6.4.1.2) compared to PCMV-SPORT6-transfected cells. There was 
28.1% reduced invasion in PCMV-SPORT6-ROPN1B-transfected MDA-MB-231 
cells compared to PCMV-SPORT6-transfected cells. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.6.4.1.2: Invasion assay on ROPN1B transfected MDA-MB-231 cells. Assays 
were performed in triplicates. There was significant decrease in invasion in 
ROPN1B over-expressing cells. Y-axis denotes relative invasion compared to 
empty plasmid. The error bar represents the standard deviation among the three 
experimental repeats. 
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3.6.4.2 Over-expression of ROPN1 and ROPN1B in MDA-MB-435s 
MDA-MB-435s was transfected with PCMV-SPORT6 plasmid, PCR4-TOPO-
ROPN1 plasmid and PCMV-SPORT6-ROPN1B plasmid. No empty plasmid control 
was generated for ROPN1 over-expression studies becuase of time constrains.  
3.6.4.2.1 qRT-PCR analysis 
ROPN1 qRT-PCR was performed on these transfected cells demonstrated a 4.2-fold 
up-regulation of ROPN1 mRNA in ROPN1 plasmid-transfected cells compared to 
cells transfected with PCMV-SPORT6 empty plasmid (Fig: 3.6.4.2.1). No change in 
expression was observed in ROPN1 mRNA in ROPN1B plasmid transfected cells 
compared to empty plasmid transfected cells (Fig 3.6.4.2.1).  
Fig 3.6.4.2.1: ROPN1 qRT-PCR. ROPN1 over-expression observed in ROPN1 
transfected cells 
ROPN1B qRT-PCR was also performed on these transfected cells and showed 31.5-
fold up-regulation of ROPN1B mRNA in PCMV-SPORT6-ROPN1B plasmid 
transfected cells compared to PCMV-SPORT6 plasmid transfected cells (Fig 
3.6.4.2.2). A 1.2-fold up-regulation of ROPN1B mRNA expression was observed in 
the PCR4-TOPO-ROPN1 plasmid transfected cells (Fig 3.6.4.2.2).  
  4.2-% 
  1.03 % 
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Fig 3.6.4.2.2: ROPN1B qRT-PCR. ROPN1B over expression was observed with 
ROPN1B over expression. 
3.6.4.2.2 Western Blot Analysis 
A Western blot was performed to check protein expression of Ropporin in cells 
transfected with ROPN1 and ROPN1B cDNA (Fig 3.6.4.2.3). As can be seen, an 
unexplained reduction in Ropporin protein was observed in PCVM-SPORT6-
ROPN1B-transfected cells.  
 
 
 
 
 
 
 
Fig 3.6.4.2.3: Western blot analysis of MDA-MB-435s cells transfected with 
ROPN1 and ROPN1B plasmid. 
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3.6.4.2.3 Motility Assay 
MDA-MB-435s was transfected with PCMV-SPORT6 plasmid, PCR4-TOPO-
ROPN1 plasmid and PCMV-SPORT6-ROPN1B plasmid and motility assays were 
performed after 72hrs. Results indicate significant (p-value =0.002) loss in invasion 
with ROPN1 over-expression and a marginal loss of invasion with ROPN1B over-
expression (Fig 3.6.4.2.3) compared to PCMV-SPORT6 empty plasmid transfected 
cells. PCR4-TOPO-ROPN1plasmid transfected cells showed 57.7% reduced invasion 
and PCMV-SPORT6-ROPN1B plasmid transfected cells showed 15.1% reduced 
motility in MDA-MB-435s cells compared to PCMV-SPORT6 empty plasmid 
transfected cells (Fig 3.6.4.2.4).  
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Fig 3.6.4.2.4: Motility assay on ROPN1 and ROPN1B transfected MDA-MB-
435S cells. Assays were performed in triplicates.There was significant loss in 
motility with ROPN1 over-expression and a marginal loss of motility with 
ROPN1B over-expression compared to PCMV-SPORT6 empty plasmid 
transfected cells. The error bar represents the standard deviation among the 
three experimental repeats. 
Invasion assay was giving highly variable (un-reproducible) results and was therefore 
removed from analysis. 
 
 
 
57.7% 
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3.6.4.3 Over-expression of ROPN1 and ROPN1B in M14 
M14 cells were transfected with PCMV-SPORT6 plasmid, PCR4-TOPO-ROPN1 
plasmid and PCMV-SPORT6-ROPN1B plasmid.  
3.6.4.3.1 qRT-PCR analysis 
ROPN1 qRT-PCR was performed on the transfected cells to check the expression of 
ROPN1 mRNA. qRT-PCR analysis showed 96.9-fold over-expression of ROPN1 in 
ROPN1 plasmid transfected cells compared to PCMV-SPORT6 empty plasmid 
transfected cells (Fig 3.6.4.3.1). No over-expression of ROPN1 mRNA was observed 
in PCMV-SPORT6-ROPN1B plasmid transfected cells compared to PCMV-SPORT6 
empty plasmid transfected cells (Fig 3.6.4.3.1).  
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Fig 3.6.4.3.1: ROPN1 qRT-PCR. ROPN1 over expression was observed in 
ROPN1 transfected M14 cells. 
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qRT-PCR was performed to analyze the expression of ROPN1B in PCMV-SPORT6 
empty plasmid, PCR4-TOPO-ROPN1 plasmid and PCMV-SPORT6-ROPN1B 
plasmid transfected cells. There was 50.0-fold and 6.1-fold over-expression of 
ROPN1B in ROPN1B plasmid transfected cells and ROPN1 plasmid transfected cells 
respectively, compared to PCMV-SPORT6 empty plasmid transfected cells (Fig 
3.6.4.3.2). 
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Fig 3.6.4.3.2: ROPN1B qRT-PCR. ROPN1B over expression was observed in 
ROPN1B transfected M14 cells.  
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3.6.4.3.2 Western Blot Analysis 
A western blot was performed to check protein expression of Ropporin in cells 
transfected with ROPN1 and ROPN1B cDNA (Fig 3.6.4.3.3). As can be seen, an 
unexplained reduction in Ropporin protein was observed in PCR4-TOPO-ROPN1 and 
PCVM-SPORT6-ROPN1B transfected cells compared to PCMV-SPORT6 transfected 
cells.  
 
 
 
 
 
 
 
Fig 3.6.4.3.3: Western blot analysis of M14 cells transfected with ROPN1 and 
ROPN1B plasmid. 
3.6.4.3.3 Motility Assay 
M14 was transfected with PCMV-SPORT6 plasmid, PCR4-TOPO-ROPN1 plasmid 
and PCMV-SPORT6-ROPN1B plasmid and motility assays were performed. Results 
indicate significant loss in motility (p-value =0.0002) with ROPN1 over-expression 
and a marginal loss of motility with ROPN1B over-expression (Fig 3.6.4.3.4) 
compared to PCMV-SPORT6 empty plasmid transfected cells. ROPN1 plasmid 
transfection resulted in 65.6% reduced motility and ROPN1B plasmid transfection 
resulted in 25.0% reduced motility in M14 cells compared to PCMV-SPORT6 empty 
plasmid transfected cells (Fig 3.6.4.3.4). 
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Fig 3.6.4.3.4: Motility assays on ROPN1 and ROPN1B transfected M14 cells. 
Assays were performed in triplicates. There was significant loss in motility with 
ROPN1 over-expression and a marginal loss of motility following ROPN1B over-
expression. Y-axis denotes relative motility compared to empty plasmid. The 
error bar represents the standard deviation among the three experimental 
repeats. 
3.6.4.3.4 Invasion Assay 
Invasion assays were was performed on M14 cells transfected with PCMV-SPORT6 
plasmid, PCR4-TOPO-ROPN1 plasmid and PCMV-SPORT6-ROPN1B plasmid. 
Results indicate significant loss in invasion (p-value =0.003) following ROPN1 over-
expression and a marginal loss of invasion with ROPN1B over-expression (Fig 
3.6.4.3.5) compared to PCMV-SPORT6 plasmid transfected cells. PCR4-TOPO-
ROPN1 plasmid transfection resulted in 48.9% and PCMV-SPORT6-ROPN1B 
  Empty plasmid   ROPN1 transfected  ROPN1B transfected 
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plasmid transfection resulted in 14.6% reduced invasion in M14 cells compared to 
PCMV-SPORT6 plasmid transfected cells (Fig 3.6.4.3.5). 
 
 
 
 
 
 
 
 
 
 
 
Fig 3.6.4.3.5: Invasion assay on ROPN1 and ROPN1B transfected M14 cells. 
Assays were performed in triplicates. There was significant loss in invasion with 
ROPN1 over-expression and a marginal loss of invasion following ROPN1B 
over-expression. Y-axis denotes relative invasion compared to empty plasmid. 
The error bar represents the standard deviation among the three experimental 
repeats. 
3.6.5 Summary 
ROPN1B over-expression was linked to breast cancer patients who relapsed. The 
gene was also linked to disease progression in melanoma. siRNA knockdown 
positively associated ROPN1B gene to be involved in cancer cell motility and 
invasion. The results from over-expression studies were inconclusive. Over-
Empty plasmid  ROPN1 transfected  ROPN1B transfected 
48.9% 
14.6% 
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expression of ROPN1 and ROPN1B resulted in reduction of Ropporin protein 
expression in M14. Over-expression of ROPN1B in M14 resulted in reduction of 
Ropporin protein. Over-expression studies of ROPN1 and ROPN1B resulted in 
reduction in protein level and reduction in invasion and motility. 
3.7 How Representative are Cell line models of clinical conditions? 
The aim of this section was to estimate the representative nature of breast cancer cell 
lines to their respective clinical specimen type using gene expression data and has 
been published previously (Mehta et al., 2007). 
Gene expression profiles of 189 breast clinical specimens (GEO accession: GSE2990) 
and 19 cell lines (GEO accession: GSE3156) were obtained from Gene Expression 
Omnibus (see section 2.1). These samples were pooled as a single experiment and 
normalized using the dChip algorithm (see section 2.2.1). Since the clinical specimens 
were analyzed using U133A and the cell lines were analyzed using U133_Plus 2.0 
microarray chips, the genes not represented in U133A were removed from the cell 
line data, giving a total available probe set number of 22,283. However, for the ER 
analysis on cell lines (see section 2.1.2), all the genes on the U133_Plus 2.0 chips 
(54,675) were included.  
3.7.1 Data filtration  
Two SD filters of 0.5 and 1.0 were applied to generate gene lists for hierarchical 
clustering. For the pooled comparison of cell lines and clinical specimens, the total 
number of DE genes identified using a SD filter of 0.5 was 8,036. For the comparison 
of cell line and clinical clustering relative to ER status, a SD filter of 1.0 was used, 
giving 7,738 filtered genes for the cell lines and 6,643 genes for the clinical 
specimens. A lower SD for pooled experiment was used, to get the optimum 
representative number of genes for clustering. 
3.7.2 Clustering  
Hierarchical clustering and PCA were performed on these gene lists. Hierarchical 
clustering, as expected, using the filtered 8036 gene-list, separated the sample set into 
two distinct clusters (Fig 3.7.2.1), one comprising the clinical specimens and the other 
comprising the cell line models. To examine whether the differences in hierarchical 
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clustering between cell lines and tumour specimens were due to differences 
incorporated by sample processing at different sites, this group replicated this 
clustering analysis substituting a separate 104-tumour dataset for the 189-tumour 
dataset detailed here. In this experiment, two separate clusters of cell lines and tumour 
specimens were again observed (data not shown). 
 
Fig 3.7.2.1: Hierarchical clustering demonstrating that cell lines and clinical 
specimens form two discrete groups. The right cluster is of 19 cell lines included 
in the study. The left cluster (incompletely shown because of large number of 
tumour specimens) represents 189 breast tumors. 
PCA was also performed on the sample using the filtered 8036 gene-list, which also 
separated the clinical specimens and cell lines into two distinct groups (Fig.3.7.2.2). 
As can be seen on the axes, the total variance accounted for in the sample set was 
27.95%. The clinical specimens also segregated into two further sub-groups, although 
not as distinct as that separating the cell lines and the clinical specimens.  
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Fig 3.7.2.2: Principal component analysis was performed on the samples and the 
two components were plotted. Clinical specimens are highlighted in red, cell line 
samples are highlighted in yellow.  
3.7.3 Significant genes 
The clinical specimens and the breast cell lines were compared for transcripts which 
were significantly up- or down-regulated in the two groups (p-value<0.001, fold 
change>2 and difference of 100 Affymetrix units). 2,615 genes passed the above 
filtration criteria, of which 1,086 were up-regulated in cell lines relative to clinical 
specimens and 1,529 genes were down-regulated in cell lines compared to clinical 
specimens.  
3.7.4 Gene ontology and pathway analysis 
GenMAPP Gene ontology and Pathway analysis was performed on the up- and down-
regulated gene lists and the over-represented GO categories/canonical pathways are 
outlined in Tables 3.7.4.1 and Table 3.7.4.2. In cell lines relative to clinical 
specimens, many of the functions which were over-represented were related to cell 
X-axis: PCA component 1 (20.37% variance)
Y-axis: PCA component 2 (7.583% variance)
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cycle functions and nucleic acid processing (Tables 3.7.4.1). Where clinical 
specimens were compared to cell lines, the majority of categories and pathways 
affected were related to the immune response and related functions (Table 3.7.4.2).  
GO Name Changed Measured Z Score 
Mitotic cell cycle 61 281 15.236 
Cell cycle 87 576 13.874 
Mitosis 29 105 12.317 
M phase of mitotic cell cycle 29 107 12.163 
M phase 33 137 11.981 
Nuclear division 31 132 11.404 
Cell proliferation 94 877 10.501 
DNA replication and chromosome cycle 30 154 9.791 
Regulation of cell cycle 45 325 9.111 
Mitotic anaphase 6 11 8.5 
MAPP Name    
Cell cycle KEGG 22 84 9.081 
DNA replication Reactome 11 42 6.347 
G1 to S cell cycle Reactome 9 65 3.311 
Translation Factors 7 48 3.069 
Pentose Phosphate Pathway 2 7 2.856 
mRNA processing Reactome 12 115 2.739 
Cholesterol Biosynthesis 3 15 2.664 
Tables 3.7.4.1: GO terms and pathways enrichment analysis for genes over-
expressed in cell line models compared to clinical specimens. Higher Z score 
represents a stronger association of that function to genes which have over-
expressed in cell lines relative to clinical specimens. 
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GO Name Changed Measured Z Score 
Immune response 107 595 12.412 
Defense response 110 650 11.847 
Response to biotic stimulus 115 710 11.586 
MHC class II receptor activity 9 11 10.458 
Extracellular matrix 48 215 9.992 
Antigen processing, exogenous antigen via 
MHC class II 8 10 9.731 
Antigen presentation, exogenous antigen 8 10 9.731 
Extracellular 105 742 9.451 
Antigen presentation 12 23 9.204 
Antigen processing 12 23 9.204 
MAPP Name    
Complement Activation Classical 7 16 5.405 
Complement and Coagulation Cascades 
KEGG 
11 49 3.897 
Matrix Metalloproteinases 7 30 3.216 
Smooth muscle contraction 19 143 2.574 
Inflammatory Response Pathway 6 31 2.435 
Tables 3.7.4.2: GO terms and pathways enrichment analysis for genes over-
expressed in clinical specimens compared to cell line models. A higher Z score 
represents a stronger association of that function to genes which have over-
expressed in clinical specimens compared to cell line models. 
3.7.5 Estrogen receptor analysis  
Hierarchical clustering was also performed separately on the two groups (i.e. cell lines 
and clinical specimens), to determine if either group clustered similarly when 
compared for ER status. This analysis segregated the cell lines into two distinct 
groups, which clustered largely according to their ER status (Fig.3.7.5.1). Exceptions 
to this rule included the ER-negative SK-BR-3 & MDA-MB-453 and the ER-positive 
HCC1428, which clustered with the opposite group. Hierarchical clustering 
performed on the 189 clinical sample dataset did not demonstrate any appreciable 
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clustering according to ER status, although there was a tendency of clinical specimens 
to cluster based on their grade (data not shown).  
 
Fig 3.7.5.1: Hierarchical clustering of cell lines. The + indicates ER-positive cell 
lines and the ER-negative represents ER-negative cell lines. The left cluster in 
enriched with ER-positive cell lines and the right cluster is enriched with ER-
negative cell lines. 
3.7.6 Summary  
The above analysis shows that there is a marked difference in gene expression in 
tissue compared to cell lines. This difference was consistent in Hierarchical clustering 
and Principal component analysis. Genes related to cell cycle, mitosis, DNA 
replication were highly up-regulated in cell line models. Similarly, genes related to 
the immune system, Complement Activation Classical pathway and Matrix 
Metalloproteinase were significantly up-regulated in tissue relative to cell lines. The 
above results indicate that cell cycle and immune response results from cell-line 
models of various clinical conditions may not accurately reflect their behaviour in-
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vivo. These results should be taken into account when extrapolating the cell line 
results to clinically relevant conditions. 
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3.8 Molecular profile of basal cell carcinoma 
The aim of this section was to investigate the gene expression profile of basal cell 
carcinoma using whole genome expression microarrays and compare these profiles 
with the gene expression profile of normal skin. This work is currently the only 
whole-genome analysis of BCC published worldwide (O‟Driscoll et al., 2006). 
Microarray gene expression profiling of 20 basal cell carcinoma tissue specimens and 
5 normal skin tissue was performed using Affymetrix U133 Plus2.0 arrays (see 
section 2.1.3). Microarray samples were processed by Lorraine O'Driscoll and Padraig 
Doolan, while my role was in the analysis of the chip data generated. Tissue 
specimens from twenty cases of BCC were obtained from Blackrock Clinic and the 
Bons Secours Hospital, Dublin, snap-frozen in liquid nitrogen, and were subsequently 
stored at -80°C. Five normal skin specimens (from consenting male and female 
volunteers of a similar age range who do not/never had skin cancer) were also 
included in the studies. Following this RNA was isolated and microarray was 
performed for each chip (see section 2.5.11).  
3.8.1 Data Normalization and Quantification 
 The microarray raw data files were normalized and quantified using the dChip 
algorithm as outlined in section 2.2.1.  
3.8.2 Data Filtration 
Data filtration was applied on 54,675 genes present on U133 Plus2.0 chip (see section 
2.2.3), to remove genes which i) did not fluctuate very highly across samples and ii) 
fluctuated too highly across samples to be trustworthy. Genes with a Standard 
deviation / Mean i) below 1 or ii) above 1000 were removed from further analysis. 
This set of genes was used for Hierarchical clustering. 692 genes passed this criterion 
and were used to carry out clustering analysis of clinical specimens.  
3.8.3 Hierarchical Clustering 
Hierarchical clustering (see section 2.2.4) was performed on the 692 member filtered 
gene list. The distance metric used was 1-correlation and the clustering algorithm 
used was Average linkage clustering. Prior to clustering, the individual samples were 
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standardised as follows: the expression of the individual genes was subtracted from 
their means for that sample and divided by their respective standard deviation. The 
results are shown in Fig 3.8.3.1. 
 
 
Fig 3.8.3.1: The hierarchical clustering represents the clustering pattern of the 
BCC and normal specimens. Type indicates whether the sample is 
Normal/Tumour.  
The results indicate that the normal specimens clustered together and the BCC 
specimens clustered together. A subset of BCC samples (JT7, T24, T22, T11 & T19) 
clustered close to the normal specimens 
3.8.4 Normal specimens vs. Basal cell carcinoma 
Up-regulated gene transcripts 
2,108 genes were identified as significantly up-regulated (p ≤ 0.05, Fold Change (FC) 
> 1.2 and Difference > 100) in cancer specimens compared to normal specimens. 
Genes were ranked by fold change and, based on this criterion, the top 20 genes are 
listed in Table 3.8.4.1 
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Gene ontology analysis was performed on the up-regulated genes (p ≤ 0.05, FC>2, 
and Difference>100). Significant functions were identified based on p-value (p ≤ 
0.05) and the 10 most significant functions represented are listed in Table 3.8.4.2.  
Pathway analysis was performed using GenMAPP database on the up-regulated genes 
(p ≤ 0.05, FC>2, and Difference > 100). Significant pathways were identified based 
on p-value (p ≤ 0.05) and the 10 most significant pathways are listed in Table 3.8.4.3.  
Down-regulated genes 
1.813 genes were identified as significantly down-regulated (p ≤ 0.05, Fold Change 
(FC) <-1.2 and Difference < -100) in cancer specimens compared to normal 
specimens. Genes were ranked by fold change and, based on this criterion, the top 20 
genes are listed in Table 3.8.4.4 
Gene ontology analysis was performed on the down-regulated genes (p ≤ 0.05, FC<-
2, and Difference < -100). Significant functions were identified based on p-value (p ≤ 
0.05) and 10 most significant functions represented are listed in Table 3.8.4.5. 
Pathway analysis was performed using GenMAPP database on the down-regulated 
genes (p ≤ 0.05, FC<-2, and Difference < -100). Significant pathways were identified 
based on p-value (p ≤ 0.05) and the 10 most significant pathways are listed in Table 
3.8.4.6. 
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probe set Gene baseline  experiment  fold change P value 
204697_s_at CHGA 19.31 2516.41 130.34 0.000001 
224590_at XIST 6.27 433.45 69.08 0.001884 
214218_s_at XIST 10.05 631.37 62.79 0.00072 
224588_at XIST 42.73 2128.81 49.82 0.000552 
204913_s_at SOX11 8.48 236.67 27.92 0.000224 
214913_at ADAMTS3 26.38 632.27 23.97 0.000002 
220345_at LRRTM4 12.72 282.87 22.24 0.0061 
230863_at --- 15.38 308.31 20.05 0.029359 
204915_s_at SOX11 28.16 553.08 19.64 0.000059 
204424_s_at LMO3 70.78 1358.37 19.19 0.003562 
208025_s_at HMGA2 30.2 536.39 17.76 0.000173 
215311_at --- 27.85 476.31 17.1 0.000013 
227671_at XIST 24.01 407.71 16.98 0.003059 
218638_s_at SPON2 188.15 3181.08 16.91 0 
208212_s_at ALK 53.02 888.43 16.76 0.000003 
226346_at LOC92312 37.28 571.83 15.34 0 
204914_s_at SOX11 22.04 332.68 15.1 0.000124 
215443_at TSHR 17.2 257.19 14.95 0.00019 
213960_at --- 40.57 575.46 14.18 0.000001 
229523_at TTMA 47.92 662.44 13.82 0.000001 
Table 3.8.4.1: Genes up-regulated in cancer specimens in comparison to normal 
specimens 
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GOID GO Name Changed Measured p-value 
5201 
Extracellular matrix structural 
constituent 16 78 0 
5581 Collagen 8 30 0 
30199 Collagen fibril organization 3 5 0 
5578 Extracellular matrix (sensu Metazoa) 34 359 0 
31012 Extracellular matrix 34 365 0 
7155 Cell adhesion 43 559 0 
7275 Development 94 1696 0 
5576 Extracellular region 63 1096 0 
8201 Heparin binding 9 62 0 
6817 Phosphate transport 10 81 0 
Table 8.1.4.2 Functions enriched among genes up-regulated in cancer specimens 
in comparison to normal specimens 
MAPP Name Changed Measured p-value 
2-Tissues-Muscle Fat and Connective 12 82 0 
2-Tissues-Blood and Lymph 11 78 0 
Focal adhesion KEGG 17 187 0 
Wnt Signaling 9 71 0 
Wnt NetPath 8 11 109 0.001 
TGF Beta Signaling Pathway 6 52 0.003 
1-Tissue-Embryonic Stem Cell 5 47 0.014 
Apoptosis 7 82 0.017 
1-Tissue-Muscle fat and connective 6 65 0.021 
Chondroitin Heparan sulfate biosynthesis 3 20 0.023 
Table 3.8.4.3: Pathways enriched among genes up-regulated in cancer specimens 
in comparison to normal specimens 
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probe set Gene baseline  experiment  fold change P value 
208962_s_at FADS1 3354.77 166.07 -20.2 0.045399 
229476_s_at THRSP 4948.62 288.53 -17.15 0.034919 
207275_s_at ACSL1 1997.95 132.25 -15.11 0.039975 
206799_at SCGB1D2 1383.74 92.43 -14.97 0.042413 
221561_at SOAT1 1087.52 88.95 -12.23 0.008422 
206714_at ALOX15B 4264.04 372.27 -11.45 0.045644 
214240_at GAL 1747.34 157.08 -11.12 0.015802 
201625_s_at INSIG1 1773.81 182.47 -9.72 0.030044 
231810_at BRI3BP 988.19 110.99 -8.9 0.021503 
211056_s_at SRD5A1 1640.77 208.21 -7.88 0.032165 
229957_at TMEM91 1397.34 183.05 -7.63 0.025272 
204675_at SRD5A1 3279.09 446.39 -7.35 0.027894 
231736_x_at MGST1 2894.74 397.53 -7.28 0.031804 
205029_s_at FABP7 608.63 84.11 -7.24 0.021739 
201627_s_at INSIG1 728.68 100.79 -7.23 0.049971 
209522_s_at CRAT 2366.24 327.16 -7.23 0.020824 
226064_s_at DGAT2 2666.99 375.45 -7.1 0.032748 
231156_at HAO2 395.01 55.75 -7.09 0.045195 
223184_s_at AGPAT3 1603.83 228.89 -7.01 0.045149 
205030_at FABP7 2208.85 344.36 -6.41 0.021392 
Table 3.8.4.4: Genes down-regulated in cancer specimens in comparison to 
normal specimens 
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GOID GO Name Changed Measured p-value 
16126 Sterol biosynthesis 14 27 0 
6695 Cholesterol biosynthesis 12 22 0 
16125 Sterol metabolism 16 67 0 
44255 Cellular lipid metabolism 44 417 0 
6629 Lipid metabolism 49 535 0 
8203 Cholesterol metabolism 14 61 0 
42579 Microbody 15 70 0 
5777 Peroxisome 15 70 0 
6694 Steroid biosynthesis 14 64 0 
16491 Oxidoreductase activity 48 579 0 
Table 3.8.4.5: Functions enriched among genes down-regulated in cancer specimens 
in comparison to normal specimens 
MAPP Name Changed Measured p-value 
Cholesterol Biosynthesis 11 15 0 
Sterol biosynthesis 9 19 0 
Fatty Acid Beta Oxidation Meta BiGCaT 8 32 0 
Terpenoid biosynthesis 3 6 0 
Fatty Acid Beta Oxidation 1 BiGCaT 6 27 0 
Bile acid biosynthesis 7 37 0 
Pyruvate metabolism 7 34 0.001 
Citrate cycle TCA cycle  5 24 0.001 
Butanoate metabolism 6 38 0.001 
1-Tissue-Muscle fat and connective 7 65 0.002 
Table 3.8.4.6: Pathways enriched among genes down-regulated in cancer specimens 
in comparison to normal specimens 
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3.8.5 Summary 
The study was the first whole genome study on Basal cell carcinoma. The analysis 
identified important genes, functions and pathways which may be important in 
transformation of normal skin to basal cell carcinoma. Wnt signaling pathways was up-
regulated in BCC vs. normal skin whereas Cholesterol Biosynthesis pathway was down-
regulated in BCC patients vs. normal skin. 
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Breast cancer is one of the most common malignancies among females. The 
heterogeneous nature of the disease coupled with the lack of robust markers for 
prediction, prognosis, and response to treatment has so far eluded our understanding of its 
complex nature. It is generally assumed that transcriptional profiling, involving multiple 
gene signatures would be more predictive of tumour behaviour rather than single genes. 
Various studies have tried to answer this question with promising results correlating gene 
expression profiles with prognosis, recurrence, metastatic potential, therapeutic response, 
as well as biological and functional aspects of the disease. The integration of genomic 
approaches into the clinic lies ahead, but such studies need to be validated on large 
datasets. The challenge also lies in getting a better understanding of the various groups 
and sub-groups of breast cancer and how they may correlate with various groups of 
prognostic mRNA. 
In order to gain a better understanding of breast cancer heterogeneity and its association 
with clinical outcome, gene expression analysis was performed on 104 cancer specimens 
and 17 normal specimens. These specimens were from patients who underwent surgery 
during 1993–1997, and for whom follow-up clinical information was available. 
Additionally large datasets were downloaded from public repositories and analysed and 
compared to our dataset to get a holistic picture in order to help find answers to the 
complex questions associated with breast cancer. We aimed to find clinical heterogeneity 
among the breast cancer, genes, functions and pathways associated with various clinical 
conditions and prognostic important genes. The aim was also to perform meta-analysis on 
prognostic important genes and ER pathway genes.  
 4.1 Clinical heterogeneity in breast cancer 
The heterogeneity of breast cancer and the variability in the clinical response to treatment 
has led to wide interest in understanding the molecular mechanisms of the different 
behavioural phenotypes of breast cancer. Currently the most widely used markers for 
breast cancer classification and treatment are ER, PR and HER2 protein. These proteins 
are estimated based on immunohistochemistry. ER and PR are used as indicators of 
endocrine-sensitive breast cancers and HER2 as indicators of breast cancer patients with 
 290 
metastatic disease who may benefit from trastuzumab therapy (Duffy 2005). Gene 
expression profiling has been widely used to understand the molecular mechanisms 
involved in disease progression (Cooper 2001), metastasis (Weigelt et al., 2005), drug 
metabolism and resistance (Brennan et al., 2005). 
Sample clustering techniques have been widely used to group samples with similar 
expression patterns and have immensely contributed to our understanding of 
heterogeneity associated with various types of cancers. In particular, such analysis has 
identified various sub-groups in breast cancer. Estrogen receptor status is the single most 
important criteria by which the clinical specimens tend to cluster (van 't Veer et al.,  
2002; Sotiriou et al.,  2003). Cluster analysis also identified Luminal subtype A and B, 
ERBB2, Basal and Normal type and identified intrinsic gene expression signatures for 
each group which correlated with patient outcome (Sorlie et al., 2001). This classification 
based on gene expression was later validated by many independent studies (Sorlie et al., 
2003; Calza et al., 2006; Hu et al., 2006).  
The sample clustering techniques were applied to the gene expression profile of our set of 
104 breast cancer and 17 normal specimens. Genes with low or extremely high variability 
among specimens were not used for the purpose of clustering. First, a correlation matrix 
using all the specimens was created followed by two-way clustering of samples. In this 
way, the similarity between the specimens and the homogeneity among the individual 
sub-groups were assessed. Additionally, this technique helped identify any further sub-
clusters within a cluster. 
The 104 cancer and 17 normal specimens divided into many distinct groups. Five main 
clusters (one of which could be sub-divided into three sub-clusters) were identified, some 
of them very specific to certain clinical parameters.  
4.1.1 High level of correlation between Normal samples (Cluster A)  
The most significant result in our study was that most of the normal specimens clustered 
together (Cluster A). However, three normal specimens did cluster with a group of cancer 
specimens over-represented by ER-positive tumors with relatively low expression of ER 
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partner (genes involved in ER pathway) genes (Cluster E). Also, the normal group 
contained one of the cancer specimens. Of the normal specimens which clustered as a 
group (Cluster A), a high level of correlation was observed among the normal specimens 
indicating that the normal breast gene expression profiles are alike (section 3.1.3).  
The remaining 103 tumour specimens represented a highly heterogeneous group, (in 
contrast to a very similar group of normal specimens in Cluster A) and there was 
relatively less correlation observed among the closely related specimens on the cluster as 
observed from the hierarchical clustering result. These results indicate that the normal 
breast specimens have very similar and unique gene expression patterns, and the 
transformation of normal breast cells to a tumour leads to a divergent pattern of gene 
expression. One possible reason for this may be that uncontrolled cell division may lead 
to higher rates of mutations occurring in the genomic DNA leading to different 
combinations and a wide diversity of aberrant expression patterns (Gagos and Irminger-
Finger 2005).  
4.1.2 Samples closest in character to Normal samples enriched for ER- & Grade1 
The group of samples that clustered closest to the normal specimen group was a set of 
specimens enriched for ER-negative status and Grade 1 (see section 1.3.1) tumors 
(Cluster B). The ESR1 gene was not over-expressed in this cluster; however ERBB2 was 
over-expressed in this group, when compared to the normal breast specimens. Similar 
results presenting gene expression profiles in groups of breast cancer specimens that are 
substantially “Normal-like” have been described in other studies (Sorlie et al., 2001; 
Calza et al., 2006)  
The rest of the samples clustered into two big groups. One was enriched for ER-negative 
specimens (Cluster C) and the other was enriched for ER-positive specimens (Cluster D 
and Cluster E). The clusters enriched with ER-negative patients were also enriched for 
patients with higher grade and who relapsed (7 year relapse).  
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4.1.3 ER-negative samples (Cluster C) display three distinct sub-clusters 
A high level of heterogeneity was observed in the ER-negative cluster (Cluster C) and 
three distinct sub-clusters were observed based on the hierarchical clustering and 
correlation among specimens. The left and right cluster had relatively worse prognosis 
based on KM (Kaplan-Meier), compared to the middle cluster. Specific genes of interest 
expressed in separate sub-clusters include high expression of the Ropporin gene, ERBB2 
and genes related to the immunoglobin family.  
KM curve analysis associated the left sub-cluster of Cluster C as having the worst 
survival. To gain further insight, the specimens of this cluster were compared to the 
specimens of middle and right sub-cluster for gene expression changes. Ropporin was 
identified as substantially over-expressed in this left sub-cluster compared to the other 
two sub-clusters and a detailed study of this mRNA was performed. Our results positively 
associated the over-expression of this gene to an ER-negative phenotype, high relapse 
and shorter survival. 
Our results also showed that the sub-cluster enriched with ERBB2 over-expressing 
patients had a higher incidence of relapse and reduced survival (right sub cluster of 
Cluster C). ERBB2-overepressing clusters of patients have been observed in other similar 
independent studies using sample clustering (Sorlie et al., 2001; Calza et al., 2006) and 
expression of this protein is associated with a poor prognosis and poor response to 
chemotherapeutic drugs (Revillion, Bonneterre and Peyrat 1998).  
The third (middle) sub-cluster had patients with relatively low relapse and longer 
survival. This cluster of patients exhibits high expression level of genes involved in 
immune response. IFI6 (interferon, gamma-inducible protein 6), IL8 (Interleukin-8), 
LOC652128 (similar to Ig heavy chain V-II region ARH-77 precursor), IGL 
(immunoglobulin lambda locus), IGHM (immunoglobulin heavy constant mu) genes 
were found to be over-expressing in this sub-cluster compared to its neighbouring cluster. 
Other studies in the literature also suggest that high expression of immune response genes 
is associated with a favourable prognosis in ER-negative sub-groups of patients 
(Teschendorff et al., 2007). Additionally, a previous study (Alexe et al., 2007) associated 
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a higher expression of lymphocyte/immune response associated genes in a HER2-over-
expressing cluster with a low recurrence subtype. While over-expression of immune 
response genes has been linked to better prognosis in ER-negative specimens, this study 
is the first to demonstrate the clustering of these clinical samples as a distinct group. This 
result positively associated the ER-negative sub-group of patients with high expression of 
immune response genes with a favourable clinical outcome. 
4.1.4 ER-positive tumors sub-divide as two groups. 
The remaining samples were all enriched for ER-positive specimens and grouped into 
two distinct clusters (D & E), which may be due to differences in the level of expression 
of ESR1 and ER partner gene expression profiles. Cluster D had a relatively higher 
expression of ER partner genes such as ESR1, GATA3, FOXA1, SPDEF and TFF3. This 
high-ER-expressing cluster contained only one specimen with an ER-negative phenotype. 
The lower-ER-expressing cluster (Cluster E) had 3 ER-negative specimens and the three 
normal specimens were clustered away from the other normal specimens clustered with 
this group. This low ER cluster had a marginally reduced survival and a slightly higher 
incidence of relapse compared to its neighbouring cluster which displayed very high ER 
partner gene expression. Therefore, higher expression of ER genes might be linked to 
better prognosis, or better response to tamoxifen, since most of the ER-positive patients 
were treated with this drug. Similar clustering patterns and links to prognosis has been 
reported in other studies (Sorlie et al., 2003; Calza et al., 2006). 
In conclusion, our gene expression profiling results identified various groups and sub-
groups of breast cancer and associated them with the clinical parameters and linked them 
with the clinical outcomes. Our results identified new clusters with clinical relevance. 
4.2 Gene expression differences between Normal and Cancer tissue 
The transition from normal tissue to cancerous tissue is an important aspect in 
understanding the biology of breast cancer. Gene expression profiling can help identify 
the differences among the normal and cancerous tissue and can help better design drugs 
to target the disease. 
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The normal and cancer specimens were compared in order to identify genes and 
pathways that contribute to the transition from normal breast tissue to a cancerous state.  
4.2.1 Cell cycle pathway up-regulated in tumors 
Gene ontology and pathways analysis identified cell cycle related pathways to be over-
expressed and over-represented in tumors compared to normal specimens. This is not 
surprising considering the fact that uncontrolled cell division is associated with tumour 
development and alteration in cell cycle checkpoints may be responsible for cancer 
(Hartwell 1992, Kastan and Bartek 2004). Our study identified TP53 to be up-regulated 
in breast cancer in comparison to the normal breast tissue (section 3.1.4). Alteration in 
TP53 gene products is involved in bad prognosis of breast cancer (Borresen et al., 1995; 
Overgaard et al., 2000; Langerod et al., 2007). A high expression of TP53 in follicular 
lymphoma was observed in high grade and oversized tumors and correlated with poor 
prognosis (Pennanen et al., 2008) and also in a subset of ductal carcinomas in situ, with 
no expression observed in atypical lesions (Chitemerere et al., 1996).  
4.2.2 Embryonic stem cell pathway up-regulated in cancer  
In our study, many genes reported to be highly expressed in embryonic stem cell pathway 
were up-regulated in cancer compared to normal tissue indicating that breast cancer 
might originate from the stem cell, or has characteristics similar to stem cells. Many other 
studies have implicated abnormality in stem cells to the origin of cancer. Mutations 
among the stem cell genes could lead to an alteration in genomic stability, resulting in 
immortality and onset of cancer (Ashkenazi, Gentry and Jackson 2008). Additionally, the 
P53 gene has roles in normal and cancer stem cell differentiation, apoptosis, self-renewal 
and the capacity for tumourigenesis (Zheng et al., 2008). 
Cyclin dependent protein and protein complex of cyclin B1 (CCNB1) induces 
phosphorylation of key substrates mediating cell cycle progression from G2 to M phase 
(Morgan 1995; Nurse 1994). Recently it has been identified as an oncogene and is over-
expressed in the cells from leukemia and other tumors including breast cancer cells from 
patient tissues at G1 phase (Shen et al., 2004). Over-expression of cyclin B1 has been 
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associated with tumor invasion and reduced survival and is also reported to be a 
prognostic marker in several tumor types (Yu, Zhan and Finn 2002; Murakami et al., 
1999).  
Increased expression of CDC20 is reported to be a common event in various cancer 
including colorectal and bladder cancer tissues as well as in oral squamous cell 
carcinoma and gastric cancer (Kidokoro et al., 2008; Mondal et al., 2007; Kim et al., 
2005). Suppression of growth by inducing G2/M arrest was observed by reducing the 
expression of CDC20 using CDC20-specific siRNA suggesting it as a potential 
therapeutic target for various cancers (Kidokoro et al., 2008). 
MELK is associated with the regulation of spliceosome assembly, gene expression and 
cell proliferation (Vulsteke et al., 2004; Saito et al., 2005; Nakano et al., 2008). It is also 
expressed in several vertebrate tissues including the blast cells of the early embryo, 
embryonic stem cells, adult germ cells (ovaries and spermatogonia), hematopoietic stem 
cells and neural stem cells (Heyer, Kochanowski and Solter 1999; Nakano et al., 2005; 
Easterday et al., 2003). MELK gene transcript controls the cell cycle and acts to regulate 
the self-renewal of neural stem cells (Nakano et al., 2005). Marie et al. (2008) found 
progressively higher expression of MELK in a study carried out on more than 100 tumors 
of the central nervous system and a high level of expression in glioblastoma multiforme. 
It has been directly associated with proliferation and anchorage-independent growth in 
glioblastoma multiforme and brain tumors, identifying it as a possible therapeutic target 
for these types of cancer (Nakano et al., 2008; Marie et al., 2008). 
PFS2 has been associated with ovule patterning by regulating cell proliferation of the 
maternal integuments and regulating the timing of cellular differentiation of the 
megaspore mother cell (Pillitteri et al., 2007; Park et al., 2005). Pillitteri et al., (2007) 
reported that PFS2 might be responsible for properly coordinating the developmental 
states of the sporophytic integument tissues and gametophytic embryo sac. 
PRC1 plays a functional role in regulating mitosis and the protein is highly expressed 
during S and G2/M phase (Jiang et al., 1998). p53 is found to directly suppress PRC1 
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gene transcription in HCT116 p53+/+, HCT116 p53-/-, MCF-7, T47D, and HeLa cells 
(Li, Lin and Liu 2004). 
4.2.3 Fatty acid biosynthesis pathway down-regulated in cancer 
Several gene members of the fatty acid biosynthesis pathway were significantly down-
regulated in cancer compared to normal tissue. Our results contradict other published 
reports where fatty acid synthesis pathway is up-regulated in cancer (Kuhajda 2000; Pizer 
et al., 1996).  
The fatty acid synthesis pathway was found to be selectively activated in a study carried 
out on human prostate cancer tissue using in situ hybridization (Swinnen et al., 2000). 
This group also reported a relationship between increased lipogenesis and cancer 
progression.  
A study carried out on a group of established human breast carcinoma cell lines-SKBR3, 
ZR-75-1, MCF-7, and MCF-7a (doxorubicin-resistant)-and normal human fibroblasts 
(HS-27) suggested that fatty acid synthesis was required by some of the cancers for their 
growth and inhibition of fatty acid synthesis can inhibit the growth of neoplastic cells 
(Kuhajda et al., 1994).  
The relationship between abnormal fatty acid synthesis and an aggressive tumor 
phenotype is still not fully understood. Fatty acids are reported to be involved in 
tumorigenesis (Cohen et al., 1986), in receptor-mediated signal transduction (Tomaska 
and Resnick 1993), as well as modulators of tumor cell adhesion. The role of increased 
endogenous fatty acid biosynthesis in tumorigenesis is unknown. One of the possibilities 
could be that lipid mediators in the tumor cells may act in an autocrine or paracrine 
fashion affecting tumor behavior. It is also found that certain tumors have an apparent 
requirement for endogenous fatty acid biosynthesis compared to normal cells. These 
reported results suggest that inhibition of fatty acid biosynthesis could be a potential 
target for chemotherapy development (Kuhajda et al., 1994). 
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The synthesis of fatty acids from acetyl-CoA and malonyl-CoA is carried out by an active 
enzyme fatty acid synthase (FASN) (Epstein, Carmichael and Partin 1995; Shurbaji et al., 
1992). FASN is an important enzyme of the fatty acid synthesis and are found to be 
highly expressed in human cancers, including carcinoma of the breast, prostate, ovary, 
endometrium and colon (Epstein, Carmichael and Partin 1995; Shurbaji et al., 1992; 
Rashid et al., 1997; Alo et al., 1996; Milgraum et al., 1997). 
Stearoyl-CoA desaturase (SCD) is an enzyme which helps in the biosynthesis of 
monounsaturated fatty acids and also controls the regulation of metabolism in liver and 
skeletal muscle (Dobrzyn and Ntambi 2005). A link between SCD activity and tumor cell 
proliferation has been observed with increased expression of SCD in colonic and 
esophageal carcinoma, hepatocellular adenoma, as well as in chemically induced tumors 
(Thai et al., 2001; Li et al., 1994). SCD regulates programmed cell death and is crucial 
for cell survival (Scaglia and Igal, 2005). Down-regulation of SCD has also been 
associated with significantly decreased proliferation and invasiveness (Scaglia and Igal, 
2005). 
Long-chain acyl-CoA synthetases (ACSL) are necessary for fatty acid degradation, 
phospholipid remodeling, and production of long acyl-CoA esters that act as a regulator 
of various physiological processes in mammals (Soupene and Kuypers 2006).  
In conclusion, our results identified genes, functions and pathways that are associated 
with transition of normal breast tissue to cancer. TP53 gene was found to be up-regulated 
in breast cancer. Cell cycle pathways and embryonic stem cells genes were up-regulated 
in cancer. Fatty acid biosynthesis pathway genes were down-regulated in breast cancer. 
4.3 Genes up-regulated in Estrogen Receptor-positive breast patients 
4.3.1 In-house study 
Clinical decision making has very much relied on ER status of patients and many 
individual studies have tried to identify genes involved in Estrogen metabolism. In our 
study, 34 ER-negative breast specimens and 67 ER-positive breast specimens were used 
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to identify differential-expressed (DE) transcripts. Further meta-analysis was performed 
using five additional publicly available datasets, including one cell line data.  
Our in-house data identified 855 up-regulated genes associated with ER-positive vs ER-
negative specimens. Affected functions and pathways over-represented by these genes 
were related to cellular morphogenesis and epidermal growth factor receptor activity. 
Cellular morphogenesis is the key feature in the development of mammary gland and is 
supposed to be influenced by ESR1 gene and Estrogen (Mallepell et al., 2006; Sternlicht 
2006). Bi-directional regulation among EGFR and ER has been reported by other studies 
(Levin 2003; Britton et al., 2006). Estrogen can regulate expression of EGF receptor 
proteins and may play a role in Estrogen-stimulated growth (Mukku and Stancel 1985). 
ER and EGFR
 
signal through various kinases and influence transcriptional and non-
transcriptional actions of Estrogen
 
in breast cancer cells (Levin 2003). Increased EGFR 
signalling is associated with tamoxifen resistance in ER-positive breast cancer cells (Fox 
et al., 2008). 
Our in-house data identified 1145 down-regulated genes associated with ER-expression. 
Affected functions and pathways over-represented by these genes were related to immune 
response. Immune response is the main molecular process associated with prognosis in 
the ER and HER2 receptor-negative subgroups (Desmedt et al., 2008). Despite ER-
negative groups having a high proliferation and poor clinical outcome, a group exists 
with high expression of immune response genes with good prognosis (Schmidt et al., 
2008; Teschendorff et al., 2007). 
4.3.2 Meta analysis  
Meta-analysis was performed on six independent datasets, using common criteria to 
identify DE genes. 62 up-regulated transcripts common to all experimental groups were 
identified, which will be discussed here. 
ESR1 gene is very critical for ER action. ESR1 is ligand-activated transcription factor 
composed of several domains important for hormone binding, DNA binding, and 
activation of transcription. This gene was over-expressed in our study among the ER-
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positive patients. This gene was also up-regulated in all cohorts among the ER-positive 
specimens. ESR1 gene amplification is quite frequent in breast cancer (Holst et al., 2007) 
and endometrial cancer (Lebeau et al., 2008). Genetic polymorphism in the gene is 
associated with transformation of benign tumors to cancer (Gallicchio et al., 2006) and 
has been linked to breast cancer risk, tumour characteristics and survival (Einarsdottir et 
al., 2008).  
GATA3 (GATA binding protein 3) is important for mammary gland morphogenesis and 
luminal cell differentiation and is closely associated with ESR1 gene expression; 
however it has little prognostic value independent of ER (Voduc, Cheang and Nielsen 
2008). GATA3 co-expresses with ESR1 gene (Tozlu et al., 2006) and ER alpha pathway 
genes (Wilson and Giguere 2008). Genetic variability in the intronic region of GATA3 is 
associated with differential susceptibility to breast cancer (Garcia-Closas et al., 2007). 
GATA3 was up-regulated in all the experimental datasets comparing ER-positive cancer 
to ER-negative cancer. 
Forkhead box A1 (FOXA1) is a forkhead family transcription factor expressed in breast 
cancer cells and is associated with luminal subtype (Thorat et al., 2008). It is also 
strongly correlated with ESR1 expression (Tozlu et al., 2006; Lacroix and Leclercq 
2004). FOXA1 is correlated with luminal subtype A (Badve et al.,  2007) and with 
favourable prognosis (Badve et al.,  2007; Habashy et al.,  2008; Wolf et al.,  2007a) and 
plays a growth inhibitory role in breast cancer (Wolf et al.,  2007a). This gene was up-
regulated in all of the cohorts of ER-positive specimens vs. ER-negative specimens. 
SPDEF (SAM pointed domain containing ets transcription factor) is an Ets transcription 
factor expressed at high levels primarily in tissues with high epithelial cell content, 
including prostate, colon, and breast (Seth and Watson 2005). Its protein product is 
reduced in human invasive breast cancer and is absent in invasive breast cancer cell lines 
(Feldman et al., 2003). SPDEF over-expression is associated with nodal metastasis and 
hormone receptor positivity in invasive breast cancer (Turcotte et al., 2007). High 
expression of this gene in tumour and peripheral blood makes it a candidate prognostic 
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marker (Ghadersohi and Sood 2001). SPDEF was also up-regulated in all our 
experimental groups of ER-positive specimens vs. ER-negative specimens.  
C1ORF34 (tetratricopeptide repeat domain 39A) expression correlates with expression of 
ER in cell lines and was also detected in primary breast carcinomas but not in normal 
breast tissue (Kuang et al., 1998). This gene was also up-regulated in all our experimental 
groups of ER-positive specimens vs. ER-negative specimens.  
Other important and well known genes involved in the ER pathway which were up-
regulated in ER-positive patients vs. ER-negative patients in our study were CA12, TFF1, 
TFF3, ERBB4, MYB, NAT1, eEF1A2, LIV-1.  
Carbonic anhydrase XII (CA12) is a marker of good prognosis in invasive breast 
carcinoma (Watson et al., 2003). CA12 expression is associated with ER-positive tumors 
(Barnett et al., 2008; Tozlu et al., 2006).  
TFF1 (trefoil factor 1) is a small cysteine-rich secreted protein that is frequently 
expressed in breast tumors in the ER-positive patients. TFF1 is expressed in ER-positive 
tumors and its expression correlates with the expression of ESR1 (Tozlu et al., 2006; 
Wilson and Giguere 2008). Estrogens can stimulate the motility of breast cancer cells via 
the induction of TFF1 (Prest, May and Westley 2002). Like TFF1, TFF3 (trefoil factor 3) 
is also frequently expressed in breast tumors. Although closely related, there are marked 
differences in shape, size, and surface charge of these proteins (May et al., 2003). Like 
TFF1, TFF3 also co-expresses with ESR1 gene in breast cancer (Wilson and Giguere 
2008). In our meta-analysis both of these genes were found to be up-regulated in all 
experimental groups among the ER-positive specimens vs. ER-negative specimens. 
ERBB4 (v-erb-a erythroblastic leukemia viral oncogene homolog 4 avian) gene is a 
member of the tyrosine protein kinase family and the epidermal growth factor receptor 
subfamily. Its expression is associated with ER-positive tumors (Zhu et al., 2006). The 
ERBB family encodes 4 proteins, ERBB (HER1), ERBB-2 (HER2, NEU), ERBB-3 
(HER3), and ERBB-4 (HER4); HERs 1-3 are associated with poor survival, however 
HER4 is associated with better survival (Witton et al.,  2003; Bieche et al.,  2003). In our 
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meta-analysis ERBB4 was up-regulated in all experimental groups among the ER-
positive specimens vs. ER-negative specimens. 
MYB (v-myb myeloblastosis viral oncogene homolog avian) is a proto-oncogene and its 
expression is strongly associated with ER and PR in breast cancer (Guerin, Barrois and 
Riou 1988). Its expression is correlated with the expression of ESR1 gene (Tozlu et al., 
2006). This gene is also associated with improved prognosis (Guerin, Barrois and Riou 
1988). However, proliferation of ER-positive breast cancer cell lines is inhibited when 
MYB expression is knocked down (Drabsch et al., 2007). In our meta-analysis MYB was 
up-regulated in all experimental groups among the ER-positive specimens vs. ER-
negative specimens. 
NAT1 (N-acetyltransferase 1 arylamine N-acetyltransferase) expression correlates with 
expression of ESR1 (Tozlu et al., 2006; Wakefield et al., 2008). DNA hypomethylation 
in the NAT1 gene is present in cancerous breast tissue indicating that this type of 
methylation may significantly influence the transcriptional activation of the gene (Kim et 
al., 2008). In our meta-analysis NAT1 was up-regulated in all experimental groups 
among the ER-positive specimens vs. ER-negative specimens. 
Translation elongation factor eEF1A2 is a potential oncoprotein that is over expressed in 
two-thirds of breast tumors (Tomlinson et al., 2005) and predicts favourable outcome in 
breast cancer (Kulkarni et al., 2007). In our meta-analysis NAT1 was up-regulated in all 
experimental groups among the ER-positive specimens vs. ER-negative specimens. 
LIV-1 (solute carrier family 39 zinc transporter, member 6) breast cancer protein belongs 
to a family of histidine-rich membrane proteins and controls intracellular Zn2+ 
homeostasis (Taylor 2000). LIV-1 is associated with ER-positive tumors (Tozlu et al., 
2006).  In our meta-analysis LIV-1 was up-regulated in all experimental groups among 
the ER-positive specimens vs. ER-negative specimens. 
Our meta-analysis also identified novel genes which may be involved in ER metabolism 
and disease progression e.g. MYO5C, TPBG, RGL2, MKL2, THRAP2, LASS6, 
INPP4B, COX6C, MCCC2, RAB17, ANXA9, THSD4, ABAT, HSPB1 for which the 
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available literature is limited. These genes were up-regulated in all experimental groups 
among the ER-positive specimens vs. ER-negative specimens. 
Gene ontology and pathways analysis provided some functional insight to the mechanism 
of ER action. Our in-house dataset identified functions related to morphology to be 
significant among the ER-positive specimens. Pathway analysis identified nuclear 
receptors to be a significant pathway. This pathway was also found to be significant in 
the meta-analysis. The gene was termed as DE if it was significantly up-regulated in at 
least 50% of the datasets among the ER-positive specimens vs. ER-negative specimens. 
The DE genes were analysed (non DE as background) to identify functions and pathways 
enriched for ER genes (see section 3.3). Not DE genes were those which were not found 
differentially expressed in any of the experimental group. The functions up-regulated in 
ER-positive specimens vs. ER-negative specimens were Zinc ion transport, Neutral 
amino acid transporter activity, unconventional myosin and Insulin-like growth factor 
receptor activity. Estradiol regulates the expression of insulin like growth factor initiating 
an intracellular signal transduction pathway that activates transcription factors, including 
the estrogen receptor (Martin and Stoica 2002). Pathway analysis identified Tissue-
Muscle fat and connective, Nuclear Receptors, Electron Transport Chain, and Androgen-
Receptor NetPath 2 as up-regulated in ER-positive specimens.  
4.3.2.1 Nuclear Receptor pathway 
Nuclear receptors are transcription factors and become active when they detect a certain 
ligand in the cellular environment and have the ability to bind to DNA and activate genes 
(Mangelsdorf et al.,  1995). The most commonly studied nuclear receptors in breast 
cancer are ER and PR. However recently many other nuclear receptors has been found to 
be important in breast cancer, including those of Androgen receptor, corticosteroids, fat-
soluble vitamins A and D, fatty acids and xenobiotic lipids derived from diet (Conzen 
2008).  
Retinoic acid receptor (RAR) alpha or RARA has found to be differentially expressed in 
ER+ (MDA-MB-231, MDA-MB-330, HBL100, and Hs0578T lines) and ER- (MDA-
MB-361, BT 474, and BT 20) cells and is thought to be regulated by estrogen or other 
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steroid hormones (Fitzgerald et al., 1997; Roman et al., 1992). Relatively high levels of 
RAR alpha was observed in ER+ mammary carcinoma cells and were responsive to 
retinoids, whereas most undifferentiated, estrogen-independent, ER-negative (ER-) cells 
showed low RAR alpha expression and retinoid resistance. It has been shown to play a 
role in retinoid-induced growth inhibition of human breast cancer cell lines that express 
the estrogen receptor (ER) (Fitzgerald et al., 1997; Roman et al., 1992; Schneider et al., 
2000). All these studies suggest that RAR alpha might regulate the normal and malignant 
mammary epithelial cell growth, differentiation, and apoptosis (Fitzgerald et al., 1997; 
Sheikh et al., 1994; Widschwendter et al., 1997). 
Nuclear receptor subfamily 2, group F, member 6 (NR2F6) expressed in lymphocyte acts 
as a regulator of T lymphocyte activation, potently antagonizing antigen-receptor-induced 
cytokine responses in vitro and in vivo (Baier 2003). A high endogenous expression of 
NR2F6 mRNA was observed in embryonic brain and developing liver (Warnecke et al., 
2005; Miyajima et al., 1988). Hermann-Kleiter et al, reported a potential function for 
NR2F6 in the immune system as it was expressed in the thymus, spleen, lymph node, and 
bone marrow, CD3+ T and CD19+ B lymphocytes (Hermann-Kleiter et al., 2008). 
Androgen receptor (AR) is the key transcription factor required for prostate cell survival 
and proliferation and is reported to play a critical role in the development and progression 
of prostate cancer (Xu et al., 2009). In an immunohistochemical study carried out on 86 
patients with gastric carcinoma it was observed that patients with AR-positive tumors 
AR-positive had worse prognosis than AR-negative patients (Kominea et al., 2004). 
AR is expressed in 60% of invasive breast carcinomas and almost 50% of the ER-
negative tumors have been shown to be AR-positive (Agoff et al., 2003; Moinfar et al., 
2003). The median survival after disease recurrence of patients with AR-expressing 
tumors was significantly longer compared to that of patients with AR-negative tumors 
(Schippinger et al., 2006). There have been reports of prognostic advantage for patients 
with AR expression in early breast cancer compared to patients with AR-negative tumors 
(Agoff et al., 2003; Bryan et al., 1984; Kuenen-Boumeester et al., 1996). Of the 232 
breast carcinomas examined by Schippinger et al., (2006), 70.7% expressed ARs 
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demonstrating its expression is a common characteristic in breast cancer and may be a 
possible therapeutic target for endocrine antitumor therapies. 
VDR is expressed in the human colon, normal epithelial cells and some cancer cells 
(Kallay et al., 2002). Increased expression of VDR is associated with a favorable 
prognosis in colorectal cancer (Cross et al., 1996; Evans et al., 1998). Some of the other 
studies report that VDR expression decreases in high-grade carcinomas to levels found in 
normal mucosa (Kallay et al., 2002; Sheinin et al., 2000; Cross et al., 2001), while others 
found diminished VDR expression already in low- and intermediate-grade tumors and a 
decrease below normal mucosa levels in high-grade carcinomas (Palmer et al., 2004).  
In conclusion, our study identified various genes and pathways which are crucial for ER 
metabolism. Important genes identified to be up-regulated in ER-positive tumors are 
ESR1, FOXA1, SPDEF, TFF1, and TFF3. Nuclear receptor pathway was found to be up-
regulated in ER-positive tumors.  
4.4 Gene interaction network for ESR1 gene 
Large scale gene expression mining can help identify and understand the intricate 
relationship among correlated genes. Our analysis focussed on building a gene interaction 
networks around the ESR1 gene, an important gene in ER metabolism. 
A 5897-sample chip dataset obtained from Array Express (E-TABM-185) was used to 
identify genes which correlate with ESR1 gene expression, the central gene in the ER-
pathway (section 3.3.3). These specimens were from diverse types of tissue and cell lines; 
however, all were on Affymetrix HG-U133A chips and were normalised as a group, thus 
making it an excellent dataset for gene correlation analysis. Correlation measure has been 
widely used to understand gene interaction from gene expression data (Almudevar et al., 
2006; Lee et al., 2004). Pearson correlation coefficient as a measure of similarity between 
expression profiles was used to construct network graphs from gene expression data 
(Freeman et al., 2007). The size of the graph produced is dependent on the threshold 
correlation value selected. At low Pearson correlation coefficient cut-offs, networks 
become large whereas at higher thresholds levels, the networks consist of a smaller 
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number of genes and tend to be more useful for most analyses (Freeman et al., 2007). A 
Pearson correlation cut-off > 0.75 was used to identify genes that correlate in expression 
to that of ESR1. Expression of GATA3, FOXA1, SPDEF and C1ORF34 were found to 
be correlated with ESR1 expression (Spearman Correlation > 0.75 across 5897 samples). 
These 5 genes were also significantly over-expressed in the ER-positive group in all the 
six experiments when comparing ER-positive to ER-negative specimens. Interestingly, 
other than C1ORF34, for which function is less known, all the other genes (ESR1, 
GATA3, FOXA1 and SPDEF) are transcription factors and therefore these genes may be 
affecting the expression of large number of other genes. These findings therefore also 
indicate that that the ER pathway may be more complex than is currently considered and 
more detailed study is needed to unravel the mechanism behind the ER-positive tumour 
progression.  
Using the expression values of these 5 genes across 5897 specimens the relationships 
among these genes were investigated. Hierarchical clustering and PCA results indicated 
that FOXA1-SPDEF and ESR1-GATA3 expression are highly correlated. K-means 
clustering was performed to get a better understanding of the expression pattern of the 
genes across all specimens. The biggest cluster (3209 specimens) had little or no 
expression of these 5 genes in most of the specimens. The second biggest cluster (899 
specimens) had good expression of all these 5 genes in most of the specimens. These 
results indicate that these genes are most often expressed together. It is possible that 
several of these genes get switched on as part of differentiation of mammary glands and 
are essential for the development of luminal epithelial cells of the mammary gland (Tong 
and Hotamisligil 2007). Since the samples in this study were of diverse origin, there is 
the obvious possibility of different types of interaction of these genes in different 
individual cancers.  
 The other clusters had relatively fewer numbers of genes, but they indicated that the 
expressions of these genes are independent of each other, except for SPDEF expression 
which is present only when there is high expression of FOXA1. 
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Correlation plots for individual combinations of genes were analysed across all 5897 
specimens to get a deeper understanding on the dependency of each gene expression on 
another. The results conclude that expression of ESR1, GATA3, C1ORF34, SPDEF, 
FOXA1 (except for SPDEF-FOXA1), although highly correlated, exist independently of 
each other. However, it seems likely that the expression of SPDEF may be dependent on 
the expression of FOXA1. A very high level of expression of FOXA1 existed with a low 
level of expression of SPDEF; however a high level of SPDEF expression was not 
observed associated with low expression of FOXA1.  
In conclusion, our study identified 4 genes (FOXA1, SPDEF, GATA3, and C1ORF34) to 
be correlated to the expression of ESR1. Additionally our results indicated the possible 
dependency of SPDEF expression on FOXA1. 
4.5 Genes up-regulated in ER-negative breast patients 
The absence of ER protein classifies the tumour as ER-negative. This phenotype is 
associated with a poor prognosis. The molecular biology of ER-negative tumors is poorly 
understood. There is lack of targeted therapies for ER-negative tumors, especially if they 
are triple negative (ER-negative, PR-negative, HER2-negative). Our study aimed to 
identify genes up-regulated in the ER-negative tumors. 
Our in-house data analysis also identified the ER-negative cluster to be enriched with 
patients who relapsed (overall) and high grade tumors. 6 datasets were compared to 
identify over-expressed genes in ER-negative tumors. Common criteria was used to 
identify DE (p ≤ 0.05, Fold Change (FC) > 1.2 and Difference > 100) genes. The meta-
analysis on these datasets identified 20 transcripts up-regulated in ER-negative specimens 
in all the datasets under study (section 3.3.2). 
SFRP1 (secreted frizzled-related protein 1) is a 35 kDa member of the SFRP family. It 
acts as a biphasic modulator of Wnt signaling, counteracting Wnt-induced effects at high 
concentrations and promoting them at lower concentrations (Uren et al., 2000). Promoter 
hypermethylation is the predominant mechanism of SFRP1 gene silencing in human 
breast cancer and SFRP1 gene inactivation in breast cancer is associated with 
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unfavourable prognosis (Veeck et al., 2006). SFRP1 showed the highest fold up-
regulation (8.25-fold average across all experiments) among the ER-negative specimens 
vs. ER-positive specimens. Our results for the first time showed a strong relation of 
SFRP1 with ER-negative phenotype. 
Other genes up-regulated by an average fold change > 2 in ER-negative specimens vs. 
ER-positive specimens were COTL1, SLC43A3, C10orf38, MSN and TRIM2. COTL1 
(coactosin-like 1) is a human filamentous actin-binding protein and is expressed in 
placenta, lung, kidney and peripheral-blood leucocytes (Provost et al., 2001). Coactosin-
like protein has been described as a cancer antigen in pancreatic cancer (Nakatsura et al., 
2002). Its function in breast cancer is unknown. SLC43A3 (solute carrier family 43, 
member 3) is expressed in microvascular endothelium (Wallgard et al., 2008) and its 
expression in cancer is poorly defined. The KLF9 (Krüppel-like factor 9) alters the 
expression of COTL1 and C10orf38 (Simmen et al., 2008). Very little information is 
available for MSN and TRIM2 as regards their role in cancer. Interestingly, most of the 
genes identified here up-regulated in ER-negative tumors have not been extensively 
studied previously for a role in cancer. This study has for the first time identified 
transcripts and genes which might be important for ER-negative breast cancer, where 
currently the understanding and therapeutic options are very limited. ER-negative tumors 
are morphologically and phenotypically very distinct from ER-positive tumors and there 
is need for more study and development of newer promising agents for the treatment of 
ER-negative breast cancer (Putti et al., 2005). Our study identifies newer targets which 
can be studied for development of targeted therapeutics for ER-negative Breast cancers.  
In conclusion, our results identified important genes up-regulated in ER-negative tumors. 
SFRP1 (secreted frizzled-related protein 1) gene was very highly expressed in ER-
negative breast tumors. 
4.6 Genes up-regulated in HER2-positive breast cancers 
ERBB2 (v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, neuro/glioblastoma 
derived oncogene homolog avian) gene amplification is associated with a sub-set of ER-
negative tumors with a very poor prognosis (Revillion, Bonneterre and Peyrat 1998). 
 308 
Two clinical and one cell line datasets (section 3.4) were analysed and compared to 
identify transcripts associated with ERBB2 expression. DE genelists were created for 
each and the genelists were compared. 13 transcripts (6 up-regulated and 7 down-
regulated) were common to all three datasets. The up-regulated transcripts common to all 
three datasets were ERBB2, C17orf37, STARD3, ERGIC1 and C7orf24. ERBB2 
(Average fold change: 9.8), C17orf37 (Average fold change: 6.7) and STARD3 (Average 
fold change: 5) are all located on chromosome 17q. Amplification of chromosome 17 has 
previously been identified in HER2-positive breast cancer (Bose et al., 2001). The other 
two genes ERGIC1 (chromosome 5) and C7orf24 (chromosome 7) with average fold 
change of 1.9 and 1.7, respectively, are on different chromosomes.  
ERBB2 gene amplification is associated with shorter disease-free survival and higher 
incidence of death due to disease (Slamon et al., 1987). The gene is located on 
chromosome 17 and is amplified in a subset of invasive breast cancer and correlates with 
poor clinical outcomes (Watters et al., 2003).  
The C17orf34 (chromosome 17 open reading frame 34) gene is located in close proximity 
to ERBB2 on chromosome 17q21 (Benusiglio et al., 2006) and is expressed in early and 
late stages of breast cancer disease, in very high amounts in metastatic patients and is 
absent or has very low expression in normal breast tissue (Evans et al., 2006). ERBB2, 
C17orf34 and STARD3 are located in a close proximity of 168kb region of chromosome 
17 (Maqani et al., 2006). STARD3, also known as Metastatic lymph node 64 protein 
(MLN64) is co-amplified with ERBB2 gene in breast cancer (Vinatzer et al., 2005) and is 
regulated by Sp/KLF transcription factors (Alpy et al., 2003).  
In conclusion, our results identified important genes up-regulated in HER- positive breast 
patients. Many of these genes were on chromosome 17. 
4.7 Lymph node-negative vs. Lymph node-positive 
Clinically, lymph node status is an important criterion in the treatment choice as patients 
with no lymph node involvement are usually spared from aggressive treatment. With the 
increase in the degree of lymph node involvement, which indicates the invasion of cancer 
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cells to naerby tissue, the survival of breast cancer patient decreases (Carter, Allen and 
Henson 1989). Since metastatic potential has been described as an inherent property of 
malignant tumors (Weigelt et al.,  2003; Weigelt et al.,  2005), the aim was to identify 
key transcriptional difference between lymph node-positive and lymph node-negative 
patients. A previously-described metagene (aggregate patterns of gene expression) study 
was able to predict lymph node status with an accuracy of 90% (Huang et al., 2003) 
indicating the prognostic value of lymph node metastasis genes. Gene ontology and 
pathway analysis in our study did not identify promising GO functions and pathways 
affected, possibly due to smaller numbers of identified DE genes. Lymph node-positive 
associated DE genes were compared to survival/relapse gene lists generated by 
comparing genes involved in five year relapse, overall relapse and survival comparisons. 
SNIP (SNAP25-interacting protein) was significantly up-regulated (FC=2.51) in patients 
with lymph node-positive compared to lymph node-negative patients. The expression of 
SNIP was not detected in normal breast specimens but was detected in 37% breast cancer 
correlating with unfavourable overall survival and was published by this laboratory 
(Kennedy et al., 2008). However, few DE genes were observed when the lymph node-
positive and lymph node-negative patients were compared. In a similar study, gene 
expression signature was not strongly associated with lymph node status (Sotiriou et al., 
2003). This indicates that there might not a definite signature for Lymph node metastasis.  
PHF21B (PHD finger protein 21B) gene was significantly down-regulated (FC = -6.15) 
in lymph node-positive specimens vs. lymph node-negative specimens. No information is 
known regarding its role in breast cancer.  
In conclusion, our study identified a limited number of genes which are up-regulated in 
breast cancer patients with Lymph node involvement. SNIP was an important gene up-
regulated in Lymph node-positive breast patients. 
4.8 Tumour Grade 
Grade is an important criterion in clinical decision making (section 1.3.1). Tumors with 
high Grade are more likely to undergo relapse and distant metastasis. Our results also 
indicate a strong association of grade with high relapse and poor survival. Hierarchical 
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clustering identified different groups of patients with differences in grade. The ER-
negative enriched group (Cluster C) was enriched with high Grade tumors; however there 
was a subset of ER-negative enriched group (Cluster B) with low grade tumors (Grade 1 
and Grade 2). The ER-positive enriched group (Cluster D and E) was enriched with low 
grade tumors (Grade 1 and Grade 2). Other independent studies have identified strong to 
moderate association of grade to gene expression profiles (Sotiriou et al., 2003; Wang et 
al., 2005; Calza et al., 2006) 
In our study, gene ontology and pathway analysis identified cytoskeleton, porin (are beta 
barrel proteins that cross a cellular membrane and act as a pore through which molecules 
can diffuse) activity, phosphatase inhibitor activity and cell division genes to be over-
expressed and overrepresented in Grade 3 cancers compared to Grade 2 cancers. Genes 
involved in cell cycle progression and proliferation have also been identified up-regulated 
in high grade cancer compared to low and intermediate grade cancer in other published 
studies (Sotiriou et al., 2003; Sotiriou et al., 2006). 
To find genes whose expression progressively increased with grade, comparisons were 
performed for genes up-regulated in Grade 2 vs. Grade 1 and Grade 3 vs. Grade 2. 
Twenty three transcripts were identified in which expression progressively increases with 
grade and two transcripts in which progression decreases with grade. IL4I1 (interleukin-
four induced gene-1) expression was 5.52-fold up-regulated in Grade 2 vs. Grade 1 and 
2.26-fold up-regulated in Grade 3 vs. Grade 2 (section table 3.1.8.7). Very little is known 
about the involvement of this gene in breast cancer although it has been found to be 
activated in primary mediastinal large B-cell lymphoma (Copie-Bergman et al., 2003). 
CCL5 (Chemokine (C-C motif) ligand 5) is an 8kDa protein classified as a chemotactic 
cytokine or chemokine and was found to be up-regulated with grade, with lowest 
expression in Grade 1 tumour and highest in Grade 3 tumour in our study. This gene is an 
inflammatory mediator and has pro-malignancy activities in breast cancer, and may have 
therapeutic potential (Soria and Ben-Baruch 2008). In stage II patients, the expression of 
CCL5 significantly increased the risk for disease progression (Yaal-Hahoshen et al., 
2006).  
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Our results indicate high expression of CDKN2A (cyclin-dependent kinase inhibitor) in 
high grade tumors, highest in Grade 3 cancers and lowest in Grade 1 cancers. CDKN2A 
encodes a protein that regulates 2 critical cell cycle regulatory pathways, the p53 pathway 
and the retinoblastoma pathway. CDKN2 germline mutations have been detected in 
patients with breast cancer and cutaneous melanoma (Monnerat et al., 2007) and families 
with prevalent childhood cancer (Magnusson et al., 2008).  
In conclusion, our study identified important genes, functions and pathways for which the 
expression increases/decreases with grade. IL4I1 (interleukin-four induced gene-1) was 
identified as an important gene whose expression increases very highly with the 
progressive grade. 
4.9 Tumour size 
Tumour size is a significant predictor of relapse-free survival in breast cancer (Hu et al., 
2006). As the tumour size increases, the survival rate decreases (Carter, Allen and 
Henson 1989). Very few DE genes were observed in our study when tumour size was 
analysed; this suggests that tumour size might not be an important parameter as far as 
gene expression differences are concerned. Only three mRNAs RPESP (Ribulose-5-
phosphate-3-epimerase-spondin), EPN3 (epsin 3) and CNTNAP2 (Contactin associated 
protein-like 2), were up-regulated by a fold change of greater than 2 in tumors with size 
greater than 2.8cm compared to tumors with size less than 2.8cm. Only seven mRNAs 
GRIA2 (Glutamate receptor, ionotropic, AMPA 2), PYDC1 (PYD (pyrin domain) 
containing 1), PTPRN2 (protein tyrosine phosphatase, receptor type, N polypeptide 2), 
CALML5 (Calmodulin-like 5), FOSB (FBJ murine osteosarcoma viral oncogene 
homolog B), SSFA2 (sperm specific antigen 2), and HSPB8 (heat shock 22kDa protein 8) 
were found to be down-regulated by a fold change of greater than 2 in tumors with size 
greater than 2.8cm compared to tumors with size less than 2.8cm. The results suggest that 
the gene expression profiles of large tumors are not very different from small tumors. 
Other studies also indicated that tumour size is not a very significant criterion as far as 
gene expression signature is concerned (Gieseg et al., 2004; Sotiriou et al., 2003) 
indicating that gene expression profile does not changes with increase in tumour size. 
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In conclusion, our result identified genes up-regulated or down-regulated with increase in 
tumour size. RPESP, EPN3 and CNTNAP2 were up-regulated in large tumors. GRIA2, 
PYDC1, PTPRN2, CALML5, FOSB, SSFA2, and HSPB8 were down-regulated in large 
tumors. 
4.10 Genes associated with relapse and survival 
4.10.1 In-house study 
Relapse-free survival is an important clinical parameter. Identifying genes with the 
prognostic importance could lead to discovery of better targeted therapies and also 
development of method to better classify patients for different kinds of treatment.  
Relapse and survival events were studied in our in-house dataset in four distinct analyses: 
overall relapse, overall survival, 5 years relapse and 5 years survival. The genelists 
compared were patients who relapsed vs. patients who did not relapse; patients who 
relapsed within 5 years vs. patients who did not relapse within 5 years; patients who 
survived vs. patients who died of the disease and patients who survived for at least 5 
years compared to patients who died within 5 years of diagnosis. The total number of 
common genes in all the four genelists was 384. 
The up-regulated genes identified from the group of patients with a  poor outcome 
outlined above (common to 4 genelist with average FC>2) were LCN2 (lipocalin 2), 
NMU (neuromedin U), SERPINB5 (serpin peptidase inhibitor, clade B ovalbumin, 
member 5), KCNG1 (potassium voltage-gated channel, KQT-like subfamily, member 1), 
SNIP (SNAP25-interacting protein), SLC4A11 (solute carrier family 4, sodium borate 
transporter, member 11), ST8SIA6 (ST8 alpha-N-acetyl-neuraminide alpha-2,8-
sialyltransferase 6), PSAT1 (phosphoserine aminotransferase 1), LOC92312, C9orf58, 
LOC92312, LOC92312, SOX11 (SRY sex determining region Y-box 11), PPARBP 
(mediator complex subunit 1), PCGF2 (polycomb group ring finger 2), ANP32E (acidic 
(leucine-rich) nuclear phosphoprotein 32 family, member E) and STARD3 (STAR-
related lipid transfer domain containing 3).  
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Similarly up-regulated genes in the group of patients with a good outcome outlined above 
(common to 4 genelist with average FC>3) were FAM79B (tumor protein p63 regulated 
1), RTN1 (reticulon 1), ZNF533 (zinc finger protein 385B), PDZK1 (PDZ domain 
containing 1), NOVA1 (neuro-oncological ventral antigen 1), SCUBE2 (signal peptide, 
CUB domain, EGF-like 2), RTN1 (reticulon 1). Additionally, ESR1 was up-regulated in 
the good outcome and lymph node-negative groups. A high expression of ESR1 is 
commonly associated with Luminal subtype A in microarray studies and correlates very 
well with better survival and disease-free outcomes (Hu et al., 2006; Sorlie et al., 2003). 
Our results are in agreement with other studies that show that high expression of ESR1 
gene is associated with favourable outcome on breast cancer patients. 
4.10.2 Meta-analysis 
Four other similar datasets (section 3.2.1) which contained relapse status of individual 
patients were cross-compared to identify transcripts up and down-regulated among all the 
datasets. No transcript was found common to all the datasets. It was therefore decided to 
identify transcripts up-regulated or down-regulated in three or more datasets. Twenty two 
transcripts were found to be DE in a minimum of three out of the five datasets under 
study. Three of them (HSPB1, KIAA0101 and PAK3) were up-regulated in four out of 
the five datasets and one (FOS) was down-regulated in four out of the five datasets. 
HSPB1 (heat shock 27kDa protein 1) is a 27 kDa heat shock protein and plays a role in 
cancer progression (Garrido et al., 2006). In four of the five experimental cohorts, this 
gene was found to be significantly up-regulated in patients who relapsed. Down-
regulation of HSPB1 in HCT116 human colon carcinoma cells caused senescence in a 
population of cells (O'Callaghan-Sunol, Gabai and Sherman 2007). In the 4T1 murine 
breast adenocarcinoma cell line, knockdown of this gene eliminates cell motility 
(Bausero et al., 2006). HSPB1 expression in human breast cancer cells can reduce 
Herceptin susceptibility by increasing Her2 protein stability (Kang et al., 2008). 
KIAA0101 (protein-coding GC15M062444) is a proliferating cell nuclear antigen-
associated (PCNA) factor and involved in cell proliferation. A high expression of this 
gene was found in plasma RNA of colorectal cancer (Collado et al., 2007). siRNA 
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knockdown of KIAA0101 in pancreatic cancer cells caused a reduction in proliferation as 
well as a significant decrease in DNA replication (Hosokawa et al., 2007). In 
hepatocellular carcinoma, a high expression of this gene was associated with increased 
stage, early tumour recurrence, and poor prognosis (Yuan et al., 2007). In our meta-
analysis comparing patients who relapsed vs. patients who did not relapse, this gene was 
found to be significantly up-regulated in patients who relapsed in four of the five 
experimental groups. 
PAK proteins are critical effectors that link Rho GTPases to cytoskeleton reorganization 
and nuclear signaling. The PAK3 gene has a significant role in the nervous system and 
mutation of this gene in involved in many diseases of the Central Nervous Sytem (Boda 
et al., 2004). PAK3 (p21 protein (Cdc42/Rac)-activated kinase 3) contributes to synapse 
formation and plasticity in the hippocampus (Boda et al., 2004). PAK3 mutations result 
in a specific form of X-linked mental retardation with fairly constant clinical features 
(Rejeb et al., 2008). However, there is limited understanding of this gene‟s involvement 
in cancer. Our results show that the expression of this gene is significantly up-regulated 
in patients who relapsed in four of the five independent studies. PAK1 phosphorylates 
histone H3 and affects the Pak1-histone H3 pathway and mitotic events in breast cancer 
cells (Li et al., 2002). PAK1 induces RAS transformation and that is essential for RAS-
induced up-regulation of cyclin D1 during the G1 to S transition (Nheu et al., 2004). 
Members of the FOS family (c-FOS, FOSB and its smaller splice variants, Fra-1 and Fra-
2) dimerise with Jun proteins to form the AP-1 transcription factor complex. Our study 
identified two members of AP-1 transcriptional factor (FOS and FOSB) to be down-
regulated in breast cancer patients who relapsed. FOS was down-regulated in four of the 
five experimental groups and FOSB was down-regulated in three of the five experimental 
groups. FOSB expression is necessary for normal proliferation and differentiation of 
mammary epithelial cells, and reduced FOSB protein levels in tumors has been found to 
be correlated with high grading, ER-negative and PR-negative, and high HER2/neu 
expression (Milde-Langosch et al.,  2003). A previous study (Milde-Langosch et al., 
2004) has reported that high FOSB levels are associated with high expression of MMP1, 
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MMP9, PAI-1 and uPAR protein in clinical models and over-expression of the gene 
increased invasion in the MCF-7 cell line.  
Meta-analysis for prognostic makers across various studies identify different sets of 
signatures and are mostly linked to proliferation This is because various mechanisms of 
cancer progression e.g ER+, ERBB2, have effects on increased cellular proliferation 
(Wirapati et al. 2008). The KIAA0101 gene was common to our meta-analysis and the 
meta-analysis performed by this group, with KIAA0101 up-regulated in the poor survival 
group in both studies. 
In conclusion, our results identified many genes up and down-regulated in aggressive 
disease. HSPB1, KIAA0101 and PAK3 were up-regulated in patients who relapsed. AP1 
transcriptional factor genes FOS and FOSB were down-regulated in patients who 
relapsed. 
4.10.3 Comparison our in-house result with OncotypeDx 
The in-house genelist comparing patients who relapsed vs. patients who did not relapse 
was compared with the expression of the 16 genes of OncotypeDx (Paik et al., 2004), a 
diagnostic kit used to assay the long term survival and the possible benefit from 
chemotherapy. AURKA, BIRC5 ERBB2, were up-regulated in both the studies in the bad 
prognosis group (patients who relapsed in our study and positive association with 
recurrence on OncotypeDX ) and ESR1, SCUBE2 were up-regulated in both the studies 
among the good prognosis group (patients who did not relapse in our study and negative 
association with recurrence). In our study, ERBB2 was also up-regulated in lymph node-
positive patients and ESR1 was down-regulated in lymph node-positive patients. Of the 6 
genes common to our analysis, all followed the same trend and were either associated 
with good or bad prognosis (section 3.2.2) indicating good aggrement among the two 
results.  
In conclusion, 37.5% of the genes were common to both the studies. Of the 6 genes 
common to both studies all followed the same trend of expression indicating good 
aggrement among the two results.  
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4.10.4 Comparison our in-house result with MammaPrint 
The relapse genelist above was also compared with that of MammaPrint (van 't Veer et 
al.,  2002). NMU (neuromedin U), GMPS (guanine monphosphate synthetase), MELK 
(maternal embryonic leucine zipper kinase) were up-regulated in both the studies 
(patients who relapsed in our study and positive association with metastasis on the 
MammaPrint genelist) and PECI (peroxisomal D3, D2-enoyl-CoA isomerase), SCUBE2 
(signal peptide, CUB domain, EGF-like 2) was down-regulated in both the studies 
(patients who did not relapse in our study and negative association with metastasis on the 
MammaPrint genelist) (section 3.2.3). No common genes were found when comparing 
with lymph node status with the genelist of MammaPrint. This may be due to differences 
in microarray platforms and differences in the sample and the way the specimens were 
selected. Also, van 't Veer et al., (2002) identified genes responsible for distant 
metastasis, while in our study relapse and lymph node metastasis were used as prognostic 
criteria. Similar conclusions were also drawn by Wang et al., (2005) as there was an 
overlap of only 3 genes among their genelist and MammaPrint genes.  
In conclusion, there were not many genes common to both studies. Of the few genes 
common to both genelist, they followed the same trend of expression. Our study does not 
compare very well with the van 't Veer et al.,  (2002) study due to the differences in the 
platform and clinical parameters used. In our study the clinical parameter was Relapse, 
whereas the clinical parameter used in the van 't Veer et al.,  (2002) study was distant 
metastasis.  
4.11 Relapse prediction 
 
 One of the many applications of microarrays is their potential use as 
prognostic/diagnostic kits. The success of these kits depends on the accuracy with which 
they can predict the prognosis of the patients. Many such algorithms can be used used for 
such types of classification. K-nearest neighbour (KNN) considers all specimens in an m-
dimensional space, where m is the number of variables and uses a distance metric to 
group them based on similarity or dissimilarity (Gregory et al., 2008). Probabilistic 
neural networks belong to the family of Radial Basic Function (RBF) networks. The 
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algorithm is very similar to a feed-forward neural network with one hidden neuron. The 
input is directly passed to the hidden layer without weights and a Gaussian density 
function is used as an activation function. The interconnecting weights are optimized 
using a least square optimization algorithm (Haykin, 1998). Linear discriminate analysis 
LDA classifies the data using the linear combination of features which best separate two 
or more classes of objects (Geoffrey, 1992). Support vector machines (SVM) construct a 
hyper plane in space so as to maximally divide the margin between the different types of 
objects (Haykin, 1998). Ensemble classification methods works on combining different 
classification methods to improve the classification accuracy. The challenge in such types 
of classifier is to analyse the results coming from different classifier to get the optimum 
results. 
 A back propagation algorithm was implemented for accurate prediction of relapse in 
breast cancer patients. One hundred and sixty two differentially-regulated genes (p ≤ 
0.001) were identified among patients who relapsed and patients who did not relapse. 
These genes were used for training the network. To test the accuracy of the system, 
leave-one-out cross validation was used. The model predicted relapse to an accuracy of 
97.87% (100% for patients who relapsed and 96.2% for the patients who did not relapse) 
with a cut-off of 0.75 for positive examples and 0.25 for negative examples i.e patients 
with score above 0.75 were considered to relapse and patinets with score below 0.25 were 
considered not to relapse. Patients whose score fell between 0.25 and 0.75 were classified 
as undetermined. However, there were 11 specimens out of total of 104 which could not 
be classified. When all samples were classified, the accuracy was 93.33% (93.7% for 
patients who relapsed and 92.9% for the patients who did not relapse). Support vector 
machine (SVM) analysis was also used to classify the same data. SVM classified the 
relapse event with an accuracy of 93.33% which is same as that of back propagation, 
when all samples were classified. 
A classifier using a 70 gene signature was able to predict distant metastasis with an 
accuracy of 83% in node-negative breast cancer (van 't Veer et al.,  2002). This was later 
developed as the MammaPrint kit for detection of distant metastasis for lymph node-
negative breast cancer patients under 61 years of age with tumors of less than 5cm. An 
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independent classifier using back propagation and support vector machines was 
constructed using van 't Veer et al.,  (2002) data. Comparing patients who developed 
distant metastasis and patients who did not, a total of 117 DE genes (p ≤ 0.001) was used 
to generate the classification model. In leave-one-out cross validation, a back propagating 
algorithm was able to predict distant metastasis with an accuracy of 89.70% (82.7% for 
patients who developed distant metastasis within 5 years and 94.8% for the patients who 
did not) when a cut-off score of 0.75 for positive examples and a cut-off score of 0.25 for 
negative examples was taken. This resulted in 10 samples out of 78 samples as 
unclassified. However, when all samples were classified, the prediction accuracy was 
87.17% (82.3% for patients who developed distant metastasis within 5 years and 90% for 
the patients who did not). Similar analysis using support vector machines had a prediction 
accuracy of 82.05% in leave-one-out cross validation model.  
Many other studies have used gene expression data to develop prognostic models using a 
variety of gene selection techniques and classification algorithms. Huang et al., (2003) 
developed a probability-based classifier using metagene to predict lymph node metastasis 
and recurrence with an accuracy of 90%. Oncotype DX is a PCR based diagnostic kit to 
calculate the recurrence score for individual patients who have no lymph node involved 
and are ER-positive (Paik et al.,  2004; Sparano and Paik 2008). This kit is based on the 
expression of 16 genes and 5 control genes using PCR. The output of the analysis is a 
recurrence score. The higher the recurrence score, the higher is the probability of 
recurrence of the disease. Based on these scores, patients are classified as low risk, 
intermediate risk and high risk with the recurrence rate of 6.8, 14.3 and 30.5% 
respectively. 
Karlsson et al., (2008) studied 46 node-negative tumors with the aim of developing a 
classifier to distinguish high risk and low risk breast cancer patients. A t-test was used to 
identify DE genes among the high and low risk patients. A total of 51 genes (p<0.001) 
were used to build a voting feature interval classifier and correlation based classifier with 
a prediction accuracy of 96 and 89% respectively in leave-one-out cross validation study. 
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Our results based on the comparative analysis on same data indicate that back-
propagation is an excellent method of developing a classification model on both 
Affymetrix and cDNA microarray data and can outperform Support Vector Machines 
based classifiers.  
The gene signature along with the back propagation training algorithm has a potential to 
be developed as a diagnostic assay. The models performed better than the existing 
diagnostic kit such as MammaPrint and OncotypeDx. The analysis also indicates that the 
gene signature generated and used in our study is more informative because of the high 
accuracy obtained. This may be due to the fact that the chips utilised to generate this data 
were Affymetrix whole-genome U133 Plus2.0 chips, which contain vastly more 
transcript data than was used to identify the other two gene signatures. 
In conclusion, the study presented here demonstrates the suitability of back-propagation 
algorithm as an efficient classifier for gene expression data with potential of its use for 
diagnostic/prognostic kits. Using this classifier, we were successful in predicting relapse 
with an accuracy of 97.87%.  
4.12 Identification and functional validation of Ropporin 
Our in-house microarray data indicated that Ropporin is over-expressed in patients who 
relapsed (overall), relapsed within 5 years and did not survive beyond 5 years. In the 
early stages of annotating the transcript, it was realised that there are two genes, ROPN1 
and ROPN1B with a very high homology (97% on DNA sequence and 95% on protein 
sequence). Both genes are located on chromosome 3 (ROPN1: 3q21.1; ROPN1B: 
3q21.2). Because of their close proximity and sequence homology, it is likely that one 
arose from the other by duplication followed by random mutations during the 
evolutionary process.  
Ropporin expression was first detected in testis and is localized in the principal piece and 
the end piece of sperm flagella and is induced at late stage of spermatogenesis (Fujita et 
al., 2000). Rhophilin protein is localised in the outer surface of the outer dense fibre of 
sperm. Ropporin is localized in the inner surface of fibrous sheath of sperm. Rhophilin 
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and Ropporin together interact with small GTPase Rho which acts as a molecular switch 
that regulates various cellular processes such as cell adhesion, motility, gene expression 
and cytokinesis (Fujita et al., 2000).   
Sperm motility and acrosome (process at the anterior end of a sperm cell that produces 
enzymes to facilitate penetration of the egg) is dependent on actin polymerization where 
AKAP (A-kinase anchor protein) and RHOA (Ras homolog gene family, member A) 
interacting proteins play an important role. The phosphorylation of AKAP3 increases its 
interaction with RHOA-interacting proteins and Ropporin (Fiedler, Bajpai and Carr 
2008). Mutants lacking RSP11 (radial spoke protein), an ortholog of Ropporin in the 
flagellum of Chlamydomonal reinhardtii demonstrated impaired and sporadic motility 
(Yang and Yang 2006). 
Ropporin shares sequence similarity with three other proteins, ASP, SP17 and CABYR, 
all of which are localised in sperm flagella. All of them contain a highly conserved 
dimerization/docking (R2D2) domain, suggesting that all of these proteins interact with 
all AKAPs. All of these proteins are also expressed in motile cilia indicating that these 
proteins are vital for sperm and cilia (Newell et al., 2008).  
However, its expression has recently been detected in multiple myeloma, chronic 
lymphocytic leukaemia and acute myeloid leukaemia (Li et al., 2007b). Ropporin gene 
expression in tumour cells is associated with the high titer IgG antibodies against 
Ropporin. Because of its restricted expression in normal tissue and immunogenicity of 
the protein to the autologous hosts, this molecule may be a good target for 
immunotherapy (Li et al., 2007a).  
 
4.12.1 Affymetrix probe annotation for Ropporin 
On the Affymetrix U133 Plus2.0 chip, there are a total of four transcripts for Ropporin. 
According to the Affymetrix guidelines, 233203_at is specific probes for ROPN1 while 
the other three (224191_x_at, 231535_x_at, 220425_x_at) are non-specific probes. The 
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“_x_at” probe sets contain some probes that are identical, or highly similar, to unrelated 
sequences. These probes may cross-hybridize with sequences other than the main target. 
The sequence of each probe was obtained from NetAffx and annotated using BLAST. 
Recently a reference sequence identifier has been provided for ROPN1 and ROPN1B. 
RefSeq annotation integrates information from various sources, and represents a 
consensus description of the sequence and its features (Pruitt, Tatusova and Maglott 
2007). In the previous Genbank build there was no reference sequence available for these 
two genes and only early accession numbers were allocated to sequences. The Affymetrix 
U133 Plus2.0 chip was designed on the earlier Genbank build and therefore the probeset 
was designed on early submission of this gene which was poorly defined and annotated. 
The BLAST result of 233203_at did not have a hit with the reference sequence of either 
ROPN1 or ROPN1B. This indicated that the probe sequence of 233203_at may not 
represent Ropporin. However, it did have a hit with ROPN1 sequence gi|6599263| (not 
the reference sequence) indicating the possibility of more isoforms of Ropporin. Early on 
in our analysis, the assumption was made that only ROPN1B, and not ROPN1 is 
expressed in our in-house study. This was because the NetAffx-defined unique probeset 
for ROPN1 (233203_at) did not report any expression from the microarrays, while the 
non-specific ROPN1B probeset (220425_x_at) did yield a reproducible signal intensity. 
Following the outcome that 233203_at cannot be considered as a valid probe for ROPN1, 
two other probes were selected to represent ROPN1 and distinguish it from ROPN1B. A 
previous study, (Gautier et al.,  2004) analysed U133A chip annotation and documented 
that 64% of the Affymetrix annotation has discrepancies with current annotation due to 
the fact that while the probes on Affymetrix arrays remain the same for several years, the 
biological knowledge concerning the genomic sequences keeps changing. The BLAST 
result on the sequence of 231535_x_at indicated this probe to be a 100% match to the 
reference sequence of ROPN1 and 97% match to the reference sequence of ROPN1B. 
Therefore 231535_x_at was used to represent ROPN1. A BLAST result on the sequence 
of 224191_x_at indicated this probe to be a 100% match to the reference sequence of 
ROPN1B and 99% match to the reference sequence of ROPN1. Therefore, probeset 
224191_x_at was not used to represent either ROPN1 or ROPN1B. The BLAST result on 
the sequence of 220425_x_at indicated this probe to be a 100% match to the reference 
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sequence of ROPN1B and 97% match to the reference sequence of ROPN1. Therefore, 
probeset 220425_x_at was used to represent ROPN1B. On analysing our in-house 
datasets, it was observed that there was no expression of 233203_at in any of the 
samples, however, there was a substantial amount of expression of the other probesets. 
The same was true for a number of the publicly available breast and melanoma datasets. 
However, for multiple myeloma, all the probe sets (including 233203_at) showed varying 
levels of expression in many of the samples indicating a possibility of more isoforms of 
this gene.  
For the microarray analysis, probeset 231535_x_at was used to represent ROPN1 and 
220425_x_at to represent ROPN1B. However, there was no way to distinguish how much 
each one cross-hybridises to their respective variants.  
4.12.2 Ropporin expression in our in-house breast dataset. 
ROPN1 was 4.97-fold and ROPN1B was 5.06-fold up-regulated in patients who relapsed 
compared to patients who did not relapse. ROPN1 was 6.81-fold and ROPN1B was 7.83-
fold up-regulated in patients who relapsed within 5 years compared to those who 
remained disease free for 5 years. ROPN1B (220425_x_at) was not expressed among 
54/57 (94.7%) of the patients who did not relapse, however it was expressed in 13/48 
(27.1%) of the patients who did relapse based on the cut-off of 100 Affymetrix unit. 
Similarly, ROPN1 (231535_x_at) was not expressed among 53/57 (92.9%) of the patients 
who did not relapse, however, it was expressed in 14/48 (29.1%) of the patients who did 
relapse.  
A high expression of ROPN1 and ROPN1B was observed in one of the sub-clusters 
enriched with ER-negative specimens. This cluster had the worst survival in comparison 
to other clusters.  
4.12.3 Confirmation of Ropporin expression by qPCR  
Using qRT-PCR on the clinical breast specimens, it was possible to confirm the high 
expression of Ropporin in the breast specimens used to generate our in-house dataset. 
Primers for both genes were designed and tested for their specificity in detecting the two 
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genes using plasmids with the ROPN1 and ROPN1B genes cloned in. While ROPN1 
primers were very specific in detecting ROPN1 gene, ROPN1B picked up ROPN1 with 
100-fold less specificity than that of ROPN1B. Therefore, it was possible to distinguish 
between the two genes, once both qRT-PCR reactions were run on all assayed samples. 
qRT-PCR was performed on 94 of the clinical specimens from our in-house study using 
the specific primers for ROPN1 and ROPN1B. There was no RNA available for the rest 
of the clinical specimens. ROPN1 was found to be 2.33-fold (baseline mean 2.39; 
experimental mean 1.81) down-regulated in patients who relapsed, whereas ROPN1B 
was found to be 6.28-fold (baseline mean 1.02; experimental mean 11.37) up-regulated in 
patients who relapsed. ROPN1B qRT-PCR results are in agreement to the results from 
microarray result, however, the results from ROPN1 qRT-PCR contradicts the findings 
from our microarray study. With no way to predict or estimate the amount of cross-
hybridization of the Affymetrix probes, the results from qRT-PCR were considered to be 
a more accurate assessment of ROPN1 and ROPN1B expression in these samples. 
Previous studies have not tried to distinguish between the two genes (both usually 
referred to as Ropporin). The studies which do mention the ROPN1 gene do not seem to 
be specific for ROPN1 (Carr et al., 2001; Li et al., 2007; Newell et al., 2008). PCR 
primers from a study of Newell et al., (2008) were blasted using primer BLAST. The 
primers picked up the ROPN1B gene instead of the ROPN1 gene. Performing the same 
analysis on primers from two other studies (Carr et al., 2001; Li et al., 2007) picked up 
both genes. The obvious reason for these differences is the constantly evolving 
annotation of Genbank. However, our primers were specific in picking up the differences 
among the two genes. The primer BLAST results were highly specific in picking up their 
respective genes (results based only on forward and reverse primer).  
4.12.4 Functional validation using in-vitro cell line models 
Since the gene is expressed in sperm tail and cilia, both of them involved in motility, a 
hypothesis was made that in cancer it might be helping the cancer cells in moving from 
their primary site (via invasion) to a different location (metastasis).  
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Cancer cell line models were used to identify the functional role of this gene in cancer. 
With the hypothesis that this gene might play a crucial role in cancer cell motility and 
invasion; siRNA and over-expression studies were performed and followed by functional 
assays (motility and invasion) to investigate any possible association between this gene 
and invasion/cell motility. siRNA knockdown of ROPN1B in MDA-MB-435s showed a 
reduction in motility. siRNA knockdown of ROPN1 was not performed as expression of 
ROPN1 was substantially less than that of ROPN1B. No invasion assay results were 
available as the cell line did not demonstrated reproducible invasion. Similarly siRNA 
knockdown of ROPN1 and ROPN1B in M14 showed a decrease in invasion and motility. 
However, knockdown by ROPN1 siRNA was not very specific and based on the qRT-
PCR results, it knocked down the ROPN1B gene too. Thus the results could not 
positively associate ROPN1 to cell motility and invasion, however, as a whole (ROPN1 
and ROPN1B) can be positively associated with cancer cell motility. 
Results from over-expression studies were somewhat inconclusive. In M14 cells, over-
expression of ROPN1 and ROPN1B led to reduction in the protein content; with a 
consequent loss observed in invasion and motility. In MDA-MB-435s cells over-
expression of ROPN1 showed no increase/reduction in protein level, however there was 
reduction in motility. Cells over-expressing ROPN1B cDNA showed a reduction in 
protein level surprisingly and a reduction in motility.  
4.12.5 Ropporin expression in cancers and normal tissues 
The Ropporin gene is classified as cancer testis genes because of its expression in testis 
and not in other tissues, but with aberrant expression in cancers (Li et al., 2007). Cancer 
testis (CT) genes encode a heterogeneous group of immunogenic proteins (CT antigens) 
expressed almost exclusively in normal testis and in a percentage of tumors of various 
origin. On the basis of their tissue specificity and immunogenicity to its autologous host, 
CT antigens are considered promising targets for development of cancer vaccines 
(Simpson et al., 2005). Scanlan, Simpson and Old (2004), identified 44 CT gene families 
and studied their expression pattern in numerous cancer types. Bladder cancer, non-small 
cell lung cancer, and melanoma had high CT gene expression, breast and prostate cancer 
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had moderate CT gene expression while renal and colon cancer had low CT gene 
expression. CT gene expression was also observed among multiple myeloma 
(Condomines et al., 2007) and oesophageal carcinoma (Liang et al., 2005).  
In normal tissue, Ropporin is expressed in testis (Fiedler, Bajpai and Carr 2008, Fujita et 
al.,  2000; Li et al.,  2007; Newell et al.,  2008), fetal liver (Li et al.,  2007), motile cilia, 
liver, brain, pancreas and prostate (Newell et al.,  2008). Our analysis on publicly 
available datasets (GSE1133) confirmed the high expression of Ropporin in testis and 
marginal expression in brain and liver. Additionally, a high expression of this gene was 
found in ganglion and marginal expression found in skin, trachea and heart. High 
expression of Ropporin is also found in epithelial cells with motile cilia and this may be 
the reason for its detection in other tissue types with presence of motile cilia (Newell et 
al., 2008).  
Ropporin is detected in tumors of multiple myeloma (Li et al., 2007; Chiriva et al., 
2007), chronic lymphocytic leukaemia and acute myeloid leukaemia (Li et al., 2007). Our 
analysis on a publicly available dataset confirmed that Ropporin is widely expressed in 
multiple myeloma. Ropporin expression was also present in normal melanocyte (from 
normal skin) and the expression dramatically increases with the progress of melanoma; 
highest in metastatic growth phase melanoma and lymph node metastasis. 
4.12.6 Previous studies identifying Ropporin expression in breast cancer. 
Expression of Ropporin was also found in other publicly available breast datasets with 
aberrant expression observed in estrogen-negative breast tumors. Ropporin expression 
has previously been shown to be correlated with GABAπ expression which is associated 
with undifferentiated cell type and high grade of breast cancer (Symmans et al., 2005). 
Ropporin expression was also observed high in patients with breast cancer which 
developed bone metastasis (Smid et al., 2006). However, while these studies have 
previously linked Ropporin expression with breast cancer and metastasis, the gene was 
listed in these publications together with several other potentially important targets and 
was not specifically highlighted. This study is the first to functionally demonstrate a role 
for this gene in invasion in breast cancer. The identification of Ropporin as up-regulated 
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in these two studies has served to complement and strengthen our findings that the gene 
is actively involved in aggressive breast cancer.  
4.13 Conclusion  
Our study on clinical breast specimens and normal breast specimens has provided a deep 
insight to the biology of breast cancer. Our results identified groups of patients with 
similar expression profiles, the possible biology driving them and the subsequent clinical 
implications for those patients.  
Two unique groups of patients, previously un-identified by other studies with significant 
differences in survival were identified. A “good” prognosis group with a high expression 
of immune response-associated genes was demonstrated among the ER-negative group of 
patients. A group of patients with ER-negative tumors associated with a very poor 
prognosis has been shown to express high levels of the Ropporin gene. Over-expression 
of this gene was also observed in patients who relapsed vs. not. Using cell lines models, 
this study positively identified the involvement of ROPN1B in breast and melanoma 
cancer cell motility and invasion. The results also indicate that ROPN1 has a similar 
function, but because of the absence of very specific siRNA, this could not be proven.  
A prognostically-important genelist was used to develop a Neural Network back 
propagation model to predict the clinical outcomes. Using an identified set of 162 genes, 
the model was successful in predicting relapse with an accuracy of 97.8%.  
Comparing the gene expression profiles of Normal and Cancer specimens identified 
genes, functions and pathway differences associated with disease. TP53, along with cell 
cycle genes were up-regulated in cancer compared to normal specimens. Embryonic stem 
cell pathway genes were up-regulated in tumors indicating the possibility of impaired 
stem cell as origin of cancer. The fatty acid biosynthesis pathway was down-regulated in 
tumour vs. normal specimens. 
To get a deeper understanding of ER involvement in breast cancer and to mine genes 
which may play an important role in the ER metabolism, meta-analysis was performed on 
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an in-house dataset together with 5 public datasets. This analysis identified novel genes 
which had not been associated with the ER pathway. The nuclear receptor pathway was 
up-regulated in ER-positive tumors/cell lines. Mining for ESR1-correlated genes across a 
5897-member microarray chip dataset identified FOXA1, SPDEF, C1ORF34 and 
GATA3 expression to be highly correlated with ESR1. Our results also indicated that 
most of them are expressed together; however, individual expression can occur 
independently (except for SPDEF expression which seems likely to be dependent on 
FOXA1).  
4.13 Discussion of some peripheral research projects 
In the course of the PhD project, I became involved in two projects which were 
somewhat peripheral to the main thesis work. One involved a bioinformatics analysis of 
publicly available data sets, to evaluate how relevant cell line models might be to human 
tumors in vivo. The second involved an opportunity to take part in bioinformatics 
analysis of a unique data set on microarray analysis of basal cell carcinoma vs. normal 
skin. 
4.13.1 How Representative are cell line models of clinical conditions? 
Cell lines are widely used as models of in-vivo systems. However, limited studies have 
been done to establish whether these models accurately reflect in-vivo scenarios. A 
separate study carried out in our laboratory examined gene expression differences and 
similarities in a representative group of breast cancer cell lines and clinical specimens to 
estimate their approximate level of similarity and was published previously (Mehta et al.,  
2007). 
Cell lines grow under very tight and well-optimized conditions, with enough space to 
grow and divide. In comparison, tumors grow in a completely different environment and 
are influenced by a varied range of conditions. In this study, a clear segregation of the 
cell lines and clinical specimens by hierarchical clustering was demonstrated. This is in 
agreement with other similar studies where cell lines and clinical specimens tend to 
cluster separately from each other (Dairkee et al., 2004; Ross and Perou 2001). PCA also 
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demonstrated a clear separation of the two groups. A segregation of the clinical 
specimens into two smaller sub-groups was also observed, although the 
clinical/biological basis for this has not been determined here. An earlier experiment 
(Dairkee et al., 2004) also reported considerable scatter among primary tumour cultures 
and cell lines compared to normal breast specimens using PCA as a comparison tool. 
From the Genmapp analysis, cell cycle, mitosis, nuclear division, cell proliferation and 
other related functions are over-represented in cell line models in comparison to the 
clinical specimens, while functions related to immune response and defence response are 
over-represented in clinical specimens relative to cell lines. A recent study (Ertel et al.,  
2006), also reported that genes related to proliferation and cell cycle are over-represented 
in cell lines relative to clinical specimens, while cell communication, cell adhesion 
molecules and ECM-receptor interaction are down-regulated in cell lines compared to 
clinical specimens. Our study also indicated a decrease in expression of genes involved in 
cell adhesion in the cell lines compared to clinical specimens, although this data did not 
make it into the top ten ontologies.  
While the analysis outlined above identified the macroscopic broad-based differences 
between breast cancer cell lines and clinical specimens, it was considered useful to assess 
the similarity relationships of the cell lines and clinical specimens with regard to their ER 
status. It was hoped that while differences had been observed when comparing cell lines 
and clinical specimens directly, both cell lines and clinical specimens would cluster 
similarly when ER status was used as the criteria. Previous studies had demonstrated that 
both cell lines (Charafe-Jauffret et al., 2006) and clinical specimens (Sotiriou et al., 
2003) cluster largely on their ER status. To this end, unsupervised clustering of the cell 
lines and clinical specimens separately was carried out to determine if either group 
clustered according to ER status. However, while the cell lines largely clustered 
according to ER status, the clinical samples did not. This result indicated that, even at a 
single parameter scale, the differences between clinical specimens and their respective 
cell line models may remain considerable.  
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In conclusion, the findings reported here indicate that significant differences in gene 
expression between clinical conditions and their respective cell line models exist at both 
the large- and small-scale levels. A previous study (Dairkee et al., 2004) concluded that 
the results obtained from cell lines may act as good models for high-grade cancer, but 
may fail as useful models for most of the low- and medium-grade breast cancers. While 
our study does not indicate a specific clinical classification for which such cell line data 
may prove relevant, the data presented here demonstrate that these differences should be 
taken into account when extrapolating in-vitro cell line results to clinically-relevant in-
vivo systems. 
4.13.2 Basal cell carcinoma 
Basal cell carcinoma (BCC) is the most common skin cancer in humans. It is locally 
aggressive, invasive but rarely metastasises (Saldanha et al., 2004; Ionescu, Arida and 
Jukic 2006). Very few studies aimed at investigating the molecular mechanisms 
associated with BCCs have been published worldwide. Howell et al., (2005) analyzed 50 
BCC tumour specimens using cDNA microarrays and reported findings from their 
analysis of 1,718 transcripts. A separate study carried out in our laboratory analyzed gene 
expression of BCCs, compared to normal skin, using whole genome microarrays. 
Following extensive analysis of our data, a number of novel potential 
biomarkers/therapeutic targets for this disease were identified (O'Driscoll et al., 2006). 
In agreement with our findings, Howell et al.,  (2005) also reported gene transcripts 
including collagens (type V, alpha 1 & alpha 2; type IV alpha 1 & 2; type VII alpha 1), 
topoisomerase IIα, tumour-associated calcium signal transducer 1, profilin 2, calretinin, 
syndecan 2, and v-myc to be up-regulated in BCC compared to normal skin. Similarity 
was also observed between these two studies for transcripts down-regulated in BCCs 
compared to normal specimens. Examples of these include cystatin B, acetyl-Coenzyme 
acyltransferase 1, 3-hydroxy-3-methylglutaryl-Coenzyme A reductase, glutaredoxin, 
amyloid β (A4) precursor-like protein and cytochrome b-5. ADP-ribosylation factor 3 
was down-regulated by 1.67-fold in our study, but was up-regulated in the study by 
Howell et al., (2005). Glia maturation factor β was 1.42-fold up-regulated in our analysis 
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but Howell et al., (2005) reported it as down-regulated. These conflicting results may be 
due to different splice variants of these transcripts being detected by cDNA compared to 
oligo microarrays. It was also noted that the results that differed between our study and 
that of Howell et al., (2005) were generally transcripts <2-fold differentially-expressed 
between BCC and normal skin. Further comparisons between these studies cannot be 
performed as the fold change was not reported by Howell et al., (2005) and no 
information is publicly available on transcripts that were present on their microarray. 
Dys-regulation of the hedgehog and Wnt pathways is associated with the development of 
BCC (Rubin, Chen and Ratner 2005, Daya-Grosjean and Couve-Privat 2005). A tumour 
suppressor gene, patched homologue 1 (PTCH1) forms a part of the hedgehog signaling 
network (Cohen 2003) is found to be associated with the development of BCC (Boonchai 
et al.,  2000). Eleven-fold up-regulation of PTCH1, 7.39-fold up-regulation of gli2 and no 
significant change in shh expression levels was observed from our analysis of BCC 
compared to normal skin tissue. SMO (smoothened homolog) gene is associated with 
Hedgehog signalling heterotrimeric G proteins (Philipp and Caron 2009). GLI gene 
encodes a nuclear protein and binds to specific genes leading to transcriptional activity 
(Kinzler and Vogelstein 1990). The mechanism of action of PTCH1 is via binding to 
another transmembrane molecule smoothed (SMO) thereby suppressing intracellular 
signaling. Then sonic hedgehog (shh) binds to PTCH1 resulting in an uninterrupted 
signal transduction by SMO, via GLI transcription factors and subsequent activation of 
target genes, including members of the Wnt pathway (Yamazaki et al., 2001) and PTCH1 
(Cohen 2003). SMO is a protein with seven transmembrane domains that is distantly 
related to G-protein coupled receptors (GPCRs) (Ingham and McMahon 2001). Activated 
SMO stimulates transcription factors of the Cubitus interruptus (Ci) or GLI family 
inducing the expression of specific genes (King 2002). GLI transcription factors belongs 
to the Kruppel family of zinc finger proteins (Buscher and Ruther 1998).  
Increased PTCH1 mRNA levels have previously been reported in nodular BCC but 
undetectable in superficial BCC (Tojo et al., 1999); however detectable PTCH1 in both 
types of BCC was observed, with no significant difference in their respective expression 
values (t-test: p = 0.637). 
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PTCH1 is associated with tumour suppressor activity (Cohen 2003) and was found to be 
up-regulated in BCC compared to normal skin. The lack of tumour suppressor activity by 
PTCH1 may be due to lack of expression of its corresponding protein and/or lack of 
binding to SMO (not significantly different between BCC and normal skin). As PTCH1 is 
found to shuttle between the cell membrane and endocytotic vesicles in response to active 
hedgehog ligand, it is obvious that the expression of both mRNA and protein (at the 
relevant location, binding of SMO) is necessary to exert its tumour suppressor activity 
(Cohen 2003).  
Wnt signaling may be able to regulate a number of the aspects of the biology of tumour 
cells and thus contribute in several ways to the tumour phenotypes including 
proliferation. In our study there was significantly increased expression of a number of 
Wnt family members including Wnt5A (3.35-fold), in agreement with a study by 
Saldanha et al.,  (2004) where Wnt5A levels were increased in BCCs compared to 
surrounding skin; and Wnt6 (4.86-fold). Increased levels of Wnt ligand binding receptors, 
Frizzled D2 (8.94-fold), D7 (2.31-fold), and D8 (5.89-fold) and decreased levels of D4 (-
2.78-fold), were also found.  
Jun is a transcription factor involved in the Wnt pathway (Weeraratna 2005) and was 
found to be increased (2.34-fold) in BCCs compared to normal skin. Transcription factor 
associated with cancer including CHES1 (checkpoint suppressor 1) is involved in 
repressing expression of genes important for tumorigenesis (Scott and Plon 2005) and 
was differential-expressed in this study. CHES1 mRNA has been reported as down-
regulated in oral squamous cell carcinoma (Chang et al., 2005) and in hepatocellular 
carcinoma (Hong, Muller and Lai 2003). CHES1 mRNA levels were found to be 
significantly (-2.03-fold) down-regulated in BCC compared to normal skin. mRNAs 
involved in inducing apoptosis were also found to be down-regulated including CIDE and 
CARD15 which are 4.18-fold and 2.31-fold down-regulated in BCC compared to normal 
skin. 
Increased levels of ChgA in serum have been associated with poor prognosis/shortened 
survival for prostate cancer patients (Ranno et al., 2006). ChgA protein levels have been 
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proposed to assist in the diagnosis of Merkel cell carcinoma patients who may benefit 
from oncological therapy (Koljonen et al., 2005; Mount and Taatjes 1994; Carlei et al., 
1986). In this study, ChgA levels were found to be significantly (130.3-fold) up-regulated 
in BCCs compared to extremely low levels in normal skin specimens.  
In summary, our analysis has identified important genes, functions and pathways 
involved in normal skin transition to basal cell carcinoma. Wnt signaling pathway was 
found to be up-regulated in Basal cell carcinoma and may be potentially involved in 
transition of normal skin to basal cell carcinoma. 
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5.1 Hierarchical clustering analysis identified clinical heterogeneity in breast cancer 
To understand the clinical heterogeneity of breast cancer, two-way clustering analysis of 
the samples was performed. Various groups of samples and their association with various 
clinical parameters were identified. The important findings are summarised below. 
 The gene expression patterns of Normal specimens are very homogenous, 
whereas the gene expression patterns of breast tumors is highly heterogeneous. 
 Group of breast cancer (mainly ER-negative) tumour specimens exists whose 
expression pattern is closer to normal specimens than to most of the tumors.  
 Two ER-positive clusters were identified, one with low ER partner gene 
expression and the other with high ER partner gene expression. The cluster with 
high ER partner gene expression had a marginally better survival than the cluster 
with relatively low ER partner gene expression. 
 An ER-negative enriched cluster was identified. This cluster was highly 
heterogeneous. There were three distinct sub-clusters in this cluster. One sub-
cluster expressed high levels of the ERBB2 gene and patients in this group were 
linked to poor survival. The second sub-cluster of samples displayed over-
expression of immune response genes and the patients in this cluster were linked 
to improved survival. The third sub-cluster expressed high levels of the Ropporin 
gene and this sub-cluster was linked to poor survival.  
In conclusion, our gene expression profiling results identified various groups and sub-
groups of breast cancer and associated them with defined clinical parameters and 
outcomes. Our results identified new clusters which may have clinical relevance. 
5.2 Association of clinical parameters with genes, functions and pathways 
Various clinical parameters associated with tumour specimens such as ER status, LN 
status, Grade and Tumour size were compared in relation to gene expression, function 
and pathways. The important findings are listed below. 
 Cell cycle pathway genes were up-regulated in cancer specimens compared to the 
normal specimens. TP53, an important molecule in cell cycle regulation, was up-
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regulated in cancer when compared to normal specimens. Genes associated with 
the embryonic stem cell pathway were also up-regulated in tumors compared to 
normal specimens. The fatty acid biosynthesis pathway genes were down-
regulated in cancer compared to normal specimens.   
 Interleukin 4-induced gene (IL4I1) and CCL5 expressions progressively increased 
with increase in genomic grade, higher in Grade 3 tumors and lowest in Grade 1 
tumors. Both of these genes are related to immune response. 
 Ropporin gene expression was found to be enriched among patients who relapsed 
(overall), patients who relapsed within 5 years and patients who did not survive 
beyond 5 years. 
 SNIP and PCGF2 over-expression was linked to relapse, shorter survival and 
Lymph node-positive patients. 
In conclusion, the analysis identified important genes and pathways up- or down- 
regulated when comparing various clinical conditions. 
5.3 Comparing our in-house genelists with publicly available datasets  
Gene expression from 4 publicly available datasets and our in-house datasets were 
analysed for genes which may be involved in relapse. Additionally our results were 
compared with genes from OncotypeDx and MammaPrint. The important findings are 
listed below. 
 HSPB1, KIAA0101 and PAK3 were up-regulated in patients who relapsed in four 
out of the five cohorts. 
 AP-1 transcriptional factor genes FOS and FOSB were down-regulated in patients 
who relapsed. FOS was down-regulated in four out of five cohorts and FOSB was 
down-regulated in three out of 5 cohorts. 
 AURKA, BIRC5 and ERBB2 were up-regulated in patients who relapsed in our 
study and were also present on OncotypeDx as an indicator of bad prognosis. 
 ESR1 and SCUBE2 were down-regulated in patients who relapsed in our study 
and were also present on OncotypeDx as an indicator of good prognosis. 
 336 
 NMU, MELK and GMPS were up-regulated in patients who relapsed in our study 
and were also present on MammaPrint as an indicator of bad prognosis. 
 PECI and SCUBE2 was down-regulated in patients who relapsed in our study and 
was also present on MammaPrint as an indicator of good prognosis 
In conclusion, our analysis identified the important genes HSPB1, KIAA0101 and PAK3 
to be up-regulated in patients who relapsed vs. those who did not relapse, and FOS and 
FOSB to be down-regulated in patients who relapsed vs. those who did not relapse. The 
NMU, GMPS, MELK, PECI and SCUBE2  genes were common to MammaPrint and our 
in-house study. AURKA, BIRC5, ERBB2, ESR1 and SCUBE2 were common to 
OncotypeDx and our in-house study. 
5.4 Meta analysis for estrogen receptor pathway genes using gene expression data 
Genes from 5 clinical and 1 cell line datasets were compared for differences in gene 
expression among ER-positive and ER-negative breast specimens and cell lines. 
Additionally gene expression profiles from 5897 microarray specimens were used to 
study the gene interaction network for ESR1 gene. The important findings are listed 
below: 
 ANXA9, ABAT, BTG2, C10orf116, C1ORF34, C6orf211, CA12, CELSR1, 
COX6C, CRIP1, CSAD, EEF1A2, ERBB3, ERBB4, ESR1, FOXA1, GATA3, 
GREB1, HSPB1, INPP4B, KIAA1467, KRT18, KRT19, KRT8, LASS6, MAPT, 
MCCC2, MKL2, MLPH, MYB, MYO5C, NAT1, NME3, RAB17, RGL2, 
RHOB, SEMA3F, SLC19A2, SLC22A5, SLC39A6, SLC7A8, SLC9A3R1, 
SPDEF, TFF1, TFF3, THRAP2, THSD4, TPBG, TSPAN13, VAV3, XBP1 and 
ZNF552 were found to be up-regulated in all the 6 experiments comparing ER-
positive specimens to ER-negative specimens 
 The Nuclear Receptors pathway genes (ESR1, AR, RARA, RORC and NR2F6) 
were over-expressed among the ER-positive specimens. 
 SFRP1, ANXA1, C10orf38, SLC43A3, PRNP, YBX1, LPIN1, TRIM2, MSN, 
COTL1, ODC1, TNFRSF21, YBX1, LPIN1, CEBPB, QKI, ENO1, FNDC3B and 
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CREB3L2 were found to be down-regulated in all the 6 experiments comparing 
ER-positive specimens to ER-negative specimens 
 Cell cycle and related pathways were over-expressed among the ER-negative 
specimens.  
 The Ropporin gene was found to be up-regulated in ER-negative patients in 3 out 
of 6 experiments studied, indicating Ropporin expression to be associated with 
ER-negativity. 
 GATA3, SPDEF, FOXA1 and C1ORF34 expression correlated with expression of 
ESR1 gene across 5897 specimens. All these genes were also up-regulated in ER-
positive specimens in the meta-analysis. 
 k-means clustering and correlation analysis indicated that all the genes expressing 
together is the most obvious result from this study, however individual expression 
can exist independent of each other except for SPDEF and FOXA1. 
 FOXA1 expression was independent of SPDEF; however SPDEF expression 
appeared dependant on FOXA1 as high expression of SPDEF only existed with 
the high expression of FOXA1 as revealed by correlation graph and k-means 
clustering. 
In conclusion, our study identified known and novel genes which are up- or down- 
regulated in ER-positive tumors compared to ER-negative tumors. The analysis also 
identified FOXA1, SPDEF, GATA3 and C1ORF34 expression to correlate with 
expression of ESR1. Furthermore, a dependency of SPDEF expression on FOXA1 
expression was also identified. 
5.5 Development of MLPERCEP, a software tool for predicting relapse in breast 
cancer 
As part of the thesis work MLPERCEP (Multiple layer perceptron) implementing Back 
propagation Neural network algorithm was developed to predict relapse in breast cancer 
patients. The algorithm was implemented on our in-house dataset and publicly available 
datasets. The results were then compared to the results obtained from support vector 
machines. The important results are listed below.  
 338 
 MLPERCEP is designed with user friendly graphics user interface and is 
available at http://www.bioinformatics.org/mlpercep/ 
 MLPERCEP can be used for gene expression arrays, or any other type of data 
which can be classified as two groups. 
 Using 162 genes (p<0.001 comparing patients who relapsed vs. patients who did 
not relapse), a classifier was developed to predict relapse in breast cancer patients. 
The classifier was able to predict relapse with an accuracy of 93.3% in a leave-
one-out cross validation study. The same accuracy was obtained using support 
vector machines. However, with more stringent cut-off, the prediction accuracy of 
back propagation algorithm was 97.9%, however 10.5% of the patients could not 
be classified.  
 Data from Van‟t Veer et al.,  (2002) was used to develop a similar classifier and 
access the accuracy of the system. 117 genes (p<0.001 comparing patients who 
developed distant metastasis vs. patients who remained disease-free) was used to 
develop the classifier. The classifier was able to predict the outcome with an 
accuracy of 87.2% in a leave-one-out cross validation study. Using support vector 
machines the prediction accuracy was 82.05%. However with more stringent cut-
off, the prediction accuracy of back propagation algorithm was 89.7% and 12.8% 
of the patients could not be classified. This analysis indicated that back-
propagation based classifier can outperform SVM classifiers. 
In conclusion, a back propagation algorithm was successfully developed as a user-
friendly software package which can be used to develop a prognostic model for breast 
cancer. The results generated were at par or better than Support Vector Machines in 
predicting relapse and distant metastasis in two of the datasets tested. Our classifier was 
better than existing diagnostic kits and has the potential to be considered for development 
of a diagnostic kit.  
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5.6 Functional analysis on Ropporin 
Ropporin was over-expressed in patients who relapsed compared to patients who did not 
relapse. This gene was also over-expressed in patients who relapsed within 5 years, 
patients who did not survive beyond 5 years and ER-negative specimens. A follow up 
study using in-silico and in-vitro models was performed to access the prevalence and 
functional role of this gene. The important findings are listed below: 
 Our in-house microarray study indicated that Ropporin gene was significantly 
up-regulated in patients who relapsed, patients who did not survive beyond 5 
years, patients who relapsed within 5 years and patients with ER-negative 
tumors. Of the 6 other publicly available breast cancer datasets analysed, 
Ropporin was found to be over-expressed in 3 datasets among the ER-
negative specimens. 
 Ropporin expression was found to progressively increase with melanoma 
progression and was highest in metastatic growth phase melanoma and lymph 
node metastasis. Ropporin expression was high in many of the melanoma cell 
lines and low in melanocytes. 
 From analysis of the multiple myeloma dataset, Ropporin expression was 
found highly expressed in multiple myeloma patients. 
 In normal cells, observation of high expression of Ropporin was limited to 
testes and cervical ganglion while marginal/low expression was observed in 
heart and liver. 
 M14 was found to have nearly equal amounts of ROPN1 and ROPN1B. 
siRNA knockdown of ROPN1 and ROPN1B in this cell line showed reduction 
in invasion and motility. Over-expression of ROPN1 and ROPN1B in this cell 
line showed reduction in protein levels with an associated reduction in 
invasion and motility. 
 MDA-MB-435s was found to have high expression of ROPN1B and low 
expression of ROPN1. siRNA knockdown of ROPN1B in this cell line 
showed reduction in motility. Over-expression of ROPN1 in this cell line 
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showed reduction in motility. Over expression of ROPN1B in this cell line 
showed a reduction in protein and marginal reduction in motility.  
 MDA-MB-231 does not express ROPN1 or ROPN1B. Over-expression of  
ROPN1B showed reduction in invasion in this cell line 
In conclusion, Ropporin over-expression was linked to breast cancer patients who 
relapsed. The gene was also linked to disease progression in melanoma. siRNA 
knockdown positively associated Ropporin gene to be involved in cancer cell motility 
and invasion. There is potential of targetting Ropporin molecule as theureupetic drug for 
a subset of breast cancer and melanoma and possibly multiple myeloma.  
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6.1 Validation of novel groups of specimens in independent studies 
Our in-house study identified clusters of samples correlating with varying degrees of 
survival and other clinical parameters. Our study identified two novel groups of 
specimens; a “Poor survival group” expressing high levels of the Ropporin gene and a 
“Good survival group” expressing high levels of immune response genes. Future work 
would involve validating these results across other available datasets and to integrate this 
information in a prognostic model for Estrogen receptor-negative breast specimens, with 
the potential to develop this knowledge in a diagnostic/prognostic kit. 
6.2 Diagnostic models  
Our results have demonstrated the suitability of Neural Network models as predictive 
models for clinical outcomes for breast cancer using our in-house generated patient 
dataset. Future work would include validating these findings in independent studies and 
extending the model to predict the therapeutic options and treatment regimens that would 
be best for breast cancer patients. This will incorporate information from the future 
chemosensitivity and resistance profiles and their relation to gene expression profile. The 
information will be integrated in Neural Network architecture to provide personalised 
information for the individual patients based on tumour gene expression profiles.  
6.3 Validation of gene interaction network 
Our study identified a gene interaction network for ESR1 gene using a 5897-member 
chip dataset. GATA3, SPDEF, FOXA1 and C1ORF34 were identified to correlate in 
expression to ESR1. Other than C1ORF34 for which the function is not known, the 
GATA3, SPDEF and FOXA1 are all transcriptional factors indicating their involvement 
in the ER metabolism. Understanding their complex interactions may help in better 
understanding of the ER metabolism and lead to a deeper insight in the disease 
progression of ER-positive cancers. A future aim would be to identify transcriptional 
factors influencing expression of these genes and the way they affect other genes.  
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A strong dependency of SPDEF expression on FOXA1 was inferred from the microarray 
results. A lab validation using siRNA technology would validate the in-silico results. 
SPDEF expression reduction with knockdown of FOXA1 would confirm this observation 
and the analysis methodology for mining high throughput microarray data.   
6.4 Ropporin as biomarker and targeted therapy 
Our results identified the Ropporin gene to be over-expressed among the breast cancer 
patients who relapsed. A high expression of this gene was correlated with melanoma 
progression and observed in multiple myeloma. Functional analysis identified the gene to 
be linked to cancer cell motility. Because of the limited expression of this gene in normal 
tissue and its antigenic property to its autologous host, such types of cancer can be 
targeted for immunogenic therapy. Future aim would be to develop technology to target 
Ropporin-positive tumors using immunogenic therapy as the expression of this gene is 
localised to sperm.  
Since the expression of this protein is very restricted in normal tissue with high 
expression in some metastatic cancers, detection of this protein or RNA in tumors could 
help determine the aggressive behaviour of cancer. There is also potential to look for the 
RNA and protein in serum and that can be developed as potential biomarker for detection 
of certain types of cancer (multiple myeloma, melanoma and a sub-set of breast cancer). 
The study by Li et al., (2007) has identified the Ropporin mRNA in multiple myeloma 
patients. Future work would involve analysing large number of tumors and serums 
samples from breast, melanoma and multiple myeloma patients to establish the 
prognostic and predictive value of Ropporin expression.     
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